

Centre of Evidence Based Dermatology

Systematic reviews on psoriasis

This mapping by topic has systematic reviews published (as final journal publication) from 2012 onwards, plus all the most recent versions of relevant Cochrane Reviews. Conference abstracts are not included.

Last search date: 1st November 2020

CONTENTS

Epidemiology and aetiology

[Prevalence & distribution](#)

[Biochemical markers](#)

[Risk factors – genetic](#)

[Risk factors - other](#)

[Infections & colonisation](#)

[Psoriatic arthritis as co-morbidity](#)

[Co-morbidities –cardiovascular](#)

[Co-morbidities – diabetes & metabolic syndrome](#)

[Co-morbidities – psychiatric and psychological/social well being](#)

[Co-morbidities – other](#)

[Diagnosis & evaluation](#)

[Outcome measures](#)

[Disease impact & quality of life](#)

[Economic burden](#)

[Service delivery](#)

[Research methodology](#)

Paediatric psoriasis

[Paediatric psoriasis](#)

Psoriasis in difficult-to-treat sites

[Nail psoriasis](#)

[Scalp psoriasis](#)

[Acral psoriasis](#)

[Flexural psoriasis](#)

[Genital psoriasis](#)

Specific psoriasis phenotypes

[Pustular psoriasis](#)

[Guttate psoriasis](#)

[Erythrodermic psoriasis](#)

Therapies in general

[Therapies in general – economic evaluation](#)

[Therapies in general – patient preferences and treatment satisfaction](#)

[Therapies in general – adherence](#)

Topical treatments

[Topical treatments - general](#)

[Topical combination treatments](#)

[Topical corticosteroids](#)

[Topical vitamin D analogues](#)

[Topical dithranol](#)

[Topical retinoids](#)

[Topical coal tar](#)

[Emollients and keratolytics](#)

[Topical urea](#)

[Other topical treatments](#)

Phototherapy

[Phototherapy](#)

[Laser therapy](#)

Systemic treatments in general

[Systemic treatments in general](#)

Conventional (non-biologic) systemic therapies

[Methotrexate](#)

[Ciclosporin](#)

[Systemic retinoids](#)

[Colchicine](#)

[Fumaric acid esters](#)

[Antibiotics](#)

[Thiazolidinediones \(including pioglitazone\)](#)

[Statins](#)

[Lactoferrin](#)

Systemic biologic therapies in general

[Biologics & small molecule inhibitors in general – efficacy & safety](#)
[Biologics – immunogenicity, treatment failure & treatment regimens](#)
[Biologics – risk of infections](#)
[Biologics – effect on co-morbidities](#)
[Biosimilars](#)

Anti-TNF agents

[Anti-TNF agents - general](#)
[Anti-TNF agents - induced psoriasis](#)
[Anti-TNF agents - etanercept](#)
[Anti-TNF agents - infliximab](#)
[Anti-TNF agents - adalimumab](#)
[Anti-TNF agents - certolizumab pegol](#)

Interleukin antagonists

[Interleukin antagonists - general](#)
[Interleukin antagonists - ustekinumab \(IL-12/23 inhibitor\)](#)
[Interleukin antagonists - secukinumab \(IL-17 inhibitor\)](#)
[Interleukin antagonists - ixekizumab \(IL-17 inhibitor\)](#)
[Interleukin antagonists - brodalumab \(IL-17 inhibitor\)](#)
[Interleukin antagonists – bimekizumab \(IL-17 inhibitor\)](#)
[Interleukin antagonists - guselkumab \(IL-23 inhibitor\)](#)
[Interleukin antagonists - tildrakizumab \(IL-23 inhibitor\)](#)
[Interleukin antagonists - risankizumab \(IL-23 inhibitor\)](#)

New small molecule systemic therapies

[Small molecules - general](#)
[Phosphodiesterase-4 inhibitors - apremilast](#)
[Janus kinase inhibitors - general](#)
[Janus kinase inhibitors - tofacitinib](#)
[Tyrosine kinase inhibitors](#)

Combination therapies

[Combination therapies](#)

Other treatments

[Psychological & educational interventions](#)
[Lifestyle changes](#)
[Weight loss](#)
[Diet & supplements](#)
[Tonsillectomy](#)
[Herbal medicine \(including Chinese herbal medicine\)](#)
[Other complementary & alternative therapies](#)

Epidemiology and aetiology

Prevalence & distribution

[Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender.](#)

Iskandar IYK, Parisi R, Griffiths CEM, Ashcroft DM; Global Psoriasis Atlas.
Br J Dermatol. 2020 May 1. doi: 10.1111/bjd.19169. [Epub ahead of print]

[National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study.](#)

Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM; Global Psoriasis Atlas.
BMJ. 2020 May 28;369:m1590. doi: 10.1136/bmj.m1590.

[Epidemiology of psoriasis and psoriatic arthritis in Italy-A systematic review.](#)

Prignano F, Rogai V, Cavallucci E, Bitossi A, Hammen V, Cantini F.
Curr Rheumatol Rep. 2018 May 30;20(7):43. doi: 10.1007/s11926-018-0753-1.

[Psoriasis in Latin America and the Caribbean: A systematic review.](#)

Hernández-Vásquez A, Molinari L, Larrea N, Ciapponi A.
J Eur Acad Dermatol Venereol. 2017 Dec;31(12):1991-1998. doi: 10.1111/jdv.14393. Epub 2017 Jul 12.

[A systematic review of worldwide epidemiology of psoriasis.](#)

Michalek IM, Loring B, John SM.
J Eur Acad Dermatol Venereol. 2017 Feb;31(2):205-212. doi: 10.1111/jdv.13854. Epub 2016 Aug 30.

[The epidemiology of childhood psoriasis: A scoping review.](#)

Burden-Teh E, Thomas KS, Ratib S, Grindlay D, Adaji E, Murphy R.
Br J Dermatol. 2016 Jun;174(6):1242-57. doi: 10.1111/bjd.14507. Epub 2016 May 22.

[The global burden of skin disease in 2010: An analysis of the prevalence and impact of skin conditions.](#)

Hay RJ, Johns NE, Williams HC, Bolliger IW, Dellavalle RP, Margolis DJ, Marks R, Naldi L, Weinstock MA, Wulf SK, Michaud C, J L Murray C, Naghavi M.
J Invest Dermatol. 2014 Jun;134(6):1527-34. doi: 10.1038/jid.2013.446. Epub 2013 Oct 28.

[Global epidemiology of psoriasis: A systematic review of incidence and prevalence.](#)

Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated Comorbidity (IMPACT) project team.
J Invest Dermatol. 2013 Feb;133(2):377-85. doi: 10.1038/jid.2012.339. Epub 2012 Sep 27.

Biochemical markers

[Evaluation of serum lipid, lipoprotein, and apolipoprotein levels in psoriatic patients: a systematic review and meta-analysis of case-control studies.](#)

Ramezani M, Zavattaro E, Sadeghi M.

Postepy Dermatol Alergol. 2019 Dec;36(6):692-702. doi: 10.5114/ada.2019.91420. Epub 2019 Dec 30.

[Association of serum lipocalin-2 concentrations with psoriasis and psoriatic arthritis: An updated meta-analysis.](#)

Wang D, Fang L, Pan G.

Dis Markers. 2019 Aug 5;2019:7361826. doi: 10.1155/2019/7361826. eCollection 2019.

[Oxidative stress involvement in psoriasis: a systematic review.](#)

Cannavò SP, Riso G, Casciaro M, Di Salvo E, Gangemi S.

Free Radic Res. 2019 Aug 8;1-12. doi: 10.1080/10715762.2019.1648800. [Epub ahead of print]

[Association of total oxidant status, total antioxidant status, and malondialdehyde and catalase levels with psoriasis: a systematic review and meta-analysis.](#)

Zhang Y, Li Z, Ma Y, Mu Z.

Clin Rheumatol. 2019 Jul 18. doi: 10.1007/s10067-019-04676-1. [Epub ahead of print]

[Serum levels of YKL-40 are increased in patients with psoriasis: a meta-analysis.](#)

Kong Y, Zhang S, Su X, Peng D, Su Y.

Postgrad Med. 2019 Jul 12. doi: 10.1080/00325481.2019.1643634. [Epub ahead of print]

[Trace elements homeostatic imbalance in psoriasis: A meta-analysis.](#)

Chen W, Zhou X, Zhu W.

Biol Trace Elem Res. 2019 Jan 15. doi: 10.1007/s12011-018-1626-1. [Epub ahead of print]

[Associations between the neutrophil-to-lymphocyte and the platelet-to-lymphocyte ratios and the presence and severity of psoriasis: a systematic review and meta-analysis.](#)

Paliogiannis P, Satta R, Deligia G, Farina G, Bassu S, Mangoni AA, Carru C, Zinellu A.

Clin Exp Med. 2019 Feb;19(1):37-45. doi: 10.1007/s10238-018-0538-x. Epub 2018 Nov 26.

[Serum homocysteine, folate, and vitamin B12 levels in patients with psoriasis: A systematic review and meta-analysis.](#)

Tsai TY, Yen H, Huang YC.

Br J Dermatol. 2019 Feb;180(2):382-389. doi: 10.1111/bjd.17034. Epub 2018 Sep 12.

[Effects of treatment for psoriasis on circulating levels of leptin, adiponectin and resistin: a systematic review and meta-analysis.](#)

Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG.

Br J Dermatol. 2018 Aug;179(2):273-281. doi: 10.1111/bjd.16437. Epub 2018 May 16.

[Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis.](#)

Bai F, Zheng W, Dong Y, Wang J, Garstka MA, Li R, An J, Ma H.

Oncotarget. 2017 Nov 1;9(1):1266-1278. doi: 10.18632/oncotarget.22260. eCollection 2018 Jan 2.

[Association between circulating 25-hydroxyvitamin D levels and psoriasis, and correlation with disease severity: a meta-analysis.](#)

Lee YH, Song GG.

Clin Exp Dermatol. 2018 Jul;43(5):529-535. doi: 10.1111/ced.13381. Epub 2018 Jan 16.

[Serum leptin, resistin, and adiponectin concentrations in psoriasis: A meta-analysis of observational studies.](#)

Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG.

Dermatology. 2017;233(5):378-389. doi: 10.1159/000481882. Epub 2017 Dec 13.

[Association between circulating prolactin levels and psoriasis and its correlation with disease severity: a meta-analysis.](#)

Lee YH, Song GG.

Clin Exp Dermatol. 2018 Jan;43(1):27-35. doi: 10.1111/ced.13228. Epub 2017 Sep 22.

[Association between plasma interleukin-17 levels and risk of psoriasis: A meta-analysis.](#)

Zhou XY, Bao J, Huang B, Jin Y.

Clin Exp Dermatol. 2017 Mar;42(2):161-166. doi: 10.1111/ced.13033. Epub 2016 Dec 7.

[Role of an imbalanced miRNAs axis in pathogenesis of psoriasis: novel perspectives based on review of the literature.](#)

Wang MJ, Xu YY, Huang RY, Chen XM, Chen HM, Han L, Yan YH, Lu CJ.

Oncotarget. 2017 Jan 17;8(3):5498-5507. doi: 10.18632/oncotarget.12534.

[Immune signatures in patients with psoriasis vulgaris of blood-heat syndrome: A systematic review and meta-analysis.](#)

Li X, Xiao QQ, Li FL, Xu R, Fan B, Wu MF, Zhou M, Li S, Chen J, Peng SG, Li B.

Evid Based Complement Alternat Med. 2016;2016:9503652. doi: 10.1155/2016/9503652. Epub 2016 May 4.

[A systematic review of the role of interleukin-17 and the interleukin-20 family in inflammatory allergic skin diseases.](#)

Hofmann MA, Kiecker F, Zuberbier T.

Curr Opin Allergy Clin Immunol. 2016 Oct;16(5):451-7. doi: 10.1097/ACI.0000000000000310.

[Association of serum uric acid levels in psoriasis: A systematic review and meta-analysis.](#)

Li X, Miao X, Wang H, Wang Y, Li F, Yang Q, Cui R, Li B.

Medicine (Baltimore). 2016 May;95(19):e3676. doi: 10.1097/MD.00000000000003676.

[An exploration of the role of microRNAs in psoriasis: A systematic review of the literature.](#)

Huang RY, Li L, Wang MJ, Chen XM, Huang QC, Lu CJ.

Medicine (Baltimore). 2015 Nov;94(45):e2030. doi: 10.1097/MD.00000000000002030.

[Increased serum resistin levels correlate with psoriasis: A meta-analysis.](#)

Huang H, Shen E, Tang S, Tan X, Guo X, Wang Q, Ding H.

Lipids Health Dis. 2015 May 16;14:44. doi: 10.1186/s12944-015-0039-9.

[Leptin levels in patients with psoriasis: A meta-analysis.](#)

Zhu KJ, Zhang C, Li M, Zhu CY, Shi G, Fan YM.

Clin Exp Dermatol. 2013 Jul;38(5):478-83. doi: 10.1111/ced.12171.

[Adiponectin levels in patients with psoriasis: A meta-analysis.](#)

Zhu KJ, Shi G, Zhang C, Li M, Zhu CY, Fan YM.

J Dermatol. 2013 Jun;40(6):438-42. doi: 10.1111/1346-8138.12121. Epub 2013 Mar 12.

Risk factors – genetic

[Assessment of the relationship between clinical variants of psoriasis and killer immunoglobulin-like receptor \(KIR\) genes: A systematic review with meta-analysis.](#)

Macías-Barragán J, Montoya-Buelna M, Enciso-Vargas M, Alvarado-Ruiz L, Ocegüera-Contreras E, Guerra-Rentería AS, Graciano-Machuca O.

Immunol Invest. 2020 Oct 29;1-16. doi: 10.1080/08820139.2020.1840582. Online ahead of print.

[Association of rs610604 in TNFAIP3 and rs17728338 in TNIP1 gene polymorphisms with psoriasis susceptibility: a meta-analysis of case-control studies.](#)

Gong HB, Gao ST, Pu XM, Kang XJ, Wu XJ.

BMC Med Genet. 2020 May 12;21(1):103. doi: 10.1186/s12881-020-01041-x.

[Epigenetic factors involved in the pathophysiology of inflammatory skin diseases.](#)

Möbus L, Weidinger S, Emmert H.

J Allergy Clin Immunol. 2020 Apr;145(4):1049-1060. doi: 10.1016/j.jaci.2019.10.015.

[Endoplasmic reticulum aminopeptidase 1 \(ERAP1\) polymorphisms and psoriasis susceptibility: A systematic review and meta-analysis.](#)

Zavattaro E, Ramezani M, Sadeghi M.

Gene. 2020 Jan 29;144416. doi: 10.1016/j.gene.2020.144416. [Epub ahead of print]

[Angiotensin-converting enzyme gene insertion/deletion polymorphism and susceptibility to psoriasis: a systematic review and meta-analysis.](#)

Ramezani M, Zavattaro E, Sadeghi M.

BMC Med Genet. 2020 Jan 8;21(1):8. doi: 10.1186/s12881-019-0943-3.

[A meta-analysis of the relationship between tumor necrosis factor- \$\alpha\$ polymorphisms and psoriasis.](#)

Wang L, Zhou H.

Dermatology. 2019 Nov 27;1-7. doi: 10.1159/000502255. [Epub ahead of print]

[Association of rs2910164 polymorphism in MiR-146a gene with psoriasis susceptibility: A meta-analysis.](#)

Gong HB, Zhang SL, Wu XJ, Pu XM, Kang XJ.

Medicine (Baltimore). 2019 Feb;98(6):e14401. doi: 10.1097/MD.00000000000014401.

[Lack of association of the IL-1RN and IL-10 polymorphisms with risk of psoriasis: A meta-analysis.](#)

Qiao J, Jia QN, Jin HZ.

Mol Genet Genomic Med. 2019 Jan;7(1):e00512. doi: 10.1002/mgg3.512. Epub 2018 Dec 6.

[Vitamin D receptor Apal, TaqI, BsmI, and FokI polymorphisms and psoriasis susceptibility: an updated meta-analysis.](#)

Lee YH.

Clin Exp Dermatol. 2019 Jul;44(5):498-505. doi: 10.1111/ced.13823. Epub 2018 Nov 25.

[A systematic review of pharmacogenetic studies on the response to biologics in psoriasis patients.](#)

van Vugt LJ, van den Reek JMPA, Coenen MJH, de Jong EMGJ.

Br J Dermatol. 2018 Jan;178(1):86-94. doi: 10.1111/bjd.15753. Epub 2017 Dec 14.

[Epigenetics of psoriatic disease: A systematic review and critical appraisal.](#)

Pollock RA, Abji F, Gladman DD.

J Autoimmun. 2017 Mar;78:29-38. doi: 10.1016/j.jaut.2016.12.002. Epub 2016 Dec 10.

[Update on the association between interleukin-12 p40 gene polymorphism and risk of psoriasis: A meta-analysis.](#)

Zhao Z., Xie F, Zhang X, Yang J, Wang R, Yang R, Li H.
Dermatologica Sinica 2016;34(3):126-30.

[The common CARD14 gene missense polymorphism rs11652075 \(c.C2458T/p.Arg820Trp\) is associated with psoriasis: A meta-analysis.](#)

Shi G, Li SJ, Wang TT, Cheng CM, Fan YM, Zhu KJ.
Genet Mol Res. 2016 Aug 19;15(3). doi: 10.4238/gmr.15038357.

[Meta-analysis of IL-6 -174G/C polymorphism and psoriasis risk.](#)

Nie G, Xie CL, Cao YJ, Xu MM, Shi X, Zou AL, Qi JH.
Genet Mol Res. 2016 Jul 14;15(2). doi: 10.4238/gmr.15028255.

[Association between rs6887695 and 3'-untranslated region polymorphisms within the interleukin-12B gene and susceptibility to autoimmune diseases in Asian and European population: A meta-analysis.](#)

Xiao JP, Wang XR, Zhang S, Wang HY, Ye L, Pan HF, Wang DG.
Autoimmunity. 2016 Jun;49(4):277-84. doi: 10.3109/08916934.2016.1166215. Epub 2016 Apr 12.

[Association between methylenetetrahydrofolate reductase C677T polymorphism and psoriasis: A meta-analysis.](#)

Wu D, Shi D, Yang L, Zhu X.
J Dermatol. 2016 Feb;43(2):162-9. doi: 10.1111/1346-8138.13039. Epub 2015 Jul 27.

[Vascular endothelial growth factor gene polymorphisms and psoriasis susceptibility: A meta-analysis.](#)

Lee YH, Song GG.
Genet Mol Res. 2015 Nov 19;14(4):14396-405. doi: 10.4238/2015.November.18.3.

[Lack of association between cytotoxic T-lymphocyte antigen-4+49A/G polymorphism and psoriasis and vitiligo: A meta-analysis of case-control studies.](#)

Liang J, Zhang S, Luo Q, Li W, Tian X, Zhang F, Zhao T, Chen X, Zhang X.
Gene. 2015 Sep 1;568(2):196-202. doi: 10.1016/j.gene.2015.05.051. Epub 2015 May 24.

[Polymorphism of VEGF gene in susceptibility to chronic immune-mediated inflammatory diseases: a meta-analysis.](#)

Wei N, Chen Z, Xue Z, Zhu Y.
Rheumatol Int. 2015 Aug;35(8):1351-60. doi: 10.1007/s00296-015-3279-0. Epub 2015 May 26.

[The angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to rheumatoid arthritis, vitiligo and psoriasis: A meta-analysis.](#)

Song GG, Bae SC, Kim JH, Lee YH.
J Renin Angiotensin Aldosterone Syst. 2015 Mar;16(1):195-202. doi: 10.1177/1470320313478285.

[Association between MTHFR 677C/T polymorphism and psoriasis risk: A meta-analysis.](#)

Qi JH, Qi JH, Shi N, Chen YJ, Nie G.
Genet Mol Res. 2015 Apr 22;14(2):3869-76. doi: 10.4238/2015.April.22.16.

[Association of the late cornified envelope-3 genes with psoriasis and psoriatic arthritis: A systematic review.](#)

Shen C, Gao J, Yin X, Sheng Y, Sun L, Cui Y, Zhang X.

J Genet Genomics. 2015 Feb 20;42(2):49-56. doi: 10.1016/j.jgg.2015.01.001. Epub 2015 Jan 10.

[Evaluation of the association between CD143 gene polymorphism and psoriasis.](#)

Xia T, Diao J, Huang H, Li J, Sun L, Li H, Lv S.

Cell Biochem Biophys. 2014 Dec;70(3):1617-23. doi: 10.1007/s12013-014-0104-4.

[Investigation of the association between psoriasis and human leucocyte antigens A by means of meta-analysis.](#)

Zhao YE, Hu L, Ma JX, Xiao SX, Zhao YL.

J Eur Acad Dermatol Venereol. 2014 Mar;28(3):355-69. doi: 10.1111/jdv.12256. Epub 2013 Aug 24.

[Four polymorphisms of VEGF \(+405C>G, -460T>C, -2578C>A, and -1154G>A\) in susceptibility to psoriasis: a meta-analysis.](#)

Qi M, Huang X, Zhou L, Zhang J.

DNA Cell Biol. 2014 Apr;33(4):234-44. doi: 10.1089/dna.2013.2252.

[Associations between the major histocompatibility complex class I chain-related gene A transmembrane \(MICA-TM\) polymorphism and susceptibility to psoriasis and psoriatic arthritis: A meta-analysis.](#)

Song GG, Kim JH, Lee YH.

Rheumatol Int. 2014 Jan;34(1):117-23. doi: 10.1007/s00296-013-2849-2. Epub 2013 Aug 22

[Associations between tumor necrosis factor- \$\alpha\$ polymorphisms and risk of psoriasis: A meta-analysis.](#)

Zhuang L, Ma W, Cai D, Zhong H, Sun Q.

PLoS One. 2013 Dec 4;8(12):e68827. doi: 10.1371/journal.pone.0068827. eCollection 2013.

[Association of the tumour necrosis factor- \$\alpha\$ polymorphisms rs361525 and rs1800629 with susceptibility to psoriasis: A meta-analysis.](#)

Jia Y, Qin HJ, Zhang JX, Liu XL, Li LJ.

Clin Exp Dermatol. 2013 Dec;38(8):836-44. doi: 10.1111/ced.12136.

[Meta-analysis of the association between psoriasis and human leucocyte antigen-B.](#)

Zhao YE, Ma JX, Hu L, Xiao SX, Zhao YL.

Br J Dermatol. 2013 Aug;169(2):417-27. doi: 10.1111/bjd.12387.

[Associations between interleukin-23R and interleukin-12B polymorphisms and psoriasis susceptibility: A meta-analysis.](#)

Lee YH, Song GG.

Immunol Invest. 2013;42(8):726-36. doi: 10.3109/08820139.2013.810241. Epub 2013 Jul 11.

[Meta-analysis of IL12B polymorphisms \(rs3212227, rs6887695\) with psoriasis and psoriatic arthritis.](#)

Zhu KJ, Zhu CY, Shi G, Fan YM.

Rheumatol Int. 2013 Jul;33(7):1785-90. doi: 10.1007/s00296-012-2637-4. Epub 2013 Jan 8.

[Apal, BsmI, FokI and TaqI polymorphisms in the vitamin D receptor \(VDR\) gene and the risk of psoriasis: A meta-analysis.](#)

Liu JL, Zhang SQ, Zeng HM.

J Eur Acad Dermatol Venereol. 2013 Jun;27(6):739-46. doi: 10.1111/j.1468-3083.2012.04553.x. Epub 2012 Apr 28.

[Angiotensin-converting enzyme gene polymorphisms and the risk of psoriasis: a meta-analysis.](#)

Liu T, Han Y, Lu L.

Clin Exp Dermatol. 2013 Jun;38(4):352-8; quiz 359. doi: 10.1111/ced.12106.

[Single nucleotide polymorphisms in the tumor necrosis factor-alpha gene promoter region alter the risk of psoriasis vulgaris and psoriatic arthritis: A meta-analysis.](#)

Zhu J, Qu H, Chen X, Wang H, Li J.

PLoS One. 2013 May 23;8(5):e64376. doi: 10.1371/journal.pone.0064376. Print 2013.

[Meta-analysis of vitamin D receptor polymorphisms and psoriasis risk.](#)

Stefanic M, Rucevic I, Barisic-Drusko V.

Int J Dermatol. 2013 Jun;52(6):705-10. doi: 10.1111/j.1365-4632.2012.5813.x. Epub 2013 Mar 14.

[CD226 Gly307Ser association with multiple autoimmune diseases: a meta-analysis.](#)

Qiu ZX, Zhang K, Qiu XS, Zhou M, Li WM.

Hum Immunol. 2013 Feb;74(2):249-55. doi: 10.1016/j.humimm.2012.10.009. Epub 2012 Oct 13.

[Apolipoprotein E gene polymorphism in psoriasis: A meta-analysis.](#)

Han Y, Liu T, Lu L.

Arch Med Res. 2013 Jan;44(1):46-53. doi: 10.1016/j.arcmed.2012.10.009. Epub 2012 Nov 6.

[Association of IL23R polymorphisms with psoriasis and psoriatic arthritis: a meta-analysis.](#)

Zhu KJ, Zhu CY, Shi G, Fan YM.

Inflamm Res. 2012 Oct;61(10):1149-54. doi: 10.1007/s00011-012-0509-8. Epub 2012 Jun 17.

[Association of STAT4 rs7574865 polymorphism with autoimmune diseases: A meta-analysis.](#)

Liang YL, Wu H, Shen X, Li PQ, Yang XQ, Liang L, Tian WH, Zhang LF, Xie XD.

Mol Biol Rep. 2012 Sep;39(9):8873-82. doi: 10.1007/s11033-012-1754-1. Epub 2012 Jun 20.

[PTPN22 C1858T and the risk of psoriasis: a meta-analysis.](#)

Chen YF, Chang JS.

Mol Biol Rep. 2012 Aug;39(8):7861-70. doi: 10.1007/s11033-012-1630-z. Epub 2012 Apr 28.

[Meta-analysis of NOD2/CARD15 polymorphisms with psoriasis and psoriatic arthritis.](#)

Zhu K, Yin X, Tang X, Zhang F, Yang S, Zhang X.

Rheumatol Int. 2012 Jul;32(7):1893-900. doi: 10.1007/s00296-011-1813-2. Epub 2011 Mar 30.

[Associations between interleukin-10 polymorphisms and susceptibility to psoriasis: A meta-analysis.](#)

Lee YH, Choi SJ, Ji JD, Song GG.

Inflamm Res. 2012 Jul;61(7):657-63. doi: 10.1007/s00011-012-0458-2. Epub 2012 Mar 18.

Risk factors - other

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.](#)

Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M,

Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A.
J Am Acad Dermatol. 2019 Apr;80(4):1073-1113. doi: 10.1016/j.jaad.2018.11.058. Epub 2019 Feb 13.

[Impact of smoking on psoriasis risk and treatment efficacy: a meta-analysis.](#)

Zhou H, Wu R, Kong Y, Zhao M, Su Y.

J Int Med Res. 2020 Oct;48(10):300060520964024. doi: 10.1177/0300060520964024.

[The skin microbiome in psoriatic disease: A systematic review and critical appraisal.](#)

Yerushalmi M, Elalouf O, Anderson M, Chandran V.

J Transl Autoimmun. 2019 Aug 20;2:100009. doi: 10.1016/j.jtauto.2019.100009. eCollection 2019

[Gut microbiome in psoriasis: An updated review.](#)

Sikora M, Stec A, Chrabaszcz M, Knot A, Waskiel-Burnat A, Rakowska A, Olszewska M, Rudnicka L. Pathogens. 2020 Jun 12;9(6). pii: E463. doi: 10.3390/pathogens9060463.

[Association between psoriasis and risk of dementia: a systematic review and meta-analysis.](#)

Lam M, Khorvash R, Drucker AM.

J Am Acad Dermatol. 2020 May 21. pii: S0190-9622(20)30961-0. doi: 10.1016/j.jaad.2020.05.091.

[Epub ahead of print] No abstract available.

[The impact of smoking on prevalence of psoriasis and psoriatic arthritis.](#)

Gazel U, Ayan G, Solmaz D, Akar S, Aydin SZ.

Rheumatology (Oxford). 2020 Jun 4. pii: keaa179. doi: 10.1093/rheumatology/keaa179. [Epub ahead of print]

[Association between uveitis and psoriatic disease: a systematic review and meta-analysis based on the evidence from cohort studies.](#)

Li CR, Chen L, Wang LF, Yan B, Liang YL, Luo J.

Int J Ophthalmol. 2020 Apr 18;13(4):650-659. doi: 10.18240/ijo.2020.04.19. eCollection 2020.

[Association of hepatitis B virus infection and psoriasis: A meta-analysis.](#)

Arafa A, Mostafa A.

Australas J Dermatol. 2020 May 14. doi: 10.1111/ajd.13320. [Epub ahead of print] No abstract available.

[Hydroxychloroquine effects on psoriasis: a systematic review and a cautionary note for COVID-19 treatment.](#)

Sachdeva M, Mufti A, Maliyar K, Lytvyn Y, Yeung J.

J Am Acad Dermatol. 2020 May 19. pii: S0190-9622(20)30942-7. doi: 10.1016/j.jaad.2020.05.074.

[Epub ahead of print]

[Epigenetic factors involved in the pathophysiology of inflammatory skin diseases.](#)

Möbus L, Weidinger S, Emmert H.

J Allergy Clin Immunol. 2020 Apr;145(4):1049-1060. doi: 10.1016/j.jaci.2019.10.015.

[Bidirectional association between psoriasis and obstructive sleep apnea: A systematic review and meta-analysis.](#)

Ger TY, Fu Y, Chi CC.

Sci Rep. 2020 Apr 3;10(1):5931. doi: 10.1038/s41598-020-62834-x.

[Hypovitaminosis D is associated with psoriasis: A systematic review and meta-analysis.](#)

Pitukweerakul S, Thavaraputta S, Prachuapthunyachart S, Karnchanasorn R.
Kans J Med. 2019 Nov 25;12(4):103-108. eCollection 2019 Nov.

[Psoriasis in family members of patients with multiple sclerosis.](#)

Charlton O, Phan K, Smith SD, Parratt J.

Mult Scler Relat Disord. 2019 Sep 30;36:101421. doi: 10.1016/j.msard.2019.101421. [Epub ahead of print]

[Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease - A systematic review and meta-analysis.](#)

Alinaghi F, Tekin HG, Burisch J, Wu JJ, Thyssen JP, Egeberg A.

J Crohns Colitis. 2019 Aug 30. pii: jjz152. doi: 10.1093/ecco-jcc/jjz152. [Epub ahead of print]

[Helicobacter pylori infection and psoriasis: A systematic review and meta-analysis.](#)

Yu M, Zhang R, Ni P, Chen S, Duan G.

Medicina (Kaunas). 2019 Sep 26;55(10). pii: E645. doi: 10.3390/medicina55100645.

[Association of total oxidant status, total antioxidant status, and malondialdehyde and catalase levels with psoriasis: a systematic review and meta-analysis.](#)

Zhang Y, Li Z, Ma Y, Mu Z.

Clin Rheumatol. 2019 Jul 18. doi: 10.1007/s10067-019-04676-1. [Epub ahead of print]

[Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A critically-appraised topic.](#)

Mahil SK, McSweeney SM, Kloczko E, McGowan B, Barker JN, Smith CH.

Br J Dermatol. 2019 Feb 6. doi: 10.1111/bjd.17741. [Epub ahead of print]

[Associations between the neutrophil-to-lymphocyte and the platelet-to-lymphocyte ratios and the presence and severity of psoriasis: a systematic review and meta-analysis.](#)

Paliogiannis P, Satta R, Deligia G, Farina G, Bassu S, Mangoni AA, Carru C, Zinellu A.

Clin Exp Med. 2019 Feb;19(1):37-45. doi: 10.1007/s10238-018-0538-x. Epub 2018 Nov 26.

[Association of multiple sclerosis with psoriasis: A systematic review and meta-analysis of observational studies.](#)

Liu CY, Tung TH, Lee CY, Chang KH, Wang SH, Chi CC.

Am J Clin Dermatol. 2019 Apr;20(2):201-208. doi: 10.1007/s40257-018-0399-9.

[Association between psoriasis and vitiligo: A systematic review and meta-analysis.](#)

Yen H, Chi CC.

Am J Clin Dermatol. 2019 Feb;20(1):31-40. doi: 10.1007/s40257-018-0394-1.

[The coexistence of pemphigus and psoriasis: a systematic review and meta-analysis.](#)

Kridin K, Kridin M, Shalom G, Cohen AD.

Immunol Res. 2019 Feb;67(1):134-141. doi: 10.1007/s12026-018-9031-6.

[Association between bullous pemphigoid and psoriasis: Systematic review and meta-analysis of case-control studies.](#)

Phan K, Goyal S, Murrell DF.

Australas J Dermatol. 2019 Feb;60(1):23-28. doi: 10.1111/ajd.12899. Epub 2018 Aug 23.

[Association between physical activity and risk of prevalent psoriasis: A MOOSE-compliant meta-analysis.](#)

Zheng Q, Sun XY, Miao X, Xu R, Ma T, Zhang YN, Li HJ, Li B, Li X.
Medicine (Baltimore). 2018 Jul;97(27):e11394. doi: 10.1097/MD.00000000000011394.

[Association between Vitamin D deficiency and psoriasis: An exploratory study.](#)

Al-Dhubaibi MS.
Int J Health Sci (Qassim). 2018 Jan-Feb;12(1):33-9.

[Body mass index, abdominal fatness, weight gain and the risk of psoriasis: a systematic review and dose-response meta-analysis of prospective studies.](#)

Aune D, Snekvik I, Schlesinger S, Norat T, Riboli E, Vatten LJ.
Eur J Epidemiol. 2018 Dec;33(12):1163-1178. doi: 10.1007/s10654-018-0366-z. Epub 2018 Apr 21.

[The associations between psychological stress and psoriasis: a systematic review.](#)

Stewart TJ, Tong W, Whitfeld MJ.
Int J Dermatol. 2018 Nov;57(11):1275-1282. doi: 10.1111/ijd.13956. Epub 2018 Mar 8.

[Psychological stress and psoriasis. A systematic review and meta-analysis.](#)

Snast I, Reiter O, Atzmony L, Leshem YA, Hodak E, Mimouni D, Pavlovsky L.
Br J Dermatol. 2018 May;178(5):1044-1055. doi: 10.1111/bjd.16116. Epub 2018 Mar 2.

[Patients with schizophrenia have a higher risk of psoriasis: A systematic review and meta-analysis.](#)

Ungrasert P, Wijarnpreecha K, Cheungpasitporn W.
Psychiatry Res. 2018 Jan;259:422-426. doi: 10.1016/j.psychres.2017.11.021. Epub 2017 Nov 7.

[The association of autoimmune thyroid disease \(AITD\) with psoriatic disease: A prospective cohort study, systematic review and meta-analysis.](#)

Khan SR, Bano A, Wakkee M, Korevaar T, Franco O, Nijsten T, Peeters RP, Chaker L.
Eur J Endocrinol. 2017 Oct;177(4):347-359. doi: 10.1530/EJE-17-0397. Epub 2017 Jul 26.

[Periodontitis and risk of psoriasis: A systematic review and meta-analysis.](#)

Ungrasert P, Wijarnpreecha K, Wetter DA.
J Eur Acad Dermatol Venereol. 2017 May;31(5):857-862. doi: 10.1111/jdv.14051. Epub 2016 Dec 7.

[Psoriasis and smoking: A systematic literature review and meta-analysis with qualitative analysis of effect of smoking on psoriasis severity.](#)

Richer V, Roubille C, Fleming P, Starnino T, McCourt C, McFarlane A, Siu S, Kraft J, Lynde C, Pope JE, Keeling S, Dutz J, Bessette L, Gulliver WP, Haraoui B, Bissonnette R.
J Cutan Med Surg. 2016 May;20(3):221-7. doi: 10.1177/1203475415616073. Epub 2015 Nov 9.

[Anti-tumor necrosis factor \$\alpha\$ -related psoriatic lesions in children with inflammatory bowel disease: Case report and systematic literature review.](#)

Romiti R, Araujo KM, Steinwurz F, Denadai R.
Pediatr Dermatol. 2016 Mar-Apr;33(2):e174-8. doi: 10.1111/pde.12820.

[The relationship of obesity with the severity of psoriasis: A systematic review.](#)

Fleming P, Kraft J, Gulliver WP, Lynde C.
J Cutan Med Surg. 2015 Sep-Oct;19(5):450-6. doi: 10.1177/1203475415586332. Epub 2015 May 7.

[A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis.](#)

Marrie RA, Reider N, Cohen J, Stuve O, Sorensen PS, Cutter G, Reingold SC, Trojano M.
Mult Scler. 2015 Mar;21(3):282-93. doi: 10.1177/1352458514564490. Epub 2014 Dec 22.

[Obesity in autoimmune diseases: not a passive bystander.](#)

Versini M, Jeandel PY, Rosenthal E, Shoenfeld Y.
Autoimmun Rev. 2014 Sep;13(9):981-1000. doi: 10.1016/j.autrev.2014.07.001. Epub 2014 Aug 2.

[Psoriasis and smoking: A systematic review and meta-analysis.](#)

Armstrong AW, Harskamp CT, Dhillon JS, Armstrong EJ.
Br J Dermatol. 2014 Feb;170(2):304-14. doi: 10.1111/bjd.12670

[\[Lithium treatment and potential long-term side effects: A systematic review of the literature\].](#)

Albert U, De Cori D, Blengino G, Bogetto F, Maina G.
Riv Psichiatr. 2014 Jan-Feb;49(1):12-21. doi: 10.1708/1407.15620. Review. Italian.

[Alcohol consumption and psoriasis: A systematic literature review.](#)

Brenaut E, Horreau C, Pouplard C, Barnetche T, Paul C, Richard MA, Joly P, Le Maître M, Aractingi S, Aubin F, Cribier B, Jullien D, Ortonne JP, Misery L.
J Eur Acad Dermatol Venereol. 2013 Aug;27 Suppl 3:30-5. doi: 10.1111/jdv.12164

[Autoimmune disease in people with multiple sclerosis and their relatives: A systematic review and meta-analysis.](#)

Dobson R, Giovannoni G.
J Neurol. 2013 May;260(5):1272-85. doi: 10.1007/s00415-012-6790-1. Epub 2013 Jan 12.

[Alcohol consumption and psoriatic risk: A meta-analysis of case-control studies.](#)

Zhu KJ, Zhu CY, Fan YM.
J Dermatol. 2012 Sep;39(9):770-3. doi: 10.1111/j.1346-8138.2012.01577.x. Epub 2012 May 9.

[The coexistence of psoriasis and vitiligo: A review.](#)

Sawchuk M, Spano F, Loo WJ, Guenther L.
J Cutan Med Surg. 2012 Sep-Oct;16(5):300-5.

Infections & colonisation

[Helicobacter pylori infection and psoriasis: A systematic review and meta-analysis.](#)

Yu M, Zhang R, Ni P, Chen S, Duan G.
Medicina (Kaunas). 2019 Sep 26;55(10). pii: E645. doi: 10.3390/medicina55100645.

[A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation.](#)

Baumrin E, Van Voorhees A, Garg A, Feldman SR, Merola JF.
J Am Acad Dermatol. 2019 Jul;81(1):102-110. doi: 10.1016/j.jaad.2019.03.017. Epub 2019 Mar 15.

[All-cause and cause-specific mortality in psoriasis: a systematic review and meta-analysis.](#)

Dhana A, Yen H, Yen H, Cho E.
J Am Acad Dermatol. 2019 May;80(5):1332-1343. doi: 10.1016/j.jaad.2018.12.037. Epub 2018 Dec 24.

[Association between psoriasis and *Helicobacter pylori* infection: A systematic review and meta-analysis.](#)

Yong WC, Upala S, Sanguankee A.

Indian J Dermatol. 2018 May-Jun;63(3):193-200. doi: 10.4103/ijd.IJD_531_17.

[Prevalence and possible role of *Candida* species in patients with psoriasis: a systematic review and meta-analysis.](#)

Pietrzak A, Grywalska E, Socha M, Roliński J, Franciszewicz-Pietrzak K, Rudnicka L, Rudzki M, Krasowska D.

Mediators Inflamm. 2018 May 6;2018:9602362. doi: 10.1155/2018/9602362. eCollection 2018.

[Infections and the risk of psoriatic arthritis among psoriasis patients: a systematic review.](#)

Thrastardottir T, Jon Love T.

Rheumatol Int. 2018 Aug;38(8):1385-1397. doi: 10.1007/s00296-017-3873-4. Epub 2017 Nov 9.

[Risks for *Staphylococcus aureus* colonization in psoriasis patients: A systematic review and meta-analysis.](#)

Ng CY, Huang YH, Chu CF, Wu TC, Liu SH.

Br J Dermatol. 2017 Oct;177(4):967-977. doi: 10.1111/bjd.15366. Epub 2017 Sep 8.

[A systematic review and meta-analysis on *Staphylococcus aureus* carriage in psoriasis, acne and rosacea.](#)

Totté JE, van der Feltz WT, Bode LG, van Belkum A, van Zuuren EJ, Pasmans SG.

Eur J Clin Microbiol Infect Dis. 2016 Jul;35(7):1069-77. doi: 10.1007/s10096-016-2647-3. Epub 2016 May 5.

[The prevalence of culture-confirmed toenail onychomycosis in at-risk patient populations.](#)

Gupta AK, Daigle D, Foley KA.

J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1039-44. doi: 10.1111/jdv.12873. Epub 2014 Nov 21.

[The prevalence of onychomycosis in psoriatic patients: A systematic review.](#)

Klaassen KM, Dulak MG, van de Kerkhof PC, Pasch MC.

J Eur Acad Dermatol Venereol. 2014 May;28(5):533-41. doi: 10.1111/jdv.12239. Epub 2013 Aug 19.

Psoriatic arthritis as co-morbidity

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.](#)

Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A.

J Am Acad Dermatol. 2019 Apr;80(4):1073-1113. doi: 10.1016/j.jaad.2018.11.058. Epub 2019 Feb 13.

[Modifiable lifestyle and environmental factors associated with onset of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational studies.](#)

Xie W, Huang H, Deng X, Gao D, Zhang Z.

J Am Acad Dermatol. 2020 Aug 19:S0190-9622(20)32453-1. doi: 10.1016/j.jaad.2020.08.060. Online ahead of print.

[Measurement properties of instruments assessing psoriatic arthritis symptoms for psoriasis clinical trials: a systematic literature review.](#)

Perez-Chada LM, Balak D, Cohen JM, Ogdie A, Merola JF, Gottlieb AB.

Expert Rev Clin Immunol. 2020 Feb 8:1-17. doi: 10.1080/1744666X.2020.1724090. [Epub ahead of print]

[Psoriatic arthritis screening: a systematic review and meta-analysis.](#)

Iragorri N, Hazlewood G, Manns B, Danthurebandara V, Spackman E.

Rheumatology (Oxford). 2019 Apr 1;58(4):692-707. doi: 10.1093/rheumatology/key314.

[Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies.](#)

Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, Gottlieb AB, Gisondi P, Wu JJ, Thyssen JP, Egeberg A.

J Am Acad Dermatol. 2019 Jan;80(1):251-265.e19. doi: 10.1016/j.jaad.2018.06.027. Epub 2018 Jun 19.

[Infections and the risk of psoriatic arthritis among psoriasis patients: a systematic review.](#)

Thrastardottir T, Jon Love T.

Rheumatol Int. 2018 Aug;38(8):1385-1397. doi: 10.1007/s00296-017-3873-4. Epub 2017 Nov 9.

[Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis.](#)

Villani AP, Rouzaud M, Sevrain M, Barnetche T, Paul C, Richard MA, Beylot-Barry M, Misery L, Joly P, Le Maître M, Aractingi S, Aubin F, Cantagrel A, Ortonne JP, Jullien D.

J Am Acad Dermatol. 2015 Aug;73(2):242-8. doi: 10.1016/j.jaad.2015.05.001. Epub 2015 Jun 6.

[Safety and efficacy of therapies for skin symptoms of psoriasis in patients with psoriatic arthritis: A systematic review.](#)

Boehncke WH, Alvarez Martinez D, Solomon JA, Gottlieb AB.

J Rheumatol. 2014 Nov;41(11):2301-5. doi: 10.3899/jrheum.140880.

[Evidence-based recommendations on the role of dermatologists in the diagnosis and management of psoriatic arthritis: systematic review and expert opinion.](#)

Richard MA, Barnetche T, Rouzaud M, Sevrain M, Villani AP, Aractingi S, Aubin F, Beylot-Barry M, Joly P, Jullien D, Le Maître M, Misery L, Ortonne JP, Cantagrel A, Paul C.

J Eur Acad Dermatol Venereol. 2014 Aug;28 Suppl 5:3-12. doi: 10.1111/jdv.12560.

[Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review.](#)

Rouzaud M, Sevrain M, Villani AP, Barnetche T, Paul C, Richard MA, Jullien D, Misery L, Le Maître M, Aractingi S, Aubin F, Joly P, Cantagrel A, Ortonne JP, Beylot-Barry M.

J Eur Acad Dermatol Venereol. 2014 Aug;28 Suppl 5:17-26. doi: 10.1111/jdv.12562.

Co-morbidities – cardiovascular

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.](#)

Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A.
J Am Acad Dermatol. 2019 Apr;80(4):1073-1113. doi: 10.1016/j.jaad.2018.11.058. Epub 2019 Feb 13.

[Risk of aortic aneurysm in patients with psoriasis: A systematic review and meta-analysis of cohort studies.](#)

Yu X, Feng X, Xia L, Cao S, Wei X.
Clin Cardiol. 2020 Aug 5. doi: 10.1002/clc.23438. Online ahead of print.

[Pediatric psoriasis and association with cardiovascular and metabolic comorbidities: Systematic review and meta-analysis.](#)

Phan K, Lee G, Fischer G.
Pediatr Dermatol. 2020 May 20. doi: 10.1111/pde.14208. [Epub ahead of print]

[A systematic review and meta-analysis of the association between psoriasis and hypertension with adjustment for covariates.](#)

Duan X, Liu J, Mu Y, Liu T, Chen Y, Yu R, Xiong X, Wu T.
Medicine (Baltimore). 2020 Feb;99(9):e19303. doi: 10.1097/MD.00000000000019303.

[Psoriasis and cardiovascular disorders: association or epiphenomenon? Meta-analysis of observational studies.](#)

Choudhary S, Patel R, Pradhan D, Deval R, Singh H, Thomas G, Jain AK.
3 Biotech. 2020 Mar;10(3):104. doi: 10.1007/s13205-020-2089-6. Epub 2020 Feb 7.

[Coronary artery disease assessed by computed tomography in patients with psoriasis: A systematic review and meta-analysis.](#)

Kaiser H, Abdulla J, Henningsen KMA, Skov L, Hansen PR.
Dermatology. 2019 Sep 3:1-10. doi: 10.1159/000502138. [Epub ahead of print]

[Psoriasis and metabolic and cardiovascular comorbidities in children: A systematic review.](#)

Badaoui A, Tounian P, Mahé E.
Arch Pediatr. 2019 Feb;26(2):86-94. doi: 10.1016/j.arcped.2018.12.005. Epub 2019 Jan 11.

[All-cause and cause-specific mortality in psoriasis: a systematic review and meta-analysis.](#)

Dhana A, Yen H, Yen H, Cho E.
J Am Acad Dermatol. 2019 May;80(5):1332-1343. doi: 10.1016/j.jaad.2018.12.037. Epub 2018 Dec 24.

[Serum homocysteine, folate, and vitamin B12 levels in patients with psoriasis: A systematic review and meta-analysis.](#)

Tsai TY, Yen H, Huang YC.
Br J Dermatol. 2019 Feb;180(2):382-389. doi: 10.1111/bjd.17034. Epub 2018 Sep 12.

[Is psoriasis a risk factor of angiography-proven coronary artery disease?](#)

Zhao J, Zhang X, Sun H, An R.

Br J Dermatol. 2018 Nov;179(5):1218-1219. doi: 10.1111/bjd.16925. Epub 2018 Sep 23. No abstract available.

[Do psoriasis patients engage in vigorous physical activity?](#)

Amin M, Lee EB, Bhutani T, Wu JJ.

Cutis. 2018 Mar;101(3):198-200.

[Homocysteine: A potential common route for cardiovascular risk and DNA methylation in psoriasis.](#)

Wang WM, Jin HZ.

Chin Med J (Engl). 2017 Aug 20;130(16):1980-1986. doi: 10.4103/0366-6999.211895.

[Psoriasis and cardiovascular events: Updating the evidence.](#)

Raaby L, Ahlehoff O, de Thurah A.

Arch Dermatol Res. 2017 Apr;309(3):225-228. doi: 10.1007/s00403-016-1712-1. Epub 2017 Feb 17.

[Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: Systematic review and meta-analysis of randomized controlled trials.](#)

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.

Br J Dermatol. 2017 Apr;176(4):890-901. doi: 10.1111/bjd.14964. Epub 2017 Mar 14.

[Psoriasis increases risk of new-onset atrial fibrillation: A systematic review and meta-analysis of prospective observational studies.](#)

Upala S, Shahnawaz A, Sanguankeo A.

J Dermatolog Treat. 2017 Aug;28(5):406-410. doi: 10.1080/09546634.2016.1255703. Epub 2016 Nov 18.

[The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: An updated meta-analysis.](#)

Yang ZS, Lin NN, Li L, Li Y.

Clin Rev Allergy Immunol. 2016 Oct;51(2):240-7. doi: 10.1007/s12016-016-8560-9.

[Psoriasis and risk of incident atrial fibrillation: A systematic review and meta-analysis.](#)

Unprasert P, Srivali N, Kittanamongkolchai W.

Indian J Dermatol Venereol Leprol. 2016 Sep-Oct;82(5):489-97. doi: 10.4103/0378-6323.186480.

[Epicardial fat tissue in patients with psoriasis: A systematic review and meta-analysis.](#)

Wang X, Guo Z, Zhu Z, Bao Y, Yang B.

Lipids Health Dis. 2016 May 31;15:103. doi: 10.1186/s12944-016-0271-y.

[Association between psoriasis and subclinical atherosclerosis: A meta-analysis.](#)

Fang N, Jiang M, Fan Y.

Medicine (Baltimore). 2016 May;95(20):e3576. doi: 10.1097/MD.00000000000003576.

[The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis.](#)

Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B.

Ann Rheum Dis. 2015 Mar;74(3):480-9. doi: 10.1136/annrheumdis-2014-206624. Epub 2015 Jan 5.

[Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: Novel therapeutic insights coming from a meta-analysis of the literature data.](#)

De Vecchis R, Baldi C, Palmisani L.

Anatol J Cardiol. 2016 Jan;16(1):2-9. doi: 10.5152/akd.2015.6136.

[Ischemic cardiovascular involvement in psoriasis: A systematic review.](#)

Mosca S, Gargiulo P, Balato N, Di Costanzo L, Parente A, Paolillo S, Ayala F, Trimarco B, Crea F, Perrone-Filardi P.

Int J Cardiol. 2015 Jan 15;178:191-9. doi: 10.1016/j.ijcard.2014.10.092. Epub 2014 Oct 23.

[Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: A systematic review.](#)

Armstrong AW, Brezinski EA, Follansbee MR, Armstrong EJ.

Curr Pharm Des. 2014;20(4):500-12.

[Psoriasis and risk of venous thromboembolism: A systematic review and meta-analysis.](#)

Unprasert P, Sanguankeo A, Upala S, Suksaranjit P.

QJM. 2014 Oct;107(10):793-7. doi: 10.1093/qjmed/hcu073. Epub 2014 Apr 8.

[Psoriasis beyond the skin: A review of the literature on cardiometabolic and psychological co-morbidities of psoriasis.](#)

Puig L, Kirby B, Mallbris L, Strohal R.

Eur J Dermatol. 2014 May-Jun;24(3):305-11. doi: 10.1684/ejd.2014.2299.

[Subclinical cardiovascular disease in plaque psoriasis: Association or causal link?](#)

Shaharyar S, Warraich H, McEvoy JW, Oni E, Ali SS, Karim A, Jamal O, Blaha MJ, Blumenthal RS, Fialkow J, Cury R, Budoff MJ, Agatston AA, Nasir K.

Atherosclerosis. 2014 Jan;232(1):72-8. doi: 10.1016/j.atherosclerosis.2013.10.023. Epub 2013 Nov 1.

[Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors.](#)

Miller IM, Ellervik C, Yazdanyar S, Jemec GB.

J Am Acad Dermatol. 2013 Dec;69(6):1014-24. doi: 10.1016/j.jaad.2013.06.053.

[Quantifying cardiovascular disease risk factors in patients with psoriasis: A meta-analysis.](#)

Miller IM, Skaaby T, Ellervik C, Jemec GB.

Br J Dermatol. 2013 Dec;169(6):1180-7. doi: 10.1111/bjd.12490.

[Role of psoriasis as independent predictor of cardiovascular disease: A meta-regression analysis.](#)

Gaeta M, Castelveccchio S, Ricci C, Pigatto P, Pellissero G, Cappato R.

Int J Cardiol. 2013 Oct 3;168(3):2282-8. doi: 10.1016/j.ijcard.2013.01.197. Epub 2013 Mar 9.

[Incidence of cardiovascular disease in individuals with psoriasis: A systematic review and meta-analysis.](#)

Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH.

J Invest Dermatol. 2013 Oct;133(10):2340-6. doi: 10.1038/jid.2013.149. Epub 2013 Feb 21.

[Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: A systematic literature review.](#)

Horreau C, Pouplard C, Brenaut E, Barnette T, Misery L, Cribier B, Jullien D, Aractingi S, Aubin F, Joly P, Le Maître M, Ortonne JP, Paul C, Richard MA.

J Eur Acad Dermatol Venereol. 2013 Aug;27 Suppl 3:12-29. doi: 10.1111/jdv.12163.

[Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: A meta-analysis of randomized controlled trials.](#)

Tzellos T, Kyrgidis A, Zouboulis CC.

J Eur Acad Dermatol Venereol. 2013 May;27(5):622-7. doi: 10.1111/j.1468-3083.2012.04500.x. Epub 2012 Mar 8.

[Psoriasis and major adverse cardiovascular events: A systematic review and meta-analysis of observational studies.](#)

Armstrong EJ, Harskamp CT, Armstrong AW.

J Am Heart Assoc. 2013 Apr 4;2(2):e000062. doi: 10.1161/JAHA.113.000062.

[The association between psoriasis and hypertension: A systematic review and meta-analysis of observational studies.](#)

Armstrong AW, Harskamp CT, Armstrong EJ.

J Hypertens. 2013 Mar;31(3):433-42; discussion 442-3. doi: 10.1097/HJH.0b013e32835bcce1.

[Examining the risk of cardiovascular disease in patients with psoriasis: a critical review.](#)

Papp K, Poulin Y, Vieira A.

J Cutan Med Surg. 2013 Mar-Apr;17(2):89-105.

[Cardiovascular aspects of psoriasis: An updated review.](#)

Pietrzak A, Bartosińska J, Chodorowska G, Szepietowski JC, Paluszkiwicz P, Schwartz RA.

Int J Dermatol. 2013 Feb;52(2):153-62. doi: 10.1111/j.1365-4632.2012.05584.x.

[Association of psoriasis with stroke and myocardial infarction: Meta-analysis of cohort studies.](#)

Xu T, Zhang YH.

Br J Dermatol. 2012 Dec;167(6):1345-50. doi: 10.1111/bjd.12002. Epub 2012 Nov 20.

Co-morbidities – diabetes & metabolic syndrome

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.](#)

Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A.

J Am Acad Dermatol. 2019 Apr;80(4):1073-1113. doi: 10.1016/j.jaad.2018.11.058. Epub 2019 Feb 13.

[The association of metabolic syndrome and psoriasis: A systematic review and meta-analysis of observational study.](#)

Choudhary S, Pradhan D, Pandey A, Khan MK, Lall R, Ramesh V, Puri P, Jain AK, Thomas G.

Endocr Metab Immune Disord Drug Targets. 2019 Oct 8. doi:

10.2174/1871530319666191008170409. [Epub ahead of print]

[The association between psoriasis and diabetes mellitus: A systematic review and meta-analysis.](#)

Mamizadeh M, Tardeh Z, Azami M.

Diabetes Metab Syndr. 2019 Mar - Apr;13(2):1405-1412. doi: 10.1016/j.dsx.2019.01.009. Epub 2019 Jan 19.

[Psoriasis and metabolic and cardiovascular comorbidities in children: A systematic review.](#)

Badaoui A, Tounian P, Mahé E.

Arch Pediatr. 2019 Feb;26(2):86-94. doi: 10.1016/j.arcped.2018.12.005. Epub 2019 Jan 11.

[Serum leptin, resistin, and adiponectin concentrations in psoriasis: A meta-analysis of observational studies.](#)

Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG.

Dermatology. 2017;233(5):378-389. doi: 10.1159/000481882. Epub 2017 Dec 13.

[Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome.](#)

Rodríguez-Zúñiga MJM, García-Perdomo HA.

J Am Acad Dermatol. 2017 Oct;77(4):657-666.e8. doi: 10.1016/j.jaad.2017.04.1133.

[An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies.](#)

Singh S, Young P, Armstrong AW.

PLoS One. 2017 Jul 18;12(7):e0181039. doi: 10.1371/journal.pone.0181039. eCollection 2017.

[Association of psoriasis and metabolic syndrome in Latin America: A systematic review and meta-analysis.](#)

Rodríguez-Zúñiga MJM, Cortez-Franco F, Quijano-Gomero E.

Actas Dermosifiliogr. 2017 May;108(4):326-334. doi: 10.1016/j.ad.2016.11.009. Epub 2017 Jan 20. English, Spanish.

[Relationship between psoriasis and metabolic syndrome: A systematic review.](#)

Singh S, Young P, Armstrong AW.

G Ital Dermatol Venereol. 2016 Dec;151(6):663-677. Epub 2016 Sep 2.

Association between psoriasis and metabolic syndrome: A meta-analysis from 12 case control studies.

Jin J.-J. , Zeng S.-W.

Int J Clin Exp Med 2016;9(9):17933-17939.

<http://www.ijcem.com/files/ijcem0031209.pdf>

[Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: A systematic review and meta-analysis.](#)

Coto-Segura P, Eiris-Salvado N, González-Lara L, Queiro-Silva R, Martinez-Cambor P, Maldonado-Seral C, García-García B, Palacios-García L, Gomez-Bernal S, Santos-Juanes J, Coto E.

Br J Dermatol. 2013 Oct;169(4):783-93. doi: 10.1111/bjd.12473.

[Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies.](#)

Armstrong AW, Harskamp CT, Armstrong EJ.

J Am Acad Dermatol. 2013 Apr;68(4):654-62. doi: 10.1016/j.jaad.2012.08.015. Epub 2013 Jan 27.

[Psoriasis and the risk of diabetes mellitus: A systematic review and meta-analysis.](#)

Armstrong AW, Harskamp CT, Armstrong EJ.

JAMA Dermatol. 2013 Jan;149(1):84-91. doi: 10.1001/2013.jamadermatol.406.

[Psoriasis increased the risk of diabetes: A meta-analysis.](#)

Cheng J, Kuai D, Zhang L, Yang X, Qiu B.

Arch Dermatol Res. 2012 Mar;304(2):119-25. doi: 10.1007/s00403-011-1200-6. Epub 2012 Jan 1.

Co-morbidities – psychiatric and psychological/social well being

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.

Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A.

J Am Acad Dermatol. 2019 Apr;80(4):1073-1113. doi: 10.1016/j.jaad.2018.11.058. Epub 2019 Feb 13.

Emotions, alexithymia, and emotion regulation in patients with psoriasis.

Panasiti MS, Ponsi G, Violani C.

Front Psychol. 2020 May 19;11:836. doi: 10.3389/fpsyg.2020.00836. eCollection 2020.

Association between psoriasis and risk of dementia: a systematic review and meta-analysis.

Lam M, Khorvash R, Drucker AM.

J Am Acad Dermatol. 2020 May 21. pii: S0190-9622(20)30961-0. doi: 10.1016/j.jaad.2020.05.091.

[Epub ahead of print] No abstract available.

Is psoriasis associated with dementia or cognitive impairment? A Critically Appraised Topic.

Yen H, Yen H, Chi CC.

Br J Dermatol. 2020 Mar 11. doi: 10.1111/bjd.19025. [Epub ahead of print]

A systematic review of cognitive and behavioral treatments for individuals with psoriasis.

Sijercic I, Ennis N, Monson CM.

J Dermatolog Treat. 2019 Nov 7;1-26. doi: 10.1080/09546634.2019.1690625. [Epub ahead of print]

Patients with psoriasis have a higher risk of schizophrenia: A systematic review and meta-analysis of observational studies.

Ungprasert P, Wijarnpreecha K, Cheungpasitporn W.

J Postgrad Med. 2019 Jul-Sep;65(3):141-145. doi: 10.4103/jpgm.JPGM_253_18.

Association between psoriasis and sexual and erectile dysfunction in epidemiologic studies: A systematic review.

Molina-Leyva A, Salvador-Rodriguez L, Martinez-Lopez A, Ruiz-Carrascosa JC, Arias-Santiago S.

JAMA Dermatol. 2019 Jan 1;155(1):98-106. doi: 10.1001/jamadermatol.2018.3442.

Effects of psychosocial interventions on patient-reported outcomes in patients with psoriasis: A systematic review and meta-analysis.

Zill JM, Christalle E, Tillenburg N, Mrowietz U, Augustin M, Härter M, Dirmaier J.

Br J Dermatol. 2018 Oct 6. doi: 10.1111/bjd.17272. [Epub ahead of print]

[Associations between non-neurological autoimmune disorders and psychosis: A meta-analysis.](#)

Cullen AE, Holmes S, Pollak TA, Blackman G, Joyce DW, Kempton MJ, Murray RM, McGuire P, Mondelli V.
Biol Psychiatry. 2019 Jan 1;85(1):35-48. doi: 10.1016/j.biopsych.2018.06.016. Epub 2018 Jun 28.

[Analysis of the prevalence of mental disorders in psoriasis: The relevance of psychiatric assessment in dermatology.](#)

Ferreira BR, Pio-Abreu JL, Reis JP, Figueiredo A.
Psychiatr Danub. 2017 Dec;29(4):401-406. doi: 10.24869/psyd.2017.401.

[Patients with schizophrenia have a higher risk of psoriasis: A systematic review and meta-analysis.](#)

Ungprasert P, Wijarnpreecha K, Cheungpasitporn W.
Psychiatry Res. 2018 Jan;259:422-426. doi: 10.1016/j.psychres.2017.11.021. Epub 2017 Nov 7.

[Psoriasis and suicidality: A systematic review and meta-analysis.](#)

Singh S, Taylor C, Kornmehl H, Armstrong AW.
J Am Acad Dermatol. 2017 Sep;77(3):425-440.e2. doi: 10.1016/j.jaad.2017.05.019.

[The prevalence of anxiety in patients with psoriasis: A systematic review of observational studies and clinical trials.](#)

Fleming P, Bai JW, Pratt M, Sibbald C, Lynde C, Gulliver WP.
J Eur Acad Dermatol Venereol. 2017 May;31(5):798-807. doi: 10.1111/jdv.13891. Epub 2016 Sep 12.

[Risk of suicidality in people with psoriasis: A systematic review and meta-analysis of cohort studies.](#)

Chi CC, Chen TH, Wang SH, Tung TH.
Am J Clin Dermatol. 2017 Oct;18(5):621-627. doi: 10.1007/s40257-017-0281-1.

[Psoriasis and sleep disorders: A systematic review.](#)

Gupta MA, Simpson FC, Gupta AK.
Sleep Med Rev. 2016 Oct;29:63-75. doi: 10.1016/j.smrv.2015.09.003. Epub 2015 Sep 21.

[Measurement, classification and evaluation of sleep disturbance in psoriasis: A systematic review.](#)

Henry AL, Kyle SD, Bhandari S, Chisholm A, Griffiths CE, Bundy C.
PLoS One. 2016 Jun 21;11(6):e0157843. doi: 10.1371/journal.pone.0157843. eCollection 2016.

[Psoriasis and associated psychiatric disorders: A systematic review on etiopathogenesis and clinical correlation.](#)

Ferreira BI, Abreu JL, Reis JP, Figueiredo AM.
J Clin Aesthet Dermatol. 2016 Jun;9(6):36-43. Epub 2016 Jun 1.

[Tumour necrosis factor- \$\alpha\$ inhibitor therapy in chronic physical illness: A systematic review and meta-analysis of the effect on depression and anxiety.](#)

Abbott R, Whear R, Nikolaou V, Bethel A, Coon JT, Stein K, Dickens C.
J Psychosom Res. 2015 Sep;79(3):175-84. doi: 10.1016/j.jpsychores.2015.04.008. Epub 2015 Apr 23.

[Effect of biologics on depressive symptoms in patients with psoriasis: A systematic review.](#)

Fleming P, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Siu S, Kraft J, Lynde C, Pope JE, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B, Gulliver WP.
J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1063-70. doi: 10.1111/jdv.12909. Epub 2014 Dec 10.

[The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: A systematic review and meta-analysis.](#)

Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T.

J Invest Dermatol. 2014 Jun;134(6):1542-51. doi: 10.1038/jid.2013.508. Epub 2013 Nov 27.

[Psoriasis beyond the skin: A review of the literature on cardiometabolic and psychological co-morbidities of psoriasis.](#)

Puig L, Kirby B, Mallbris L, Strohal R.

Eur J Dermatol. 2014 May-Jun;24(3):305-11. doi: 10.1684/ejd.2014.2299.

Co-morbidities – other

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.](#)

Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A.

J Am Acad Dermatol. 2019 Apr;80(4):1073-1113. doi: 10.1016/j.jaad.2018.11.058. Epub 2019 Feb 13.

[Association of psoriasis with colorectal cancer: A systematic review and meta-analysis.](#)

Fu Y, Lee CH, Chi CC.

J Am Acad Dermatol. 2020 Sep 28:S0190-9622(20)32643-8. doi: 10.1016/j.jaad.2020.09.050. Online ahead of print.

[Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review.](#)

Conforti C, Dianzani C, Zalaudek I, Cicala M, Persichetti P, Giuffrida R, Morariu SH, Neagu N.

J Dermatolog Treat. 2020 Oct 22:1-8. doi: 10.1080/09546634.2020.1836313. Online ahead of print.

[Association between pemphigus and psoriasis: a systematic review and meta-analysis.](#)

Phan K, Ramachandran V, Smith SD.

Dermatol Online J. 2020 Aug 15;26(8):13030/qt5g78q4f4.

[The incidence and prevalence of uveitis in psoriasis: A systematic review and meta-analysis.](#)

Lam M, Steen J, Lu JD, Vender R.

J Cutan Med Surg. 2020 Aug 31:1203475420952420. doi: 10.1177/1203475420952420. Online ahead of print.

[Periodontitis in patients with psoriasis: a systematic review and meta-analysis.](#)

Zhang X, Gu H, Xie S, Su Y.

Oral Dis. 2020 Aug 27. doi: 10.1111/odi.13617. Online ahead of print.

[Male sexual health and reproduction in cutaneous immune-mediated diseases: A systematic review.](#)

Perez-Garcia Luis LF, Dolhain R, Te Winkel B, Carrizales JP, Bramer WM, Vorstenbosch S, van

Puijenbroek E, Hazes M, van Doorn MBA.

Sex Med Rev. 2020 Aug 31:S2050-0521(20)30074-3. doi: 10.1016/j.sxmr.2020.07.004. Online ahead of print.

[Psoriatic disease and body composition: A systematic review and narrative synthesis.](#)

Blake T, Gullick NJ, Hutchinson CE, Barber TM.

PLoS One. 2020 Aug 13;15(8):e0237598. doi: 10.1371/journal.pone.0237598. eCollection 2020.

[Psoriasis and risk of uveitis: A systematic review and meta-analysis.](#)

Chaiyabutr C, Ungprasert P, Silpa-Archa N, Wongpraparut C, Chularojanamontri L.

Biomed Res Int. 2020 Jul 15;2020:9308341. doi: 10.1155/2020/9308341. eCollection 2020.

[Association between psoriasis and risk of dementia: a systematic review and meta-analysis.](#)

Lam M, Khorvash R, Drucker AM.

J Am Acad Dermatol. 2020 May 21. pii: S0190-9622(20)30961-0. doi: 10.1016/j.jaad.2020.05.091.

[Epub ahead of print] No abstract available.

[Association between uveitis and psoriatic disease: a systematic review and meta-analysis based on the evidence from cohort studies.](#)

Li CR, Chen L, Wang LF, Yan B, Liang YL, Luo J.

Int J Ophthalmol. 2020 Apr 18;13(4):650-659. doi: 10.18240/ijo.2020.04.19. eCollection 2020.

[Association of hepatitis B virus infection and psoriasis: A meta-analysis.](#)

Arafa A, Mostafa A.

Australas J Dermatol. 2020 May 14. doi: 10.1111/ajd.13320. [Epub ahead of print] No abstract available.

[Bidirectional association between psoriasis and obstructive sleep apnea: A systematic review and meta-analysis.](#)

Ger TY, Fu Y, Chi CC.

Sci Rep. 2020 Apr 3;10(1):5931. doi: 10.1038/s41598-020-62834-x.

[Is psoriasis associated with dementia or cognitive impairment? A Critically Appraised Topic.](#)

Yen H, Yen H, Chi CC.

Br J Dermatol. 2020 Mar 11. doi: 10.1111/bjd.19025. [Epub ahead of print]

[Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.](#)

Vaengebjerg S, Skov L, Egeberg A, Loft ND.

JAMA Dermatol. 2020 Feb 19. doi: 10.1001/jamadermatol.2020.0024. [Epub ahead of print]

[Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review.](#)

Al-Janabi A, Foulkes AC, Mason K, Smith CH, Griffiths C, Warren RB.

J Eur Acad Dermatol Venereol. 2020 Jan 30. doi: 10.1111/jdv.16246. [Epub ahead of print]

[Risk of non-melanoma skin cancer in patients with psoriasis: An updated evidence from systematic review with meta-analysis.](#)

Wang X, Liu Q, Wu L, Nie Z, Mei Z.

J Cancer. 2020 Jan 1;11(5):1047-1055. doi: 10.7150/jca.37015. eCollection 2020.

[Risk of mycosis fungoides in psoriatic patients: A critical review.](#)

Giovanni B, Cerroni L, Brunasso AMG, Sola S, Cota C, Javor S, Massone C.

J Eur Acad Dermatol Venereol. 2019 Dec 19. doi: 10.1111/jdv.16160. [Epub ahead of print]

[Association between psoriasis and celiac disease: a systematic review and meta-analysis.](#)

Acharya P, Mathur M.

J Am Acad Dermatol. 2019 Dec 3. pii: S0190-9622(19)33131-7. doi: 10.1016/j.jaad.2019.11.039. [Epub ahead of print]

[Association of psoriasis with the risk of developing or dying of cancer: a systematic review and meta-analysis.](#)

Trafford AM, Parisi R, Kontopantelis E, Griffiths CEM, Ashcroft DM.

JAMA Dermatol. 2019 Oct 16. doi: 10.1001/jamadermatol.2019.3056. [Epub ahead of print]

[Psoriasis in family members of patients with multiple sclerosis.](#)

Charlton O, Phan K, Smith SD, Parratt J.

Mult Scler Relat Disord. 2019 Sep 30;36:101421. doi: 10.1016/j.msard.2019.101421. [Epub ahead of print]

[Psoriasis patients suffer from worse periodontal status - A meta-analysis.](#)

Qiao P, Shi Q, Zhang R, E L, Wang P, Wang J, Liu H.

Front Med (Lausanne). 2019 Oct 1;6:212. doi: 10.3389/fmed.2019.00212. eCollection 2019.

[Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease - A systematic review and meta-analysis.](#)

Alinaghi F, Tekin HG, Burisch J, Wu JJ, Thyssen JP, Egeberg A.

J Crohns Colitis. 2019 Aug 30. pii: jjz152. doi: 10.1093/ecco-jcc/jjz152. [Epub ahead of print]

[Relationship between psoriasis and non-alcoholic fatty liver disease - Updated systematic review and adjusted meta-analysis.](#)

Phan K, Onggo J, Charlton O, Smith SD.

Australas J Dermatol. 2019 Mar 24. doi: 10.1111/ajd.13015. [Epub ahead of print] No abstract available.

[Association between geographic tongue and psoriasis. A systematic review and meta-analyses.](#)

González-Álvarez L, García-Martín JM, García-Pola MJ.

J Oral Pathol Med. 2019 May;48(5):365-372. doi: 10.1111/jop.12840. Epub 2019 Feb 27.

[Psoriasis and metabolic and cardiovascular comorbidities in children: A systematic review.](#)

Badaoui A, Tounian P, Mahé E.

Arch Pediatr. 2019 Feb;26(2):86-94. doi: 10.1016/j.arcped.2018.12.005. Epub 2019 Jan 11.

[Increase risk of multiple sclerosis in patients with psoriasis disease: An evidence of observational studies.](#)

Islam MM, Poly TN, Yang HC, Wu CC, Li YJ.

Neuroepidemiology. 2019;52(3-4):152-160. doi: 10.1159/000495112. Epub 2019 Jan 22.

[All-cause and cause-specific mortality in psoriasis: a systematic review and meta-analysis.](#)

Dhana A, Yen H, Yen H, Cho E.

J Am Acad Dermatol. 2019 May;80(5):1332-1343. doi: 10.1016/j.jaad.2018.12.037. Epub 2018 Dec 24.

[High prevalence of erectile dysfunction in men with psoriasis: evidence from a systematic review and meta-analysis.](#)

Zhao S, Wang J, Xie Q, Liu Y, Luo L, Zhu Z, Li E, Zhao Z.

Int J Impot Res. 2019 Mar;31(2):74-84. doi: 10.1038/s41443-018-0093-8. Epub 2018 Nov 23.

[Association of psoriasis with inflammatory bowel disease: A systematic review and meta-analysis.](#)

Fu Y, Lee CH, Chi CC.

JAMA Dermatol. 2018 Dec 1;154(12):1417-1423. doi: 10.1001/jamadermatol.2018.3631.

[Special aspects of biologics treatment in psoriasis: Management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis.](#)

Plachouri KM, Georgiou S.

J Dermatolog Treat. 2019 Nov;30(7):668-673. doi: 10.1080/09546634.2018.1544413. Epub 2018 Dec 2.

[Association between psoriasis and sexual and erectile dysfunction in epidemiologic studies: A systematic review.](#)

Molina-Leyva A, Salvador-Rodriguez L, Martinez-Lopez A, Ruiz-Carrascosa JC, Arias-Santiago S.

JAMA Dermatol. 2019 Jan 1;155(1):98-106. doi: 10.1001/jamadermatol.2018.3442.

[Association of multiple sclerosis with psoriasis: A systematic review and meta-analysis of observational studies.](#)

Liu CY, Tung TH, Lee CY, Chang KH, Wang SH, Chi CC.

Am J Clin Dermatol. 2019 Apr;20(2):201-208. doi: 10.1007/s40257-018-0399-9.

[Association between psoriasis and vitiligo: A systematic review and meta-analysis.](#)

Yen H, Chi CC.

Am J Clin Dermatol. 2019 Feb;20(1):31-40. doi: 10.1007/s40257-018-0394-1.

[The coexistence of pemphigus and psoriasis: a systematic review and meta-analysis.](#)

Kridin K, Kridin M, Shalom G, Cohen AD.

Immunol Res. 2019 Feb;67(1):134-141. doi: 10.1007/s12026-018-9031-6.

[Association between bullous pemphigoid and psoriasis: Systematic review and meta-analysis of case-control studies.](#)

Phan K, Goyal S, Murrell DF.

Australas J Dermatol. 2019 Feb;60(1):23-28. doi: 10.1111/ajd.12899. Epub 2018 Aug 23.

[Geographic tongue: Predisposing factors, diagnosis and treatment. A systematic review.](#)

González-Álvarez L, García-Pola MJ, Garcia-Martin JM.

Rev Clin Esp. 2018 Dec;218(9):481-488. doi: 10.1016/j.rce.2018.05.006. Epub 2018 Jun 11. English, Spanish.

[Association between psoriasis and erectile dysfunction: A meta-analysis.](#)

Wu T, Duan X, Chen S, Chen X, Yu R, Yu X.

J Sex Med. 2018 Jun;15(6):839-847. doi: 10.1016/j.jsxm.2018.04.630. Epub 2018 May 4.

[\[Correlation of psoriasis with erectile dysfunction: A meta-analysis\].](#)

Zhang FB, Wu BC, Xie LB, Jiang R.

Zhonghua Nan Ke Xue. 2017 Mar;23(3):256-261. Chinese.

[Psoriasis and risk of incident chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis.](#)

Ungprasert P, Raksasuk S.

Int Urol Nephrol. 2018 Jul;50(7):1277-1283. doi: 10.1007/s11255-018-1868-z. Epub 2018 Apr 11.

[Association between psoriasis and asthma risk: A meta-analysis.](#)

Wang J, Ke R, Shi W, Yan X, Wang Q, Zhang Q, Chai L, Li M.

Allergy Asthma Proc. 2018 Mar 1;39(2):103-109. doi: 10.2500/aap.2018.39.4109.

[Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.](#)

Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, Merola JF, Ryan C, Siegel MP, Weinberg JM, Wu JJ, Van Voorhees AS.

J Am Acad Dermatol. 2018 Feb;78(2):383-394. doi: 10.1016/j.jaad.2017.06.043.

[Psoriasis in solid organ transplant patients: best practice recommendations from The Medical Board of the National Psoriasis Foundation.](#)

Prussick R, Wu JJ, Armstrong AW, Siegel MP, Van Voorhees AS.

J Dermatolog Treat. 2018 Jun;29(4):329-333. doi: 10.1080/09546634.2017.1373737. Epub 2017 Oct 24.

[Relative versus absolute risk of comorbidities in patients with psoriasis.](#)

Saleem MD, Kesty C, Feldman SR.

J Am Acad Dermatol. 2017 Mar;76(3):531-537. doi: 10.1016/j.jaad.2016.11.037. Epub 2016 Dec 13.

[Psoriasis and risk of celiac disease: A systematic review and meta-analysis.](#)

Ungprasert P, Wijarnpreecha K, Kittanamongkolchai W.

Indian J Dermatol. 2017 Jan-Feb;62(1):41-46. doi: 10.4103/0019-5154.198031.

[Association between psoriasis and chronic obstructive pulmonary disease: A systematic review and meta-analysis.](#)

Ungprasert P, Srivali N, Thongprayoon C.

J Dermatolog Treat. 2016 Aug;27(4):316-21. doi: 10.3109/09546634.2015.1107180. Epub 2015 Nov 18.

[Psoriasis and adverse pregnancy outcomes: A systematic review of observational studies.](#)

Bobotsis R, Gulliver WP, Monaghan K, Lynde C, Fleming P.

Br J Dermatol. 2016 Sep;175(3):464-72. doi: 10.1111/bjd.14547. Epub 2016 Jul 24.

[Association of serum uric acid levels in psoriasis: A systematic review and meta-analysis.](#)

Li X, Miao X, Wang H, Wang Y, Li F, Yang Q, Cui R, Li B.

Medicine (Baltimore). 2016 May;95(19):e3676. doi: 10.1097/MD.0000000000003676.

[Risk of Parkinson's disease among patients with psoriasis: A systematic review and meta-analysis.](#)

Ungprasert P, Srivali N, Kittanamongkolchai W.

Indian J Dermatol. 2016 Mar-Apr;61(2):152-6. doi: 10.4103/0019-5154.177771.

[Association between psoriasis and chronic obstructive pulmonary disease: A systematic review and meta-analysis.](#)

Li X, Kong L, Li F, Chen C, Xu R, Wang H, Peng S, Zhou M, Li B.

PLoS One. 2015 Dec 23;10(12):e0145221. doi: 10.1371/journal.pone.0145221. eCollection 2015.

[Family history of autoimmune diseases is associated with an increased risk of autism in children: A systematic review and meta-analysis.](#)

Wu S, Ding Y, Wu F, Li R, Xie G, Hou J, Mao P.

Neurosci Biobehav Rev. 2015 Aug;55:322-32. doi: 10.1016/j.neubiorev.2015.05.004. Epub 2015 May 15.

[Risk of non-alcoholic fatty liver disease in patients with psoriasis: A systematic review and meta-analysis.](#)

Candia R, Ruiz A, Torres-Robles R, Chávez-Tapia N, Méndez-Sánchez N, Arrese M.

J Eur Acad Dermatol Venereol. 2015 Apr;29(4):656-62. doi: 10.1111/jdv.12847. Epub 2014 Nov 21

[Sexual dysfunction in psoriasis: A systematic review.](#)

Molina-Leyva A, Jiménez-Moleón JJ, Naranjo-Sintes R, Ruiz-Carrascosa JC.

J Eur Acad Dermatol Venereol. 2015 Apr;29(4):649-55. doi: 10.1111/jdv.12845. Epub 2014 Nov 26.

[Diet and psoriasis, part II: celiac disease and role of a gluten-free diet.](#)

Bhatia BK, Millsop JW, Debbaneh M, Koo J, Linos E, Liao W.

J Am Acad Dermatol. 2014 Aug;71(2):350-8. doi: 10.1016/j.jaad.2014.03.017. Epub 2014 Apr 26.

[Risk of cancer in psoriasis: A systematic review and meta-analysis of epidemiological studies.](#)

Poupard C, Brenaut E, Horreau C, Barnette T, Misery L, Richard MA, Aractingi S, Aubin F, Cribier B, Joly P, Jullien D, Le Maître M, Ortonne JP, Paul C.

J Eur Acad Dermatol Venereol. 2013 Aug;27 Suppl 3:36-46. doi: 10.1111/jdv.12165.

[The association between psoriasis and dyslipidaemia: A systematic review.](#)

Ma C, Harskamp CT, Armstrong EJ, Armstrong AW.

Br J Dermatol. 2013 Mar;168(3):486-95. doi: 10.1111/bjd.12101. Epub 2013 Jan 18.

[The association between psoriasis and obesity: A systematic review and meta-analysis of observational studies.](#)

Armstrong AW, Harskamp CT, Armstrong EJ.

Nutr Diabetes. 2012 Dec 3;2:e54. doi: 10.1038/nutd.2012.26.

[Sexual dysfunction in patients with psoriasis and psoriatic arthritis--a systematic review.](#)

Kurizky PS, Mota LM.

Rev Bras Reumatol. 2012 Dec;52(6):943-8. Review. English, Portuguese.

[The coexistence of psoriasis and vitiligo: A review.](#)

Sawchuk M, Spano F, Loo WJ, Guenther L.

J Cutan Med Surg. 2012 Sep-Oct;16(5):300-5.

Diagnosis & evaluation

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Psoriasis severity: Commonly used clinical thresholds may not adequately convey patient impact.](#)

Golbari NM, van der Walt JM, Blauvelt A, Ryan C, van de Kerkhof P, Kimball AB.

J Eur Acad Dermatol Venereol. 2020 Sep 25. doi: 10.1111/jdv.16966. Online ahead of print.

[Associations between the neutrophil-to-lymphocyte and the platelet-to-lymphocyte ratios and the presence and severity of psoriasis: a systematic review and meta-analysis.](#)

Paliogiannis P, Satta R, Deligia G, Farina G, Bassu S, Mangoni AA, Carru C, Zinellu A.
Clin Exp Med. 2019 Feb;19(1):37-45. doi: 10.1007/s10238-018-0538-x. Epub 2018 Nov 26.

[Dermoscopic features of psoriasis of the skin, scalp and nails - A systematic review.](#)

Golińska J, Sar-Pomian M, Rudnicka L.
J Eur Acad Dermatol Venereol. 2019 Apr;33(4):648-660. doi: 10.1111/jdv.15344.

[Dermoscopy in the diagnosis of inflammatory dermatoses: Systematic review findings reported for psoriasis, lupus, and lichen planus.](#)

Cook LC, Hanna C, Foulke GT, Seiverling EV.
J Clin Aesthet Dermatol. 2018 Apr;11(4):41-42. Epub 2018 Apr 1.

[Scaly pink patches: differentiating psoriasis from basal cell carcinoma.](#)

Hanna C, Cook L, Foulke G, Seiverling EV.
Cutis. 2018 Jan;101(1):44-46.

[A systematic review of diagnostic criteria for psoriasis in adults and children: Evidence from studies with a primary aim to develop or validate diagnostic criteria.](#)

Burden-Teh E, Phillips RC, Thomas KS, Ratib S, Grindlay D, Murphy R.
Br J Dermatol. 2018 May;178(5):1035-1043. doi: 10.1111/bjd.16104. Epub 2018 Mar 6.

[Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: A systematic literature review.](#)

Zabotti A, Bandinelli F, Batticciotto A, Scirè CA, Iagnocco A, Sakellariou G; Musculoskeletal Ultrasound Study Group of the Italian Society of Rheumatology.
Rheumatology (Oxford). 2017 Sep 1;56(9):1518-1532. doi: 10.1093/rheumatology/kex179.

[A four-phase strategy for the implementation of reflectance confocal microscopy in dermatology.](#)

Hoogedoorn L, Gerritsen MJ, Wolberink EA, Peppelman M, van de Kerkhof PC, van Erp PE.
J Eur Acad Dermatol Venereol. 2016 Aug;30(8):1308-14. doi: 10.1111/jdv.13627. Epub 2016 Apr 2.

[Effects of narrow band ultraviolet B on serum levels of vascular endothelial growth factor and interleukin-8 in patients with psoriasis.](#)

Chen HQ, Li X, Tang R.
Am J Ther. 2016 May-Jun;23(3):e655-62. doi: 10.1097/MJT.0000000000000330.

[The value of in vivo reflectance confocal microscopy in the diagnosis and monitoring of inflammatory and infectious skin diseases: a systematic review.](#)

Hoogedoorn L, Peppelman M, van de Kerkhof PC, van Erp PE, Gerritsen MJ.
Br J Dermatol. 2015;172(5):1222-48. doi: 10.1111/bjd.13499. Epub 2015 Mar 19.

[Markers of systemic inflammation in psoriasis: A systematic review and meta-analysis.](#)

Dowlatshahi EA, van der Voort EA, Arends LR, Nijsten T.
Br J Dermatol. 2013 Aug;169(2):266-82. doi: 10.1111/bjd.12355.

Outcome measures

[Psoriasis severity: Commonly used clinical thresholds may not adequately convey patient impact.](#)

Golbari NM, van der Walt JM, Blauvelt A, Ryan C, van de Kerkhof P, Kimball AB.

J Eur Acad Dermatol Venereol. 2020 Sep 25. doi: 10.1111/jdv.16966. Online ahead of print.

[Is clear always clear? Comparison of Psoriasis Area and Severity Index \(PASI\) and the Physician's Global Assessment \(PGA\) in psoriasis clearance.](#)

Wu AG, Conway J, Barazani L, Roy B, Cline A, Pereira F.

Dermatol Ther (Heidelb). 2020 Aug 17. doi: 10.1007/s13555-020-00435-2. Online ahead of print.

[Health state utility values derived from EQ-5D in psoriatic patients: A systematic review and meta-analysis.](#)

Yang Z, Li S, Wang X, Chen G.

J Dermatolog Treat. 2020 Jul 27:1-27. doi: 10.1080/09546634.2020.1800571. Online ahead of print.

[Definition of minimal disease activity in psoriasis.](#)

Carretero G, Carrascosa JM, Puig L, Sánchez-Carazo JL, López-Ferrer A, de la Cueva P, Soria C, Rivera R, Belinchón I; Psoriasis Group of the Spanish Academy of Dermatology and Venereology.

J Eur Acad Dermatol Venereol. 2020 May 4. doi: 10.1111/jdv.16564. [Epub ahead of print]

[Investigator and patient global assessment measures for psoriasis clinical trials: A systematic review on measurement properties from the International Dermatology Outcome Measures \(IDEOM\) Initiative.](#)

Perez-Chada LM, Salame NF, Ford AR, Duffin KC, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong AW.

Am J Clin Dermatol. 2020 Jan 16. doi: 10.1007/s40257-019-00496-w. [Epub ahead of print]

[\[Severity scores for childhood psoriasis: A systematic literature review\].](#)

Lavaud J, Mahé E.

Ann Dermatol Venereol. 2019 May 4. pii: S0151-9638(19)30158-9. doi:

10.1016/j.annder.2019.03.007. [Epub ahead of print] **French.**

[Patient-reported outcomes assessment tools for use in psoriasis in Spain: A systematic review.](#)

Lizán L, Gabás-Rivera C, Belinchón I, Dilla T, Huete T, Díaz S.

Actas Dermosifiliogr. 2019 May 13. pii: S0001-7310(19)30121-8. doi: 10.1016/j.ad.2019.02.009.

[Epub ahead of print] English, Spanish.

[Effectiveness end points in real-world studies on biological therapies in psoriasis: Systematic review with focus on drug survival.](#)

Costanzo A, Malara G, Pelucchi C, Fatiga F, Barbera G, Franchi A, Galeone C.

Dermatology. 2018;234(1-2):1-12. doi: 10.1159/000488586. Epub 2018 May 15.

[Reporting of outcomes in randomised controlled trials on nail psoriasis; a systematic review.](#)

Busard CIM, Nolte JYC, Pasch MC, Spuls PI.

Br J Dermatol. 2018 Mar;178(3):640-649. doi: 10.1111/bjd.15831. Epub 2018 Feb 14.

[Measuring the impact of dermatological conditions on family and caregivers: A review of dermatology-specific instruments.](#)

Sampogna F, Finlay AY, Salek SS, Chernyshov P, Dalgard FJ, Evers AWM, Linder D, Manolache L, Marron SE, Poot F, Spillekom-van Koulil S, Svensson Å, Szepietowski JC, Tomas-Aragones L, Abeni D; European Academy of Dermatology and Venereology TaskForce on Quality of Life. J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1429-1439. doi: 10.1111/jdv.14288. Epub 2017 May 19.

[A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis.](#)

Ali FM, Cueva AC, Vyas J, Atwan AA, Salek MS, Finlay AY, Piguet V. Br J Dermatol. 2017 Mar;176(3):577-593. doi: 10.1111/bjd.14788. Epub 2016 Oct 12.

[EQ-5D in skin conditions: An assessment of validity and responsiveness.](#)

Yang Y, Brazier J, Longworth L. Eur J Health Econ. 2015 Dec;16(9):927-39. doi: 10.1007/s10198-014-0638-9. Epub 2014 Oct 31.

[Patient-reported outcome measures in psoriasis: The good, the bad and the missing!](#)

Kitchen H, Cordingley L, Young H, Griffiths CE, Bundy C. Br J Dermatol. 2015;172(5):1210-21. doi: 10.1111/bjd.13691. Epub 2015 Apr 12.

[Patient-reported functional health and well-being outcomes with drug therapy: A systematic review of randomized trials using the SF-36 health survey.](#)

Frendl DM, Ware JE Jr. Med Care. 2014 May;52(5):439-45. doi: 10.1097/MLR.00000000000010311.

[Psoriasis Area Severity Index \(PASI\) and the Dermatology Life Quality Index \(DLQI\): The correlation between disease severity and psychological burden in patients treated with biological therapies.](#)

Mattei PL, Corey KC, Kimball AB. J Eur Acad Dermatol Venereol. 2014 Mar;28(3):333-7. doi: 10.1111/jdv.12106. Epub 2013 Feb 21.

[Physician Global Assessment \(PGA\) and Psoriasis Area and Severity Index \(PASI\): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.](#)

Robinson A, Kardos M, Kimball AB. J Am Acad Dermatol. 2012 Mar;66(3):369-75. doi: 10.1016/j.jaad.2011.01.022. Epub 2011 Oct 29.

Disease impact & quality of life

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.](#)

Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A. J Am Acad Dermatol. 2019 Apr;80(4):1073-1113. doi: 10.1016/j.jaad.2018.11.058. Epub 2019 Feb 13.

[Male sexual health and reproduction in cutaneous immune-mediated diseases: A systematic review.](#)

Perez-Garcia Luis LF, Dolhain R, Te Winkel B, Carrizales JP, Bramer WM, Vorstenbosch S, van Puijenbroek E, Hazes M, van Doorn MBA. Sex Med Rev. 2020 Aug 31:S2050-0521(20)30074-3. doi: 10.1016/j.sxmr.2020.07.004. Online ahead of print.

[Health state utility values derived from EQ-5D in psoriatic patients: A systematic review and meta-analysis.](#)

Yang Z, Li S, Wang X, Chen G.

J Dermatolog Treat. 2020 Jul 27;1-27. doi: 10.1080/09546634.2020.1800571. Online ahead of print.

[Emotions, alexithymia, and emotion regulation in patients with psoriasis.](#)

Panasiti MS, Ponsi G, Violani C.

Front Psychol. 2020 May 19;11:836. doi: 10.3389/fpsyg.2020.00836. eCollection 2020.

[Patient-physician discrepancy in the perception of immune-mediated inflammatory diseases: rheumatoid arthritis, psoriatic arthritis and psoriasis. A qualitative systematic review of the literature.](#)

Sacristán JA, Dilla T, Díaz-Cerezo S, Gabás-Rivera C, Aceituno S, Lizán L.

PLoS One. 2020 Jun 17;15(6):e0234705. doi: 10.1371/journal.pone.0234705. eCollection 2020.

[Psoriasis patients suffer from worse periodontal status - A meta-analysis.](#)

Qiao P, Shi Q, Zhang R, E L, Wang P, Wang J, Liu H.

Front Med (Lausanne). 2019 Oct 1;6:212. doi: 10.3389/fmed.2019.00212. eCollection 2019.

[Patients' perspectives and experience of psoriasis and psoriatic arthritis: a systematic review and thematic synthesis of qualitative studies.](#)

Sumpton D, Kelly A, Tunnicliffe DJ, Craig JC, Hassett G, Chessman D, Tong A.

Arthritis Care Res (Hoboken). 2019 Mar 30. doi: 10.1002/acr.23896. [Epub ahead of print]

[All-cause and cause-specific mortality in psoriasis: a systematic review and meta-analysis.](#)

Dhana A, Yen H, Yen H, Cho E.

J Am Acad Dermatol. 2019 May;80(5):1332-1343. doi: 10.1016/j.jaad.2018.12.037. Epub 2018 Dec 24.

[Association between physical activity and risk of prevalent psoriasis: A MOOSE-compliant meta-analysis.](#)

Zheng Q, Sun XY, Miao X, Xu R, Ma T, Zhang YN, Li HJ, Li B, Li X.

Medicine (Baltimore). 2018 Jul;97(27):e11394. doi: 10.1097/MD.00000000000011394.

[Association between psoriasis and erectile dysfunction: A meta-analysis.](#)

Wu T, Duan X, Chen S, Chen X, Yu R, Yu X.

J Sex Med. 2018 Jun;15(6):839-847. doi: 10.1016/j.jsxm.2018.04.630. Epub 2018 May 4.

[\[Correlation of psoriasis with erectile dysfunction: A meta-analysis\].](#)

Zhang FB, Wu BC, Xie LB, Jiang R.

Zhonghua Nan Ke Xue. 2017 Mar;23(3):256-261. Chinese.

[Do psoriasis patients engage in vigorous physical activity?](#)

Amin M, Lee EB, Bhutani T, Wu JJ.

Cutis. 2018 Mar;101(3):198-200.

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Théréné C, Brenaut E, Barnette T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[Psoriasis in Latin America and the Caribbean: A systematic review.](#)

Hernández-Vásquez A, Molinari L, Larrea N, Ciapponi A.

J Eur Acad Dermatol Venereol. 2017 Dec;31(12):1991-1998. doi: 10.1111/jdv.14393. Epub 2017 Jul 12.

[Global skin disease morbidity and mortality: An update from the Global Burden of Disease Study 2013.](#)

Karimkhani C, Dellavalle RP, Coffeng LE, Flohr C, Hay RJ, Langan SM, Nsoesie EO, Ferrari AJ, Erskine HE, Silverberg JI, Vos T, Naghavi M.

JAMA Dermatol. 2017 May 1;153(5):406-412. doi: 10.1001/jamadermatol.2016.5538.

[Itch intensity in moderate-to-severe plaque psoriasis versus atopic dermatitis: A meta-analysis.](#)

Shahwan KT, Kimball AB.

J Am Acad Dermatol. 2017 Jun;76(6):1198-1200.e1. doi: 10.1016/j.jaad.2017.02.002.

[Health-related quality of life in children and adolescents with psoriasis: A systematic review and meta-analysis.](#)

Randa H, Todberg T, Skov L, Larsen LS, Zachariae R.

Acta Derm Venereol. 2017 May 8;97(5):555-563. doi: 10.2340/00015555-2600.

[Measuring the impact of dermatological conditions on family and caregivers: A review of dermatology-specific instruments.](#)

Sampogna F, Finlay AY, Salek SS, Chernyshov P, Dalgard FJ, Evers AWM, Linder D, Manolache L, Marron SE, Poot F, Spillekom-van Koulil S, Svensson Å, Szepietowski JC, Tomas-Aragones L, Abeni D; European Academy of Dermatology and Venereology TaskForce on Quality of Life.

J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1429-1439. doi: 10.1111/jdv.14288. Epub 2017 May 19.

[A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis.](#)

Ali FM, Cueva AC, Vyas J, Atwan AA, Salek MS, Finlay AY, Piguet V.

Br J Dermatol. 2017 Mar;176(3):577-593. doi: 10.1111/bjd.14788. Epub 2016 Oct 12.

[Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: A systematic review and meta-analysis.](#)

Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS.

J Eur Acad Dermatol Venereol. 2017 Feb;31(2):213-220. doi: 10.1111/jdv.14007. Epub 2016 Oct 28.

[Systematic review of health-related quality of life in adolescents with psoriasis.](#)

Gonzalez J, Cunningham K, Perlmutter J, Gottlieb A.

Dermatology. 2016;232(5):541-549. doi: 10.1159/000450826. Epub 2016 Nov 4.

[Health-related quality of life in patients with psoriasis: A systematic review of the European literature.](#)

Obradors M, Blanch C, Comellas M, Figueras M, Lizan L.

Qual Life Res. 2016 Nov;25(11):2739-2754. Epub 2016 Jun 3.

[Quality of life impact of childhood skin conditions measured using the Children's Dermatology Life Quality Index \(CDLQI\): A meta-analysis.](#)

Olsen JR, Gallacher J, Finlay AY, Piguet V, Francis NA.

Br J Dermatol. 2016 Apr;174(4):853-61. doi: 10.1111/bjd.14361. Epub 2016 Mar 6.

[EQ-5D in skin conditions: An assessment of validity and responsiveness.](#)

Yang Y, Brazier J, Longworth L.

Eur J Health Econ. 2015 Dec;16(9):927-39. doi: 10.1007/s10198-014-0638-9. Epub 2014 Oct 31.

[A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values.](#)

Møller AH, Erntoft S, Vinding GR, Jemec GB.

Patient Relat Outcome Meas. 2015 Jul 7;6:167-77. doi: 10.2147/PROM.S81428. eCollection 2015.

[Effect of the psoriasis on the health-related quality of life: Meta-analyses 2003-2013]

Cardona-Arias JA, Franco-Aguirre JQ.

Revista Argentina de Dermatologia 2014;95(2). Spanish.

http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S1851-300X2014000200002

[The global burden of skin disease in 2010: An analysis of the prevalence and impact of skin conditions.](#)

Hay RJ, Johns NE, Williams HC, Bolliger IW, Dellavalle RP, Margolis DJ, Marks R, Naldi L, Weinstock MA, Wulf SK, Michaud C, J L Murray C, Naghavi M.

J Invest Dermatol. 2014 Jun;134(6):1527-34. doi: 10.1038/jid.2013.446. Epub 2013 Oct 28.

[Psoriasis Area Severity Index \(PASI\) and the Dermatology Life Quality Index \(DLQI\): The correlation between disease severity and psychological burden in patients treated with biological therapies.](#)

Mattei PL, Corey KC, Kimball AB.

J Eur Acad Dermatol Venereol. 2014 Mar;28(3):333-7. doi: 10.1111/jdv.12106. Epub 2013 Feb 21.

[Impact of TNF- \$\alpha\$ antagonists on the quality of life in selected skin diseases.](#)

Gisoni P, Girolomoni G.

G Ital Dermatol Venereol. 2013 Jun;148(3):243-8.

Economic burden

[The cost of psoriasis and psoriatic arthritis in 5 European countries: A systematic review.](#)

Burgos-Pol R, Martínez-Sesmero JM, Ventura-Cerdá JM, Elías I, Caloto MT, Casado MÁ.

Actas Dermosifiliogr. 2016 Sep;107(7):577-90. doi: 10.1016/j.ad.2016.04.018. Epub 2016 Jun 15.

English, Spanish.

[Economic burden of psoriasis in the United States: A systematic review.](#)

Brezinski EA, Dhillon JS, Armstrong AW.

JAMA Dermatol. 2015 Jun;151(6):651-8. doi: 10.1001/jamadermatol.2014.3593

[Evaluating the economic burden of psoriasis in the United States.](#)

Vanderpuye-Orgle J, Zhao Y, Lu J, Shrestha A, Sexton A, Seabury S, Lebwohl M.

J Am Acad Dermatol. 2015 Jun;72(6):961-7.e5. doi: 10.1016/j.jaad.2015.02.1099. Epub 2015 Apr 14.

[The economic burden of psoriasis: A systematic literature review.](#)

Feldman SR, Burudpakdee C, Gala S, Nanavaty M, Mallya UG.

Expert Rev Pharmacoecon Outcomes Res. 2014 Oct;14(5):685-705. doi:

10.1586/14737167.2014.933671. Epub 2014 Jul 23.

Service delivery

[Patients with specific skin disorders who are affected by COVID-19: what do experiences say about management strategies? : A systematic review.](#)

Najar Nobar N, Goodarzi A.

Dermatol Ther. 2020 Jun 18:e13867. doi: 10.1111/dth.13867. [Epub ahead of print]

[Telemedicine approach for psoriasis management, time for application? A systematic review of published studies.](#)

Dahy A, El-Qushayri AE, Mahmoud AR, Al-Kelany TA, Salman S.

Dermatol Ther. 2020 Jun 27:e13908. doi: 10.1111/dth.13908. [Epub ahead of print]

[Patient-initiated appointment systems for adults with chronic conditions in secondary care.](#)

Whear R, Thompson-Coon J, Rogers M, Abbott RA, Anderson L, Ukoumunne O, Matthews J, Goodwin VA, Briscoe S, Perry M, Stein K.

Cochrane Database Syst Rev. 2020 Apr 9;4:CD010763. doi: 10.1002/14651858.CD010763.pub2.

[Shared decision making in psoriasis: A systematic review of quantitative and qualitative studies.](#)

Larsen MH, Hagen KB, Krogstad AL, Wahl AK.

Am J Clin Dermatol. 2019 Feb;20(1):13-29. doi: 10.1007/s40257-018-0390-5.

[Multidisciplinary dermatology-rheumatology management for patients with moderate-to-severe psoriasis and psoriatic arthritis: a systematic review.](#)

Cobo-Ibáñez T, Villaverde V, Seoane-Mato D, Muñoz-Fernández S, Guerra M, Del Campo PD, Cañete JD.

Rheumatol Int. 2016 Feb;36(2):221-9. doi: 10.1007/s00296-015-3377-z. Epub 2015 Oct 5.

Research methodology

[Placebo response in phase 3 trials of systemic therapies for moderate-to-severe plaque psoriasis: A systematic review and meta-analysis.](#)

Ambikaibalan D, Quaade AS, Halling AS, Thyssen JP, Egeberg A.

Dermatology. 2020 Sep 7:1-8. doi: 10.1159/000509295. Online ahead of print.

[Is clear always clear? Comparison of Psoriasis Area and Severity Index \(PASI\) and the Physician's Global Assessment \(PGA\) in psoriasis clearance.](#)

Wu AG, Conway J, Barazani L, Roy B, Cline A, Pereira F.

Dermatol Ther (Heidelb). 2020 Aug 17. doi: 10.1007/s13555-020-00435-2. Online ahead of print.

[Patient characteristics as effect modifiers for psoriasis biologic treatment response: an assessment using network meta-analysis subgroups.](#)

Wade R, Sharif-Hurst S, Dias S.

Syst Rev. 2020 Jun 5;9(1):132. doi: 10.1186/s13643-020-01395-6.

[Meta-analysis results do not reflect the real safety of biologics in psoriasis.](#)

Afach S, Chaimani A, Evrenoglou T, Pensio L, Brouste E, Sbidian É, Le Cleach L.

Br J Dermatol. 2020 May 23. doi: 10.1111/bjd.19244. [Epub ahead of print]

[Measurement properties of instruments assessing psoriatic arthritis symptoms for psoriasis clinical trials: a systematic literature review.](#)

Perez-Chada LM, Balak D, Cohen JM, Ogdie A, Merola JF, Gottlieb AB.

Expert Rev Clin Immunol. 2020 Feb 8;1-17. doi: 10.1080/1744666X.2020.1724090. [Epub ahead of print]

[Representation of older adults in randomized controlled trials on systemic treatment in plaque psoriasis: A systematic review.](#)

Schaap MJ, van Winden MEC, Seyger MMB, de Jong EMGJ, Lubeek SFK.

J Am Acad Dermatol. 2019 Jul 29. pii: S0190-9622(19)32472-7. doi: 10.1016/j.jaad.2019.07.079. [Epub ahead of print]

[Effectiveness end points in real-world studies on biological therapies in psoriasis: Systematic review with focus on drug survival.](#)

Costanzo A, Malara G, Pelucchi C, Fatiga F, Barbera G, Franchi A, Galeone C.

Dermatology. 2018;234(1-2):1-12. doi: 10.1159/000488586. Epub 2018 May 15.

[Head-to-head trials of systemic psoriasis therapies: A systematic review of study design and maximum acceptable treatment differences.](#)

Wan MT, Alvarez J, Shin DB, Dommasch ED, Wu JJ, Gelfand JM.

J Eur Acad Dermatol Venereol. 2019 Jan;33(1):42-55. doi: 10.1111/jdv.15174. Epub 2018 Aug 5.

[Most systematic reviews of high methodological quality on psoriasis interventions are classified as high risk of bias using ROBIS tool.](#)

Gómez-García F, Ruano J, Gay-Mimbrera J, Aguilar-Luque M, Sanz-Cabanillas JL, Alcalde-Mellado P, Maestre-López B, Carmona-Fernández PJ, González-Padilla M, García-Nieto AV, Isla-Tejera B.

J Clin Epidemiol. 2017 Dec;92:79-88. doi: 10.1016/j.jclinepi.2017.08.015. Epub 2017 Sep 9.

[Author-paper affiliation network architecture influences the methodological quality of systematic reviews and meta-analyses of psoriasis.](#)

Sanz-Cabanillas JL, Ruano J, Gomez-Garcia F, Alcalde-Mellado P, Gay-Mimbrera J, Aguilar-Luque M, Maestre-Lopez B, Gonzalez-Padilla M, Carmona-Fernandez PJ, Velez Garcia-Nieto A, Isla-Tejera B.

PLoS One. 2017 Apr 12;12(4):e0175419. doi: 10.1371/journal.pone.0175419. eCollection 2017.

[Systematic reviews and meta-analyses on psoriasis: Role of funding sources, conflict of interest and bibliometric indices as predictors of methodological quality.](#)

Gómez-García F, Ruano J, Aguilar-Luque M, Gay-Mimbrera J, Maestre-Lopez B, Sanz-Cabanillas JL, Carmona-Fernández PJ, González-Padilla M, Vélez García-Nieto A, Isla-Tejera B.

Br J Dermatol. 2017 Jun;176(6):1633-1644. doi: 10.1111/bjd.15380. Epub 2017 May 19.

[Psoriasis registries worldwide: Systematic overview on registry publications.](#)

Eissing L, Rustenbach SJ, Krenselt M, Zander N, Spehr C, Radtke MA, Naldi L, Augustin M.

J Eur Acad Dermatol Venereol. 2016 Jul;30(7):1100-6. doi: 10.1111/jdv.13634. Epub 2016 May 2

[Placebo effects on itch: A meta-analysis of clinical trials of patients with dermatological conditions.](#)

van Laarhoven AI, van der Sman-Mauriks IM, Donders AR, Pronk MC, van de Kerkhof PC, Evers AW.

J Invest Dermatol. 2015 May;135(5):1234-43. doi: 10.1038/jid.2014.522. Epub 2014 Dec 1.

[Placebo response in relation to clinical trial design: A systematic review and meta-analysis of randomized controlled trials for determining biologic efficacy in psoriasis treatment.](#)

Lamel SA, Myer KA, Younes N, Zhou JA, Maibach H, Maibach HI.

Arch Dermatol Res. 2012 Nov;304(9):707-17. doi: 10.1007/s00403-012-1266-9. Epub 2012 Jul 29.

[Physician Global Assessment \(PGA\) and Psoriasis Area and Severity Index \(PASI\): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.](#)

Robinson A, Kardos M, Kimball AB.

J Am Acad Dermatol. 2012 Mar;66(3):369-75. doi: 10.1016/j.jaad.2011.01.022. Epub 2011 Oct 29.

Paediatric psoriasis

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

[Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.](#)

Menter A, Cordoro KM, Davis DMR, *et al.*

J Am Acad Dermatol. 2019 Oct 24. pii: S0190-9622(19)32655-6. doi: 10.1016/j.jaad.2019.08.049.
[Epub ahead of print]

[Use of narrowband ultraviolet B \(NBUVB\) in paediatric psoriasis: A systematic literature review and meta-analysis.](#)

Kim E, Lee G, Fischer G.

Australas J Dermatol. 2020 Oct 18. doi: 10.1111/ajd.13471. Online ahead of print.

[FDA approved biologics: Can etanercept and ustekinumab be considered a first-line systemic therapy for pediatric/adolescents in moderate to severe psoriasis? A systematic review.](#)

Aslam N, Saleem H, Murtazaliev S, Quazi SJ, Khan S.

Cureus. 2020 Aug 17;12(8):e9812. doi: 10.7759/cureus.9812.

[Pediatric psoriasis and association with cardiovascular and metabolic comorbidities: Systematic review and meta-analysis.](#)

Phan K, Lee G, Fischer G.

Pediatr Dermatol. 2020 May 20. doi: 10.1111/pde.14208. [Epub ahead of print]

[The efficacy and evidence-based use of biologics in children and adolescents.](#)

Niehues T, Özgür TT.

Dtsch Arztebl Int. 2019 Oct 18;116(42):703-710. doi: 10.3238/arztebl.2019.0703.

[\[Severity scores for childhood psoriasis: A systematic literature review\].](#)

Lavaud J, Mahé E.

Ann Dermatol Venereol. 2019 May 4. pii: S0151-9638(19)30158-9. doi: 10.1016/j.annder.2019.03.007. [Epub ahead of print] **French.**

[Challenges in the treatment of psoriasis with biologics: vaccination, history of malignancy, human immunodeficiency virus \(HIV\) infection, and pediatric psoriasis.](#)

Plachouri KM, Georgiou S.

Int J Dermatol. 2019 Sep;58(9):1008-1013. doi: 10.1111/ijd.14436. Epub 2019 Mar 19.

[Psoriasis and metabolic and cardiovascular comorbidities in children: A systematic review.](#)

Badaoui A, Tounian P, Mahé E.

Arch Pediatr. 2019 Feb;26(2):86-94. doi: 10.1016/j.arcped.2018.12.005. Epub 2019 Jan 11.

[Tongue psoriasis: Clinical aspects and analysis of epidemiological associations in 313 children, with a systematic literature review.](#)

Pourchot D, Chiaverini C, Bourrat E, Barbarot S, Vabres P, Hubiche T, Droicourt C, Piram M, Kupfer-Bessaguet I, Ferneiny M, Puzeat E, Balguérie X, Beauchet A, Bursztejn AC, Mahé E; Groupe de recherche de la Société française de dermatologie pédiatrique.

Ann Dermatol Venereol. 2018 Oct;145(10):578-586. doi: 10.1016/j.annder.2018.04.003.

[Use of topical therapies for pediatric psoriasis: A systematic review.](#)

Kravvas G, Gholam K.

Pediatr Dermatol. 2018 May;35(3):296-302. doi: 10.1111/pde.13422. Epub 2018 Mar 1.

[Biologics in pediatric psoriasis - efficacy and safety.](#)

Dogra S, Mahajan R.

Expert Opin Drug Saf. 2018 Jan;17(1):9-16. doi: 10.1080/14740338.2018.1391787. Epub 2017 Oct 30.

[Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.](#)

Duarte A, Mebrahtu T, Goncalves PS, Harden M, Murphy R, Palmer S, Woolacott N, Rodgers M, Rothery C.

Health Technol Assess. 2017 Nov;21(64):1-244. doi: 10.3310/hta21640.

[Treatment of severe psoriasis in children: recommendations of an Italian expert group.](#)

Fortina AB, Bardazzi F, Berti S, Carnevale C, Di Lernia V, El Hachem M, Neri I, Gelmetti CM, Lora V, Mazzatenta C, Milioto M, Moretta G, Patrizi A, Peris K, Villani A.

Eur J Pediatr. 2017 Oct;176(10):1339-1354. doi: 10.1007/s00431-017-2985-x. Epub 2017 Aug 23.

[Health-related quality of life in children and adolescents with psoriasis: A systematic review and meta-analysis.](#)

Randa H, Todberg T, Skov L, Larsen LS, Zachariae R.

Acta Derm Venereol. 2017 May 8;97(5):555-563. doi: 10.2340/00015555-2600.

[The epidemiology of childhood psoriasis: A scoping review.](#)

Burden-Teh E, Thomas KS, Ratib S, Grindlay D, Adaji E, Murphy R.

Br J Dermatol. 2016 Jun;174(6):1242-57. doi: 10.1111/bjd.14507. Epub 2016 May 22.

[Systemic treatment of pediatric psoriasis: A review.](#)

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.

Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

[Systematic review of health-related quality of life in adolescents with psoriasis.](#)

Gonzalez J, Cunningham K, Perlmutter J, Gottlieb A.

Dermatology. 2016;232(5):541-549. doi: 10.1159/000450826. Epub 2016 Nov 4.

[Quality of life impact of childhood skin conditions measured using the Children's Dermatology Life Quality Index \(CDLQI\): A meta-analysis.](#)

Olsen JR, Gallacher J, Finlay AY, Piguat V, Francis NA.

Br J Dermatol. 2016 Apr;174(4):853-61. doi: 10.1111/bjd.14361. Epub 2016 Mar 6.

[Anti-tumor necrosis factor \$\alpha\$ -related psoriatic lesions in children with inflammatory bowel disease: Case report and systematic literature review.](#)

Romiti R, Araujo KM, Steinwurz F, Denadai R.

Pediatr Dermatol. 2016 Mar-Apr;33(2):e174-8. doi: 10.1111/pde.12820.

[Anti-TNF agents for paediatric psoriasis.](#)

Sanclemente G, Murphy R, Contreras J, García H, Bonfill Cosp X.

Cochrane Database Syst Rev. 2015 Nov 24;(11):CD010017. doi: 10.1002/14651858.CD010017.pub2.

[Systemic treatments in paediatric psoriasis: A systematic evidence-based update.](#)

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

[A systematic review of systemic medications for pustular psoriasis in pediatrics.](#)

Posso-De Los Rios CJ, Pope E, Lara-Corrales I.

Pediatr Dermatol. 2014 Jul-Aug;31(4):430-9. doi: 10.1111/pde.12351. Epub 2014 May 29.

Psoriasis in difficult-to-treat sites

Nail psoriasis

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Efficacy of biologics targeting tumour necrosis factor-alpha, interleukin-17 -12/23, -23 and small molecules targeting JAK and PDE4 in the treatment of nail psoriasis: A network meta-analysis.](#)

Szebényi J, Gede N, Hegyi P, Szakács Z, Solymár M, Erőss B, Garami A, Farkas K, Csupor D, Gyulai R. Acta Derm Venereol. 2020 Sep 23. doi: 10.2340/00015555-3640. Online ahead of print.

[The use of ultrasonography in the diagnosis of nail disease among patients with psoriasis and psoriatic arthritis: a systematic review.](#)

Mendonça JA, Aydin SZ, D'Agostino MA.

Adv Rheumatol. 2019 Sep 5;59(1):41. doi: 10.1186/s42358-019-0081-9.

[Nail ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review.](#)

Fassio A, Giovannini I, Idolazzi L, Zabotti A, Iagnocco A, Sakellariou G.

Clin Rheumatol. 2019 Aug 22. doi: 10.1007/s10067-019-04748-2. [Epub ahead of print]

[Reporting of outcomes in randomised controlled trials on nail psoriasis; a systematic review.](#)

Busard CIM, Nolte JYC, Pasch MC, Spuls PI.

Br J Dermatol. 2018 Mar;178(3):640-649. doi: 10.1111/bjd.15831. Epub 2018 Feb 14.

[Splinter hemorrhages of the nails: A systematic review of clinical features and associated conditions.](#)

Haber R, Khoury R, Kechichian E, Tomb R.

Int J Dermatol. 2016 Dec;55(12):1304-1310. doi: 10.1111/ijd.13347. Epub 2016 Jul 15.

[Treatment of nail psoriasis: Best practice recommendations from the Medical Board of the National Psoriasis Foundation.](#)

Crowley JJ, Weinberg JM, Wu JJ, Robertson AD, Van Voorhees AS; National Psoriasis Foundation.

JAMA Dermatol. 2015 Jan;151(1):87-94. doi: 10.1001/jamadermatol.2014.2983.

[Evidence-based guidelines of the Spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites \(nails, scalp, palms, and soles\).](#)

Sánchez-Regaña M, Aldunce Soto MJ, Belinchón Romero I, Ribera Pibernat M, Lafuente-Urrez RF, Carrascosa Carrillo JM, Ferrándiz Foraster C, Puig Sanz L, Daudén Tello E, Vidal Sarró D, Ruiz-Villaverde R, Fonseca Capdevila E, Rodríguez Cerdeira MC, Alsina Gibert MM, Herrera Acosta E, Marrón Moya SE; en representación del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología.

Actas Dermosifiliogr. 2014 Dec;105(10):923-34. doi: 10.1016/j.ad.2014.02.015. Epub 2014 May 19. English, Spanish

[Treatments for nail psoriasis: a systematic review by the GRAPPA Nail Psoriasis Work Group.](#)

Armstrong AW, Tuong W, Love TJ, Carneiro S, Grynszpan R, Lee SS, Kavanaugh A.

J Rheumatol. 2014 Nov;41(11):2306-14. doi: 10.3899/jrheum.140881.

[Interventions for nail psoriasis.](#)

de Vries AC, Bogaards NA, Hooft L, Velema M, Pasch M, Lebwohl M, Spuls PI.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD007633. doi: 10.1002/14651858.CD007633.pub2.

[Treatment of nail psoriasis with TNF- \$\alpha\$ or IL12/23 inhibitors.](#)

Jemec GB, Ibler KS.

J Drugs Dermatol. 2012 Aug;11(8):939-42

Scalp psoriasis

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Biologics and small molecules in patients with scalp psoriasis: a systematic review.](#)

Alsenaid A, Ezmerli M, Srouf J, Heppt M, Illigens BM, Prinz JC.

J Dermatolog Treat. 2020 May 14:1-38. doi: 10.1080/09546634.2020.1770167. [Epub ahead of print]

[Topical treatments for scalp psoriasis: Summary of a Cochrane Systematic Review.](#)

Schlager JG, Rosumeck S, Werner RN, Jacobs A, Schmitt J, Schlager C, Nast A.

Br J Dermatol. 2017 Mar;176(3):604-614. doi: 10.1111/bjd.14811. Epub 2016 Oct 19.

[Managing scalp psoriasis: An evidence-based review.](#)

Wang TS, Tsai TF.

Am J Clin Dermatol. 2017 Feb;18(1):17-43. doi: 10.1007/s40257-016-0222-4.

[Topical treatments for scalp psoriasis.](#)

Schlager JG, Rosumeck S, Werner RN, Jacobs A, Schmitt J, Schlager C, Nast A.

Cochrane Database Syst Rev. 2016 Feb 26;2:CD009687. doi: 10.1002/14651858.CD009687.pub2.

Scalp psoriasis: Systematic review comparing topical treatments and placebo.

Jales R, Hirata S, Attalah Á, Sá-Caputo D, Arnóbio A, Frederico É, Bernardo-Filho M, Saconato H.

Journal of Cosmetics, Dermatological Sciences and Applications 2015;5:142-150. doi:

10.4236/jcdsa.2015.52017.

http://file.scirp.org/pdf/JCDSA_2015062913403448.pdf

[Evidence-based guidelines of the Spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites \(nails, scalp, palms, and soles\).](#)

Sánchez-Regaña M, Aldunce Soto MJ, Belinchón Romero I, Ribera Pibernat M, Lafuente-Urrez RF, Carrascosa Carrillo JM, Ferrándiz Foraster C, Puig Sanz L, Daudén Tello E, Vidal Sarró D, Ruiz-Villaverde R, Fonseca Capdevila E, Rodríguez Cerdeira MC, Alsina Gibert MM, Herrera Acosta E, Marrón Moya SE; en representación del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología.

Actas Dermosifiliogr. 2014 Dec;105(10):923-34. doi: 10.1016/j.ad.2014.02.015. Epub 2014 May 19.

English, Spanish

[Topical treatments for chronic plaque psoriasis of the scalp: A systematic review.](#)

Mason AR, Mason JM, Cork MJ, Hancock H, Dooley G.

Br J Dermatol. 2013 Sep;169(3):519-27. doi: 10.1111/bjd.12393.

[Topical therapies for the treatment of plaque psoriasis: Systematic review and network meta-analyses.](#)

Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH.

Br J Dermatol. 2013 May;168(5):954-67. doi: 10.1111/bjd.12276.

Acral psoriasis

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

[Evidence-based guidelines of the Spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites \(nails, scalp, palms, and soles\).](#)

Sánchez-Regaña M, Aldunce Soto MJ, Belinchón Romero I, Ribera Pibernat M, Lafuente-Urrez RF, Carrascosa Carrillo JM, Ferrándiz Foraster C, Puig Sanz L, Daudén Tello E, Vidal Sarró D, Ruiz-Villaverde R, Fonseca Capdevila E, Rodríguez Cerdeira MC, Alsina Gibert MM, Herrera Acosta E, Marrón Moya SE; en representación del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología.
Actas Dermosifiliogr. 2014 Dec;105(10):923-34. doi: 10.1016/j.ad.2014.02.015. Epub 2014 May 19. English, Spanish

Flexural psoriasis

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

[Treatments for inverse psoriasis: A systematic review.](#)

Reynolds KA, Pithadia DJ, Lee EB, Wu JJ.
J Dermatolog Treat. 2019 May 17:1-23. doi: 10.1080/09546634.2019.1620912. [Epub ahead of print]

[Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review.](#)

Dattola A, Silvestri M, Bennardo L, Del Duca E, Longo C, Bianchi L, Nisticò S.
Dermatol Ther. 2018 Nov;31(6):e12728. doi: 10.1111/dth.12728. Epub 2018 Oct 8.

[Psoriasis inversa: A separate identity or a variant of psoriasis vulgaris?](#)

Omland SH, Gniadecki R.
Clin Dermatol. 2015 Jul-Aug;33(4):456-61. doi: 10.1016/j.clindermatol.2015.04.007. Epub 2015 Apr 8.

Genital psoriasis

[The impact of genital psoriasis on quality of life: a systematic review.](#)

Yang EJ, Beck KM, Sanchez IM, Koo J, Liao W.
Psoriasis (Auckl). 2018 Aug 28;8:41-47. doi: 10.2147/PTT.S169389. eCollection 2018.

[Treatment of genital psoriasis: A systematic review.](#)

Beck KM, Yang EJ, Sanchez IM, Liao W.
Dermatol Ther (Heidelb). 2018 Dec;8(4):509-525. doi: 10.1007/s13555-018-0257-y. Epub 2018 Aug 25.

Specific psoriasis phenotypes

Pustular psoriasis & palmoplantar pustulosis

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Interventions for chronic palmoplantar pustulosis.](#)

Obeid G, Do G, Kirby L, Hughes C, Sbidian E, Le Cleach L.

Cochrane Database Syst Rev. 2020 Jan 20;1:CD011628. doi: 10.1002/14651858.CD011628.pub2.

[How frequently does palmoplantar psoriasis affect the palms and/or soles? A systematic review and meta-analysis.](#)

Timotijević ZS, Trajković G, Jankovic J, Relić M, Đorić D, Vukićević D, Relić G, Rašić D, Filipović M, Janković S.

Postepy Dermatol Alergol. 2019 Oct;36(5):595-603. doi: 10.5114/ada.2019.89508. Epub 2019 Nov 12.

[Review of treatments for generalized pustular psoriasis.](#)

Kearns DG, Chat VS, Zang PD, Han G, Wu JJ.

J Dermatolog Treat. 2019 Nov 7:1-13. doi: 10.1080/09546634.2019.1682502. [Epub ahead of print]

[Biological therapy for pustular psoriasis: a systematic review.](#)

Falto-Aizpurua LA, Martin-Garcia RF, Carrasquillo OY, Nevares-Pomales OW, Sánchez-Flores X, Lorenzo-Rios D.

Int J Dermatol. 2019 Oct 15. doi: 10.1111/ijd.14671. [Epub ahead of print]

[Palmoplantar pustulosis and allergies: A systematic review.](#)

Brunasso Vernetti AMG, Puntoni M, Massone C.

Dermatol Pract Concept. 2019 Apr 30;9(2):105-110. doi: 10.5826/dpc.0902a05. eCollection 2019 Apr.

[Generalized pustular psoriasis - A model disease for specific targeted immunotherapy, systematic review.](#)

Boehner A, Navarini AA, Eyerich K.

Exp Dermatol. 2018 Oct;27(10):1067-1077. doi: 10.1111/exd.13699. Epub 2018 Jul 20.

[Systemic monotherapy treatments for generalized pustular psoriasis: A systematic review.](#)

Zhou LL, Georgakopoulos JR, Ighani A, Yeung J.

J Cutan Med Surg. 2018 Nov/Dec;22(6):591-601. doi: 10.1177/1203475418773358. Epub 2018 Apr 30.

[The efficacy of biologic therapy for the management of palmoplantar psoriasis and palmoplantar pustulosis: A systematic review.](#)

Sanchez IM, Sorenson E, Levin E, Liao W.

Dermatol Ther (Heidelb). 2017 Dec;7(4):425-446. doi: 10.1007/s13555-017-0207-0. Epub 2017 Nov 15.

[What do we know about palmoplantar pustulosis?](#)

Misiak-Galazka M, Wolska H, Rudnicka L.

J Eur Acad Dermatol Venereol. 2017 Jan;31(1):38-44. doi: 10.1111/jdv.13846. Epub 2016 Aug 13.

[Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion.](#)

Sevrain M, Richard MA, Barnetche T, Rouzaud M, Villani AP, Paul C, Beylot-Barry M, Jullien D, Aractingi S, Aubin F, Joly P, Le Maitre M, Cantagrel A, Ortonne JP, Misery L.

J Eur Acad Dermatol Venereol. 2014 Aug;28 Suppl 5:13-6. doi: 10.1111/jdv.12561.

Guttate psoriasis

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Non-antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis.](#)

Maruani A, Samimi M, Stemberge N, Abdel Hay R, Tavernier E, Hughes C, Le Cleach L.

Cochrane Database Syst Rev. 2019 Apr 8;4:CD011541. doi: 10.1002/14651858.CD011541.pub2.

[Antistreptococcal interventions for guttate and chronic plaque psoriasis.](#)

Dupire G, Droitcourt C, Hughes C, Le Cleach L.

Cochrane Database Syst Rev. 2019 Mar 5;3:CD011571. doi: 10.1002/14651858.CD011571.pub2.

[Interventions for guttate psoriasis.](#)

Chalmers RJ, O'Sullivan T, Owen CM, Griffiths CE.

Cochrane Database Syst Rev. 2000;(2):CD001213.

Erythrodermic psoriasis

[Treatment of erythrodermic psoriasis with biologics: A systematic review.](#)

Carrasquillo OY, Pabón-Cartagena G, Falto-Aizpurua LA, Santiago-Vázquez M, Cancel-Artau KJ, Arias-Berrios G, Martín-García RF.

J Am Acad Dermatol. 2020 Apr 2. pii: S0190-9622(20)30496-5. doi: 10.1016/j.jaad.2020.03.073.

[Epub ahead of print]

[A systematic review of treatment strategies for erythrodermic psoriasis.](#)

Reynolds KA, Pithadia DJ, Lee EB, Liao W, Wu JJ.

J Dermatolog Treat. 2019 Nov 4:1-21. doi: 10.1080/09546634.2019.1689228. [Epub ahead of print]

Therapies in general

Therapies in general – economic evaluation

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.](#)

Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.

Curr Med Res Opin. 2018 Jul;34(7):1325-1333. doi: 10.1080/03007995.2018.1457516. Epub 2018 Apr 23.

[Biologics and small molecules in psoriasis: A systematic review of economic evaluations.](#)

Kromer C, Celis D, Sonntag D, Peitsch WK.

PLoS One. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765. eCollection 2018.

[Health economic analyses of psoriasis management: A systematic literature search.](#)

Gutknecht M, Krensel M, Augustin M.

Arch Dermatol Res. 2016 Nov;308(9):601-616. Epub 2016 Jul 19.

[Systematic review of cost-effectiveness analyses of treatments for psoriasis.](#)

Zhang W, Islam N, Ma C, Anis AH.

Pharmacoeconomics. 2015 Apr;33(4):327-40. doi: 10.1007/s40273-014-0244-9.

[Psoriasis treatment and management - A systematic review of full economic evaluations.](#)

Hamilton MP, Ntais D, Griffiths CE, Davies LM; Identification and Management of Psoriasis-Associated Comorbidity (IMPACT) Team..

Br J Dermatol. 2015 Mar;172(3):574-83. doi: 10.1111/bjd.13486. Epub 2015 Feb 11.

[Network meta-analysis of treatments for chronic plaque psoriasis in Canada.](#)

Gupta AK, Daigle D, Lyons DC.

J Cutan Med Surg. 2014 Nov;18(6):371-8.

[Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system.](#)

Wang SH, Chi CC, Hu S.

Int J Dermatol. 2014 Sep;53(9):1151-6. doi: 10.1111/ijd.12462. Epub 2014 Apr 16.

[Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: A systematic review of published models and clinical practice guidelines.](#)

Mauskopf J, Samuel M, McBride D, Mallya UG, Feldman SR.

Pharmacoeconomics. 2014 Apr;32(4):395-409. doi: 10.1007/s40273-014-0130-5.

[Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: A meta-analysis and cost-efficacy analysis using the intention-to-treat principle.](#)

Chi CC, Wang SH.

Biomed Res Int. 2014;2014:862851. doi: 10.1155/2014/862851. Epub 2014 Jan 29.

[Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.](#)

Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P.
Adv Ther. 2012 Jul;29(7):620-34. doi: 10.1007/s12325-012-0035-7. Epub 2012 Jul 27.

Therapies in general – patient preferences and treatment satisfaction

[Patient-physician discrepancy in the perception of immune-mediated inflammatory diseases: rheumatoid arthritis, psoriatic arthritis and psoriasis. A qualitative systematic review of the literature.](#)

Sacristán JA, Dilla T, Díaz-Cerezo S, Gabás-Rivera C, Aceituno S, Lizán L.
PLoS One. 2020 Jun 17;15(6):e0234705. doi: 10.1371/journal.pone.0234705. eCollection 2020.

[The importance of understanding patient and physician preferences for psoriasis treatment characteristics: a systematic review of discrete-choice experiments.](#)

Sain N, Willems D, Charokopou M, Hilgsmann M.
Curr Med Res Opin. 2020 May 29;1. doi: 10.1080/03007995.2020.1776233. [Epub ahead of print]

[Psoriasis patient preferences for topical drugs: a systematic review.](#)

Svendsen MT, Feldman SR, Tiedemann SN, Sørensen ASS, Rivas CMR, Andersen KE.
J Dermatolog Treat. 2019 Oct 15;1-6. doi: 10.1080/09546634.2019.1675855. [Epub ahead of print]

[Patients' perspectives and experience of psoriasis and psoriatic arthritis: a systematic review and thematic synthesis of qualitative studies.](#)

Sumpton D, Kelly A, Tunnicliffe DJ, Craig JC, Hassett G, Chessman D, Tong A.
Arthritis Care Res (Hoboken). 2019 Mar 30. doi: 10.1002/acr.23896. [Epub ahead of print]

[Are your patients satisfied? A systematic review of treatment satisfaction measures in psoriasis.](#)

Salame N, Perez-Chada LM, Singh S, Callis Duffin K, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong AW.
Dermatology. 2018;234(5-6):157-165. doi: 10.1159/000490413. Epub 2018 Aug 17.

[Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review.](#)

Florek AG, Wang CJ, Armstrong AW.
Arch Dermatol Res. 2018 May;310(4):271-319. doi: 10.1007/s00403-018-1808-x. Epub 2018 Feb 13.

[Evaluating risk tolerance from a systematic review of preferences: The case of patients with psoriasis.](#)

Gonzalez JM.
Patient. 2018 Jun;11(3):285-300. doi: 10.1007/s40271-017-0295-z.

[Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: A systematic review of the literature.](#)

Belinchón I, Rivera R, Blanch C, Comellas M, Lizán L.
Patient Prefer Adherence. 2016 Nov 17;10:2357-2367. eCollection 2016.

[A systematic review on methods used to evaluate patient preferences in psoriasis treatments.](#)

Gutknecht M, Schaarschmidt ML, Herrlein O, Augustin M.
J Eur Acad Dermatol Venereol. 2016 Sep;30(9):1454-64. doi: 10.1111/jdv.13749. Epub 2016 Jul 19.

[Elicitation and use of patients' preferences in the treatment of psoriasis: A systematic review.](#)

Umar N, Yamamoto S, Loerbroks A, Terris D.

Acta Derm Venereol. 2012 Jul;92(4):341-6. doi: 10.2340/00015555-1304.

Therapies in general – adherence

[Do mobile device apps designed to support medication adherence demonstrate efficacy? A systematic review of randomised controlled trials, with meta-analysis.](#)

Armitage LC, Kassavou A, Sutton S.

BMJ Open. 2020 Jan 30;10(1):e032045. doi: 10.1136/bmjopen-2019-032045.

[A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease - strategies for optimizing treatment outcome.](#)

Eicher L, Knop M, Aszodi N, Senner S, French LE, Wollenberg A.

J Eur Acad Dermatol Venereol. 2019 Aug 27. doi: 10.1111/jdv.15913. [Epub ahead of print]

[Improving psoriasis patients' adherence to topical drugs: A systematic review.](#)

Svendsen MT, Feldmann S, Tiedemann SN, Sørensen ASS, Rivas CMR, Andersen KE.

J Dermatolog Treat. 2019 May 24;1-28. doi: 10.1080/09546634.2019.1623371. [Epub ahead of print]

[Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review.](#)

Murage MJ, Tongbram V, Feldman SR, Malatestinic WN, Larmore CJ, Muram TM, Burge RT, Bay C, Johnson N, Clifford S, Araujo AB.

Patient Prefer Adherence. 2018 Aug 21;12:1483-1503. doi: 10.2147/PPA.S167508. eCollection 2018.

[Adherence and resource use among psoriasis patients treated with biologics.](#)

Aleshaki JS, Cardwell LA, Muse ME, Feldman SR.

Expert Rev Pharmacoecon Outcomes Res. 2018 Dec;18(6):609-617. doi:

10.1080/14737167.2018.1512408. Epub 2018 Sep 10.

[eHealth technologies as an intervention to improve adherence to topical antipsoriatics: A systematic review.](#)

Svendsen MT, Andersen F, Andersen KE.

J Dermatolog Treat. 2018 Mar;29(2):123-128. doi: 10.1080/09546634.2017.1341612. Epub 2017 Jun 29.

[Medical adherence to topical corticosteroid preparations prescribed for psoriasis: A systematic review.](#)

Svendsen MT, Andersen F, Hansen J, Johannessen H, Andersen KE.

J Dermatolog Treat. 2017 Feb;28(1):32-39. doi: 10.1080/09546634.2016.1178375. Epub 2016 May 6.

[Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: A systematic review of the literature.](#)

Belinchón I, Rivera R, Blanch C, Comellas M, Lizán L.

Patient Prefer Adherence. 2016 Nov 17;10:2357-2367. eCollection 2016.

[Methodologies for medication adherence evaluation: Focus on psoriasis topical treatment.](#)

Teixeira A, Teixeira M, Almeida V, Torres T, Sousa Lobo JM, Almeida IF.

J Dermatol Sci. 2016 May;82(2):63-8. doi: 10.1016/j.jdermsci.2016.02.008. Epub 2016 Feb 18.

[Interventions to improve adherence in patients with immune-mediated inflammatory disorders: A systematic review.](#)

Depont F, Berenbaum F, Filippi J, Le Maitre M, Nataf H, Paul C, Peyrin-Biroulet L, Thibout E.
PLoS One. 2015 Dec 16;10(12):e0145076. doi: 10.1371/journal.pone.0145076. eCollection 2015.

[A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases.](#)

Vangeli E, Bakhshi S, Baker A, Fisher A, Bucknor D, Mrowietz U, Östör AJ, Peyrin-Biroulet L, Lacerda AP, Weinman J.
Adv Ther. 2015 Nov;32(11):983-1028. doi: 10.1007/s12325-015-0256-7. Epub 2015 Nov 7.

[Does mHealth increase adherence to medication? Results of a systematic review.](#)

Anglada-Martinez H, Riu-Viladoms G, Martin-Conde M, Rovira-Illamola M, Sotoca-Momblona JM, Codina-Jane C.
Int J Clin Pract. 2015 Jan;69(1):9-32. doi: 10.1111/ijcp.12582. Epub 2014 Dec 4.

[Adherence to medication in patients with psoriasis: A systematic literature review.](#)

Thorneloe RJ, Bundy C, Griffiths CE, Ashcroft DM, Cordingley L.
Br J Dermatol. 2013 Jan;168(1):20-31. doi: 10.1111/bjd.12039.

[Adherence to topical treatment in psoriasis: A systematic literature review.](#)

Devaux S, Castela A, Archier E, Gallini A, Joly P, Misery L, Aractingi S, Aubin F, Bachelez H, Cribier B, Jullien D, Le Maître M, Richard MA, Ortonne JP, Paul C.
J Eur Acad Dermatol Venereol. 2012 May;26 Suppl 3:61-7. doi: 10.1111/j.1468-3083.2012.04525.x.

Topical treatments

Topical treatments - general

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Psoriasis in solid organ transplant patients: best practice recommendations from The Medical Board of the National Psoriasis Foundation.](#)

Prussick R, Wu JJ, Armstrong AW, Siegel MP, Van Voorhees AS.

J Dermatolog Treat. 2018 Jun;29(4):329-333. doi: 10.1080/09546634.2017.1373737. Epub 2017 Oct 24.

[Psoriasis patient preferences for topical drugs: a systematic review.](#)

Svendsen MT, Feldman SR, Tiedemann SN, Sørensen ASS, Rivas CMR, Andersen KE.

J Dermatolog Treat. 2019 Oct 15:1-6. doi: 10.1080/09546634.2019.1675855. [Epub ahead of print]

[Improving psoriasis patients' adherence to topical drugs: A systematic review.](#)

Svendsen MT, Feldmann S, Tiedemann SN, Sørensen ASS, Rivas CMR, Andersen KE.

J Dermatolog Treat. 2019 May 24:1-28. doi: 10.1080/09546634.2019.1623371. [Epub ahead of print]

[Use of topical therapies for pediatric psoriasis: A systematic review.](#)

Kravvas G, Gholam K.

Pediatr Dermatol. 2018 May;35(3):296-302. doi: 10.1111/pde.13422. Epub 2018 Mar 1.

[eHealth technologies as an intervention to improve adherence to topical antipsoriatics: A systematic review.](#)

Svendsen MT, Andersen F, Andersen KE.

J Dermatolog Treat. 2018 Mar;29(2):123-128. doi: 10.1080/09546634.2017.1341612. Epub 2017 Jun 29.

[Beyond monotherapy: a systematic review on creative strategies in topical therapy of psoriasis.](#)

Koo K, Jeon C, Bhutani T.

J Dermatolog Treat. 2017 Dec;28(8):702-708. doi: 10.1080/09546634.2017.1328098. Epub 2017 Jun 6.

[Worldwide utilization of topical remedies in treatment of psoriasis: A systematic review.](#)

Svendsen MT, Jeyabalan J, Andersen KE, Andersen F, Johannessen H.

J Dermatolog Treat. 2017 Aug;28(5):374-383. doi: 10.1080/09546634.2016.1254331. Epub 2016 Nov 13.

[Comparative effectiveness of topical drugs in dermatologic priority diseases: Geometry of randomized trial networks.](#)

Maruani A, Samimi M, Lorette G, le Cleach L.

J Invest Dermatol. 2015 Jan;135(1):76-83. doi: 10.1038/jid.2014.296. Epub 2014 Jun 21.

[Topical treatments for chronic plaque psoriasis: An abridged Cochrane systematic review.](#)

Mason A, Mason J, Cork M, Hancock H, Dooley G.

J Am Acad Dermatol. 2013 Nov;69(5):799-807. doi: 10.1016/j.jaad.2013.06.027.

[Topical therapies for the treatment of plaque psoriasis: Systematic review and network meta-analyses.](#)

Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH.
Br J Dermatol. 2013 May;168(5):954-67. doi: 10.1111/bjd.12276.

[Topical treatments for chronic plaque psoriasis.](#)

Mason AR, Mason J, Cork M, Dooley G, Hancock H.
Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3.

Topical combination treatments

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

[Combination of targeted UVB phototherapy and calcipotriene versus targeted UVB alone in psoriasis: systematic review and meta-analysis of randomized controlled trials.](#)

Gu X, Shen M, Zhao S, Chen X.
J Dermatolog Treat. 2020 May 18:1-16. doi: 10.1080/09546634.2020.1770177. [Epub ahead of print]

[Beyond monotherapy: a systematic review on creative strategies in topical therapy of psoriasis.](#)

Koo K, Jeon C, Bhutani T.
J Dermatolog Treat. 2017 Dec;28(8):702-708. doi: 10.1080/09546634.2017.1328098. Epub 2017 Jun 6.

[Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients.](#)

Iversen L, Dauden E, Segaeert S, Freeman K, Magina S, Rigopoulos D, Thaci D.
J Eur Acad Dermatol Venereol. 2017 Aug;31(8):1271-1284. doi: 10.1111/jdv.14277. Epub 2017 May 22.

[Topical calcipotriol/betamethasone dipropionate for psoriasis vulgaris: A systematic review.](#)

Yan R, Jiang S, Wu Y, Gao XH, Chen HD.
Indian J Dermatol Venereol Leprol. 2016 Mar-Apr;82(2):135-44. doi: 10.4103/0378-6323.175919.

[Topical long-term therapy of psoriasis with vitamin D₃ analogues, corticosteroids and their two compound formulations: Position paper on evidence and use in daily practice.](#)

Augustin M, Mrowietz U, Bonnekoh B, Rosenbach T, Thaçi D, Reusch M, Ardabili M, Reich K.
J Dtsch Dermatol Ges. 2014 Aug;12(8):667-82. doi: 10.1111/ddg.12396. Epub 2014 Jul 17.

[Topical treatments for chronic plaque psoriasis: An abridged Cochrane systematic review.](#)

Mason A, Mason J, Cork M, Hancock H, Dooley G.
J Am Acad Dermatol. 2013 Nov;69(5):799-807. doi: 10.1016/j.jaad.2013.06.027.

[Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: A systematic literature review.](#)

Hendriks AG, Keijsers RR, de Jong EM, Seyger MM, van de Kerkhof PC.
J Eur Acad Dermatol Venereol. 2013 Aug;27(8):931-51. doi: 10.1111/jdv.12058. Epub 2012 Dec 20.

[Combinations of classical time-honoured topicals in plaque psoriasis: A systematic review.](#)

Hendriks AG, Keijsers RR, de Jong EM, Seyger MM, van de Kerkhof PC.

J Eur Acad Dermatol Venereol. 2013 Apr;27(4):399-410. doi: 10.1111/j.1468-3083.2012.04640.x. Epub 2012 Jul 11.

[Topical therapies for the treatment of plaque psoriasis: Systematic review and network meta-analyses.](#)

Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH.
Br J Dermatol. 2013 May;168(5):954-67. doi: 10.1111/bjd.12276.

[Topical treatments for chronic plaque psoriasis.](#)

Mason AR, Mason J, Cork M, Dooley G, Hancock H.
Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3.

Topical corticosteroids

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

[Long-term topical corticosteroid use and risk of skin cancer: a systematic review.](#)

Ratib S, Burden-Teh E, Leonardi-Bee J, Harwood C, Bath-Hextall F.
JBI Database System Rev Implement Rep. 2018 Jun;16(6):1387-1397. doi: 10.11124/JBISRI-2017-003393.

[Use of topical therapies for pediatric psoriasis: A systematic review.](#)

Kravvas G, Gholam K.
Pediatr Dermatol. 2018 May;35(3):296-302. doi: 10.1111/pde.13422. Epub 2018 Mar 1.

[Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients.](#)

Iversen L, Dauden E, Segaert S, Freeman K, Magina S, Rigopoulos D, Thaci D.
J Eur Acad Dermatol Venereol. 2017 Aug;31(8):1271-1284. doi: 10.1111/jdv.14277. Epub 2017 May 22.

[Medical adherence to topical corticosteroid preparations prescribed for psoriasis: A systematic review.](#)

Svensden MT, Andersen F, Hansen J, Johannessen H, Andersen KE.
J Dermatolog Treat. 2017 Feb;28(1):32-39. doi: 10.1080/09546634.2016.1178375. Epub 2016 May 6.

[Topical long-term therapy of psoriasis with vitamin D₃ analogues, corticosteroids and their two compound formulations: Position paper on evidence and use in daily practice.](#)

Augustin M, Mrowietz U, Bonnekoh B, Rosenbach T, Thaçi D, Reusch M, Ardabili M, Reich K.
J Dtsch Dermatol Ges. 2014 Aug;12(8):667-82. doi: 10.1111/ddg.12396. Epub 2014 Jul 17.

[Topical treatments for chronic plaque psoriasis: An abridged Cochrane systematic review.](#)

Mason A, Mason J, Cork M, Hancock H, Dooley G.
J Am Acad Dermatol. 2013 Nov;69(5):799-807. doi: 10.1016/j.jaad.2013.06.027.

[Topical therapies for the treatment of plaque psoriasis: Systematic review and network meta-analyses.](#)

Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH.
Br J Dermatol. 2013 May;168(5):954-67. doi: 10.1111/bjd.12276.

[Topical treatments for chronic plaque psoriasis.](#)

Mason AR, Mason J, Cork M, Dooley G, Hancock H.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3.

[Topical corticosteroids in plaque psoriasis: A systematic review of efficacy and treatment modalities.](#)

Castela E, Archier E, Devaux S, Gallini A, Aractingi S, Cribier B, Jullien D, Aubin F, Bachelez H, Joly P, Le Maître M, Misery L, Richard MA, Paul C, Ortonne JP.

J Eur Acad Dermatol Venereol. 2012 May;26 Suppl 3:36-46. doi: 10.1111/j.1468-3083.2012.04522.x.

[Topical corticosteroids in plaque psoriasis: A systematic review of risk of adrenal axis suppression and skin atrophy.](#)

Castela E, Archier E, Devaux S, Gallini A, Aractingi S, Cribier B, Jullien D, Aubin F, Bachelez H, Joly P, Le Maître M, Misery L, Richard MA, Paul C, Ortonne JP.

J Eur Acad Dermatol Venereol. 2012 May;26 Suppl 3:47-51. doi: 10.1111/j.1468-3083.2012.04523.x.

Topical vitamin D analogues

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Combination of targeted UVB phototherapy and calcipotriene versus targeted UVB alone in psoriasis: systematic review and meta-analysis of randomized controlled trials.](#)

Gu X, Shen M, Zhao S, Chen X.

J Dermatolog Treat. 2020 May 18:1-16. doi: 10.1080/09546634.2020.1770177. [Epub ahead of print]

[Use of topical therapies for pediatric psoriasis: A systematic review.](#)

Kravvas G, Gholam K.

Pediatr Dermatol. 2018 May;35(3):296-302. doi: 10.1111/pde.13422. Epub 2018 Mar 1.

[Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients.](#)

Iversen L, Dauden E, Segaert S, Freeman K, Magina S, Rigopoulos D, Thaci D.

J Eur Acad Dermatol Venereol. 2017 Aug;31(8):1271-1284. doi: 10.1111/jdv.14277. Epub 2017 May 22.

[Topical long-term therapy of psoriasis with vitamin D₃ analogues, corticosteroids and their two compound formulations: Position paper on evidence and use in daily practice.](#)

Augustin M, Mrowietz U, Bonnekoh B, Rosenbach T, Thaçi D, Reusch M, Ardabili M, Reich K.

J Dtsch Dermatol Ges. 2014 Aug;12(8):667-82. doi: 10.1111/ddg.12396. Epub 2014 Jul 17.

[Topical treatments for chronic plaque psoriasis: An abridged Cochrane systematic review.](#)

Mason A, Mason J, Cork M, Hancock H, Dooley G.

J Am Acad Dermatol. 2013 Nov;69(5):799-807. doi: 10.1016/j.jaad.2013.06.027.

[Topical therapies for the treatment of plaque psoriasis: Systematic review and network meta-analyses.](#)

Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH.

Br J Dermatol. 2013 May;168(5):954-67. doi: 10.1111/bjd.12276.

[Topical treatments for chronic plaque psoriasis.](#)

Mason AR, Mason J, Cork M, Dooley G, Hancock H.
Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3.

[Topical vitamin D analogues alone or in association with topical steroids for psoriasis: A systematic review.](#)

Devaux S, Castela A, Archier E, Gallini A, Joly P, Misery L, Aractingi S, Aubin F, Bachelez H, Cribier B, Jullien D, Le Maître M, Richard MA, Ortonne JP, Paul C.
J Eur Acad Dermatol Venereol. 2012 May;26 Suppl 3:52-60. doi: 10.1111/j.1468-3083.2012.04524.x.

Topical dithranol

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

[Use of topical therapies for pediatric psoriasis: A systematic review.](#)

Kravvas G, Gholam K.
Pediatr Dermatol. 2018 May;35(3):296-302. doi: 10.1111/pde.13422. Epub 2018 Mar 1.

[Topical treatments for chronic plaque psoriasis: An abridged Cochrane systematic review.](#)

Mason A, Mason J, Cork M, Hancock H, Dooley G.
J Am Acad Dermatol. 2013 Nov;69(5):799-807. doi: 10.1016/j.jaad.2013.06.027.

[Topical therapies for the treatment of plaque psoriasis: Systematic review and network meta-analyses.](#)

Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH.
Br J Dermatol. 2013 May;168(5):954-67. doi: 10.1111/bjd.12276.

[Topical treatments for chronic plaque psoriasis.](#)

Mason AR, Mason J, Cork M, Dooley G, Hancock H.
Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3.

Topical retinoids

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

[Treating psoriasis with halobetasol propionate and tazarotene combination: A review of phase II and III clinical trials.](#)

Ramachandran V, Bertus B, Bashyam AM, Feldman SR.
Ann Pharmacother. 2020 Mar 4;1060028020910439. doi: 10.1177/1060028020910439. [Epub ahead of print]

[Tazarotene revisited: Safety and efficacy in plaque psoriasis and its emerging role in treatment strategy](#)

Tanghetti E, Lebwohl M, Stein Gold L.
J Drugs Dermatol. 2018 Dec 1;17(12):1280-1287.

[Topical treatments for chronic plaque psoriasis: An abridged Cochrane systematic review.](#)

Mason A, Mason J, Cork M, Hancock H, Dooley G.
J Am Acad Dermatol. 2013 Nov;69(5):799-807. doi: 10.1016/j.jaad.2013.06.027.

[Topical therapies for the treatment of plaque psoriasis: Systematic review and network meta-analyses.](#)

Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH.
Br J Dermatol. 2013 May;168(5):954-67. doi: 10.1111/bjd.12276.

[Topical treatments for chronic plaque psoriasis.](#)

Mason AR, Mason J, Cork M, Dooley G, Hancock H.
Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3.

Topical coal tar

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

[Topical therapies for the treatment of plaque psoriasis: Systematic review and network meta-analyses.](#)

Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH.
Br J Dermatol. 2013 May;168(5):954-67. doi: 10.1111/bjd.12276.

[Topical treatments for chronic plaque psoriasis.](#)

Mason AR, Mason J, Cork M, Dooley G, Hancock H.
Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3.

Emollients and keratolytics

[Keratolytics and emollients and their role in the therapy of psoriasis: A systematic review.](#)

Jacobi A, Mayer A, Augustin M.
Dermatol Ther (Heidelb). 2015 Mar;5(1):1-18. doi: 10.1007/s13555-015-0068-3. Epub 2015 Jan 21.

[Topical treatments for chronic plaque psoriasis.](#)

Mason AR, Mason J, Cork M, Dooley G, Hancock H.
Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3.

Topical urea

[Urea: a comprehensive review of the clinical literature.](#)

Pan M, Heinecke G, Bernardo S, Tsui C, Levitt J.
Dermatol Online J. 2013 Nov 15;19(11):20392.

[Topical treatments for chronic plaque psoriasis.](#)

Mason AR, Mason J, Cork M, Dooley G, Hancock H.
Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3.

Other topical treatments

[Topical methotrexate in dermatology: A review of the literature.](#)

Aickara D, Bashyam AM, Pichardo RO, Feldman SR.

J Dermatolog Treat. 2020 May 15;1-21. doi: 10.1080/09546634.2020.1770170. [Epub ahead of print]

[Topical Janus kinase inhibitors: A review of applications in dermatology.](#)

Hosking AM, Juhasz M, Mesinkovska NA.

J Am Acad Dermatol. 2018 Sep;79(3):535-544. doi: 10.1016/j.jaad.2018.04.018. Epub 2018 Apr 16.

[Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review.](#)

Dattola A, Silvestri M, Bennardo L, Del Duca E, Longo C, Bianchi L, Nisticò S.

Dermatol Ther. 2018 Nov;31(6):e12728. doi: 10.1111/dth.12728. Epub 2018 Oct 8.

[Use of topical therapies for pediatric psoriasis: A systematic review.](#)

Kravvas G, Gholam K.

Pediatr Dermatol. 2018 May;35(3):296-302. doi: 10.1111/pde.13422. Epub 2018 Mar 1.

[Topical treatments for chronic plaque psoriasis.](#)

Mason AR, Mason J, Cork M, Dooley G, Hancock H.

Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3.

Phototherapy

Phototherapy

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with phototherapy.](#)

Elmets CA, Lim HW, Stoff B, Connor C, Cordoro KM, Lebwohl M, Armstrong AW, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Leonardi CL, Lichten J, Mehta NN, Paller AS, Parra SL, Pathy AL, Farley Prater EA, Rupani RN, Siegel M, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A.

J Am Acad Dermatol. 2019 Sep;81(3):775-804. doi: 10.1016/j.jaad.2019.04.042. Epub 2019 Jul 25.

[Use of narrowband ultraviolet B \(NBUVB\) in paediatric psoriasis: A systematic literature review and meta-analysis.](#)

Kim E, Lee G, Fischer G.

Australas J Dermatol. 2020 Oct 18. doi: 10.1111/ajd.13471. Online ahead of print.

[Indoor salt water baths followed by artificial ultraviolet B-light for chronic plaque psoriasis: abridged Cochrane review.](#)

Peinemann F, Harari M, Peternel S, Chan T, Chan D, Labeit AM, Gambichler T.

Br J Dermatol. 2020 Jul 6. doi: 10.1111/bjd.19385. [Epub ahead of print]

[Indoor salt water baths followed by artificial ultraviolet B light for chronic plaque psoriasis.](#)

Peinemann F, Harari M, Peternel S, Chan T, Chan D, Labeit AM, Gambichler T.

Cochrane Database Syst Rev. 2020 May 5;5:CD011941. doi: 10.1002/14651858.CD011941.pub2

[Combination of targeted UVB phototherapy and calcipotriene versus targeted UVB alone in psoriasis: systematic review and meta-analysis of randomized controlled trials.](#)

Gu X, Shen M, Zhao S, Chen X.

J Dermatolog Treat. 2020 May 18:1-16. doi: 10.1080/09546634.2020.1770177. [Epub ahead of print]

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Théréné C, Brenaut E, Barnette T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[Treatment of severe psoriasis in children: recommendations of an Italian expert group.](#)

Fortina AB, Bardazzi F, Berti S, Carnevale C, Di Lernia V, El Hachem M, Neri I, Gelmetti CM, Lora V, Mazzatenta C, Milioto M, Moretta G, Patrizi A, Peris K, Villani A.

Eur J Pediatr. 2017 Oct;176(10):1339-1354. doi: 10.1007/s00431-017-2985-x. Epub 2017 Aug 23.

[A systematic review of light emitting diode \(LED\) phototherapy for treatment of psoriasis: An emerging therapeutic modality.](#)

Ho D, Koo E, Mamalis A, Jagdeo J.

J Drugs Dermatol. 2017 May 1;16(5):482-488.

[Beyond monotherapy: a systematic review on creative strategies in topical therapy of psoriasis.](#)

Koo K, Jeon C, Bhutani T.

J Dermatolog Treat. 2017 Dec;28(8):702-708. doi: 10.1080/09546634.2017.1328098. Epub 2017 Jun 6.

[Systemic treatment of pediatric psoriasis: A review.](#)

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.

Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

[Improving access to home phototherapy for patients with psoriasis: current challenges and future prospects.](#)

Franken SM, Vierstra CL, Rustemeyer T.

Psoriasis (Auckl). 2016 May 18;6:55-64. doi: 10.2147/PTT.S81958. eCollection 2016.

[Effects of narrow band ultraviolet B on serum levels of vascular endothelial growth factor and interleukin-8 in patients with psoriasis.](#)

Chen HQ, Li X, Tang R.

Am J Ther. 2016 May-Jun;23(3):e655-62. doi: 10.1097/MJT.0000000000000330.

[Targeted phototherapy.](#)

Mysore V, Shashikumar BM.

Indian J Dermatol Venereol Leprol. 2016 Jan-Feb;82(1):1-6. doi: 10.4103/0378-6323.172902.

[Photodynamic therapy for psoriasis.](#)

Choi YM, Adelzadeh L, Wu JJ.

J Dermatolog Treat. 2015 Jun;26(3):202-7. doi: 10.3109/09546634.2014.927816. Epub 2014 Jun 17.

[Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.](#)

Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.

JAMA Dermatol. 2015 Apr;151(4):432-8. doi: 10.1001/jamadermatol.2014.3456.

[Efficacy of localized phototherapy and photodynamic therapy for psoriasis: A systematic review and meta-analysis.](#)

Almutawa F, Thalib L, Hekman D, Sun Q, Hamzavi I, Lim HW.

Photodermatol Photoimmunol Photomed. 2015 Jan;31(1):5-14. doi: 10.1111/phpp.12092. Epub 2013 Dec 20.

[Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis.](#)

Chen X, Yang M, Cheng Y, Liu GJ, Zhang M.

Cochrane Database Syst Rev. 2013 Oct 23;(10):CD009481. doi: 10.1002/14651858.CD009481.pub2

[Systematic review of UV-based therapy for psoriasis.](#)

Almutawa F, Alnomair N, Wang Y, Hamzavi I, Lim HW.

Am J Clin Dermatol. 2013 Apr;14(2):87-109. doi: 10.1007/s40257-013-0015-y.

[Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis \[Internet\].](#)

Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J, Sobieraj DM.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

[Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: A systematic literature review.](#)

Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maître M, Aractingi S, Bachelez H, Cribier B, Joly P, Jullien D, Misery L, Paul C, Ortonne JP, Richard MA.

J Eur Acad Dermatol Venereol. 2012 May;26 Suppl 3:22-31. doi: 10.1111/j.1468-3083.2012.04520.x.

[Efficacy of psoralen UV-A therapy vs. narrowband UV-B therapy in chronic plaque psoriasis: A systematic literature review.](#)

Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maître M, Aractingi S, Bachelez H, Cribier B, Joly P, Jullien D, Misery L, Paul C, Ortonne JP, Richard MA.

J Eur Acad Dermatol Venereol. 2012 May;26 Suppl 3:11-21. doi: 10.1111/j.1468-3083.2012.04519.x.

[Guidelines for bath PUVA, bathing suit PUVA and soak PUVA.](#)

Pai SB, Shetty S.

Indian J Dermatol Venereol Leprol. 2015 Nov-Dec;81(6):559-67. doi: 10.4103/0378-6323.168336.

[A review of targeted ultraviolet B phototherapy for psoriasis.](#)

Mudigonda T, Dabade TS, Feldman SR.

J Am Acad Dermatol. 2012 Apr;66(4):664-72. doi: 10.1016/j.jaad.2011.07.011. Epub 2011 Oct 14.

Laser therapy

[308nm excimer laser in dermatology.](#)

Mehraban S, Feily A.

J Lasers Med Sci. 2014 Winter;5(1):8-12.

[The efficacy of pulsed dye laser treatment for inflammatory skin diseases: A systematic review.](#)

Erceg A, de Jong EM, van de Kerkhof PC, Seyger MM.

J Am Acad Dermatol. 2013 Oct;69(4):609-615.e8. doi: 10.1016/j.jaad.2013.03.029. Epub 2013 May 24.

Systemic treatments in general

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Effectiveness and safety of systemic therapy for psoriasis in older adults: A systematic review.](#)

van Winden MEC, van der Schoot LS, van de L'Isle Arias M, van Vugt LJ, van den Reek JMPA, van de Kerkhof PCM, de Jong EMGJ, Lubeek SFK.

JAMA Dermatol. 2020 Aug 19. doi: 10.1001/jamadermatol.2020.2311. Online ahead of print.

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L.

Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

[Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.](#)

Sawyer LM, Malottki K, Sabry-Grant C, Yasmeen N, Wright E, Sohr A, Borg E, Warren RB.

PLoS One. 2019 Aug 14;14(8):e0220868. doi: 10.1371/journal.pone.0220868. eCollection 2019.

[Persistence and effectiveness of non-biologic systemic therapies for moderate-severe psoriasis in adults: A systematic review.](#)

Mason KJ, Williams S, Yiu ZZN, McElhone K, Ashcroft DM, Kleyn CE, Jabbar-Lopez ZK, Owen CM, Reynolds NJ, Smith CH, Wilson N, Warren RB, Griffiths CEM.

Br J Dermatol. 2019 Aug;181(2):256-264. doi: 10.1111/bjd.17625. Epub 2019 Mar 27.

[Network meta-analyses of systemic treatments for psoriasis: a critical appraisal.](#)

Ellis AG, Flohr C, Drucker AM.

Br J Dermatol. 2018 Oct 22. doi: 10.1111/bjd.17335. [Epub ahead of print]

[Not in itself a systematic review, but included for information]

[Psoriasis in solid organ transplant patients: best practice recommendations from The Medical Board of the National Psoriasis Foundation.](#)

Prussick R, Wu JJ, Armstrong AW, Siegel MP, Van Voorhees AS.

J Dermatolog Treat. 2018 Jun;29(4):329-333. doi: 10.1080/09546634.2017.1373737. Epub 2017 Oct 24.

[Systemic monotherapy treatments for generalized pustular psoriasis: A systematic review.](#)

Zhou LL, Georgakopoulos JR, Ighani A, Yeung J.

J Cutan Med Surg. 2018 Nov/Dec;22(6):591-601. doi: 10.1177/1203475418773358. Epub 2018 Apr 30.

[Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies.](#)

Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T.

Cutis. 2018 Jan;101(1):38;42;56.

[Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review.](#)

Florek AG, Wang CJ, Armstrong AW.

Arch Dermatol Res. 2018 May;310(4):271-319. doi: 10.1007/s00403-018-1808-x. Epub 2018 Feb 13.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.

Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Systemic treatment of pediatric psoriasis: A review.](#)

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.

Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

[Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: A systematic review.](#)

Zweegers J, Otero ME, van den Reek JM, van Lümig PP, Driessen RJ, Kievit W, Seyger MM, van de Kerkhof PC, de Jong EM.

Acta Derm Venereol. 2016 May;96(4):453-8. doi: 10.2340/00015555-2276.

[Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: A systematic review and meta-analysis.](#)

Nast A, Jacobs A, Rosumeck S, Werner RN.

J Invest Dermatol. 2015 Nov;135(11):2641-8. doi: 10.1038/jid.2015.206. Epub 2015 Jun 5.

[Systematic review on the maintenance of response during systemic antipsoriatic therapy.](#)

Jacobs A, Rosumeck S, Nast A.

Br J Dermatol. 2015 Oct;173(4):910-21. doi: 10.1111/bjd.14077. Epub 2015 Oct 6.

[Systemic treatments in paediatric psoriasis: A systematic evidence-based update.](#)

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

[The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis.](#)

Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B.

Ann Rheum Dis. 2015 Mar;74(3):480-9. doi: 10.1136/annrheumdis-2014-206624. Epub 2015 Jan 5.

[Safety and efficacy of therapies for skin symptoms of psoriasis in patients with psoriatic arthritis: A systematic review.](#)

Boehncke WH, Alvarez Martinez D, Solomon JA, Gottlieb AB.

J Rheumatol. 2014 Nov;41(11):2301-5. doi: 10.3899/jrheum.140880.

[Network meta-analysis of treatments for chronic plaque psoriasis in Canada.](#)

Gupta AK, Daigle D, Lyons DC.

J Cutan Med Surg. 2014 Nov;18(6):371-8.

[Combined use of systemic agents for psoriasis: A systematic review.](#)

Busard C, Zweegers J, Limpens J, Langendam M, Spuls PI.

JAMA Dermatol. 2014 Nov;150(11):1213-20. doi: 10.1001/jamadermatol.2014.1111.

[A systematic review of systemic medications for pustular psoriasis in pediatrics.](#)

Posso-De Los Rios CJ, Pope E, Lara-Corrales I.

Pediatr Dermatol. 2014 Jul-Aug;31(4):430-9. doi: 10.1111/pde.12351. Epub 2014 May 29.

[Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: A systematic review.](#)

Armstrong AW, Brezinski EA, Follansbee MR, Armstrong EJ.

Curr Pharm Des. 2014;20(4):500-12.

[Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials.](#)

Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A.

Br J Dermatol. 2014 Feb;170(2):274-303. doi: 10.1111/bjd.12663

[Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.](#)

Nast A, Sporbeck B, Rosumeck S, Pathirana D, Jacobs A, Werner RN, Schmitt J.

J Invest Dermatol. 2013 Aug;133(8):1963-70. doi: 10.1038/jid.2013.78. Epub 2013 Feb 20.

[Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis \[Internet\].](#)

Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J, Sobieraj DM.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

[Efficacy of systemic therapies for moderate-to-severe psoriasis: A systematic review and meta-analysis of long-term treatment.](#)

Lucka TC, Pathirana D, Sammain A, Bachmann F, Rosumeck S, Erdmann R, Schmitt J, Orawa H, Rzany B, Nast A.

J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1331-44. doi: 10.1111/j.1468-3083.2012.04492.x.

Epub 2012 Mar 9. Review. Erratum in: J Eur Acad Dermatol Venereol. 2012 Jul;26(7):930.

[The safety of systemic treatments that can be used for geriatric psoriasis patients: A review.](#)

Wong JW, Koo JY.

Dermatol Res Pract. 2012;2012:367475. doi: 10.1155/2012/367475. Epub 2012 May 28.

Conventional (non-biologic) systemic therapies

Methotrexate

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Effectiveness and safety of systemic therapy for psoriasis in older adults: A systematic review.](#)

van Winden MEC, van der Schoot LS, van de L'Isle Arias M, van Vugt LJ, van den Reek JMPA, van de Kerkhof PCM, de Jong EMGJ, Lubeek SFK.

JAMA Dermatol. 2020 Aug 19. doi: 10.1001/jamadermatol.2020.2311. Online ahead of print.

[Joint AAD-NPF Guidelines of Care for the Management of Psoriasis with Systemic Non-Biological Therapies.](#)

Menter A, Gelfand JM, et al.

J Am Acad Dermatol. 2020 Feb 28. pii: S0190-9622(20)30284-X. doi: 10.1016/j.jaad.2020.02.044.

[Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L.

Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

[Review of treatments for generalized pustular psoriasis.](#)

Kearns DG, Chat VS, Zang PD, Han G, Wu JJ.

J Dermatolog Treat. 2019 Nov 7;1-13. doi: 10.1080/09546634.2019.1682502. [Epub ahead of print]

[Persistence and effectiveness of non-biologic systemic therapies for moderate-severe psoriasis in adults: A systematic review.](#)

Mason KJ, Williams S, Yiu ZZN, McElhone K, Ashcroft DM, Kleyn CE, Jabbar-Lopez ZK, Owen CM, Reynolds NJ, Smith CH, Wilson N, Warren RB, Griffiths CEM.

Br J Dermatol. 2019 Aug;181(2):256-264. doi: 10.1111/bjd.17625. Epub 2019 Mar 27.

[Systemic monotherapy treatments for generalized pustular psoriasis: A systematic review.](#)

Zhou LL, Georgakopoulos JR, Ighani A, Yeung J.

J Cutan Med Surg. 2018 Nov/Dec;22(6):591-601. doi: 10.1177/1203475418773358. Epub 2018 Apr 30.

[Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies.](#)

Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T.

Cutis. 2018 Jan;101(1):38;42;56.

[Quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.](#)

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.

Mol Pain. 2018 Jan-Dec;14:1744806918762205. doi: 10.1177/1744806918762205. Epub 2018 Feb 15.

[Treatment of severe psoriasis in children: recommendations of an Italian expert group.](#)

Fortina AB, Bardazzi F, Berti S, Carnevale C, Di Lernia V, El Hachem M, Neri I, Gelmetti CM, Lora V, Mazzatenta C, Milioto M, Moretta G, Patrizi A, Peris K, Villani A.
Eur J Pediatr. 2017 Oct;176(10):1339-1354. doi: 10.1007/s00431-017-2985-x. Epub 2017 Aug 23.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.
Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Quantitative evaluation of biologic therapy options for psoriasis: A systematic review and network meta-analysis.](#)

Jabbar-Lopez ZK, Yiu ZZN, Ward V, Exton LS, Mustapa MFM, Samarasekera E, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Warren RB, Smith CH.
J Invest Dermatol. 2017 Aug;137(8):1646-1654. doi: 10.1016/j.jid.2017.04.009. Epub 2017 Apr 27.

[Relative risk of and determinants for adverse events of methotrexate prescribed at a low dose: A systematic review and meta-analysis of randomized, placebo-controlled trials.](#)

Mazaud C, Fardet L.
Br J Dermatol. 2017 Oct;177(4):978-986. doi: 10.1111/bjd.15377. Epub 2017 Aug 30.

[Systemic treatment of pediatric psoriasis: A review.](#)

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.
Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

[Safety and efficacy of methotrexate in psoriasis: A meta-analysis of published trials.](#)

West J, Ogston S, Foerster J.
PLoS One. 2016 May 11;11(5):e0153740. doi: 10.1371/journal.pone.0153740. eCollection 2016.
Erratum in: [PLoS One. 2016;11\(7\):e0158928.](#)

[Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: A systematic review.](#)

Zweegers J, Otero ME, van den Reek JM, van Lümig PP, Driessen RJ, Kievit W, Seyger MM, van de Kerkhof PC, de Jong EM.
Acta Derm Venereol. 2016 May;96(4):453-8. doi: 10.2340/00015555-2276.

[Methotrexate in moderate to severe psoriasis: Review of the literature and expert recommendations.](#)

Carrascosa JM, de la Cueva P, Ara M, Puig L, Bordas X, Carretero G, Ferrándiz L, Sánchez-Carazo JL, Daudén E, López-Esteban JL, Vidal D, Herranz P, Jorquera E, Coto-Segura P, Ribera M.
Actas Dermosifiliogr. 2016 Apr;107(3):194-206. doi: 10.1016/j.ad.2015.10.005. Epub 2015 Nov 21.
English, Spanish.

[Methotrexate dosing regimen for plaque-type psoriasis: A systematic review of the use of test-dose, start-dose, dosing scheme, dose adjustments, maximum dose and folic acid supplementation.](#)

Menting SP, Dekker PM, Limpens J, Hooft L, Spuls PI.
Acta Derm Venereol. 2016 Jan;96(1):23-8. doi: 10.2340/00015555-2081.

[Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: Novel therapeutic insights coming from a meta-analysis of the literature data.](#)

De Vecchis R, Baldi C, Palmisani L.
Anatol J Cardiol. 2016 Jan;16(1):2-9. doi: 10.5152/akd.2015.6136.

[Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: A systematic review and meta-analysis.](#)

Nast A, Jacobs A, Rosumeck S, Werner RN.
J Invest Dermatol. 2015 Nov;135(11):2641-8. doi: 10.1038/jid.2015.206. Epub 2015 Jun 5.

[Systematic review on the maintenance of response during systemic antipsoriatic therapy.](#)

Jacobs A, Rosumeck S, Nast A.
Br J Dermatol. 2015 Oct;173(4):910-21. doi: 10.1111/bjd.14077. Epub 2015 Oct 6.

[Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trials.](#)

Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ.
Semin Arthritis Rheum. 2015 Oct;45(2):156-62. doi: 10.1016/j.semarthrit.2015.05.003. Epub 2015 May 19.

[Combining biologics with methotrexate in psoriasis: A systematic review.](#)

van Bezooijen JS, Prens EP, Pradeepti MS, Atiqi R, Schreurs MW, Koch BC, van Gelder T, van Doorn MB.
Br J Dermatol. 2015 Jun;172(6):1676-80. doi: 10.1111/bjd.13573. Epub 2015 Apr 29.

[Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.](#)

Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.
JAMA Dermatol. 2015 Apr;151(4):432-8. doi: 10.1001/jamadermatol.2014.3456.

[Systemic treatments in paediatric psoriasis: A systematic evidence-based update.](#)

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.
J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

[Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: Systematic literature review and meta-analysis of randomised controlled trials.](#)

Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ.
BMJ. 2015 Mar 13;350:h1269. doi: 10.1136/bmj.h1269.

[The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis.](#)

Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B.
Ann Rheum Dis. 2015 Mar;74(3):480-9. doi: 10.1136/annrheumdis-2014-206624. Epub 2015 Jan 5.

[Network meta-analysis of treatments for chronic plaque psoriasis in Canada.](#)

Gupta AK, Daigle D, Lyons DC.
J Cutan Med Surg. 2014 Nov;18(6):371-8.

[Combined use of systemic agents for psoriasis: A systematic review.](#)

Busard C, Zweegers J, Limpens J, Langendam M, Spuls PI.
JAMA Dermatol. 2014 Nov;150(11):1213-20. doi: 10.1001/jamadermatol.2014.1111.

[Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.](#)

Lorenzetti R, Zullo A, Ridola L, Diamanti AP, Laganà B, Gatta L, Migliore A, Armuzzi A, Hassan C, Bruzzese V.

Ann Med. 2014 Nov;46(7):547-54. doi: 10.3109/07853890.2014.941919. Epub 2014 Aug 8.

[Methotrexate and liver fibrosis in people with psoriasis: A systematic review of observational studies.](#)

Maybury CM, Jabbar-Lopez ZK, Wong T, Dhillon AP, Barker JN, Smith CH.

Br J Dermatol. 2014 Jul;171(1):17-29. doi: 10.1111/bjd.12941. Epub 2014 Jul 15.

[A systematic review of systemic medications for pustular psoriasis in pediatrics.](#)

Posso-De Los Rios CJ, Pope E, Lara-Corrales I.

Pediatr Dermatol. 2014 Jul-Aug;31(4):430-9. doi: 10.1111/pde.12351. Epub 2014 May 29.

[Diagnostic accuracy of noninvasive markers of liver fibrosis in patients with psoriasis taking methotrexate: A systematic review and meta-analysis.](#)

Maybury CM, Samarasekera E, Douiri A, Barker JN, Smith CH.

Br J Dermatol. 2014 Jun;170(6):1237-47. doi: 10.1111/bjd.12905.

[Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials.](#)

Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A.

Br J Dermatol. 2014 Feb;170(2):274-303. doi: 10.1111/bjd.12663

[Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: A systematic review.](#)

Armstrong AW, Brezinski EA, Follansbee MR, Armstrong EJ.

Curr Pharm Des. 2014;20(4):500-12.

[The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis.](#)

Garcês S, Demengeot J, Benito-Garcia E.

Ann Rheum Dis. 2013 Dec;72(12):1947-55. doi: 10.1136/annrheumdis-2012-202220. Epub 2012 Dec 6.

[Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.](#)

Nast A, Sporbeck B, Rosumeck S, Pathirana D, Jacobs A, Werner RN, Schmitt J.

J Invest Dermatol. 2013 Aug;133(8):1963-70. doi: 10.1038/jid.2013.78. Epub 2013 Feb 20.

[Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis \[Internet\].](#)

Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J, Sobieraj DM.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

Ciclosporin

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Joint AAD-NPF Guidelines of Care for the Management of Psoriasis with Systemic Non-Biological Therapies.](#)

Menter A, Gelfand JM, et al.

J Am Acad Dermatol. 2020 Feb 28. pii: S0190-9622(20)30284-X. doi: 10.1016/j.jaad.2020.02.044. [Epub ahead of print]

[Effectiveness and safety of systemic therapy for psoriasis in older adults: A systematic review.](#)

van Winden MEC, van der Schoot LS, van de L'Isle Arias M, van Vugt LJ, van den Reek JMPA, van de Kerkhof PCM, de Jong EMGJ, Lubeek SFK.

JAMA Dermatol. 2020 Aug 19. doi: 10.1001/jamadermatol.2020.2311. Online ahead of print.

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L.

Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

[Review of treatments for generalized pustular psoriasis.](#)

Kearns DG, Chat VS, Zang PD, Han G, Wu JJ.

J Dermatolog Treat. 2019 Nov 7;1-13. doi: 10.1080/09546634.2019.1682502. [Epub ahead of print]

[Persistence and effectiveness of non-biologic systemic therapies for moderate-severe psoriasis in adults: A systematic review.](#)

Mason KJ, Williams S, Yiu ZZN, McElhone K, Ashcroft DM, Kleyn CE, Jabbar-Lopez ZK, Owen CM, Reynolds NJ, Smith CH, Wilson N, Warren RB, Griffiths CEM.

Br J Dermatol. 2019 Aug;181(2):256-264. doi: 10.1111/bjd.17625. Epub 2019 Mar 27.

[Systemic monotherapy treatments for generalized pustular psoriasis: A systematic review.](#)

Zhou LL, Georgakopoulos JR, Ighani A, Yeung J.

J Cutan Med Surg. 2018 Nov/Dec;22(6):591-601. doi: 10.1177/1203475418773358. Epub 2018 Apr 30.

[Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies.](#)

Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T.

Cutis. 2018 Jan;101(1):38;42;56.

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Théréné C, Brenaut E, Barnette T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[Treatment of severe psoriasis in children: recommendations of an Italian expert group.](#)

Fortina AB, Bardazzi F, Berti S, Carnevale C, Di Lernia V, El Hachem M, Neri I, Gelmetti CM, Lora V, Mazzatenta C, Milioto M, Moretta G, Patrizi A, Peris K, Villani A.

Eur J Pediatr. 2017 Oct;176(10):1339-1354. doi: 10.1007/s00431-017-2985-x. Epub 2017 Aug 23.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.

Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Systemic treatment of pediatric psoriasis: A review.](#)

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.

Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

[Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: A systematic review.](#)

Zweegers J, Otero ME, van den Reek JM, van Lümig PP, Driessen RJ, Kievit W, Seyger MM, van de Kerkhof PC, de Jong EM.

Acta Derm Venereol. 2016 May;96(4):453-8. doi: 10.2340/00015555-2276.

[Systematic review on the maintenance of response during systemic antipsoriatic therapy.](#)

Jacobs A, Rosumeck S, Nast A.

Br J Dermatol. 2015 Oct;173(4):910-21. doi: 10.1111/bjd.14077. Epub 2015 Oct 6.

[Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.](#)

Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.

JAMA Dermatol. 2015 Apr;151(4):432-8. doi: 10.1001/jamadermatol.2014.3456.

[Systemic treatments in paediatric psoriasis: A systematic evidence-based update.](#)

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

[Combined use of systemic agents for psoriasis: A systematic review.](#)

Busard C, Zweegers J, Limpens J, Langendam M, Spuls PI.

JAMA Dermatol. 2014 Nov;150(11):1213-20. doi: 10.1001/jamadermatol.2014.1111.

[A systematic review of systemic medications for pustular psoriasis in pediatrics.](#)

Posso-De Los Rios CJ, Pope E, Lara-Corrales I.

Pediatr Dermatol. 2014 Jul-Aug;31(4):430-9. doi: 10.1111/pde.12351. Epub 2014 May 29.

[Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials.](#)

Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A.

Br J Dermatol. 2014 Feb;170(2):274-303. doi: 10.1111/bjd.12663

[Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: A systematic review.](#)

Armstrong AW, Brezinski EA, Follansbee MR, Armstrong EJ.

Curr Pharm Des. 2014;20(4):500-12.

[Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.](#)

Nast A, Sporbeck B, Rosumeck S, Pathirana D, Jacobs A, Werner RN, Schmitt J.

J Invest Dermatol. 2013 Aug;133(8):1963-70. doi: 10.1038/jid.2013.78. Epub 2013 Feb 20.

[Ciclosporin use during pregnancy.](#)

Paziana K, Del Monaco M, Cardonick E, Moritz M, Keller M, Smith B, Coscia L, Armenti V.

Drug Saf. 2013 May;36(5):279-94. doi: 10.1007/s40264-013-0034-x.

[Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis \[Internet\].](#)

Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J, Sobieraj DM.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

[The safety of systemic treatments that can be used for geriatric psoriasis patients: A review.](#)

Wong JW, Koo JY.
Dermatol Res Pract. 2012;2012:367475. doi: 10.1155/2012/367475. Epub 2012 May 28.

Systemic retinoids

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

[Joint AAD-NPF Guidelines of Care for the Management of Psoriasis with Systemic Non-Biological Therapies.](#)

Menter A, Gelfand JM, et al.
J Am Acad Dermatol. 2020 Feb 28. pii: S0190-9622(20)30284-X. doi: 10.1016/j.jaad.2020.02.044.
[Epub ahead of print]

[Effectiveness and safety of systemic therapy for psoriasis in older adults: A systematic review.](#)

van Winden MEC, van der Schoot LS, van de L'Isle Arias M, van Vugt LJ, van den Reek JMPA, van de Kerkhof PCM, de Jong EMGJ, Lubeek SFK.
JAMA Dermatol. 2020 Aug 19. doi: 10.1001/jamadermatol.2020.2311. Online ahead of print.

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L.
Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

[Review of treatments for generalized pustular psoriasis.](#)

Kearns DG, Chat VS, Zang PD, Han G, Wu JJ.
J Dermatolog Treat. 2019 Nov 7;1-13. doi: 10.1080/09546634.2019.1682502. [Epub ahead of print]

[Persistence and effectiveness of non-biologic systemic therapies for moderate-severe psoriasis in adults: A systematic review.](#)

Mason KJ, Williams S, Yiu ZZN, McElhone K, Ashcroft DM, Kleyn CE, Jabbar-Lopez ZK, Owen CM, Reynolds NJ, Smith CH, Wilson N, Warren RB, Griffiths CEM.
Br J Dermatol. 2019 Aug;181(2):256-264. doi: 10.1111/bjd.17625. Epub 2019 Mar 27.

[Generalized pustular psoriasis - A model disease for specific targeted immunotherapy, systematic review.](#)

Boehner A, Navarini AA, Eyerich K.
Exp Dermatol. 2018 Oct;27(10):1067-1077. doi: 10.1111/exd.13699. Epub 2018 Jul 20.

[Systemic monotherapy treatments for generalized pustular psoriasis: A systematic review.](#)

Zhou LL, Georgakopoulos JR, Ighani A, Yeung J.
J Cutan Med Surg. 2018 Nov/Dec;22(6):591-601. doi: 10.1177/1203475418773358. Epub 2018 Apr 30.

[Treatment of severe psoriasis in children: recommendations of an Italian expert group.](#)

Fortina AB, Bardazzi F, Berti S, Carnevale C, Di Lernia V, El Hachem M, Neri I, Gelmetti CM, Lora V, Mazzatenta C, Milioto M, Moretta G, Patrizi A, Peris K, Villani A.

Eur J Pediatr. 2017 Oct;176(10):1339-1354. doi: 10.1007/s00431-017-2985-x. Epub 2017 Aug 23.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.

Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Systemic treatment of pediatric psoriasis: A review.](#)

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.

Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

[Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: A systematic review.](#)

Zweegers J, Otero ME, van den Reek JM, van Lümig PP, Driessen RJ, Kievit W, Seyger MM, van de Kerkhof PC, de Jong EM.

Acta Derm Venereol. 2016 May;96(4):453-8. doi: 10.2340/00015555-2276.

[Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: A systematic review and meta-analysis.](#)

Nast A, Jacobs A, Rosumeck S, Werner RN.

J Invest Dermatol. 2015 Nov;135(11):2641-8. doi: 10.1038/jid.2015.206. Epub 2015 Jun 5.

[Systematic review on the maintenance of response during systemic antipsoriatic therapy.](#)

Jacobs A, Rosumeck S, Nast A.

Br J Dermatol. 2015 Oct;173(4):910-21. doi: 10.1111/bjd.14077. Epub 2015 Oct 6.

[Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.](#)

Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.

JAMA Dermatol. 2015 Apr;151(4):432-8. doi: 10.1001/jamadermatol.2014.3456.

[Systemic treatments in paediatric psoriasis: A systematic evidence-based update.](#)

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

[A systematic review of systemic medications for pustular psoriasis in pediatrics.](#)

Posso-De Los Rios CJ, Pope E, Lara-Corrales I.

Pediatr Dermatol. 2014 Jul-Aug;31(4):430-9. doi: 10.1111/pde.12351. Epub 2014 May 29.

[Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials.](#)

Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A.

Br J Dermatol. 2014 Feb;170(2):274-303. doi: 10.1111/bjd.12663

[Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis \[Internet\].](#)

Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J, Sobieraj DM.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

Colchicine

[Systemic treatments in paediatric psoriasis: A systematic evidence-based update.](#)

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.
J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

Fumaric acid esters

[Joint AAD-NPF Guidelines of Care for the Management of Psoriasis with Systemic Non-Biological Therapies.](#)

Menter A, Gelfand JM, et al.
J Am Acad Dermatol. 2020 Feb 28. pii: S0190-9622(20)30284-X. doi: 10.1016/j.jaad.2020.02.044.
[Epub ahead of print]

[Effectiveness and safety of systemic therapy for psoriasis in older adults: A systematic review.](#)

van Winden MEC, van der Schoot LS, van de L'Isle Arias M, van Vugt LJ, van den Reek JMPA, van de Kerkhof PCM, de Jong EMGJ, Lubeek SFK.
JAMA Dermatol. 2020 Aug 19. doi: 10.1001/jamadermatol.2020.2311. Online ahead of print.

[Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis.](#)

Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M.
JAMA Dermatol. 2020 Feb 5. doi: 10.1001/jamadermatol.2019.4029. [Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L.
Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

[Persistence and effectiveness of non-biologic systemic therapies for moderate-severe psoriasis in adults: A systematic review.](#)

Mason KJ, Williams S, Yiu ZZN, McElhone K, Ashcroft DM, Kleyn CE, Jabbar-Lopez ZK, Owen CM, Reynolds NJ, Smith CH, Wilson N, Warren RB, Griffiths CEM.
Br J Dermatol. 2019 Aug;181(2):256-264. doi: 10.1111/bjd.17625. Epub 2019 Mar 27.

[Progressive multifocal leukoencephalopathy associated with fumaric acid esters treatment in psoriasis patients.](#)

Balak DMW, Hajdarbegovic E, Bramer WM, Neumann HAM, Thio HB.
J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1475-1482. doi: 10.1111/jdv.14236. Epub 2017 Apr 25.

[Fumaric acid esters for psoriasis: A systematic review.](#)

Smith D.
Ir J Med Sci. 2017 Feb;186(1):161-177. doi: 10.1007/s11845-016-1470-2. Epub 2016 Jun 7.

[Oral fumaric acid esters for psoriasis: Abridged Cochrane systematic review including GRADE assessments.](#)

Atwan A, Ingram JR, Abbott R, Kelson MJ, Pickles T, Bauer A, Piguet V.
Br J Dermatol. 2016 Nov;175(5):873-881. doi: 10.1111/bjd.14676. Epub 2016 Aug 29.

[Efficacy, effectiveness and safety of fumaric acid esters in the treatment of psoriasis: A systematic review of randomized and observational studies.](#)

Balak DM, Fallah Arani S, Hajdarbegovic E, Hagemans CA, Bramer WM, Thio HB, Neumann HA.
Br J Dermatol. 2016 Aug;175(2):250-62. doi: 10.1111/bjd.14500. Epub 2016 Jul 19.

[Systemic treatment of pediatric psoriasis: A review.](#)

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.
Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

[Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: A systematic review.](#)

Zweegers J, Otero ME, van den Reek JM, van Lümig PP, Driessen RJ, Kievit W, Seyger MM, van de Kerkhof PC, de Jong EM.
Acta Derm Venereol. 2016 May;96(4):453-8. doi: 10.2340/00015555-2276.

[Systematic review on the maintenance of response during systemic antipsoriatic therapy.](#)

Jacobs A, Rosumeck S, Nast A.
Br J Dermatol. 2015 Oct;173(4):910-21. doi: 10.1111/bjd.14077. Epub 2015 Oct 6.

[Oral fumaric acid esters for psoriasis.](#)

Atwan A, Ingram JR, Abbott R, Kelson MJ, Pickles T, Bauer A, Piguet V.
Cochrane Database Syst Rev. 2015 Aug 10;(8):CD010497. doi: 10.1002/14651858.CD010497.pub2.

[Systemic treatments in paediatric psoriasis: A systematic evidence-based update.](#)

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.
J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

[Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials.](#)

Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A.
Br J Dermatol. 2014 Feb;170(2):274-303. doi: 10.1111/bjd.12663

Antibiotics

[Antistreptococcal interventions for guttate and chronic plaque psoriasis.](#)

Dupire G, Droitcourt C, Hughes C, Le Cleach L.
Cochrane Database Syst Rev. 2019 Mar 5;3:CD011571. doi: 10.1002/14651858.CD011571.pub2.

[Systemic treatments in paediatric psoriasis: A systematic evidence-based update.](#)

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.
J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

Thiazolidinediones (including pioglitazone)

[The efficacy and safety of pioglitazone in psoriasis vulgaris: A meta-analysis of randomized controlled trials.](#)

Chen P, Chen X, Lei L, Zhang Y, Xiang J, Zhou J, Lv J.
Medicine (Baltimore). 2020 Aug 7;99(32):e21549. doi: 10.1097/MD.00000000000021549.

[Effectiveness and safety of different doses of pioglitazone in psoriasis: a meta-analysis of randomized controlled trials.](#)

Zhang JZ, Ding Y, Xiang F, Yu SR, Zhang DZ, Guan MM, Kang XJ.
Chin Med J (Engl). 2020 Jan 22. doi: 10.1097/CM9.0000000000000642. [Epub ahead of print]

[Efficacy and safety of pioglitazone for treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.](#)

Chang G, Wang J, Song J, Zhang Z, Zhang L.
J Dermatolog Treat. 2019 May 22;1-17. doi: 10.1080/09546634.2019.1610552. [Epub ahead of print]

[Thiazolidinediones for plaque psoriasis: A systematic review and meta-analysis.](#)

Malhotra A, Shafiq N, Rajagopalan S, Dogra S, Malhotra S.
Evid Based Med. 2012 Dec;17(6):171-6. doi: 10.1136/ebmed-2011-100388. Epub 2012 Apr 20.

Statins

[The effect of statins on psoriasis severity: a meta-analysis of randomized clinical trials.](#)

Socha M, Pietrzak A, Grywalska E, Pietrzak D, Matosiuk D, Kiciński P, Rolinski J.
Arch Med Sci. 2019 Dec 6;16(1):1-7. doi: 10.5114/aoms.2019.90343. eCollection 2020.

[The effect of statins on severity of psoriasis: A systematic review.](#)

Ramessur R, Gill D.
Indian J Dermatol Venereol Leprol. 2017 Mar-Apr;83(2):154-161. doi: 10.4103/0378-6323.188655.

Lactoferrin

[A systematic review of lactoferrin use in dermatology.](#)

Hassoun LA, Sivamani RK.
Crit Rev Food Sci Nutr. 2017 Nov 22;57(17):3632-3639. doi: 10.1080/10408398.2015.1137859.

Systemic biologic therapies in general

Biologics & small molecule inhibitors in general – efficacy & safety

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.](#)

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA.

J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.

[British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 - a rapid update.](#)

Smith CH, Yiu ZZ, Bale T, Burden AD, Coates LC, Edwards W, MacMahon E, Mahil S, McGuire A, Murphy R, Nelson-Piercy C, Owen CM, Parslew R, Uthman OA, Woolf RT, Manounah L, Ezejimofor MC, Exton LS, Mohd Mustapa MF; British Association of Dermatologists' Clinical Standards Unit. Br J Dermatol. 2020 Mar 18. doi: 10.1111/bjd.19039. [Epub ahead of print].

[Impact of smoking on psoriasis risk and treatment efficacy: a meta-analysis.](#)

Zhou H, Wu R, Kong Y, Zhao M, Su Y.

J Int Med Res. 2020 Oct;48(10):300060520964024. doi: 10.1177/0300060520964024.

[Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review.](#)

Conforti C, Dianzani C, Zalaudek I, Cicala M, Persichetti P, Giuffrida R, Morariu SH, Neagu N.

J Dermatolog Treat. 2020 Oct 22:1-8. doi: 10.1080/09546634.2020.1836313. Online ahead of print.

[Effectiveness and safety of systemic therapy for psoriasis in older adults: A systematic review.](#)

van Winden MEC, van der Schoot LS, van de L'Isle Arias M, van Vugt LJ, van den Reek JMPA, van de Kerkhof PCM, de Jong EMGJ, Lubeek SFK.

JAMA Dermatol. 2020 Aug 19. doi: 10.1001/jamadermatol.2020.2311. Online ahead of print.

[Development of morphea in patients on biologic therapies: A systematic review.](#)

Maliyar K, Mufti A, Sachdeva M, Lytvyn Y, Salsberg J, Yeung J.

J Am Acad Dermatol. 2020 Jul 17:S0190-9622(20)32222-2. doi: 10.1016/j.jaad.2020.06.1027. Online ahead of print.

[Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Tada Y, Watanabe R, Noma H, Kanai Y, Nomura T, Kaneko K.

J Dermatol Sci. 2020 Jun 18. pii: S0923-1811(20)30199-7. doi: 10.1016/j.jdermsci.2020.06.003. [Epub ahead of print]

[Patient characteristics as effect modifiers for psoriasis biologic treatment response: an assessment using network meta-analysis subgroups.](#)

Wade R, Sharif-Hurst S, Dias S.

Syst Rev. 2020 Jun 5;9(1):132. doi: 10.1186/s13643-020-01395-6.

[Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.](#)

Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, de Brito M, McGuire A, Murphy R, Owen CM, Parslew R, Woolf RT, Yiu ZZN, Uthman OA, Mohd Mustapa MF, Smith CH. Br J Dermatol. 2020 Jun 20. doi: 10.1111/bjd.19325. [Epub ahead of print]

[Meta-analysis results do not reflect the real safety of biologics in psoriasis.](#)

Afach S, Chaimani A, Evrenoglou T, Penso L, Brouste E, Sbidian É, Le Cleach L. Br J Dermatol. 2020 May 23. doi: 10.1111/bjd.19244. [Epub ahead of print]

[Melanoma risk in patients treated with biologic therapy for common inflammatory diseases: A systematic review and meta-analysis.](#)

Esse S, Mason KJ, Green AC, Warren RB. JAMA Dermatol. 2020 May 20. doi: 10.1001/jamadermatol.2020.1300. [Epub ahead of print]

[Biologics and small molecules in patients with scalp psoriasis: a systematic review.](#)

Alsenaid A, Ezmerli M, Srour J, Heppt M, Illigens BM, Prinz JC. J Dermatolog Treat. 2020 May 14:1-38. doi: 10.1080/09546634.2020.1770167. [Epub ahead of print]

[Treatment of erythrodermic psoriasis with biologics: A systematic review.](#)

Carrasquillo OY, Pabón-Cartagena G, Falto-Aizpurua LA, Santiago-Vázquez M, Cancel-Artau KJ, Arias-Berrios G, Martín-García RF. J Am Acad Dermatol. 2020 Apr 2. pii: S0190-9622(20)30496-5. doi: 10.1016/j.jaad.2020.03.073. [Epub ahead of print]

[Biologics in atopic disease in pregnancy: an EAACI position paper.](#)

Pfaller B, Yepes-Nuñez JJ, Agache I, Akdis CA, Alsalamah M, Bavbek S, Bossios A, Boyman O, Chaker A, Chan S, Chatzipetrou A, du Toit G, Jutel M, Kauppi P, Kolios A, Li C, Matucci A, Marson A, Bendien S, Palomares O, Rogala B, Szepfalusi Z, Untersmayr E, Vultaggio A, Eiwegger T. Allergy. 2020 Mar 18. doi: 10.1111/all.14282. [Epub ahead of print]

[Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.](#)

Yasmeen N, Sawyer LM, Malottki K, Levin LÅ, Apol ED, Jemec GB. J Dermatolog Treat. 2020 Mar 23:1-50. doi: 10.1080/09546634.2020.1743811. [Epub ahead of print]

[Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis.](#)

Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M. JAMA Dermatol. 2020 Feb 5. doi: 10.1001/jamadermatol.2019.4029. [Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L. Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

[Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review.](#)

Al-Janabi A, Foulkes AC, Mason K, Smith CH, Griffiths C, Warren RB. J Eur Acad Dermatol Venereol. 2020 Jan 30. doi: 10.1111/jdv.16246. [Epub ahead of print]

[Biologic treatment in elderly patients with psoriasis: A systematic review.](#)

Sandhu VK, Ighani A, Fleming P, Lynde CW.

J Cutan Med Surg. 2020 Jan 17;1203475419897578. doi: 10.1177/1203475419897578. [Epub ahead of print]

[Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.](#)

Warren RB, Gooderham M, Burge R, Zhu B, Amato D, Liu KH, Shrom D, Guo J, Brnabic A, Blauvelt A. J Am Acad Dermatol. 2019 Dec 26. pii: S0190-9622(19)33315-8. doi: 10.1016/j.jaad.2019.12.038. [Epub ahead of print]

[Review of treatments for generalized pustular psoriasis.](#)

Kearns DG, Chat VS, Zang PD, Han G, Wu JJ.

J Dermatolog Treat. 2019 Nov 7;1-13. doi: 10.1080/09546634.2019.1682502. [Epub ahead of print]

[The efficacy and evidence-based use of biologics in children and adolescents.](#)

Niehues T, Özgür TT.

Dtsch Arztebl Int. 2019 Oct 18;116(42):703-710. doi: 10.3238/arztebl.2019.0703.

[Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: A comprehensive investigation using Bayesian and frequentist network meta-analyses.](#)

Warren RB, See K, Burge R, Zhang Y, Brnabic A, Gallo G, Garrelts A, Egeberg A.

Dermatol Ther (Heidelb). 2019 Nov 4. doi: 10.1007/s13555-019-00337-y. [Epub ahead of print]

[Autoimmune blistering diseases provoked during the treatment of chronic inflammatory disease with biologic agents: a systematic review.](#)

Gibson FT, Amber KT.

Int J Dermatol. 2019 Oct 20. doi: 10.1111/ijd.14686. [Epub ahead of print]

[Change in body weight and body mass index in psoriasis patients receiving biologics: a systematic review and network meta-analysis.](#)

Wu MY, Yu CL, Yang SJ, Chi CC.

J Am Acad Dermatol. 2019 Aug 7. pii: S0190-9622(19)32498-3. doi: 10.1016/j.jaad.2019.07.103. [Epub ahead of print]

[Biologics switch in psoriasis.](#)

Wang TS, Tsai TF.

Immunotherapy. 2019 Apr;11(6):531-541. doi: 10.2217/imt-2018-0131.

[Effect of biological treatment on fatigue in psoriasis: A systematic review and meta-analysis.](#)

Skoie IM, Dalen I, Omdal R.

Am J Clin Dermatol. 2019 Aug;20(4):493-502. doi: 10.1007/s40257-019-00434-w.

[Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis.](#)

Xu G, Xia M, Jiang C, Yu Y, Wang G, Yuan J, Duan X.

J Pharmacol Sci. 2019 Apr;139(4):289-303. doi: 10.1016/j.jphs.2018.12.006. Epub 2018 Dec 27.

[Safety of biologic therapy in older patients with immune-mediated diseases: A systematic review and meta-analysis.](#)

Borren NZ, Ananthakrishnan AN.

Clin Gastroenterol Hepatol. 2019 Aug;17(9):1736-1743.e4. doi: 10.1016/j.cgh.2018.12.032. Epub 2019 Jan 4.

[Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review.](#)

Bartos G, Cline A, Beroukhim K, Burrall BA, Feldman SR.
Dermatol Online J. 2018 Nov 15;24(11). pii: 13030/qt3db748cg.

[Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis.](#)

Geng W, Zhao J, Fu J, Zhang H, Qiao S.
Exp Ther Med. 2018 Dec;16(6):5085-5095. doi: 10.3892/etm.2018.6859. Epub 2018 Oct 15.

[Special aspects of biologics treatment in psoriasis: Management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis.](#)

Plachouri KM, Georgiou S.
J Dermatolog Treat. 2019 Nov;30(7):668-673. doi: 10.1080/09546634.2018.1544413. Epub 2018 Dec 2.

[Effectiveness end points in real-world studies on biological therapies in psoriasis: Systematic review with focus on drug survival.](#)

Costanzo A, Malara G, Pelucchi C, Fatiga F, Barbera G, Franchi A, Galeone C.
Dermatology. 2018;234(1-2):1-12. doi: 10.1159/000488586. Epub 2018 May 15.

[Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review.](#)

Murage MJ, Tongbram V, Feldman SR, Malatestinic WN, Larmore CJ, Muram TM, Burge RT, Bay C, Johnson N, Clifford S, Araujo AB.
Patient Prefer Adherence. 2018 Aug 21;12:1483-1503. doi: 10.2147/PPA.S167508. eCollection 2018.

[Adherence and resource use among psoriasis patients treated with biologics.](#)

Aleshaki JS, Cardwell LA, Muse ME, Feldman SR.
Expert Rev Pharmacoecon Outcomes Res. 2018 Dec;18(6):609-617. doi: 10.1080/14737167.2018.1512408. Epub 2018 Sep 10.

[Systemic monotherapy treatments for generalized pustular psoriasis: A systematic review.](#)

Zhou LL, Georgakopoulos JR, Ighani A, Yeung J.
J Cutan Med Surg. 2018 Nov/Dec;22(6):591-601. doi: 10.1177/1203475418773358. Epub 2018 Apr 30.

[Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.](#)

Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.
Curr Med Res Opin. 2018 Jul;34(7):1325-1333. doi: 10.1080/03007995.2018.1457516. Epub 2018 Apr 23.

[Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies.](#)

Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T.
Cutis. 2018 Jan;101(1):38;42;56.

[Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.](#)

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.

J Am Acad Dermatol. 2018 Jul;79(1):135-144.e7. doi: 10.1016/j.jaad.2018.02.027. Epub 2018 Feb 10.

[Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review.](#)

Florek AG, Wang CJ, Armstrong AW.

Arch Dermatol Res. 2018 May;310(4):271-319. doi: 10.1007/s00403-018-1808-x. Epub 2018 Feb 13.

[Biologics in pediatric psoriasis - efficacy and safety.](#)

Dogra S, Mahajan R.

Expert Opin Drug Saf. 2018 Jan;17(1):9-16. doi: 10.1080/14740338.2018.1391787. Epub 2017 Oct 30.

[Biologics and small molecules in psoriasis: A systematic review of economic evaluations.](#)

Kromer C, Celis D, Sonntag D, Peitsch WK.

PLoS One. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765. eCollection 2018.

[The efficacy of biologic therapy for the management of palmoplantar psoriasis and palmoplantar pustulosis: A systematic review.](#)

Sanchez IM, Sorenson E, Levin E, Liao W.

Dermatol Ther (Heidelb). 2017 Dec;7(4):425-446. doi: 10.1007/s13555-017-0207-0. Epub 2017 Nov 15.

[A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.](#)

No DJ, Amin M, Bhutani T, Wu JJ.

J Dermatolog Treat. 2018 Aug;29(5):467-474. doi: 10.1080/09546634.2017.1402116. Epub 2017 Nov 22.

[Drug survival of biologic treatments in psoriasis: a systematic review.](#)

No DJ, Inkeles MS, Amin M, Wu JJ.

J Dermatolog Treat. 2018 Aug;29(5):460-466. doi: 10.1080/09546634.2017.1398393. Epub 2017 Nov 10.

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Thér  ne C, Brenaut E, Barnette T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[Exposure to biologic therapies during conception and pregnancy: A systematic review.](#)

Pottinger EM, Woolf RT, Exton LS, Burden AD, Nelson-Piercy C, Smith CH.

Br J Dermatol. 2018 Jan;178(1):95-102. doi: 10.1111/bjd.15802. Epub 2017 Dec 14.

[Risk of cancer in patients with psoriasis on biologic therapies: A systematic review.](#)

Peleva E, Exton LS, Kelley K, Mason KJ, Smith CH.

Br J Dermatol. 2018 Jan;178(1):103-113. doi: 10.1111/bjd.15830. Epub 2017 Dec 18.

[A systematic review of pharmacogenetic studies on the response to biologics in psoriasis patients.](#)

van Vugt LJ, van den Reek JMPA, Coenen MJH, de Jong EMGJ.

Br J Dermatol. 2018 Jan;178(1):86-94. doi: 10.1111/bjd.15753. Epub 2017 Dec 14.

[Quantitative evaluation of biologic therapy options for psoriasis: A systematic review and network meta-analysis.](#)

Jabbar-Lopez ZK, Yiu ZZN, Ward V, Exton LS, Mustapa MFM, Samarasekera E, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Warren RB, Smith CH.

J Invest Dermatol. 2017 Aug;137(8):1646-1654. doi: 10.1016/j.jid.2017.04.009. Epub 2017 Apr 27.

[Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: A systematic review and meta-analysis of randomized clinical trials.](#)

de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR.

Drugs R D. 2017 Mar;17(1):29-51. doi: 10.1007/s40268-016-0152-x.

[Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Gómez-García F, Epstein D, Isla-Tejera B, Lorente A, Vélez García-Nieto A, Ruano J.

Br J Dermatol. 2017 Mar;176(3):594-603. doi: 10.1111/bjd.14814. Epub 2016 Oct 13

[Systematic review of the efficacy and safety of biological therapy for inflammatory conditions in HIV-infected individuals.](#)

Fink DL, Hedley L, Miller RF.

Int J STD AIDS. 2017 Feb;28(2):110-119. doi: 10.1177/0956462416675109. Epub 2016 Oct 13.

[Systemic treatment of pediatric psoriasis: A review.](#)

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.

Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

[Subcutaneous biological treatments for moderate to severe psoriasis: Interpreting safety data by network meta-analysis.](#)

Messori A, Trippoli S, Fadda V, Maratea D, Marinai C.

Drugs Real World Outcomes. 2015 Mar;2(1):23-27.

[Combining biologics with methotrexate in psoriasis: A systematic review.](#)

van Bezooijen JS, Prens EP, Pradeepti MS, Atiqi R, Schreurs MW, Koch BC, van Gelder T, van Doorn MB.

Br J Dermatol. 2015 Jun;172(6):1676-80. doi: 10.1111/bjd.13573. Epub 2015 Apr 29.

[Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.](#)

Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.

JAMA Dermatol. 2015 Apr;151(4):432-8. doi: 10.1001/jamadermatol.2014.3456.

[Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.](#)

Sorenson E, Koo J.

J Dermatolog Treat. 2015;26(6):493-501. doi: 10.3109/09546634.2015.1027167. Epub 2015 Apr 17.

[Comparative efficacy of biological treatments for moderate-to-severe psoriasis: A network meta-analysis adjusting for cross-trial differences in reference arm response.](#)

Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P.

Br J Dermatol. 2015 Feb;172(2):504-12. doi: 10.1111/bjd.13437. Epub 2015 Jan 21.

[Evidence-based guidelines of the Spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites \(nails, scalp, palms, and soles\).](#)

Sánchez-Regaña M, Aldunce Soto MJ, Belinchón Romero I, Ribera Pibernat M, Lafuente-Urrez RF, Carrascosa Carrillo JM, Ferrándiz Foraster C, Puig Sanz L, Daudén Tello E, Vidal Sarró D, Ruiz-Villaverde R, Fonseca Capdevila E, Rodríguez Cerdeira MC, Alsina Gibert MM, Herrera Acosta E, Marrón Moya SE; en representación del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología.
Actas Dermosifiliogr. 2014 Dec;105(10):923-34. doi: 10.1016/j.ad.2014.02.015. Epub 2014 May 19. English, Spanish

[Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials with different time points.](#)

Puig L, López A, Vilarrasa E, García I.
J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1633-53. doi: 10.1111/jdv.12238. Epub 2013 Aug 19.

[Safety and efficacy of therapies for skin symptoms of psoriasis in patients with psoriatic arthritis: A systematic review.](#)

Boehncke WH, Alvarez Martinez D, Solomon JA, Gottlieb AB.
J Rheumatol. 2014 Nov;41(11):2301-5. doi: 10.3899/jrheum.140880.

[Network meta-analysis of treatments for chronic plaque psoriasis in Canada.](#)

Gupta AK, Daigle D, Lyons DC.
J Cutan Med Surg. 2014 Nov;18(6):371-8.

[Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system.](#)

Wang SH, Chi CC, Hu S.
Int J Dermatol. 2014 Sep;53(9):1151-6. doi: 10.1111/ijd.12462. Epub 2014 Apr 16.

[Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials.](#)

Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A.
Br J Dermatol. 2014 Feb;170(2):274-303. doi: 10.1111/bjd.12663

[Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: A meta-analysis and cost-efficacy analysis using the intention-to-treat principle.](#)

Chi CC, Wang SH.
Biomed Res Int. 2014;2014:862851. doi: 10.1155/2014/862851. Epub 2014 Jan 29.

[Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: A systematic review.](#)

Armstrong AW, Brezinski EA, Follansbee MR, Armstrong EJ.
Curr Pharm Des. 2014;20(4):500-12.

[Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: A comprehensive meta-analysis of randomized controlled trials.](#)

Correr CJ, Rotta I, Teles Tde S, Godoy RR, Riveros BS, Garcia MM, Gonçalves PR, Otuki MF.
Cad Saude Publica. 2013 Nov;29 Suppl 1:S17-31.

[Biological treatments for moderate-to-severe psoriasis: indirect comparison.](#)

Galván-Banqueri M, Marín Gil R, Santos Ramos B, Bautista Paloma FJ.

J Clin Pharm Ther. 2013 Apr;38(2):121-30. doi: 10.1111/jcpt.12044. Epub 2013 Feb 26.

[Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis \[Internet\].](#)

Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J, Sobieraj DM.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

[Effect of biologic agents on non-PASI outcomes in moderate-to-severe plaque psoriasis: Systematic review and meta-analyses.](#)

Baker EL, Coleman CI, Reinhart KM, Phung OJ, Kugelman L, Chen W, White CM, Mamolo CM, Cappelleri JC, Baker WL.

Dermatol Ther (Heidelb). 2012 Dec;2(1):9. doi: 10.1007/s13555-012-0009-3. Epub 2012 Jun 19.

[Efficacy of systemic therapies for moderate-to-severe psoriasis: A systematic review and meta-analysis of long-term treatment.](#)

Lucka TC, Pathirana D, Sammain A, Bachmann F, Rosumeck S, Erdmann R, Schmitt J, Orawa H, Rzany B, Nast A.

J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1331-44. doi: 10.1111/j.1468-3083.2012.04492.x.

Epub 2012 Mar 9. Review. Erratum in: J Eur Acad Dermatol Venereol. 2012 Jul;26(7):930.

[Treatment of nail psoriasis with TNF- \$\alpha\$ or IL12/23 inhibitors.](#)

Jemec GB, Ibler KS.

J Drugs Dermatol. 2012 Aug;11(8):939-42

[The safety of systemic treatments that can be used for geriatric psoriasis patients: A review.](#)

Wong JW, Koo JY.

Dermatol Res Pract. 2012;2012:367475. doi: 10.1155/2012/367475. Epub 2012 May 28.

[Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials.](#)

Reich K, Burden AD, Eaton JN, Hawkins NS.

Br J Dermatol. 2012 Jan;166(1):179-88. doi: 10.1111/j.1365-2133.2011.10583.x. Epub 2011 Nov 11.

Biologics – immunogenicity, treatment failure & treatment regimens

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.](#)

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA.

J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.

[British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 - a rapid update.](#)

Smith CH, Yiu ZZ, Bale T, Burden AD, Coates LC, Edwards W, MacMahon E, Mahil S, McGuire A, Murphy R, Nelson-Piercy C, Owen CM, Parslew R, Uthman OA, Woolf RT, Manounah L, Ezejimofor MC, Exton LS, Mohd Mustapa MF; British Association of Dermatologists' Clinical Standards Unit.

Br J Dermatol. 2020 Mar 18. doi: 10.1111/bjd.19039. [Epub ahead of print].

[Patients with specific skin disorders who are affected by COVID-19: what do experiences say about management strategies? : A systematic review.](#)

Najar Nobar N, Goodarzi A.

Dermatol Ther. 2020 Jun 18:e13867. doi: 10.1111/dth.13867. [Epub ahead of print]

[Factors predicting persistence of biologic drugs in psoriasis: A systematic review and meta-analysis.](#)

Mourad A, Straube S, Armijo-Olivo S, Gniadecki R.

Br J Dermatol. 2019 Feb 6. doi: 10.1111/bjd.17738. [Epub ahead of print]

[Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence.](#)

Lin PT, Wang SH, Chi CC.

Sci Rep. 2018 Oct 30;8(1):16068. doi: 10.1038/s41598-018-34293-y.

[Effectiveness end points in real-world studies on biological therapies in psoriasis: Systematic review with focus on drug survival.](#)

Costanzo A, Malara G, Pelucchi C, Fatiga F, Barbera G, Franchi A, Galeone C.

Dermatology. 2018;234(1-2):1-12. doi: 10.1159/000488586. Epub 2018 May 15.

[Immunogenicity of biologics in chronic inflammatory diseases: A systematic review.](#)

Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L.

BioDrugs. 2017 Aug;31(4):299-316. doi: 10.1007/s40259-017-0231-8.

[Review of maintenance of response to psoriasis treatments.](#)

Bartos S, Hill D, Feldman SR.

J Dermatolog Treat. 2016 Aug;27(4):293-7. doi: 10.1080/09546634.2016.1177158.

[Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: A systematic review of published models and clinical practice guidelines.](#)

Mauskopf J, Samuel M, McBride D, Mallya UG, Feldman SR.

Pharmacoeconomics. 2014 Apr;32(4):395-409. doi: 10.1007/s40273-014-0130-5.

[Antidrug antibodies in psoriasis: A systematic review.](#)

Hsu L, Snodgrass BT, Armstrong AW.

Br J Dermatol. 2014 Feb;170(2):261-73. doi: 10.1111/bjd.12654.

[The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis.](#)

Garcês S, Demengeot J, Benito-Garcia E.

Ann Rheum Dis. 2013 Dec;72(12):1947-55. doi: 10.1136/annrheumdis-2012-202220. Epub 2012 Dec 6.

[Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: Systematic review and meta-analysis.](#)

Maneiro JR, Salgado E, Gomez-Reino JJ.

JAMA Intern Med. 2013 Aug 12;173(15):1416-28. doi: 10.1001/jamainternmed.2013.7430.

[Off-label biologic regimens in psoriasis: A systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy.](#)

Brezinski EA, Armstrong AW.

PLoS One. 2012;7(4):e33486. doi: 10.1371/journal.pone.0033486. Epub 2012 Apr 11.

Biologics – risk of infections

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.](#)

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmetts CA.
J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.

[British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 - a rapid update.](#)

Smith CH, Yiu ZZ, Bale T, Burden AD, Coates LC, Edwards W, MacMahon E, Mahil S, McGuire A, Murphy R, Nelson-Piercy C, Owen CM, Parslew R, Uthman OA, Woolf RT, Manounah L, Ezejimofor MC, Exton LS, Mohd Mustapa MF; British Association of Dermatologists' Clinical Standards Unit.
Br J Dermatol. 2020 Mar 18. doi: 10.1111/bjd.19039. [Epub ahead of print].

[Effectiveness and safety of systemic therapy for psoriasis in older adults: A systematic review.](#)

van Winden MEC, van der Schoot LS, van de L'Isle Arias M, van Vugt LJ, van den Reek JMPA, van de Kerkhof PCM, de Jong EMGJ, Lubeek SFK.
JAMA Dermatol. 2020 Aug 19. doi: 10.1001/jamadermatol.2020.2311. Online ahead of print.

[Biologic treatment in elderly patients with psoriasis: A systematic review.](#)

Sandhu VK, Ighani A, Fleming P, Lynde CW.
J Cutan Med Surg. 2020 Jan 17:1203475419897578. doi: 10.1177/1203475419897578. [Epub ahead of print]

[Active tuberculosis in patients with psoriasis receiving biologic therapy: A systematic review.](#)

Snast I, Bercovici E, Solomon-Cohen E, Avni T, Shitenberg D, Hodak E, Pavlovsky L.
Am J Clin Dermatol. 2019 Aug;20(4):483-491. doi: 10.1007/s40257-019-00432-y.

[A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation.](#)

Baumrin E, Van Voorhees A, Garg A, Feldman SR, Merola JF.
J Am Acad Dermatol. 2019 Jul;81(1):102-110. doi: 10.1016/j.jaad.2019.03.017. Epub 2019 Mar 15.

[Safety of biologic therapy in older patients with immune-mediated diseases: A systematic review and meta-analysis.](#)

Borren NZ, Ananthakrishnan AN.
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1736-1743.e4. doi: 10.1016/j.cgh.2018.12.032. Epub 2019 Jan 4.

[Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature.](#)

Snast I, Atzmony L, Braun M, Hodak E, Pavlovsky L.
J Am Acad Dermatol. 2017 Jul;77(1):88-97.e5. doi: 10.1016/j.jaad.2017.01.037. Epub 2017 May 9.

[Risk of tuberculosis in patients treated with TNF- \$\alpha\$ antagonists: A systematic review and meta-analysis of randomised controlled trials.](#)

Zhang Z, Fan W, Yang G, Xu Z, Wang J, Cheng Q, Yu M.
BMJ Open. 2017 Mar 22;7(3):e012567. doi: 10.1136/bmjopen-2016-012567.

[Risk of herpes zoster in individuals on biologics, disease-modifying antirheumatic drugs, and/or corticosteroids for autoimmune diseases: A systematic review and meta-analysis.](#)

Marra F, Lo E, Kalashnikov V, Richardson K.
Open Forum Infect Dis. 2016 Sep 28;3(4):ofw205. eCollection 2016 Oct.

[Risk of serious infections in patients with psoriasis on biologic therapies: A systematic review and meta-analysis.](#)

Yiu ZZ, Exton LS, Jabbar-Lopez Z, Mohd Mustapa MF, Samarasekera EJ, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Ashcroft DM, Griffiths CE, Smith CH, Warren RB.
J Invest Dermatol. 2016 Aug;136(8):1584-91. doi: 10.1016/j.jid.2016.03.035. Epub 2016 Apr 13.

[Comparative risk of harm associated with the use of targeted immunomodulators: A systematic review.](#)

Desai RJ, Thaler KJ, Mahlknecht P, Gartlehner G, McDonagh MS, Mesgarpour B, Mazinianian A, Glechner A, Gopalakrishnan C, Hansen RA.
Arthritis Care Res (Hoboken). 2016 Aug;68(8):1078-88. doi: 10.1002/acr.22815.

[To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis.](#)

Ahn CS, Dothard EH, Garner ML, Feldman SR, Huang WW.
J Am Acad Dermatol. 2015 Sep;73(3):420-8.e1. doi: 10.1016/j.jaad.2015.06.004. Epub 2015 Jul 14.

[Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.](#)

Sorenson E, Koo J.
J Dermatolog Treat. 2015;26(6):493-501. doi: 10.3109/09546634.2015.1027167. Epub 2015 Apr 17.

[Subcutaneous biological treatments for moderate to severe psoriasis: Interpreting safety data by network meta-analysis.](#)

Messori A, Trippoli S, Fadda V, Maratea D, Marinai C.
Drugs Real World Outcomes. 2015 Mar;2(1):23-27.

[Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.](#)

Lorenzetti R, Zullo A, Ridola L, Diamanti AP, Laganà B, Gatta L, Migliore A, Armuzzi A, Hassan C, Bruzzese V.
Ann Med. 2014 Nov;46(7):547-54. doi: 10.3109/07853890.2014.941919. Epub 2014 Aug 8.

[Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: A systematic review and meta-analysis of randomized controlled trials and long-term extension studies.](#)

Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ.
Rheumatology (Oxford). 2014 Oct;53(10):1872-85. doi: 10.1093/rheumatology/keu172. Epub 2014 May 11.

[The safety of systemic treatments that can be used for geriatric psoriasis patients: A review.](#)

Wong JW, Koo JY.
Dermatol Res Pract. 2012;2012:367475. doi: 10.1155/2012/367475. Epub 2012 May 28.

Biologics – effect on co-morbidities

[Development of morphea in patients on biologic therapies: A systematic review.](#)

Maliyar K, Mufti A, Sachdeva M, Lytvyn Y, Salsberg J, Yeung J.

J Am Acad Dermatol. 2020 Jul 17:S0190-9622(20)32222-2. doi: 10.1016/j.jaad.2020.06.1027. Online ahead of print.

[Melanoma risk in patients treated with biologic therapy for common inflammatory diseases: A systematic review and meta-analysis.](#)

Esse S, Mason KJ, Green AC, Warren RB.

JAMA Dermatol. 2020 May 20. doi: 10.1001/jamadermatol.2020.1300. [Epub ahead of print]

[Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis.](#)

Vaengebjerg S, Skov L, Egeberg A, Loft ND.

JAMA Dermatol. 2020 Feb 19. doi: 10.1001/jamadermatol.2020.0024. [Epub ahead of print]

[Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review.](#)

Al-Janabi A, Foulkes AC, Mason K, Smith CH, Griffiths C, Warren RB.

J Eur Acad Dermatol Venereol. 2020 Jan 30. doi: 10.1111/jdv.16246. [Epub ahead of print]

[Effect of biological treatment on fatigue in psoriasis: A systematic review and meta-analysis.](#)

Skoie IM, Dalen I, Omdal R.

Am J Clin Dermatol. 2019 Aug;20(4):493-502. doi: 10.1007/s40257-019-00434-w.

[Challenges in the treatment of psoriasis with biologics: vaccination, history of malignancy, human immunodeficiency virus \(HIV\) infection, and pediatric psoriasis.](#)

Plachouri KM, Georgiou S.

Int J Dermatol. 2019 Sep;58(9):1008-1013. doi: 10.1111/ijd.14436. Epub 2019 Mar 19.

[Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials.](#)

Champs B, Degboé Y, Barnette T, Cantagrel A, Ruysen-Witrand A, Constantin A.

RMD Open. 2019 Jan 24;5(1):e000763. doi: 10.1136/rmdopen-2018-000763. eCollection 2019.

[Safety of biologic therapy in older patients with immune-mediated diseases: A systematic review and meta-analysis.](#)

Borren NZ, Ananthakrishnan AN.

Clin Gastroenterol Hepatol. 2019 Aug;17(9):1736-1743.e4. doi: 10.1016/j.cgh.2018.12.032. Epub 2019 Jan 4.

[Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review.](#)

Bartos G, Cline A, Beroukhim K, Burrall BA, Feldman SR.

Dermatol Online J. 2018 Nov 15;24(11). pii: 13030/qt3db748cg.

[Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies.](#)

Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T.
Cutis. 2018 Jan;101(1):38;42;56.

[Systematic review of the efficacy and safety of biological therapy for inflammatory conditions in HIV-infected individuals.](#)

Fink DL, Hedley L, Miller RF.

Int J STD AIDS. 2017 Feb;28(2):110-119. doi: 10.1177/0956462416675109. Epub 2016 Oct 13.

[Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: Systematic review and meta-analysis of randomized controlled trials.](#)

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.

Br J Dermatol. 2017 Apr;176(4):890-901. doi: 10.1111/bjd.14964. Epub 2017 Mar 14.

[The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: An updated meta-analysis.](#)

Yang ZS, Lin NN, Li L, Li Y.

Clin Rev Allergy Immunol. 2016 Oct;51(2):240-7. doi: 10.1007/s12016-016-8560-9.

[Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: A systematic review and meta-analysis.](#)

Shelton E, Laharie D, Scott FI, Mamtani R, Lewis JD, Colombel JF, Ananthakrishnan AN.

Gastroenterology. 2016 Jul;151(1):97-109.e4. doi: 10.1053/j.gastro.2016.03.037. Epub 2016 Apr 1.

[Tumour necrosis factor- \$\alpha\$ inhibitor therapy in chronic physical illness: A systematic review and meta-analysis of the effect on depression and anxiety.](#)

Abbott R, Whear R, Nikolaou V, Bethel A, Coon JT, Stein K, Dickens C.

J Psychosom Res. 2015 Sep;79(3):175-84. doi: 10.1016/j.jpsychores.2015.04.008. Epub 2015 Apr 23.

[Effect of biologics on depressive symptoms in patients with psoriasis: A systematic review.](#)

Fleming P, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Siu S, Kraft J, Lynde C, Pope JE, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B, Gulliver WP.

J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1063-70. doi: 10.1111/jdv.12909. Epub 2014 Dec 10.

[Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.](#)

Sorenson E, Koo J.

J Dermatolog Treat. 2015;26(6):493-501. doi: 10.3109/09546634.2015.1027167. Epub 2015 Apr 17.

[The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis.](#)

Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B.

Ann Rheum Dis. 2015 Mar;74(3):480-9. doi: 10.1136/annrheumdis-2014-206624. Epub 2015 Jan 5.

[Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: A systematic review.](#)

Armstrong AW, Brezinski EA, Follansbee MR, Armstrong EJ.

Curr Pharm Des. 2014;20(4):500-12.

[An evidence-based review of skin cancer rates on biologic therapies.](#)

Kamangar F, Neuhaus IM, Koo JY.
J Dermatolog Treat. 2012 Aug;23(4):305-15. doi: 10.3109/09546634.2011.652064.

[The safety of systemic treatments that can be used for geriatric psoriasis patients: A review.](#)

Wong JW, Koo JY.

Dermatol Res Pract. 2012;2012:367475. doi: 10.1155/2012/367475. Epub 2012 May 28.

Biosimilars

[Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab.](#)

Feagan BG, Lam G, Ma C, Lichtenstein GR.

Aliment Pharmacol Ther. 2019 Jan;49(1):31-40. doi: 10.1111/apt.14997. Epub 2018 Nov 8.

[Focus on biosimilar etanercept - bioequivalence and interchangeability.](#)

Cantini F, Benucci M.

Biologics. 2018 Aug 30;12:87-95. doi: 10.2147/BTT.S126854. eCollection 2018.

[Efficacy and safety outcomes for originator TNF inhibitors and biosimilars in rheumatoid arthritis and psoriasis trials: a systematic literature review.](#)

Moots RJ, Curiale C, Petersel D, Rolland C, Jones H, Mysler E.

BioDrugs. 2018 Jun;32(3):193-199. doi: 10.1007/s40259-018-0283-4.

[How similar are the treatment responses to biosimilars in patients with psoriasis? A systematic review of statistical margins in comparative clinical trials.](#)

Wan MT, Strober BE, Wu JJ, Shin DB, Gelfand JM.

J Am Acad Dermatol. 2017 Sep;77(3):569-572. doi: 10.1016/j.jaad.2017.05.032. No abstract available.

[Immunogenicity of biologics in chronic inflammatory diseases: A systematic review.](#)

Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L.

BioDrugs. 2017 Aug;31(4):299-316. doi: 10.1007/s40259-017-0231-8.

[Biosimilars for the treatment of chronic inflammatory diseases: A systematic review of published evidence.](#)

Jacobs I, Petersel D, Isakov L, Lula S, Lea Sewell K.

BioDrugs. 2016 Dec;30(6):525-570.

[Biosimilars: a systematic review of published and ongoing clinical trials of antipsoriatics in chronic inflammatory diseases.](#)

Nast A, Rosumeck S, Seidenschnur K.

J Dtsch Dermatol Ges. 2015 Apr;13(4):294-300. doi: 10.1111/ddg.12621.

Anti-TNF agents

Anti-TNF agents - general

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.](#)

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA.

J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.

[British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 - a rapid update.](#)

Smith CH, Yiu ZZ, Bale T, Burden AD, Coates LC, Edwards W, MacMahon E, Mahil S, McGuire A, Murphy R, Nelson-Piercy C, Owen CM, Parslew R, Uthman OA, Woolf RT, Manounah L, Ezejimofor MC, Exton LS, Mohd Mustapa MF; British Association of Dermatologists' Clinical Standards Unit. Br J Dermatol. 2020 Mar 18. doi: 10.1111/bjd.19039. [Epub ahead of print].

[Effectiveness and safety of systemic therapy for psoriasis in older adults: A systematic review.](#)

van Winden MEC, van der Schoot LS, van de L'Isle Arias M, van Vugt LJ, van den Reek JMPA, van de Kerkhof PCM, de Jong EMGJ, Lubeek SFK.

JAMA Dermatol. 2020 Aug 19. doi: 10.1001/jamadermatol.2020.2311. Online ahead of print.

[Development of morphea in patients on biologic therapies: A systematic review.](#)

Maliyar K, Mufti A, Sachdeva M, Lytvyn Y, Salsberg J, Yeung J.

J Am Acad Dermatol. 2020 Jul 17:S0190-9622(20)32222-2. doi: 10.1016/j.jaad.2020.06.1027. Online ahead of print.

[Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Tada Y, Watanabe R, Noma H, Kanai Y, Nomura T, Kaneko K.

J Dermatol Sci. 2020 Jun 18. pii: S0923-1811(20)30199-7. doi: 10.1016/j.jdermsci.2020.06.003. [Epub ahead of print]

[Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.](#)

Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, de Brito M, McGuire A, Murphy R, Owen CM, Parslew R, Woolf RT, Yiu ZZN, Uthman OA, Mohd Mustapa MF, Smith CH. Br J Dermatol. 2020 Jun 20. doi: 10.1111/bjd.19325. [Epub ahead of print]

[Biologics and small molecules in patients with scalp psoriasis: a systematic review.](#)

Alsenaid A, Ezmerli M, Srour J, Heppt M, Illigens BM, Prinz JC.

J Dermatolog Treat. 2020 May 14:1-38. doi: 10.1080/09546634.2020.1770167. [Epub ahead of print]

[Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.](#)

Yasmeen N, Sawyer LM, Malottki K, Levin LÅ, Apol ED, Jemec GB.

J Dermatolog Treat. 2020 Mar 23;1-50. doi: 10.1080/09546634.2020.1743811. [Epub ahead of print]

[Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis.](#)

Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M.

JAMA Dermatol. 2020 Feb 5. doi: 10.1001/jamadermatol.2019.4029. [Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L.

Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

[Biologic treatment in elderly patients with psoriasis: A systematic review.](#)

Sandhu VK, Ighani A, Fleming P, Lynde CW.

J Cutan Med Surg. 2020 Jan 17:1203475419897578. doi: 10.1177/1203475419897578. [Epub ahead of print]

[Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.](#)

Warren RB, Gooderham M, Burge R, Zhu B, Amato D, Liu KH, Shrom D, Guo J, Brnabic A, Blauvelt A.

J Am Acad Dermatol. 2019 Dec 26. pii: S0190-9622(19)33315-8. doi: 10.1016/j.jaad.2019.12.038.

[Epub ahead of print]

[Review of treatments for generalized pustular psoriasis.](#)

Kearns DG, Chat VS, Zang PD, Han G, Wu JJ.

J Dermatolog Treat. 2019 Nov 7:1-13. doi: 10.1080/09546634.2019.1682502. [Epub ahead of print]

[The efficacy and evidence-based use of biologics in children and adolescents.](#)

Niehues T, Özgür TT.

Dtsch Arztebl Int. 2019 Oct 18;116(42):703-710. doi: 10.3238/arztebl.2019.0703.

[Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: A comprehensive investigation using Bayesian and frequentist network meta-analyses.](#)

Warren RB, See K, Burge R, Zhang Y, Brnabic A, Gallo G, Garrelts A, Egeberg A.

Dermatol Ther (Heidelb). 2019 Nov 4. doi: 10.1007/s13555-019-00337-y. [Epub ahead of print]

[Autoimmune blistering diseases provoked during the treatment of chronic inflammatory disease with biologic agents: a systematic review.](#)

Gibson FT, Amber KT.

Int J Dermatol. 2019 Oct 20. doi: 10.1111/ijd.14686. [Epub ahead of print]

[Biological therapy for pustular psoriasis: a systematic review.](#)

Falto-Aizpurua LA, Martin-Garcia RF, Carrasquillo OY, Nevares-Pomales OW, Sánchez-Flores X, Lorenzo-Rios D.

Int J Dermatol. 2019 Oct 15. doi: 10.1111/ijd.14671. [Epub ahead of print]

[Change in body weight and body mass index in psoriasis patients receiving biologics: a systematic review and network meta-analysis.](#)

Wu MY, Yu CL, Yang SJ, Chi CC.

J Am Acad Dermatol. 2019 Aug 7. pii: S0190-9622(19)32498-3. doi: 10.1016/j.jaad.2019.07.103.

[Epub ahead of print]

[Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis.](#)

Xu G, Xia M, Jiang C, Yu Y, Wang G, Yuan J, Duan X.

J Pharmacol Sci. 2019 Apr;139(4):289-303. doi: 10.1016/j.jphs.2018.12.006. Epub 2018 Dec 27.

[Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis.](#)

Geng W, Zhao J, Fu J, Zhang H, Qiao S.

Exp Ther Med. 2018 Dec;16(6):5085-5095. doi: 10.3892/etm.2018.6859. Epub 2018 Oct 15.

[Obesity and response to anti-tumor necrosis factor- \$\alpha\$ agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis.](#)

Singh S, Facciorusso A, Singh AG, Castele NV, Zarrinpar A, Prokop LJ, Grunvald EL, Curtis JR, Sandborn WJ.

PLoS One. 2018 May 17;13(5):e0195123. doi: 10.1371/journal.pone.0195123. eCollection 2018.

[Efficacy and safety outcomes for originator TNF inhibitors and biosimilars in rheumatoid arthritis and psoriasis trials: a systematic literature review.](#)

Moots RJ, Curiale C, Petersel D, Rolland C, Jones H, Mysler E.

BioDrugs. 2018 Jun;32(3):193-199. doi: 10.1007/s40259-018-0283-4.

[Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: a systematic review and meta-analysis.](#)

Juan S, Jiabi Z.

Joint Bone Spine. 2019 Mar;86(2):173-183. doi: 10.1016/j.jbspin.2018.03.007. Epub 2018 Apr 7.

[Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.](#)

Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.

Curr Med Res Opin. 2018 Jul;34(7):1325-1333. doi: 10.1080/03007995.2018.1457516. Epub 2018 Apr 23.

[Quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.](#)

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.

Mol Pain. 2018 Jan-Dec;14:1744806918762205. doi: 10.1177/1744806918762205. Epub 2018 Feb 15.

[Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.](#)

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.

J Am Acad Dermatol. 2018 Jul;79(1):135-144.e7. doi: 10.1016/j.jaad.2018.02.027. Epub 2018 Feb 10.

[Biologics and small molecules in psoriasis: A systematic review of economic evaluations.](#)

Kromer C, Celis D, Sonntag D, Peitsch WK.

PLoS One. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765. eCollection 2018.

[Biologics in pediatric psoriasis - efficacy and safety.](#)

Dogra S, Mahajan R.

Expert Opin Drug Saf. 2018 Jan;17(1):9-16. doi: 10.1080/14740338.2018.1391787. Epub 2017 Oct 30.

[The efficacy of biologic therapy for the management of palmoplantar psoriasis and palmoplantar pustulosis: A systematic review.](#)

Sanchez IM, Sorenson E, Levin E, Liao W.

Dermatol Ther (Heidelb). 2017 Dec;7(4):425-446. doi: 10.1007/s13555-017-0207-0. Epub 2017 Nov 15.

[A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.](#)

No DJ, Amin M, Bhutani T, Wu JJ.

J Dermatolog Treat. 2018 Aug;29(5):467-474. doi: 10.1080/09546634.2017.1402116. Epub 2017 Nov 22.

[Drug survival of biologic treatments in psoriasis: a systematic review.](#)

No DJ, Inkeles MS, Amin M, Wu JJ.

J Dermatolog Treat. 2018 Aug;29(5):460-466. doi: 10.1080/09546634.2017.1398393. Epub 2017 Nov 10.

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Théréné C, Brenaut E, Barnette T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[Exposure to biologic therapies during conception and pregnancy: A systematic review.](#)

Pottinger EM, Woolf RT, Exton LS, Burden AD, Nelson-Piercy C, Smith CH.

Br J Dermatol. 2018 Jan;178(1):95-102. doi: 10.1111/bjd.15802. Epub 2017 Dec 14.

[Risk of cancer in patients with psoriasis on biologic therapies: A systematic review.](#)

Peleva E, Exton LS, Kelley K, Mason KJ, Smith CH.

Br J Dermatol. 2018 Jan;178(1):103-113. doi: 10.1111/bjd.15830. Epub 2017 Dec 18.

[A systematic review of pharmacogenetic studies on the response to biologics in psoriasis patients.](#)

van Vugt LJ, van den Reek JMPA, Coenen MJH, de Jong EMGJ.

Br J Dermatol. 2018 Jan;178(1):86-94. doi: 10.1111/bjd.15753. Epub 2017 Dec 14.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.

Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: Systematic review and meta-analysis of randomized controlled trials.](#)

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.

Br J Dermatol. 2017 Apr;176(4):890-901. doi: 10.1111/bjd.14964. Epub 2017 Mar 14.

[Risk of tuberculosis in patients treated with TNF- \$\alpha\$ antagonists: A systematic review and meta-analysis of randomised controlled trials.](#)

Zhang Z, Fan W, Yang G, Xu Z, Wang J, Cheng Q, Yu M.

BMJ Open. 2017 Mar 22;7(3):e012567. doi: 10.1136/bmjopen-2016-012567.

[Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?](#)

Chen Y, Friedman M, Liu G, Deodhar A, Chu CQ.

Cytokine. 2018 Jan;101:78-88. doi: 10.1016/j.cyto.2016.09.013. Epub 2016 Sep 26.

[The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: An updated meta-analysis.](#)

Yang ZS, Lin NN, Li L, Li Y.

Clin Rev Allergy Immunol. 2016 Oct;51(2):240-7. doi: 10.1007/s12016-016-8560-9.

[Systematic review of efficacy of anti-tumor necrosis factor \(TNF\) therapy in patients with psoriasis previously treated with a different anti-TNF agent.](#)

Yamauchi PS, Bissonnette R, Teixeira HD, Valdecantos WC.

J Am Acad Dermatol. 2016 Sep;75(3):612-618.e6. doi: 10.1016/j.jaad.2016.02.1221. Epub 2016 Apr 6.

[Comparative risk of harm associated with the use of targeted immunomodulators: A systematic review.](#)

Desai RJ, Thaler KJ, Mahlknecht P, Gartlehner G, McDonagh MS, Mesgarpour B, Mazinianian A, Glechner A, Gopalakrishnan C, Hansen RA.

Arthritis Care Res (Hoboken). 2016 Aug;68(8):1078-88. doi: 10.1002/acr.22815.

[Associations between functional FCGR2A R131H and FCGR3A F158V polymorphisms and responsiveness to TNF blockers in spondyloarthritis, psoriasis and Crohn's disease: A meta-analysis.](#)

Lee YH, Choi SJ, Ji JD, Song GG.

Pharmacogenomics. 2016 Aug;17(13):1465-77. doi: 10.2217/pgs.16.27. Epub 2016 Aug 4.

[Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: A systematic review and meta-analysis.](#)

Shelton E, Laharie D, Scott FI, Mamtani R, Lewis JD, Colombel JF, Ananthakrishnan AN.

Gastroenterology. 2016 Jul;151(1):97-109.e4. doi: 10.1053/j.gastro.2016.03.037. Epub 2016 Apr 1.

[Malignancy risk of anti-tumor necrosis factor alpha blockers: An overview of systematic reviews and meta-analyses.](#)

Chen Y, Sun J, Yang Y, Huang Y, Liu G.

Clin Rheumatol. 2016 Jan;35(1):1-18. doi: 10.1007/s10067-015-3115-7. Epub 2015 Nov 16.

[Anti-TNF agents for paediatric psoriasis.](#)

Sanclemente G, Murphy R, Contreras J, García H, Bonfill Cosp X.

Cochrane Database Syst Rev. 2015 Nov 24;(11):CD010017. doi: 10.1002/14651858.CD010017.pub2.

[The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis.](#)

Chen W, Xu H, Wang X, Gu J, Xiong H, Shi Y.

Int Immunopharmacol. 2015 Sep;28(1):146-53. doi: 10.1016/j.intimp.2015.05.049. Epub 2015 Jun 9.

[Tumour necrosis factor- \$\alpha\$ inhibitor therapy in chronic physical illness: A systematic review and meta-analysis of the effect on depression and anxiety.](#)

Abbott R, Whear R, Nikolaou V, Bethel A, Coon JT, Stein K, Dickens C.

J Psychosom Res. 2015 Sep;79(3):175-84. doi: 10.1016/j.jpsychores.2015.04.008. Epub 2015 Apr 23.

[Association between TNF- \$\alpha\$ \(-308 A/G, -238 A/G, -857 C/T\) polymorphisms and responsiveness to TNF- \$\alpha\$ blockers in spondyloarthropathy, psoriasis and Crohn's disease: A meta-analysis.](#)

Song GG, Seo YH, Kim JH, Choi SJ, Ji JD, Lee YH.

Pharmacogenomics. 2015;16(12):1427-37. doi: 10.2217/pgs.15.90. Epub 2015 Aug 5.

[Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review.](#)

Gilbert KE, Manalo IF, Wu JJ.

J Am Acad Dermatol. 2015 Aug;73(2):329-31. doi: 10.1016/j.jaad.2015.04.012.

[The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis.](#)

Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Siu S, Kraft J, Lynde C, Pope J, Gulliver W, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B.

Ann Rheum Dis. 2015 Mar;74(3):480-9. doi: 10.1136/annrheumdis-2014-206624. Epub 2015 Jan 5.

[Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.](#)

Lorenzetti R, Zullo A, Ridola L, Diamanti AP, Laganà B, Gatta L, Migliore A, Armuzzi A, Hassan C, Bruzzese V.

Ann Med. 2014 Nov;46(7):547-54. doi: 10.3109/07853890.2014.941919. Epub 2014 Aug 8.

[Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: A systematic review.](#)

Brezinski EA, Follansbee MR, Armstrong EJ, Armstrong AW.

Curr Pharm Des. 2014;20(4):513-28.

[The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis.](#)

Garcês S, Demengeot J, Benito-Garcia E.

Ann Rheum Dis. 2013 Dec;72(12):1947-55. doi: 10.1136/annrheumdis-2012-202220. Epub 2012 Dec 6.

[Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: Systematic review and meta-analysis.](#)

Maneiro JR, Salgado E, Gomez-Reino JJ.

JAMA Intern Med. 2013 Aug 12;173(15):1416-28. doi: 10.1001/jamainternmed.2013.7430.

[Impact of TNF- \$\alpha\$ antagonists on the quality of life in selected skin diseases.](#)

Gisoni P, Girolomoni G.

G Ital Dermatol Venereol. 2013 Jun;148(3):243-8.

[Biological treatments for moderate-to-severe psoriasis: indirect comparison.](#)

Galván-Banqueri M, Marín Gil R, Santos Ramos B, Bautista Paloma FJ.

J Clin Pharm Ther. 2013 Apr;38(2):121-30. doi: 10.1111/jcpt.12044. Epub 2013 Feb 26.

[Treatment of nail psoriasis with TNF- \$\alpha\$ or IL12/23 inhibitors.](#)

Jemec GB, Ibler KS.

J Drugs Dermatol. 2012 Aug;11(8):939-42

[Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.](#)

Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P.
Adv Ther. 2012 Jul;29(7):620-34. doi: 10.1007/s12325-012-0035-7. Epub 2012 Jul 27.

[The safety of systemic treatments that can be used for geriatric psoriasis patients: A review.](#)

Wong JW, Koo JY.
Dermatol Res Pract. 2012;2012:367475. doi: 10.1155/2012/367475. Epub 2012 May 28.

Anti-TNF agents – induced psoriasis

[Clinical management of anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review.](#)

Melo FJ, Magina S.
Int J Dermatol. 2018 Dec;57(12):1521-1532. doi: 10.1111/ijd.14072. Epub 2018 Jul 20.

[Tumor necrosis factor-α inhibitor-induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience.](#)

Brown G, Wang E, Leon A, Huynh M, Wehner M, Matro R, Linos E, Liao W, Haemel A.
J Am Acad Dermatol. 2017 Feb;76(2):334-341. doi: 10.1016/j.jaad.2016.08.012. Epub 2016 Oct 5.

[Paradoxical reactions induced by tumor necrosis factor-alpha antagonists: A literature review based on 46 cases.](#)

Olteanu R, Zota A.
Indian J Dermatol Venereol Leprol. 2016 Jan-Feb;82(1):7-12. doi: 10.4103/0378-6323.172898.

[Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: A systematic literature review based on 222 cases.](#)

Denadai R, Teixeira FV, Steinwurz F, Romiti R, Saad-Hossne R.
J Crohns Colitis. 2013 Aug;7(7):517-24. doi: 10.1016/j.crohns.2012.08.007. Epub 2012 Sep 7.

[The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: Should biological therapy be suspended?](#)

Denadai R, Teixeira FV, Saad-Hossne R.
Arq Gastroenterol. 2012 Apr-Jun;49(2):172-6

Anti-TNF agents - etanercept

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.](#)

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA.
J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.

[FDA approved biologics: Can etanercept and ustekinumab be considered a first-line systemic therapy for pediatric/adolescents in moderate to severe psoriasis? A systematic review.](#)

Aslam N, Saleem H, Murtazaliev S, Quazi SJ, Khan S.

Cureus. 2020 Aug 17;12(8):e9812. doi: 10.7759/cureus.9812.

[Efficacy of biologics targeting tumour necrosis factor-alpha, interleukin-17 -12/23, -23 and small molecules targeting JAK and PDE4 in the treatment of nail psoriasis: A network meta-analysis.](#)

Szebényi J, Gede N, Hegyi P, Szakács Z, Solymár M, Erőss B, Garami A, Farkas K, Csupor D, Gyulai R.

Acta Derm Venereol. 2020 Sep 23. doi: 10.2340/00015555-3640. Online ahead of print.

[Effectiveness and safety of systemic therapy for psoriasis in older adults: A systematic review.](#)

van Winden MEC, van der Schoot LS, van de L'Isle Arias M, van Vugt LJ, van den Reek JMPA, van de Kerkhof PCM, de Jong EMGJ, Lubeek SFK.

JAMA Dermatol. 2020 Aug 19. doi: 10.1001/jamadermatol.2020.2311. Online ahead of print.

[Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.](#)

Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, de Brito M, McGuire A, Murphy R, Owen CM, Parslew R, Woolf RT, Yiu ZZN, Uthman OA, Mohd Mustapa MF, Smith CH.

Br J Dermatol. 2020 Jun 20. doi: 10.1111/bjd.19325. [Epub ahead of print]

[Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.](#)

Yasmeen N, Sawyer LM, Malottki K, Levin LÅ, Apol ED, Jemec GB.

J Dermatolog Treat. 2020 Mar 23:1-50. doi: 10.1080/09546634.2020.1743811. [Epub ahead of print]

[Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis.](#)

Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M.

JAMA Dermatol. 2020 Feb 5. doi: 10.1001/jamadermatol.2019.4029. [Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L.

Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

[Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.](#)

Warren RB, Gooderham M, Burge R, Zhu B, Amato D, Liu KH, Shrom D, Guo J, Brnabic A, Blauvelt A.

J Am Acad Dermatol. 2019 Dec 26. pii: S0190-9622(19)33315-8. doi: 10.1016/j.jaad.2019.12.038.

[Epub ahead of print]

[The efficacy and evidence-based use of biologics in children and adolescents.](#)

Niehues T, Özgür TT.

Dtsch Arztebl Int. 2019 Oct 18;116(42):703-710. doi: 10.3238/arztebl.2019.0703.

[Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: A comprehensive investigation using Bayesian and frequentist network meta-analyses.](#)

Warren RB, See K, Burge R, Zhang Y, Brnabic A, Gallo G, Garrelts A, Egeberg A.

Dermatol Ther (Heidelb). 2019 Nov 4. doi: 10.1007/s13555-019-00337-y. [Epub ahead of print]

[Biologics switch in psoriasis.](#)

Wang TS, Tsai TF.
Immunotherapy. 2019 Apr;11(6):531-541. doi: 10.2217/imt-2018-0131.

[Economic impact of etanercept in patients with psoriasis and psoriatic arthritis in Spain: A systematic review.](#)

Puig L, Fernández-Freire LR, Burgos-Pol R, Gomez I, Peral C, Gomez S, Laserna FJR.
Dermatol Ther (Heidelb). 2019 May 6. doi: 10.1007/s13555-019-0301-6. [Epub ahead of print]

[Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis.](#)

Xu G, Xia M, Jiang C, Yu Y, Wang G, Yuan J, Duan X.
J Pharmacol Sci. 2019 Apr;139(4):289-303. doi: 10.1016/j.jphs.2018.12.006. Epub 2018 Dec 27.

[Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis.](#)

Geng W, Zhao J, Fu J, Zhang H, Qiao S.
Exp Ther Med. 2018 Dec;16(6):5085-5095. doi: 10.3892/etm.2018.6859. Epub 2018 Oct 15.

[Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence.](#)

Lin PT, Wang SH, Chi CC.
Sci Rep. 2018 Oct 30;8(1):16068. doi: 10.1038/s41598-018-34293-y.

[Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.](#)

Sawyer LM, Cornic L, Levin LÅ, Gibbons C, Møller AH, Jemec GB.
J Eur Acad Dermatol Venereol. 2019 Feb;33(2):355-366. doi: 10.1111/jdv.15277. Epub 2018 Oct 31.

[Focus on biosimilar etanercept - bioequivalence and interchangeability.](#)

Cantini F, Benucci M.
Biologics. 2018 Aug 30;12:87-95. doi: 10.2147/BTT.S126854. eCollection 2018.

[Effects of etanercept on the patient-perceived results \(PROs\) in patients with moderate-to-severe plaque psoriasis: Systematic review of the literature and meta-analysis.](#)

Carrascosa JM, Rebollo F, Gómez S, de la Cueva P.
J Dermatolog Treat. 2018 Dec;29(8):806-811. doi: 10.1080/09546634.2018.1467536. Epub 2018 May 8.

[Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.](#)

Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.
Curr Med Res Opin. 2018 Jul;34(7):1325-1333. doi: 10.1080/03007995.2018.1457516. Epub 2018 Apr 23.

[Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies.](#)

Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T.
Cutis. 2018 Jan;101(1):38;42;56.

[Quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.](#)

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.

Mol Pain. 2018 Jan-Dec;14:1744806918762205. doi: 10.1177/1744806918762205. Epub 2018 Feb 15.

[Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.](#)

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.

J Am Acad Dermatol. 2018 Jul;79(1):135-144.e7. doi: 10.1016/j.jaad.2018.02.027. Epub 2018 Feb 10.

[Biologicals and small molecules in psoriasis: A systematic review of economic evaluations.](#)

Kromer C, Celis D, Sonntag D, Peitsch WK.

PLoS One. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765. eCollection 2018.

[A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.](#)

No DJ, Amin M, Bhutani T, Wu JJ.

J Dermatolog Treat. 2018 Aug;29(5):467-474. doi: 10.1080/09546634.2017.1402116. Epub 2017 Nov 22.

[Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.](#)

Duarte A, Mebrahtu T, Goncalves PS, Harden M, Murphy R, Palmer S, Woolacott N, Rodgers M, Rothery C.

Health Technol Assess. 2017 Nov;21(64):1-244. doi: 10.3310/hta21640.

[Drug survival of biologic treatments in psoriasis: a systematic review.](#)

No DJ, Inkeles MS, Amin M, Wu JJ.

J Dermatolog Treat. 2018 Aug;29(5):460-466. doi: 10.1080/09546634.2017.1398393. Epub 2017 Nov 10.

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Théréné C, Brenaut E, Barnette T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[Treatment of severe psoriasis in children: recommendations of an Italian expert group.](#)

Fortina AB, Bardazzi F, Berti S, Carnevale C, Di Lernia V, El Hachem M, Neri I, Gelmetti CM, Lora V, Mazzatenta C, Milioto M, Moretta G, Patrizi A, Peris K, Villani A.

Eur J Pediatr. 2017 Oct;176(10):1339-1354. doi: 10.1007/s00431-017-2985-x. Epub 2017 Aug 23.

[A systematic review of pharmacogenetic studies on the response to biologics in psoriasis patients.](#)

van Vugt LJ, van den Reek JMPA, Coenen MJH, de Jong EMGJ.

Br J Dermatol. 2018 Jan;178(1):86-94. doi: 10.1111/bjd.15753. Epub 2017 Dec 14.

[Immunogenicity of biologics in chronic inflammatory diseases: A systematic review.](#)

Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L.

BioDrugs. 2017 Aug;31(4):299-316. doi: 10.1007/s40259-017-0231-8.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.
Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: Systematic review and meta-analysis of randomized controlled trials.](#)

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.
Br J Dermatol. 2017 Apr;176(4):890-901. doi: 10.1111/bjd.14964. Epub 2017 Mar 14.

[Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: A systematic review and meta-analysis of randomized clinical trials.](#)

de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR.
Drugs R D. 2017 Mar;17(1):29-51. doi: 10.1007/s40268-016-0152-x.

[Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Gómez-García F, Epstein D, Isla-Tejera B, Lorente A, Vélez García-Nieto A, Ruano J.
Br J Dermatol. 2017 Mar;176(3):594-603. doi: 10.1111/bjd.14814. Epub 2016 Oct 13

[The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: An updated meta-analysis.](#)

Yang ZS, Lin NN, Li L, Li Y.
Clin Rev Allergy Immunol. 2016 Oct;51(2):240-7. doi: 10.1007/s12016-016-8560-9.

[Review of maintenance of response to psoriasis treatments.](#)

Bartos S, Hill D, Feldman SR.
J Dermatolog Treat. 2016 Aug;27(4):293-7. doi: 10.1080/09546634.2016.1177158.

[Systemic treatment of pediatric psoriasis: A review.](#)

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.
Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

[Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: A systematic review.](#)

Zweegers J, Otero ME, van den Reek JM, van Lümig PP, Driessen RJ, Kievit W, Seyger MM, van de Kerkhof PC, de Jong EM.
Acta Derm Venereol. 2016 May;96(4):453-8. doi: 10.2340/00015555-2276.

[Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: A systematic review and meta-analysis.](#)

Nast A, Jacobs A, Rosumeck S, Werner RN.
J Invest Dermatol. 2015 Nov;135(11):2641-8. doi: 10.1038/jid.2015.206. Epub 2015 Jun 5.

[Anti-TNF agents for paediatric psoriasis.](#)

Sanclemente G, Murphy R, Contreras J, García H, Bonfill Cosp X.
Cochrane Database Syst Rev. 2015 Nov 24;(11):CD010017. doi: 10.1002/14651858.CD010017.pub2.

[Systematic review on the maintenance of response during systemic antipsoriatic therapy.](#)

Jacobs A, Rosumeck S, Nast A.
Br J Dermatol. 2015 Oct;173(4):910-21. doi: 10.1111/bjd.14077. Epub 2015 Oct 6.

[Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review.](#)

Gilbert KE, Manalo IF, Wu JJ.

J Am Acad Dermatol. 2015 Aug;73(2):329-31. doi: 10.1016/j.jaad.2015.04.012.

[Combining biologics with methotrexate in psoriasis: A systematic review.](#)

van Bezooijen JS, Prens EP, Pradeepti MS, Atiqi R, Schreurs MW, Koch BC, van Gelder T, van Doorn MB.

Br J Dermatol. 2015 Jun;172(6):1676-80. doi: 10.1111/bjd.13573. Epub 2015 Apr 29.

[Effect of biologics on depressive symptoms in patients with psoriasis: A systematic review.](#)

Fleming P, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Siu S, Kraft J, Lynde C, Pope JE, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B, Gulliver WP.

J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1063-70. doi: 10.1111/jdv.12909. Epub 2014 Dec 10.

[Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.](#)

Sorenson E, Koo J.

J Dermatolog Treat. 2015;26(6):493-501. doi: 10.3109/09546634.2015.1027167. Epub 2015 Apr 17.

[Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.](#)

Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.

JAMA Dermatol. 2015 Apr;151(4):432-8. doi: 10.1001/jamadermatol.2014.3456.

[Systemic treatments in paediatric psoriasis: A systematic evidence-based update.](#)

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

[Subcutaneous biological treatments for moderate to severe psoriasis: Interpreting safety data by network meta-analysis.](#)

Messori A, Trippoli S, Fadda V, Maratea D, Marinai C.

Drugs Real World Outcomes. 2015 Mar;2(1):23-27.

[Comparative efficacy of biological treatments for moderate-to-severe psoriasis: A network meta-analysis adjusting for cross-trial differences in reference arm response.](#)

Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P.

Br J Dermatol. 2015 Feb;172(2):504-12. doi: 10.1111/bjd.13437. Epub 2015 Jan 21.

[Evidence-based guidelines of the Spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites \(nails, scalp, palms, and soles\).](#)

Sánchez-Regaña M, Aldunce Soto MJ, Belinchón Romero I, Ribera Pibernat M, Lafuente-Urrez RF, Carrascosa Carrillo JM, Ferrándiz Foraster C, Puig Sanz L, Daudén Tello E, Vidal Sarró D, Ruiz-Villaverde R, Fonseca Capdevila E, Rodríguez Cerdeira MC, Alsina Gibert MM, Herrera Acosta E, Marrón Moya SE; en representación del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología.

Actas Dermosifiliogr. 2014 Dec;105(10):923-34. doi: 10.1016/j.ad.2014.02.015. Epub 2014 May 19. English, Spanish

[Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials with different time points.](#)

Puig L, López A, Vilarrasa E, García I.
J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1633-53. doi: 10.1111/jdv.12238. Epub 2013 Aug 19.

[Network meta-analysis of treatments for chronic plaque psoriasis in Canada.](#)

Gupta AK, Daigle D, Lyons DC.
J Cutan Med Surg. 2014 Nov;18(6):371-8.

[Combined use of systemic agents for psoriasis: A systematic review.](#)

Busard C, Zweegers J, Limpens J, Langendam M, Spuls PI.
JAMA Dermatol. 2014 Nov;150(11):1213-20. doi: 10.1001/jamadermatol.2014.1111.

[Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system.](#)

Wang SH, Chi CC, Hu S.
Int J Dermatol. 2014 Sep;53(9):1151-6. doi: 10.1111/ijd.12462. Epub 2014 Apr 16.

[Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials.](#)

Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A.
Br J Dermatol. 2014 Feb;170(2):274-303. doi: 10.1111/bjd.12663

[Antidrug antibodies in psoriasis: A systematic review.](#)

Hsu L, Snodgrass BT, Armstrong AW.
Br J Dermatol. 2014 Feb;170(2):261-73. doi: 10.1111/bjd.12654.

[Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: A meta-analysis and cost-efficacy analysis using the intention-to-treat principle.](#)

Chi CC, Wang SH.
Biomed Res Int. 2014;2014:862851. doi: 10.1155/2014/862851. Epub 2014 Jan 29.

[The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis.](#)

Garcês S, Demengeot J, Benito-Garcia E.
Ann Rheum Dis. 2013 Dec;72(12):1947-55. doi: 10.1136/annrheumdis-2012-202220. Epub 2012 Dec 6.

[Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: A comprehensive meta-analysis of randomized controlled trials.](#)

Correr CJ, Rotta I, Teles Tde S, Godoy RR, Riveros BS, Garcia MM, Gonçalves PR, Otuki MF.
Cad Saude Publica. 2013 Nov;29 Suppl 1:S17-31.

[Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.](#)

Nast A, Sporbeck B, Rosumeck S, Pathirana D, Jacobs A, Werner RN, Schmitt J.
J Invest Dermatol. 2013 Aug;133(8):1963-70. doi: 10.1038/jid.2013.78. Epub 2013 Feb 20.

[Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: A systematic review of current evidence.](#)

Strohal R, Chimenti S, Vena GA, Girolomoni G.
J Dermatolog Treat. 2013 Jun;24(3):199-208. doi: 10.3109/09546634.2012.713462. Epub 2012 Nov 10.

[Impact of TNF- \$\alpha\$ antagonists on the quality of life in selected skin diseases.](#)

Gisondi P, Girolomoni G.

G Ital Dermatol Venereol. 2013 Jun;148(3):243-8.

[Biological treatments for moderate-to-severe psoriasis: indirect comparison.](#)

Galván-Banqueri M, Marín Gil R, Santos Ramos B, Bautista Paloma FJ.

J Clin Pharm Ther. 2013 Apr;38(2):121-30. doi: 10.1111/jcpt.12044. Epub 2013 Feb 26.

[Effect of biologic agents on non-PASI outcomes in moderate-to-severe plaque psoriasis: Systematic review and meta-analyses.](#)

Baker EL, Coleman CI, Reinhart KM, Phung OJ, Kugelman L, Chen W, White CM, Mamolo CM, Cappelleri JC, Baker WL.

Dermatol Ther (Heidelb). 2012 Dec;2(1):9. doi: 10.1007/s13555-012-0009-3. Epub 2012 Jun 19.

[Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis \[Internet\].](#)

Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J, Sobieraj DM.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

[Efficacy of systemic therapies for moderate-to-severe psoriasis: A systematic review and meta-analysis of long-term treatment.](#)

Lucka TC, Pathirana D, Sammain A, Bachmann F, Rosumeck S, Erdmann R, Schmitt J, Orawa H, Rzyany B, Nast A.

J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1331-44. doi: 10.1111/j.1468-3083.2012.04492.x.

Epub 2012 Mar 9. Review. Erratum in: J Eur Acad Dermatol Venereol. 2012 Jul;26(7):930.

[An evidence-based review of skin cancer rates on biologic therapies.](#)

Kamangar F, Neuhaus IM, Koo JY.

J Dermatolog Treat. 2012 Aug;23(4):305-15. doi: 10.3109/09546634.2011.652064.

[Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis.](#)

Pariser DM, Leonardi CL, Gordon K, Gottlieb AB, Tying S, Papp KA, Li J, Baumgartner SW.

J Am Acad Dermatol. 2012 Aug;67(2):245-56. doi: 10.1016/j.jaad.2011.07.040. Epub 2011 Oct 19.

[Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.](#)

Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P.

Adv Ther. 2012 Jul;29(7):620-34. doi: 10.1007/s12325-012-0035-7. Epub 2012 Jul 27.

[Off-label biologic regimens in psoriasis: A systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy.](#)

Brezinski EA, Armstrong AW.

PLoS One. 2012;7(4):e33486. doi: 10.1371/journal.pone.0033486. Epub 2012 Apr 11.

[Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials.](#)

Reich K, Burden AD, Eaton JN, Hawkins NS.

Br J Dermatol. 2012 Jan;166(1):179-88. doi: 10.1111/j.1365-2133.2011.10583.x. Epub 2011 Nov 11.

Anti-TNF agents - infliximab

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.](#)

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA.
J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.

[Effectiveness and safety of systemic therapy for psoriasis in older adults: A systematic review.](#)

van Winden MEC, van der Schoot LS, van de L'Isle Arias M, van Vugt LJ, van den Reek JMPA, van de Kerkhof PCM, de Jong EMGJ, Lubeek SFK.
JAMA Dermatol. 2020 Aug 19. doi: 10.1001/jamadermatol.2020.2311. Online ahead of print.

[Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Tada Y, Watanabe R, Noma H, Kanai Y, Nomura T, Kaneko K.
J Dermatol Sci. 2020 Jun 18. pii: S0923-1811(20)30199-7. doi: 10.1016/j.jdermsci.2020.06.003. [Epub ahead of print]

[Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.](#)

Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, de Brito M, McGuire A, Murphy R, Owen CM, Parslew R, Woolf RT, Yiu ZZN, Uthman OA, Mohd Mustapa MF, Smith CH.
Br J Dermatol. 2020 Jun 20. doi: 10.1111/bjd.19325. [Epub ahead of print]

[Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.](#)

Yasmeen N, Sawyer LM, Malottki K, Levin LÅ, Apol ED, Jemec GB.
J Dermatolog Treat. 2020 Mar 23:1-50. doi: 10.1080/09546634.2020.1743811. [Epub ahead of print]

[Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis.](#)

Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M.
JAMA Dermatol. 2020 Feb 5. doi: 10.1001/jamadermatol.2019.4029. [Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L.
Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

[Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.](#)

Warren RB, Gooderham M, Burge R, Zhu B, Amato D, Liu KH, Shrom D, Guo J, Brnabic A, Blauvelt A.
J Am Acad Dermatol. 2019 Dec 26. pii: S0190-9622(19)33315-8. doi: 10.1016/j.jaad.2019.12.038. [Epub ahead of print]

[Review of treatments for generalized pustular psoriasis.](#)

Kearns DG, Chat VS, Zang PD, Han G, Wu JJ.
J Dermatolog Treat. 2019 Nov 7;1-13. doi: 10.1080/09546634.2019.1682502. [Epub ahead of print]

[Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: A comprehensive investigation using Bayesian and frequentist network meta-analyses.](#)

Warren RB, See K, Burge R, Zhang Y, Brnabic A, Gallo G, Garrelts A, Egeberg A.
Dermatol Ther (Heidelb). 2019 Nov 4. doi: 10.1007/s13555-019-00337-y. [Epub ahead of print]

[Biological therapy for pustular psoriasis: a systematic review.](#)

Falto-Aizpurua LA, Martin-Garcia RF, Carrasquillo OY, Nevares-Pomales OW, Sánchez-Flores X, Lorenzo-Rios D.
Int J Dermatol. 2019 Oct 15. doi: 10.1111/ijd.14671. [Epub ahead of print]

[Biologics switch in psoriasis.](#)

Wang TS, Tsai TF.
Immunotherapy. 2019 Apr;11(6):531-541. doi: 10.2217/imt-2018-0131.

[Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis.](#)

Xu G, Xia M, Jiang C, Yu Y, Wang G, Yuan J, Duan X.
J Pharmacol Sci. 2019 Apr;139(4):289-303. doi: 10.1016/j.jphs.2018.12.006. Epub 2018 Dec 27.

[Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis.](#)

Geng W, Zhao J, Fu J, Zhang H, Qiao S.
Exp Ther Med. 2018 Dec;16(6):5085-5095. doi: 10.3892/etm.2018.6859. Epub 2018 Oct 15.

[Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence.](#)

Lin PT, Wang SH, Chi CC.
Sci Rep. 2018 Oct 30;8(1):16068. doi: 10.1038/s41598-018-34293-y.

[Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab.](#)

Feagan BG, Lam G, Ma C, Lichtenstein GR.
Aliment Pharmacol Ther. 2019 Jan;49(1):31-40. doi: 10.1111/apt.14997. Epub 2018 Nov 8.

[Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.](#)

Sawyer LM, Cornic L, Levin LÅ, Gibbons C, Møller AH, Jemec GB.
J Eur Acad Dermatol Venereol. 2019 Feb;33(2):355-366. doi: 10.1111/jdv.15277. Epub 2018 Oct 31.

[Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.](#)

Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.
Curr Med Res Opin. 2018 Jul;34(7):1325-1333. doi: 10.1080/03007995.2018.1457516. Epub 2018 Apr 23.

[Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies.](#)

Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T.
Cutis. 2018 Jan;101(1):38;42;56.

[Quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.](#)

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.

Mol Pain. 2018 Jan-Dec;14:1744806918762205. doi: 10.1177/1744806918762205. Epub 2018 Feb 15.

[Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.](#)

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.

J Am Acad Dermatol. 2018 Jul;79(1):135-144.e7. doi: 10.1016/j.jaad.2018.02.027. Epub 2018 Feb 10.

[Biologicals and small molecules in psoriasis: A systematic review of economic evaluations.](#)

Kromer C, Celis D, Sonntag D, Peitsch WK.

PLoS One. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765. eCollection 2018.

[Drug survival of biologic treatments in psoriasis: a systematic review.](#)

No DJ, Inkeles MS, Amin M, Wu JJ.

J Dermatolog Treat. 2018 Aug;29(5):460-466. doi: 10.1080/09546634.2017.1398393. Epub 2017 Nov 10.

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Théréné C, Brenaut E, Barnette T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[Treatment of severe psoriasis in children: recommendations of an Italian expert group.](#)

Fortina AB, Bardazzi F, Berti S, Carnevale C, Di Lernia V, El Hachem M, Neri I, Gelmetti CM, Lora V, Mazzatenta C, Milioto M, Moretta G, Patrizi A, Peris K, Villani A.

Eur J Pediatr. 2017 Oct;176(10):1339-1354. doi: 10.1007/s00431-017-2985-x. Epub 2017 Aug 23.

[A systematic review of pharmacogenetic studies on the response to biologics in psoriasis patients.](#)

van Vugt LJ, van den Reek JMPA, Coenen MJH, de Jong EMGJ.

Br J Dermatol. 2018 Jan;178(1):86-94. doi: 10.1111/bjd.15753. Epub 2017 Dec 14.

[Immunogenicity of biologics in chronic inflammatory diseases: A systematic review.](#)

Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L.

BioDrugs. 2017 Aug;31(4):299-316. doi: 10.1007/s40259-017-0231-8.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadiet S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.

Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Quantitative evaluation of biologic therapy options for psoriasis: A systematic review and network meta-analysis.](#)

Jabbar-Lopez ZK, Yiu ZZN, Ward V, Exton LS, Mustapa MFM, Samarasekera E, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Warren RB, Smith CH.

J Invest Dermatol. 2017 Aug;137(8):1646-1654. doi: 10.1016/j.jid.2017.04.009. Epub 2017 Apr 27.

[Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: Systematic review and meta-analysis of randomized controlled trials.](#)

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.
Br J Dermatol. 2017 Apr;176(4):890-901. doi: 10.1111/bjd.14964. Epub 2017 Mar 14.

[Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: A systematic review and meta-analysis of randomized clinical trials.](#)

de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR.
Drugs R D. 2017 Mar;17(1):29-51. doi: 10.1007/s40268-016-0152-x.

[Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Gómez-García F, Epstein D, Isla-Tejera B, Lorente A, Vélez García-Nieto A, Ruano J.
Br J Dermatol. 2017 Mar;176(3):594-603. doi: 10.1111/bjd.14814. Epub 2016 Oct 13

[The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: An updated meta-analysis.](#)

Yang ZS, Lin NN, Li L, Li Y.
Clin Rev Allergy Immunol. 2016 Oct;51(2):240-7. doi: 10.1007/s12016-016-8560-9.

[Review of maintenance of response to psoriasis treatments.](#)

Bartos S, Hill D, Feldman SR.
J Dermatolog Treat. 2016 Aug;27(4):293-7. doi: 10.1080/09546634.2016.1177158.

[Systemic treatment of pediatric psoriasis: A review.](#)

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.
Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

[Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: A systematic review.](#)

Zweegers J, Otero ME, van den Reek JM, van Lümig PP, Driessen RJ, Kievit W, Seyger MM, van de Kerkhof PC, de Jong EM.
Acta Derm Venereol. 2016 May;96(4):453-8. doi: 10.2340/00015555-2276.

[A systematic review on the efficacy and safety of infliximab in patients with psoriasis.](#)

Wang J, Zhan Q, Zhang L.
Hum Vaccin Immunother. 2016;12(2):431-7. doi: 10.1080/21645515.2015.1081322.

[Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: A systematic review and meta-analysis.](#)

Nast A, Jacobs A, Rosumeck S, Werner RN.
J Invest Dermatol. 2015 Nov;135(11):2641-8. doi: 10.1038/jid.2015.206. Epub 2015 Jun 5.

[Systematic review on the maintenance of response during systemic antipsoriatic therapy.](#)

Jacobs A, Rosumeck S, Nast A.
Br J Dermatol. 2015 Oct;173(4):910-21. doi: 10.1111/bjd.14077. Epub 2015 Oct 6.

[Combining biologics with methotrexate in psoriasis: A systematic review.](#)

van Bezooijen JS, Prens EP, Pradeepti MS, Atiqi R, Schreurs MW, Koch BC, van Gelder T, van Doorn MB.
Br J Dermatol. 2015 Jun;172(6):1676-80. doi: 10.1111/bjd.13573. Epub 2015 Apr 29.

[Serum infliximab concentrations in psoriatic patients treated with infliximab: a systematic review.](#)

Dannepond C, Maruani A, Machet L, Ternant D, Paintaud G, Samimi M.
Acta Derm Venereol. 2015 Apr;95(4):401-6. doi: 10.2340/00015555-1980.

[Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.](#)

Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.
JAMA Dermatol. 2015 Apr;151(4):432-8. doi: 10.1001/jamadermatol.2014.3456.

[Systemic treatments in paediatric psoriasis: A systematic evidence-based update.](#)

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.
J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

[Comparative efficacy of biological treatments for moderate-to-severe psoriasis: A network meta-analysis adjusting for cross-trial differences in reference arm response.](#)

Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P.
Br J Dermatol. 2015 Feb;172(2):504-12. doi: 10.1111/bjd.13437. Epub 2015 Jan 21.

Comparison of infliximab and ustekinumab for the treatment of moderate-to-severe psoriasis: An indirect comparison meta-analysis

Fan T, Bennett HA, Smith NE, Marin M, Sen SS.

Comparative Effectiveness Research 2015;5:1-11.

<https://www.dovepress.com/comparison-of-infliximab-and-ustekinumab-for-the-treatment-of-moderate-peer-reviewed-article-CER>

[Evidence-based guidelines of the Spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites \(nails, scalp, palms, and soles\).](#)

Sánchez-Regaña M, Aldunce Soto MJ, Belinchón Romero I, Ribera Pibernat M, Lafuente-Urrez RF, Carrascosa Carrillo JM, Ferrándiz Foraster C, Puig Sanz L, Daudén Tello E, Vidal Sarró D, Ruiz-Villaverde R, Fonseca Capdevila E, Rodríguez Cerdeira MC, Alsina Gibert MM, Herrera Acosta E, Marrón Moya SE; en representación del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología.
Actas Dermosifiliogr. 2014 Dec;105(10):923-34. doi: 10.1016/j.ad.2014.02.015. Epub 2014 May 19.
English, Spanish

[Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials with different time points.](#)

Puig L, López A, Vilarrasa E, García I.
J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1633-53. doi: 10.1111/jdv.12238. Epub 2013 Aug 19.

[Network meta-analysis of treatments for chronic plaque psoriasis in Canada.](#)

Gupta AK, Daigle D, Lyons DC.
J Cutan Med Surg. 2014 Nov;18(6):371-8.

[Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.](#)

Lorenzetti R, Zullo A, Ridola L, Diamanti AP, Laganà B, Gatta L, Migliore A, Armuzzi A, Hassan C, Bruzzese V.
Ann Med. 2014 Nov;46(7):547-54. doi: 10.3109/07853890.2014.941919. Epub 2014 Aug 8.

[Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials.](#)

Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A.
Br J Dermatol. 2014 Feb;170(2):274-303. doi: 10.1111/bjd.12663

[Antidrug antibodies in psoriasis: A systematic review.](#)

Hsu L, Snodgrass BT, Armstrong AW.
Br J Dermatol. 2014 Feb;170(2):261-73. doi: 10.1111/bjd.12654.

[Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: A meta-analysis and cost-efficacy analysis using the intention-to-treat principle.](#)

Chi CC, Wang SH.
Biomed Res Int. 2014;2014:862851. doi: 10.1155/2014/862851. Epub 2014 Jan 29.

[The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis.](#)

Garcês S, Demengeot J, Benito-Garcia E.
Ann Rheum Dis. 2013 Dec;72(12):1947-55. doi: 10.1136/annrheumdis-2012-202220. Epub 2012 Dec 6.

[Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: A comprehensive meta-analysis of randomized controlled trials.](#)

Correr CJ, Rotta I, Teles Tde S, Godoy RR, Riveros BS, Garcia MM, Gonçalves PR, Otuki MF.
Cad Saude Publica. 2013 Nov;29 Suppl 1:S17-31.

[Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: Systematic review and meta-analysis.](#)

Maneiro JR, Salgado E, Gomez-Reino JJ.
JAMA Intern Med. 2013 Aug 12;173(15):1416-28. doi: 10.1001/jamainternmed.2013.7430.

[Meta-analysis: Rapid infliximab infusions are safe.](#)

Neef HC, Riebschleger MP, Adler J.
Aliment Pharmacol Ther. 2013 Aug;38(4):365-76. doi: 10.1111/apt.12389. Epub 2013 Jul 1.

[Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.](#)

Nast A, Sporbeck B, Rosumeck S, Pathirana D, Jacobs A, Werner RN, Schmitt J.
J Invest Dermatol. 2013 Aug;133(8):1963-70. doi: 10.1038/jid.2013.78. Epub 2013 Feb 20.

[Impact of TNF- \$\alpha\$ antagonists on the quality of life in selected skin diseases.](#)

Gisondi P, Girolomoni G.
G Ital Dermatol Venereol. 2013 Jun;148(3):243-8.

[Biological treatments for moderate-to-severe psoriasis: indirect comparison.](#)

Galván-Banqueri M, Marín Gil R, Santos Ramos B, Bautista Paloma FJ.
J Clin Pharm Ther. 2013 Apr;38(2):121-30. doi: 10.1111/jcpt.12044. Epub 2013 Feb 26.

[Effect of biologic agents on non-PASI outcomes in moderate-to-severe plaque psoriasis: Systematic review and meta-analyses.](#)

Baker EL, Coleman CI, Reinhart KM, Phung OJ, Kugelman L, Chen W, White CM, Mamolo CM, Cappelleri JC, Baker WL.

Dermatol Ther (Heidelb). 2012 Dec;2(1):9. doi: 10.1007/s13555-012-0009-3. Epub 2012 Jun 19.

[Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis \[Internet\].](#)

Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J, Sobieraj DM.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

[An evidence-based review of skin cancer rates on biologic therapies.](#)

Kamangar F, Neuhaus IM, Koo JY.
J Dermatolog Treat. 2012 Aug;23(4):305-15. doi: 10.3109/09546634.2011.652064.

[Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.](#)

Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P.
Adv Ther. 2012 Jul;29(7):620-34. doi: 10.1007/s12325-012-0035-7. Epub 2012 Jul 27.

[Efficacy of systemic therapies for moderate-to-severe psoriasis: A systematic review and meta-analysis of long-term treatment.](#)

Lucka TC, Pathirana D, Sammain A, Bachmann F, Rosumeck S, Erdmann R, Schmitt J, Orawa H, Rzany B, Nast A.
J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1331-44. doi: 10.1111/j.1468-3083.2012.04492.x. Epub 2012 Mar 9. Review. Erratum in: J Eur Acad Dermatol Venereol. 2012 Jul;26(7):930.

[Off-label biologic regimens in psoriasis: A systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy.](#)

Brezinski EA, Armstrong AW.
PLoS One. 2012;7(4):e33486. doi: 10.1371/journal.pone.0033486. Epub 2012 Apr 11.

[Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials.](#)

Reich K, Burden AD, Eaton JN, Hawkins NS.
Br J Dermatol. 2012 Jan;166(1):179-88. doi: 10.1111/j.1365-2133.2011.10583.x. Epub 2011 Nov 11.

Anti-TNF agents - adalimumab

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.](#)

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA.
J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.

[Effectiveness and safety of systemic therapy for psoriasis in older adults: A systematic review.](#)

van Winden MEC, van der Schoot LS, van de L'Isle Arias M, van Vugt LJ, van den Reek JMPA, van de Kerkhof PCM, de Jong EMGJ, Lubeek SFK.
JAMA Dermatol. 2020 Aug 19. doi: 10.1001/jamadermatol.2020.2311. Online ahead of print.

[Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Tada Y, Watanabe R, Noma H, Kanai Y, Nomura T, Kaneko K.

J Dermatol Sci. 2020 Jun 18. pii: S0923-1811(20)30199-7. doi: 10.1016/j.jdermsci.2020.06.003. [Epub ahead of print]

[Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.](#)

Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, de Brito M, McGuire A, Murphy R, Owen CM, Parslew R, Woolf RT, Yiu ZZN, Uthman OA, Mohd Mustapa MF, Smith CH.

Br J Dermatol. 2020 Jun 20. doi: 10.1111/bjd.19325. [Epub ahead of print]

[Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.](#)

Yasmeen N, Sawyer LM, Malottki K, Levin LÅ, Apol ED, Jemec GB.

J Dermatolog Treat. 2020 Mar 23:1-50. doi: 10.1080/09546634.2020.1743811. [Epub ahead of print]

[Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis.](#)

Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M.

JAMA Dermatol. 2020 Feb 5. doi: 10.1001/jamadermatol.2019.4029. [Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L.

Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

[Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.](#)

Warren RB, Gooderham M, Burge R, Zhu B, Amato D, Liu KH, Shrom D, Guo J, Brnabic A, Blauvelt A.

J Am Acad Dermatol. 2019 Dec 26. pii: S0190-9622(19)33315-8. doi: 10.1016/j.jaad.2019.12.038. [Epub ahead of print]

[The efficacy and evidence-based use of biologics in children and adolescents.](#)

Niehues T, Özgür TT.

Dtsch Arztebl Int. 2019 Oct 18;116(42):703-710. doi: 10.3238/arztebl.2019.0703.

[Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: A comprehensive investigation using Bayesian and frequentist network meta-analyses.](#)

Warren RB, See K, Burge R, Zhang Y, Brnabic A, Gallo G, Garrelts A, Egeberg A.

Dermatol Ther (Heidelb). 2019 Nov 4. doi: 10.1007/s13555-019-00337-y. [Epub ahead of print]

[Meta-analyses of clinical efficacy of risankizumab and adalimumab in chronic plaque psoriasis: Supporting evidence of risankizumab superiority.](#)

Witjes H, Khatri A, Diderichsen PM, Mandema J, Othman AA.

Clin Pharmacol Ther. 2019 Sep 10. doi: 10.1002/cpt.1624. [Epub ahead of print]

[Biologics switch in psoriasis.](#)

Wang TS, Tsai TF.

Immunotherapy. 2019 Apr;11(6):531-541. doi: 10.2217/imt-2018-0131.

[Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis.](#)

Xu G, Xia M, Jiang C, Yu Y, Wang G, Yuan J, Duan X.

J Pharmacol Sci. 2019 Apr;139(4):289-303. doi: 10.1016/j.jphs.2018.12.006. Epub 2018 Dec 27.

[An update on clinical safety of adalimumab in treating psoriasis: A systematic review and meta-analysis based on 20 randomized controlled trials.](#)

Guan X, Zhang CL.

J Cosmet Dermatol. 2019 Feb 4. doi: 10.1111/jocd.12868. [Epub ahead of print]

[Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis.](#)

Geng W, Zhao J, Fu J, Zhang H, Qiao S.

Exp Ther Med. 2018 Dec;16(6):5085-5095. doi: 10.3892/etm.2018.6859. Epub 2018 Oct 15.

[Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence.](#)

Lin PT, Wang SH, Chi CC.

Sci Rep. 2018 Oct 30;8(1):16068. doi: 10.1038/s41598-018-34293-y.

[Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.](#)

Sawyer LM, Cornic L, Levin LÅ, Gibbons C, Møller AH, Jemec GB.

J Eur Acad Dermatol Venereol. 2019 Feb;33(2):355-366. doi: 10.1111/jdv.15277. Epub 2018 Oct 31.

[Systematic review of the real-world evidence of adalimumab safety in psoriasis registries.](#)

Strober B, Crowley J, Langley RG, Gordon K, Menter A, Leonardi C, Arian D, Valdecantos WC.

J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2126-2133. doi: 10.1111/jdv.15203. Epub 2018 Aug 28.

[Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.](#)

Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.

Curr Med Res Opin. 2018 Jul;34(7):1325-1333. doi: 10.1080/03007995.2018.1457516. Epub 2018 Apr 23.

[Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies.](#)

Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T.

Cutis. 2018 Jan;101(1):38;42;56.

[Quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.](#)

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.

Mol Pain. 2018 Jan-Dec;14:1744806918762205. doi: 10.1177/1744806918762205. Epub 2018 Feb 15.

[Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.](#)

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.

J Am Acad Dermatol. 2018 Jul;79(1):135-144.e7. doi: 10.1016/j.jaad.2018.02.027. Epub 2018 Feb 10.

[Biologics and small molecules in psoriasis: A systematic review of economic evaluations.](#)

Kromer C, Celis D, Sonntag D, Peitsch WK.
PLoS One. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765. eCollection 2018.

[A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.](#)

No DJ, Amin M, Bhutani T, Wu JJ.
J Dermatolog Treat. 2018 Aug;29(5):467-474. doi: 10.1080/09546634.2017.1402116. Epub 2017 Nov 22.

[Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.](#)

Duarte A, Mebrahtu T, Goncalves PS, Harden M, Murphy R, Palmer S, Woolacott N, Rodgers M, Rothery C.
Health Technol Assess. 2017 Nov;21(64):1-244. doi: 10.3310/hta21640.

[Drug survival of biologic treatments in psoriasis: a systematic review.](#)

No DJ, Inkeles MS, Amin M, Wu JJ.
J Dermatolog Treat. 2018 Aug;29(5):460-466. doi: 10.1080/09546634.2017.1398393. Epub 2017 Nov 10.

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Théréné C, Brenaut E, Barnetche T, Misery L.
J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[Treatment of severe psoriasis in children: recommendations of an Italian expert group.](#)

Fortina AB, Bardazzi F, Berti S, Carnevale C, Di Lernia V, El Hachem M, Neri I, Gelmetti CM, Lora V, Mazzatenta C, Milioto M, Moretta G, Patrizi A, Peris K, Villani A.
Eur J Pediatr. 2017 Oct;176(10):1339-1354. doi: 10.1007/s00431-017-2985-x. Epub 2017 Aug 23.

[A systematic review of pharmacogenetic studies on the response to biologics in psoriasis patients.](#)

van Vugt LJ, van den Reek JMPA, Coenen MJH, de Jong EMGJ.
Br J Dermatol. 2018 Jan;178(1):86-94. doi: 10.1111/bjd.15753. Epub 2017 Dec 14.

[Immunogenicity of biologics in chronic inflammatory diseases: A systematic review.](#)

Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L.
BioDrugs. 2017 Aug;31(4):299-316. doi: 10.1007/s40259-017-0231-8.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadié S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.
Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Quantitative evaluation of biologic therapy options for psoriasis: A systematic review and network meta-analysis.](#)

Jabbar-Lopez ZK, Yiu ZZN, Ward V, Exton LS, Mustapa MFM, Samarasekera E, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Warren RB, Smith CH.
J Invest Dermatol. 2017 Aug;137(8):1646-1654. doi: 10.1016/j.jid.2017.04.009. Epub 2017 Apr 27.

[Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: Systematic review and meta-analysis of randomized controlled trials.](#)

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.

Br J Dermatol. 2017 Apr;176(4):890-901. doi: 10.1111/bjd.14964. Epub 2017 Mar 14.

[Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Gómez-García F, Epstein D, Isla-Tejera B, Lorente A, Vélez García-Nieto A, Ruano J.

Br J Dermatol. 2017 Mar;176(3):594-603. doi: 10.1111/bjd.14814. Epub 2016 Oct 13

[Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: A systematic review and meta-analysis of randomized clinical trials.](#)

de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR.

Drugs R D. 2017 Mar;17(1):29-51. doi: 10.1007/s40268-016-0152-x.

[The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: An updated meta-analysis.](#)

Yang ZS, Lin NN, Li L, Li Y.

Clin Rev Allergy Immunol. 2016 Oct;51(2):240-7. doi: 10.1007/s12016-016-8560-9.

[Review of maintenance of response to psoriasis treatments.](#)

Bartos S, Hill D, Feldman SR.

J Dermatolog Treat. 2016 Aug;27(4):293-7. doi: 10.1080/09546634.2016.1177158.

[Risk of serious infections in patients with psoriasis on biologic therapies: A systematic review and meta-analysis.](#)

Yiu ZZ, Exton LS, Jabbar-Lopez Z, Mohd Mustapa MF, Samarasekera EJ, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Ashcroft DM, Griffiths CE, Smith CH, Warren RB.

J Invest Dermatol. 2016 Aug;136(8):1584-91. doi: 10.1016/j.jid.2016.03.035. Epub 2016 Apr 13.

[Systemic treatment of pediatric psoriasis: A review.](#)

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.

Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

[Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: A systematic review.](#)

Zweegers J, Otero ME, van den Reek JM, van Lümig PP, Driessen RJ, Kievit W, Seyger MM, van de Kerkhof PC, de Jong EM.

Acta Derm Venereol. 2016 May;96(4):453-8. doi: 10.2340/00015555-2276.

[Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: A systematic review and meta-analysis.](#)

Nast A, Jacobs A, Rosumeck S, Werner RN.

J Invest Dermatol. 2015 Nov;135(11):2641-8. doi: 10.1038/jid.2015.206. Epub 2015 Jun 5.

[Systematic review on the maintenance of response during systemic antipsoriatic therapy.](#)

Jacobs A, Rosumeck S, Nast A.

Br J Dermatol. 2015 Oct;173(4):910-21. doi: 10.1111/bjd.14077. Epub 2015 Oct 6.

[Efficacy and safety of etanercept and adalimumab with and without a loading dose for psoriasis: A systematic review.](#)

Gilbert KE, Manalo IF, Wu JJ.

J Am Acad Dermatol. 2015 Aug;73(2):329-31. doi: 10.1016/j.jaad.2015.04.012.

[Combining biologics with methotrexate in psoriasis: A systematic review.](#)

van Bezooijen JS, Prens EP, Pradeepti MS, Atiqi R, Schreurs MW, Koch BC, van Gelder T, van Doorn MB.

Br J Dermatol. 2015 Jun;172(6):1676-80. doi: 10.1111/bjd.13573. Epub 2015 Apr 29.

[Effect of biologics on depressive symptoms in patients with psoriasis: A systematic review.](#)

Fleming P, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Siu S, Kraft J, Lynde C, Pope JE, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B, Gulliver WP.

J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1063-70. doi: 10.1111/jdv.12909. Epub 2014 Dec 10.

[Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.](#)

Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.

JAMA Dermatol. 2015 Apr;151(4):432-8. doi: 10.1001/jamadermatol.2014.3456.

[Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.](#)

Sorenson E, Koo J.

J Dermatolog Treat. 2015;26(6):493-501. doi: 10.3109/09546634.2015.1027167. Epub 2015 Apr 17.

[Systemic treatments in paediatric psoriasis: A systematic evidence-based update.](#)

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

[Subcutaneous biological treatments for moderate to severe psoriasis: Interpreting safety data by network meta-analysis.](#)

Messori A, Trippoli S, Fadda V, Maratea D, Marinai C.

Drugs Real World Outcomes. 2015 Mar;2(1):23-27.

[Comparative efficacy of biological treatments for moderate-to-severe psoriasis: A network meta-analysis adjusting for cross-trial differences in reference arm response.](#)

Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P.

Br J Dermatol. 2015 Feb;172(2):504-12. doi: 10.1111/bjd.13437. Epub 2015 Jan 21.

[Antidrug antibodies in psoriasis: A systematic review.](#)

Hsu L, Snodgrass BT, Armstrong AW.

Br J Dermatol. 2014 Feb;170(2):261-73. doi: 10.1111/bjd.12654.

[Evidence-based guidelines of the Spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites \(nails, scalp, palms, and soles\).](#)

Sánchez-Regaña M, Aldunce Soto MJ, Belinchón Romero I, Ribera Pibernat M, Lafuente-Urrez RF, Carrascosa Carrillo JM, Ferrándiz Foraster C, Puig Sanz L, Daudén Tello E, Vidal Sarró D, Ruiz-Villaverde R, Fonseca Capdevila E, Rodríguez Cerdeira MC, Alsina Gibert MM, Herrera Acosta E, Marrón Moya SE; en representación del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología.

Actas Dermosifiliogr. 2014 Dec;105(10):923-34. doi: 10.1016/j.ad.2014.02.015. Epub 2014 May 19. English, Spanish

[Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials with different time points.](#)

Puig L, López A, Vilarrasa E, García I.

J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1633-53. doi: 10.1111/jdv.12238. Epub 2013 Aug 19.

[Network meta-analysis of treatments for chronic plaque psoriasis in Canada.](#)

Gupta AK, Daigle D, Lyons DC.

J Cutan Med Surg. 2014 Nov;18(6):371-8.

[Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.](#)

Lorenzetti R, Zullo A, Ridola L, Diamanti AP, Laganà B, Gatta L, Migliore A, Armuzzi A, Hassan C, Bruzzese V.

Ann Med. 2014 Nov;46(7):547-54. doi: 10.3109/07853890.2014.941919. Epub 2014 Aug 8.

[Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system.](#)

Wang SH, Chi CC, Hu S.

Int J Dermatol. 2014 Sep;53(9):1151-6. doi: 10.1111/ijd.12462. Epub 2014 Apr 16.

[Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials.](#)

Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A.

Br J Dermatol. 2014 Feb;170(2):274-303. doi: 10.1111/bjd.12663

[Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: A meta-analysis and cost-efficacy analysis using the intention-to-treat principle.](#)

Chi CC, Wang SH.

Biomed Res Int. 2014;2014:862851. doi: 10.1155/2014/862851. Epub 2014 Jan 29.

[The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis.](#)

Garcês S, Demengeot J, Benito-Garcia E.

Ann Rheum Dis. 2013 Dec;72(12):1947-55. doi: 10.1136/annrheumdis-2012-202220. Epub 2012 Dec 6.

[Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: A comprehensive meta-analysis of randomized controlled trials.](#)

Correr CJ, Rotta I, Teles Tde S, Godoy RR, Riveros BS, Garcia MM, Gonçalves PR, Otuki MF.

Cad Saude Publica. 2013 Nov;29 Suppl 1:S17-31.

[Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis.](#)

Saraceno R, Bavetta M, Zangrilli A, Chiricozzi A, Potenza C, Chimenti S, Chimenti MS.

Expert Opin Biol Ther. 2013 Sep;13(9):1325-34. doi: 10.1517/14712598.2013.820701.

[Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: Systematic review and meta-analysis.](#)

Maneiro JR, Salgado E, Gomez-Reino JJ.

JAMA Intern Med. 2013 Aug 12;173(15):1416-28. doi: 10.1001/jamainternmed.2013.7430.

[Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.](#)

Nast A, Sporbeck B, Rosumeck S, Pathirana D, Jacobs A, Werner RN, Schmitt J.
J Invest Dermatol. 2013 Aug;133(8):1963-70. doi: 10.1038/jid.2013.78. Epub 2013 Feb 20.

[Impact of TNF- \$\alpha\$ antagonists on the quality of life in selected skin diseases.](#)

Gisondi P, Girolomoni G.
G Ital Dermatol Venereol. 2013 Jun;148(3):243-8.

[Adalimumab: Long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.](#)

Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP.
Ann Rheum Dis. 2013 Apr;72(4):517-24. doi: 10.1136/annrheumdis-2011-201244. Epub 2012 May 5.

[Biological treatments for moderate-to-severe psoriasis: indirect comparison.](#)

Galván-Banqueri M, Marín Gil R, Santos Ramos B, Bautista Paloma FJ.
J Clin Pharm Ther. 2013 Apr;38(2):121-30. doi: 10.1111/jcpt.12044. Epub 2013 Feb 26.

[Effect of biologic agents on non-PASI outcomes in moderate-to-severe plaque psoriasis: Systematic review and meta-analyses.](#)

Baker EL, Coleman CI, Reinhart KM, Phung OJ, Kugelman L, Chen W, White CM, Mamolo CM, Cappelleri JC, Baker WL.
Dermatol Ther (Heidelb). 2012 Dec;2(1):9. doi: 10.1007/s13555-012-0009-3. Epub 2012 Jun 19.

[Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis \[Internet\].](#)

Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J, Sobieraj DM.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

[An evidence-based review of skin cancer rates on biologic therapies.](#)

Kamangar F, Neuhaus IM, Koo JY.
J Dermatolog Treat. 2012 Aug;23(4):305-15. doi: 10.3109/09546634.2011.652064.

[Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.](#)

Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P.
Adv Ther. 2012 Jul;29(7):620-34. doi: 10.1007/s12325-012-0035-7. Epub 2012 Jul 27.

[Off-label biologic regimens in psoriasis: A systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy.](#)

Brezinski EA, Armstrong AW.
PLoS One. 2012;7(4):e33486. doi: 10.1371/journal.pone.0033486. Epub 2012 Apr 11.

[Efficacy of systemic therapies for moderate-to-severe psoriasis: A systematic review and meta-analysis of long-term treatment.](#)

Lucka TC, Pathirana D, Sammain A, Bachmann F, Rosumeck S, Erdmann R, Schmitt J, Orawa H, Rzany B, Nast A.
J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1331-44. doi: 10.1111/j.1468-3083.2012.04492.x. Epub 2012 Mar 9. Review. Erratum in: J Eur Acad Dermatol Venereol. 2012 Jul;26(7):930.

[Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials.](#)

Reich K, Burden AD, Eaton JN, Hawkins NS.

Br J Dermatol. 2012 Jan;166(1):179-88. doi: 10.1111/j.1365-2133.2011.10583.x. Epub 2011 Nov 11.

Anti-TNF agents – certolizumab pegol

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.](#)

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA.

J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.

[Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.](#)

Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, de Brito M, McGuire A, Murphy R, Owen CM, Parslew R, Woolf RT, Yiu ZZN, Uthman OA, Mohd Mustapa MF, Smith CH.

Br J Dermatol. 2020 Jun 20. doi: 10.1111/bjd.19325. [Epub ahead of print]

[Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.](#)

Yasmeen N, Sawyer LM, Malottki K, Levin LÅ, Apol ED, Jemec GB.

J Dermatolog Treat. 2020 Mar 23:1-50. doi: 10.1080/09546634.2020.1743811. [Epub ahead of print]

[Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis.](#)

Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M.

JAMA Dermatol. 2020 Feb 5. doi: 10.1001/jamadermatol.2019.4029. [Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L.

Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

[Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: A comprehensive investigation using Bayesian and frequentist network meta-analyses.](#)

Warren RB, See K, Burge R, Zhang Y, Brnabic A, Gallo G, Garrelts A, Egeberg A.

Dermatol Ther (Heidelb). 2019 Nov 4. doi: 10.1007/s13555-019-00337-y. [Epub ahead of print]

[Emerging therapies in psoriasis: A systematic review.](#)

Lee EB, Amin M, Bhutani T, Wu JJ.

Cutis. 2018 Mar;101(3S):5-9.

Interleukin antagonists

Interleukin antagonists - general

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.](#)

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA.
J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.

[British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 - a rapid update.](#)

Smith CH, Yiu ZZ, Bale T, Burden AD, Coates LC, Edwards W, MacMahon E, Mahil S, McGuire A, Murphy R, Nelson-Piercy C, Owen CM, Parslew R, Uthman OA, Woolf RT, Manounah L, Ezejimofor MC, Exton LS, Mohd Mustapa MF; British Association of Dermatologists' Clinical Standards Unit.
Br J Dermatol. 2020 Mar 18. doi: 10.1111/bjd.19039. [Epub ahead of print].

[Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review.](#)

Conforti C, Dianzani C, Zalaudek I, Cicala M, Persichetti P, Giuffrida R, Morariu SH, Neagu N.
J Dermatolog Treat. 2020 Oct 22:1-8. doi: 10.1080/09546634.2020.1836313. Online ahead of print.

[The risk of respiratory tract infections and interstitial lung disease with IL-12/23 and IL-23 antagonists in patients with autoimmune diseases: a systematic review and meta-analysis.](#)

Akiyama S, Yamada A, Micic D, Sakuraba A.
J Am Acad Dermatol. 2020 Aug 10:S0190-9622(20)32414-2. doi: 10.1016/j.jaad.2020.08.026. Online ahead of print.

[Effectiveness and safety of systemic therapy for psoriasis in older adults: A systematic review.](#)

van Winden MEC, van der Schoot LS, van de L'Isle Arias M, van Vugt LJ, van den Reek JMPA, van de Kerkhof PCM, de Jong EMGJ, Lubeek SFK.
JAMA Dermatol. 2020 Aug 19. doi: 10.1001/jamadermatol.2020.2311. Online ahead of print.

[Efficacy of a second IL-17 inhibitor in patients with psoriasis: a systematic review and meta-analysis.](#)

Loft ND, Halling AS, Egeberg A, Skov L.
J Am Acad Dermatol. 2020 Jul 27:S0190-9622(20)32286-6. doi: 10.1016/j.jaad.2020.07.085. Online ahead of print.

[Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Tada Y, Watanabe R, Noma H, Kanai Y, Nomura T, Kaneko K.
J Dermatol Sci. 2020 Jun 18. pii: S0923-1811(20)30199-7. doi: 10.1016/j.jdermsci.2020.06.003. [Epub ahead of print]

[Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis.](#)

Burisch J, Eigner W, Schreiber S, Aletaha D, Weninger W, Trauner M, Reinisch W, Narula N.
PLoS One. 2020 May 27;15(5):e0233781. doi: 10.1371/journal.pone.0233781. eCollection 2020.

[A network meta-analysis for the comparison of efficacy and safety of interleukin \(IL\)-23 targeted drugs in the treatment of moderate to severe psoriasis.](#)

Jianzhen S, Xu J, Yanmei C.

Dermatol Ther. 2020 Jun 10:e13802. doi: 10.1111/dth.13802. [Epub ahead of print]

[Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.](#)

Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, de Brito M, McGuire A, Murphy R, Owen CM, Parslew R, Woolf RT, Yiu ZZN, Uthman OA, Mohd Mustapa MF, Smith CH. Br J Dermatol. 2020 Jun 20. doi: 10.1111/bjd.19325. [Epub ahead of print]

[Biologics and small molecules in patients with scalp psoriasis: a systematic review.](#)

Alsenaid A, Ezmerli M, Srour J, Heppt M, Illigens BM, Prinz JC.

J Dermatolog Treat. 2020 May 14:1-38. doi: 10.1080/09546634.2020.1770167. [Epub ahead of print]

[Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.](#)

Yasmeen N, Sawyer LM, Malottki K, Levin LÅ, Apol ED, Jemec GB.

J Dermatolog Treat. 2020 Mar 23:1-50. doi: 10.1080/09546634.2020.1743811. [Epub ahead of print]

[Risk of tuberculosis reactivation during IL-17 inhibitor therapy for psoriasis: A systematic review.](#)

Fowler E, Ghamrawi RI, Ghiam N, Liao W, Wu JJ.

J Eur Acad Dermatol Venereol. 2020 Feb 3. doi: 10.1111/jdv.16254. [Epub ahead of print]

[Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis.](#)

Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M.

JAMA Dermatol. 2020 Feb 5. doi: 10.1001/jamadermatol.2019.4029. [Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L.

Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

[Biologic treatment in elderly patients with psoriasis: A systematic review.](#)

Sandhu VK, Ighani A, Fleming P, Lynde CW.

J Cutan Med Surg. 2020 Jan 17:1203475419897578. doi: 10.1177/1203475419897578. [Epub ahead of print]

[Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.](#)

Warren RB, Gooderham M, Burge R, Zhu B, Amato D, Liu KH, Shrom D, Guo J, Brnabic A, Blauvelt A.

J Am Acad Dermatol. 2019 Dec 26. pii: S0190-9622(19)33315-8. doi: 10.1016/j.jaad.2019.12.038. [Epub ahead of print]

[Review of treatments for generalized pustular psoriasis.](#)

Kearns DG, Chat VS, Zang PD, Han G, Wu JJ.

J Dermatolog Treat. 2019 Nov 7:1-13. doi: 10.1080/09546634.2019.1682502. [Epub ahead of print]

[The efficacy and evidence-based use of biologics in children and adolescents.](#)

Niehues T, Özgür TT.

Dtsch Arztebl Int. 2019 Oct 18;116(42):703-710. doi: 10.3238/arztebl.2019.0703.

[Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies.](#)

Loft ND, Vaengebjerg S, Halling-Sønderby AS, Skov L, Egeberg A.
J Eur Acad Dermatol Venereol. 2019 Nov 13. doi: 10.1111/jdv.16073. [Epub ahead of print]

[Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: A comprehensive investigation using Bayesian and frequentist network meta-analyses.](#)

Warren RB, See K, Burge R, Zhang Y, Brnabic A, Gallo G, Garrelts A, Egeberg A.
Dermatol Ther (Heidelb). 2019 Nov 4. doi: 10.1007/s13555-019-00337-y. [Epub ahead of print]

[Biological therapy for pustular psoriasis: a systematic review.](#)

Falto-Aizpurua LA, Martin-Garcia RF, Carrasquillo OY, Nevares-Pomales OW, Sánchez-Flores X, Lorenzo-Rios D.
Int J Dermatol. 2019 Oct 15. doi: 10.1111/ijd.14671. [Epub ahead of print]

[Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: A systematic review and network meta-analysis of randomized controlled trials.](#)

Bai F, Li GG, Liu Q, Niu X, Li R, Ma H.
J Immunol Res. 2019 Sep 10;2019:2546161. doi: 10.1155/2019/2546161. eCollection 2019.

[Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis.](#)

Xu S, Zhang X, Pan M, Shuai Z, Xu S, Pan F.
Int Immunopharmacol. 2019 Aug 26;75:105841. doi: 10.1016/j.intimp.2019.105841. [Epub ahead of print]

[Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.](#)

Egeberg A, Andersen YMF, Halling-Overgaard AS, Alignah F, Thyssen JP, Burge R, Mallbris L.
J Eur Acad Dermatol Venereol. 2019 Aug 29. doi: 10.1111/jdv.15920. [Epub ahead of print]

[Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.](#)

Sawyer LM, Malottki K, Sabry-Grant C, Yasmeen N, Wright E, Sohr A, Borg E, Warren RB.
PLoS One. 2019 Aug 14;14(8):e0220868. doi: 10.1371/journal.pone.0220868. eCollection 2019.

[Biologic therapies targeting the IL-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis.](#)

Erichsen CY, Jensen P, Kofoed K.
J Eur Acad Dermatol Venereol. 2019 Aug 16. doi: 10.1111/jdv.15879. [Epub ahead of print]

[Short-term effect and safety of a new generation of monoclonal antibodies targeting interleukin-23p19 for treatment of psoriasis: a systematic review and meta-analysis.](#)

Hou M, Xing H, Cai Y, Wang X, Xie Z, Zhang Q, Ma Y, Chen J.
Eur J Dermatol. 2019 Jun 1;29(3):302-314. doi: 10.1684/ejd.2019.3553.

[Change in body weight and body mass index in psoriasis patients receiving biologics: a systematic review and network meta-analysis.](#)

Wu MY, Yu CL, Yang SJ, Chi CC.

J Am Acad Dermatol. 2019 Aug 7. pii: S0190-9622(19)32498-3. doi: 10.1016/j.jaad.2019.07.103. [Epub ahead of print]

[Biologics switch in psoriasis.](#)

Wang TS, Tsai TF.

Immunotherapy. 2019 Apr;11(6):531-541. doi: 10.2217/imt-2018-0131.

[Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis.](#)

Xu G, Xia M, Jiang C, Yu Y, Wang G, Yuan J, Duan X.

J Pharmacol Sci. 2019 Apr;139(4):289-303. doi: 10.1016/j.jphs.2018.12.006. Epub 2018 Dec 27.

[Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis.](#)

Geng W, Zhao J, Fu J, Zhang H, Qiao S.

Exp Ther Med. 2018 Dec;16(6):5085-5095. doi: 10.3892/etm.2018.6859. Epub 2018 Oct 15.

[Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.](#)

Sawyer LM, Cornic L, Levin LÅ, Gibbons C, Møller AH, Jemec GB.

J Eur Acad Dermatol Venereol. 2019 Feb;33(2):355-366. doi: 10.1111/jdv.15277. Epub 2018 Oct 31.

[Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.](#)

Cui L, Chen R, Subedi S, Yu Q, Gong Y, Chen Z, Shi Y.

Int Immunopharmacol. 2018 Sep;62:46-58. doi: 10.1016/j.intimp.2018.06.020. Epub 2018 Jul 3.

[Emerging therapies in psoriasis: A systematic review.](#)

Lee EB, Amin M, Bhutani T, Wu JJ.

Cutis. 2018 Mar;101(3S):5-9.

[Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis.](#)

Thomas LW, Lee EB, Wu JJ.

J Dermatolog Treat. 2019 Mar;30(2):110-116. doi: 10.1080/09546634.2018.1473552. Epub 2018 May 18.

[Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.](#)

Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.

Curr Med Res Opin. 2018 Jul;34(7):1325-1333. doi: 10.1080/03007995.2018.1457516. Epub 2018 Apr 23.

[A systematic review and meta-analysis of the efficacy and safety of the interleukin \(IL\)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, and tildrakizumab for the treatment of moderate to severe plaque psoriasis.](#)

Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB.

J Dermatolog Treat. 2018 Sep;29(6):569-578. doi: 10.1080/09546634.2017.1422591. Epub 2018 Mar 28.

[Quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.](#)

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.
Mol Pain. 2018 Jan-Dec;14:1744806918762205. doi: 10.1177/1744806918762205. Epub 2018 Feb 15.

[Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.](#)

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.
J Am Acad Dermatol. 2018 Jul;79(1):135-144.e7. doi: 10.1016/j.jaad.2018.02.027. Epub 2018 Feb 10.

[A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.](#)

No DJ, Amin M, Bhutani T, Wu JJ.
J Dermatolog Treat. 2018 Aug;29(5):467-474. doi: 10.1080/09546634.2017.1402116. Epub 2017 Nov 22.

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Théréné C, Brenaut E, Barnette T, Misery L.
J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[\[A systematic review of anti-interleukin-17 antibody in the treatment of plaque psoriasis\].](#)

Fan XD, Xia X, Zhang CY, Kong WQ, Zhou CY, DU B.
Nan Fang Yi Ke Da Xue Xue Bao. 2017 Sep 20;37(9):1274-1279. Chinese.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadié S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.
Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: Systematic review and meta-analysis of randomized controlled trials.](#)

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.
Br J Dermatol. 2017 Apr;176(4):890-901. doi: 10.1111/bjd.14964. Epub 2017 Mar 14.

[Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Gómez-García F, Epstein D, Isla-Tejera B, Lorente A, Vélez García-Nieto A, Ruano J.
Br J Dermatol. 2017 Mar;176(3):594-603. doi: 10.1111/bjd.14814. Epub 2016 Oct 13

[Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: A meta-analysis from phase 3 randomized controlled trials.](#)

Wu D, Hou SY, Zhao S, Hou LX, Jiao T, Xu NN, Zhang N.
J Eur Acad Dermatol Venereol. 2017 Jun;31(6):992-1003. doi: 10.1111/jdv.14125. Epub 2017 Feb 8.

[Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management.](#)

Saunte DM, Mrowietz U, Puig L, Zachariae C.
Br J Dermatol. 2017 Jul;177(1):47-62. doi: 10.1111/bjd.15015. Epub 2017 Jun 1.

[No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents.](#)

Chiricozzi A, Romanelli M, Saraceno R, Torres T.
Expert Opin Drug Saf. 2016 Dec;15(12):1653-1659. Epub 2016 Aug 31.

[Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis.](#)

Chen Y, Qian T, Zhang D, Yan H, Hao F.
Immunotherapy. 2015;7(9):1023-37. doi: 10.2217/imt.15.50. Epub 2015 Jun 9.

[Anti-IL-17 phase II data for psoriasis: A review.](#)

Brown G, Malakouti M, Wang E, Koo JY, Levin E.
J Dermatolog Treat. 2015 Feb;26(1):32-6. doi: 10.3109/09546634.2013.878448. Epub 2014 Feb 20.

[Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: A meta-analysis of randomized controlled trials.](#)

Tzellos T, Kyrgidis A, Zouboulis CC.
J Eur Acad Dermatol Venereol. 2013 May;27(5):622-7. doi: 10.1111/j.1468-3083.2012.04500.x. Epub 2012 Mar 8.

[Effect of biologic agents on non-PASI outcomes in moderate-to-severe plaque psoriasis: Systematic review and meta-analyses.](#)

Baker EL, Coleman CI, Reinhart KM, Phung OJ, Kugelman L, Chen W, White CM, Mamolo CM, Cappelleri JC, Baker WL.
Dermatol Ther (Heidelb). 2012 Dec;2(1):9. doi: 10.1007/s13555-012-0009-3. Epub 2012 Jun 19.

[An evidence-based review of skin cancer rates on biologic therapies.](#)

Kamangar F, Neuhaus IM, Koo JY.
J Dermatolog Treat. 2012 Aug;23(4):305-15. doi: 10.3109/09546634.2011.652064.

Interleukin antagonists – ustekinumab (IL-12/23 inhibitor)

NICE Clinical guideline [CG153] - Psoriasis: assessment and management
<https://www.nice.org.uk/guidance/cg153/evidence>

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.](#)

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselya M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA.
J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.

[FDA approved biologics: Can etanercept and ustekinumab be considered a first-line systemic therapy for pediatric/adolescents in moderate to severe psoriasis? A systematic review.](#)

Aslam N, Saleem H, Murtazaliev S, Quazi SJ, Khan S.
Cureus. 2020 Aug 17;12(8):e9812. doi: 10.7759/cureus.9812.

[The risk of respiratory tract infections and interstitial lung disease with IL-12/23 and IL-23 antagonists in patients with autoimmune diseases: a systematic review and meta-analysis.](#)

Akiyama S, Yamada A, Micic D, Sakuraba A.

J Am Acad Dermatol. 2020 Aug 10:S0190-9622(20)32414-2. doi: 10.1016/j.jaad.2020.08.026. Online ahead of print.

[Effectiveness and safety of systemic therapy for psoriasis in older adults: A systematic review.](#)

van Winden MEC, van der Schoot LS, van de L'Isle Arias M, van Vugt LJ, van den Reek JMPA, van de Kerkhof PCM, de Jong EMGJ, Lubeek SFK.

JAMA Dermatol. 2020 Aug 19. doi: 10.1001/jamadermatol.2020.2311. Online ahead of print.

[Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Tada Y, Watanabe R, Noma H, Kanai Y, Nomura T, Kaneko K.

J Dermatol Sci. 2020 Jun 18. pii: S0923-1811(20)30199-7. doi: 10.1016/j.jdermsci.2020.06.003. [Epub ahead of print]

[A network meta-analysis for the comparison of efficacy and safety of interleukin \(IL\)-23 targeted drugs in the treatment of moderate to severe psoriasis.](#)

Jianzhen S, Xu J, Yanmei C.

Dermatol Ther. 2020 Jun 10:e13802. doi: 10.1111/dth.13802. [Epub ahead of print]

[Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.](#)

Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, de Brito M, McGuire A, Murphy R, Owen CM, Parslew R, Woolf RT, Yiu ZZN, Uthman OA, Mohd Mustapa MF, Smith CH.

Br J Dermatol. 2020 Jun 20. doi: 10.1111/bjd.19325. [Epub ahead of print]

[Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.](#)

Yasmeen N, Sawyer LM, Malottki K, Levin LÅ, Apol ED, Jemec GB.

J Dermatolog Treat. 2020 Mar 23:1-50. doi: 10.1080/09546634.2020.1743811. [Epub ahead of print]

[Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis.](#)

Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M.

JAMA Dermatol. 2020 Feb 5. doi: 10.1001/jamadermatol.2019.4029. [Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L.

Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

[Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.](#)

Warren RB, Gooderham M, Burge R, Zhu B, Amato D, Liu KH, Shrom D, Guo J, Brnabic A, Blauvelt A.

J Am Acad Dermatol. 2019 Dec 26. pii: S0190-9622(19)33315-8. doi: 10.1016/j.jaad.2019.12.038. [Epub ahead of print]

[Review of treatments for generalized pustular psoriasis.](#)

Kearns DG, Chat VS, Zang PD, Han G, Wu JJ.

J Dermatolog Treat. 2019 Nov 7:1-13. doi: 10.1080/09546634.2019.1682502. [Epub ahead of print]

[The efficacy and evidence-based use of biologics in children and adolescents.](#)

Niehues T, Özgür TT.

Dtsch Arztebl Int. 2019 Oct 18;116(42):703-710. doi: 10.3238/arztebl.2019.0703.

[Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: A comprehensive investigation using Bayesian and frequentist network meta-analyses.](#)

Warren RB, See K, Burge R, Zhang Y, Brnabic A, Gallo G, Garrelts A, Egeberg A.
Dermatol Ther (Heidelb). 2019 Nov 4. doi: 10.1007/s13555-019-00337-y. [Epub ahead of print]

[Biological therapy for pustular psoriasis: a systematic review.](#)

Falto-Aizpurua LA, Martin-Garcia RF, Carrasquillo OY, Nevares-Pomales OW, Sánchez-Flores X, Lorenzo-Rios D.
Int J Dermatol. 2019 Oct 15. doi: 10.1111/ijd.14671. [Epub ahead of print]

[Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: A systematic review and network meta-analysis of randomized controlled trials.](#)

Bai F, Li GG, Liu Q, Niu X, Li R, Ma H.
J Immunol Res. 2019 Sep 10;2019:2546161. doi: 10.1155/2019/2546161. eCollection 2019.

[Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.](#)

Sawyer LM, Malottki K, Sabry-Grant C, Yasmeen N, Wright E, Sohr A, Borg E, Warren RB.
PLoS One. 2019 Aug 14;14(8):e0220868. doi: 10.1371/journal.pone.0220868. eCollection 2019.

[Biologic therapies targeting the IL-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis.](#)

Erichsen CY, Jensen P, Kofoed K.
J Eur Acad Dermatol Venereol. 2019 Aug 16. doi: 10.1111/jdv.15879. [Epub ahead of print]

[Biologics switch in psoriasis.](#)

Wang TS, Tsai TF.
Immunotherapy. 2019 Apr;11(6):531-541. doi: 10.2217/imt-2018-0131.

[Association of HLA-C*06:02 status with differential response to ustekinumab in patients with psoriasis: A systematic review and meta-analysis.](#)

van Vugt LJ, van den Reek JMPA, Hannink G, Coenen MJH, de Jong EMGJ.
JAMA Dermatol. 2019 Jun 1;155(6):708-715. doi: 10.1001/jamadermatol.2019.0098.

[Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis.](#)

Xu G, Xia M, Jiang C, Yu Y, Wang G, Yuan J, Duan X.
J Pharmacol Sci. 2019 Apr;139(4):289-303. doi: 10.1016/j.jphs.2018.12.006. Epub 2018 Dec 27.

[Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis.](#)

Geng W, Zhao J, Fu J, Zhang H, Qiao S.
Exp Ther Med. 2018 Dec;16(6):5085-5095. doi: 10.3892/etm.2018.6859. Epub 2018 Oct 15.

[Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence.](#)

Lin PT, Wang SH, Chi CC.

Sci Rep. 2018 Oct 30;8(1):16068. doi: 10.1038/s41598-018-34293-y.

[Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.](#)

Sawyer LM, Cornic L, Levin LÅ, Gibbons C, Møller AH, Jemec GB.

J Eur Acad Dermatol Venereol. 2019 Feb;33(2):355-366. doi: 10.1111/jdv.15277. Epub 2018 Oct 31.

[Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.](#)

Cui L, Chen R, Subedi S, Yu Q, Gong Y, Chen Z, Shi Y.

Int Immunopharmacol. 2018 Sep;62:46-58. doi: 10.1016/j.intimp.2018.06.020. Epub 2018 Jul 3.

[Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.](#)

Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.

Curr Med Res Opin. 2018 Jul;34(7):1325-1333. doi: 10.1080/03007995.2018.1457516. Epub 2018 Apr 23.

[Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies.](#)

Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T.

Cutis. 2018 Jan;101(1):38;42;56.

[A systematic review and meta-analysis of the efficacy and safety of the interleukin \(IL\)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, and tildrakizumab for the treatment of moderate to severe plaque psoriasis.](#)

Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB.

J Dermatolog Treat. 2018 Sep;29(6):569-578. doi: 10.1080/09546634.2017.1422591. Epub 2018 Mar 28.

[Quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.](#)

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.

Mol Pain. 2018 Jan-Dec;14:1744806918762205. doi: 10.1177/1744806918762205. Epub 2018 Feb 15.

[Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.](#)

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.

J Am Acad Dermatol. 2018 Jul;79(1):135-144.e7. doi: 10.1016/j.jaad.2018.02.027. Epub 2018 Feb 10.

[Biologics and small molecules in psoriasis: A systematic review of economic evaluations.](#)

Kromer C, Celis D, Sonntag D, Peitsch WK.

PLoS One. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765. eCollection 2018.

[A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.](#)

No DJ, Amin M, Bhutani T, Wu JJ.

J Dermatolog Treat. 2018 Aug;29(5):467-474. doi: 10.1080/09546634.2017.1402116. Epub 2017 Nov 22.

[Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.](#)

Duarte A, Mebrahtu T, Goncalves PS, Harden M, Murphy R, Palmer S, Woolacott N, Rodgers M, Rothery C.

Health Technol Assess. 2017 Nov;21(64):1-244. doi: 10.3310/hta21640.

[Drug survival of biologic treatments in psoriasis: a systematic review.](#)

No DJ, Inkeles MS, Amin M, Wu JJ.

J Dermatolog Treat. 2018 Aug;29(5):460-466. doi: 10.1080/09546634.2017.1398393. Epub 2017 Nov 10.

[Treatment of severe psoriasis in children: recommendations of an Italian expert group.](#)

Fortina AB, Bardazzi F, Berti S, Carnevale C, Di Lernia V, El Hachem M, Neri I, Gelmetti CM, Lora V, Mazzatenta C, Milioto M, Moretta G, Patrizi A, Peris K, Villani A.

Eur J Pediatr. 2017 Oct;176(10):1339-1354. doi: 10.1007/s00431-017-2985-x. Epub 2017 Aug 23.

[Risk of cancer in patients with psoriasis on biologic therapies: A systematic review.](#)

Peleva E, Exton LS, Kelley K, Mason KJ, Smith CH.

Br J Dermatol. 2018 Jan;178(1):103-113. doi: 10.1111/bjd.15830. Epub 2017 Dec 18.

[A systematic review of pharmacogenetic studies on the response to biologics in psoriasis patients.](#)

van Vugt LJ, van den Reek JMPA, Coenen MJH, de Jong EMGJ.

Br J Dermatol. 2018 Jan;178(1):86-94. doi: 10.1111/bjd.15753. Epub 2017 Dec 14.

[Immunogenicity of biologics in chronic inflammatory diseases: A systematic review.](#)

Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L.

BioDrugs. 2017 Aug;31(4):299-316. doi: 10.1007/s40259-017-0231-8.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.

Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Quantitative evaluation of biologic therapy options for psoriasis: A systematic review and network meta-analysis.](#)

Jabbar-Lopez ZK, Yiu ZZN, Ward V, Exton LS, Mustapa MFM, Samarasekera E, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Warren RB, Smith CH.

J Invest Dermatol. 2017 Aug;137(8):1646-1654. doi: 10.1016/j.jid.2017.04.009. Epub 2017 Apr 27.

[Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: Systematic review and meta-analysis of randomized controlled trials.](#)

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.

Br J Dermatol. 2017 Apr;176(4):890-901. doi: 10.1111/bjd.14964. Epub 2017 Mar 14.

[Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: A systematic review and meta-analysis of randomized clinical trials.](#)

de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR.

Drugs R D. 2017 Mar;17(1):29-51. doi: 10.1007/s40268-016-0152-x.

[Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Gómez-García F, Epstein D, Isla-Tejera B, Lorente A, Vélez García-Nieto A, Ruano J.
Br J Dermatol. 2017 Mar;176(3):594-603. doi: 10.1111/bjd.14814. Epub 2016 Oct 13

[Review of maintenance of response to psoriasis treatments.](#)

Bartos S, Hill D, Feldman SR.
J Dermatolog Treat. 2016 Aug;27(4):293-7. doi: 10.1080/09546634.2016.1177158.

[Systemic treatment of pediatric psoriasis: A review.](#)

Napolitano M, Megna M, Balato A, Ayala F, Lembo S, Villani A, Balato N.
Dermatol Ther (Heidelb). 2016 Jun;6(2):125-42. doi: 10.1007/s13555-016-0117-6. Epub 2016 Apr 16.

[Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: A systematic review.](#)

Zweegers J, Otero ME, van den Reek JM, van Lümig PP, Driessen RJ, Kievit W, Seyger MM, van de Kerkhof PC, de Jong EM.
Acta Derm Venereol. 2016 May;96(4):453-8. doi: 10.2340/00015555-2276.

[Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: A systematic review and meta-analysis.](#)

Nast A, Jacobs A, Rosumeck S, Werner RN.
J Invest Dermatol. 2015 Nov;135(11):2641-8. doi: 10.1038/jid.2015.206. Epub 2015 Jun 5.

[Systematic review on the maintenance of response during systemic antipsoriatic therapy.](#)

Jacobs A, Rosumeck S, Nast A.
Br J Dermatol. 2015 Oct;173(4):910-21. doi: 10.1111/bjd.14077. Epub 2015 Oct 6.

[Effect of biologics on depressive symptoms in patients with psoriasis: A systematic review.](#)

Fleming P, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Siu S, Kraft J, Lynde C, Pope JE, Keeling S, Dutz J, Bessette L, Bissonnette R, Haraoui B, Gulliver WP.
J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1063-70. doi: 10.1111/jdv.12909. Epub 2014 Dec 10.

[Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.](#)

Sorenson E, Koo J.
J Dermatolog Treat. 2015;26(6):493-501. doi: 10.3109/09546634.2015.1027167. Epub 2015 Apr 17.

[Subcutaneous biological treatments for moderate to severe psoriasis: Interpreting safety data by network meta-analysis.](#)

Messori A, Trippoli S, Fadda V, Maratea D, Marinai C.
Drugs Real World Outcomes. 2015 Mar;2(1):23-27.

[Systemic treatments in paediatric psoriasis: A systematic evidence-based update.](#)

van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM.
J Eur Acad Dermatol Venereol. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23.

[Comparative efficacy of biological treatments for moderate-to-severe psoriasis: A network meta-analysis adjusting for cross-trial differences in reference arm response.](#)

Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P.
Br J Dermatol. 2015 Feb;172(2):504-12. doi: 10.1111/bjd.13437. Epub 2015 Jan 21.

Comparison of infliximab and ustekinumab for the treatment of moderate-to-severe psoriasis: An indirect comparison meta-analysis

Fan T, Bennett HA, Smith NE, Marin M, Sen SS.

Comparative Effectiveness Research 2015;5:1-11.

<https://www.dovepress.com/comparison-of-infliximab-and-ustekinumab-for-the-treatment-of-moderate-peer-reviewed-article-CER>

[Evidence-based guidelines of the Spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites \(nails, scalp, palms, and soles\).](#)

Sánchez-Regaña M, Aldunce Soto MJ, Belinchón Romero I, Ribera Pibernat M, Lafuente-Urrez RF, Carrascosa Carrillo JM, Ferrándiz Foraster C, Puig Sanz L, Daudén Tello E, Vidal Sarró D, Ruiz-Villaverde R, Fonseca Capdevila E, Rodríguez Cerdeira MC, Alsina Gibert MM, Herrera Acosta E, Marrón Moya SE; en representación del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología.

Actas Dermosifiliogr. 2014 Dec;105(10):923-34. doi: 10.1016/j.ad.2014.02.015. Epub 2014 May 19. English, Spanish

[Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials with different time points.](#)

Puig L, López A, Vilarrasa E, García I.

J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1633-53. doi: 10.1111/jdv.12238. Epub 2013 Aug 19.

[Network meta-analysis of treatments for chronic plaque psoriasis in Canada.](#)

Gupta AK, Daigle D, Lyons DC.

J Cutan Med Surg. 2014 Nov;18(6):371-8.

[Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system.](#)

Wang SH, Chi CC, Hu S.

Int J Dermatol. 2014 Sep;53(9):1151-6. doi: 10.1111/ijd.12462. Epub 2014 Apr 16.

[Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis.](#)

Meng Y, Dongmei L, Yanbin P, Jinju F, Meile T, Binzhu L, Xiao H, Ping T, Jianmin L.

Clin Exp Dermatol. 2014 Aug;39(6):696-707. doi: 10.1111/ced.12390.

[Therapeutic effect and safety of ustekinumab for plaque psoriasis: A meta-analysis.](#)

Liu Y, Gong JP, Li WF.

Chin Med Sci J. 2014 Sep;29(3):131-8.

[Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials.](#)

Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A.

Br J Dermatol. 2014 Feb;170(2):274-303. doi: 10.1111/bjd.12663

[Antidrug antibodies in psoriasis: A systematic review.](#)

Hsu L, Snodgrass BT, Armstrong AW.

Br J Dermatol. 2014 Feb;170(2):261-73. doi: 10.1111/bjd.12654.

[Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: A meta-analysis and cost-efficacy analysis using the intention-to-treat principle.](#)

Chi CC, Wang SH.

Biomed Res Int. 2014;2014:862851. doi: 10.1155/2014/862851. Epub 2014 Jan 29.

[Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: A comprehensive meta-analysis of randomized controlled trials.](#)

Correr CJ, Rotta I, Teles Tde S, Godoy RR, Riveros BS, Garcia MM, Gonçalves PR, Otuki MF.

Cad Saude Publica. 2013 Nov;29 Suppl 1:S17-31.

[Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.](#)

Nast A, Sporbeck B, Rosumeck S, Pathirana D, Jacobs A, Werner RN, Schmitt J.

J Invest Dermatol. 2013 Aug;133(8):1963-70. doi: 10.1038/jid.2013.78. Epub 2013 Feb 20.

[Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: A meta-analysis of randomized controlled trials.](#)

Tzellos T, Kyrgidis A, Zouboulis CC.

J Eur Acad Dermatol Venereol. 2013 May;27(5):622-7. doi: 10.1111/j.1468-3083.2012.04500.x. Epub 2012 Mar 8.

[Biological treatments for moderate-to-severe psoriasis: indirect comparison.](#)

Galván-Banqueri M, Marín Gil R, Santos Ramos B, Bautista Paloma FJ.

J Clin Pharm Ther. 2013 Apr;38(2):121-30. doi: 10.1111/jcpt.12044. Epub 2013 Feb 26.

[Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: A Bayesian network meta-analysis.](#)

Lin VW, Ringold S, Devine EB.

Arch Dermatol. 2012 Dec;148(12):1403-10. doi: 10.1001/2013.jamadermatol.238.

[Effect of biologic agents on non-PASI outcomes in moderate-to-severe plaque psoriasis: Systematic review and meta-analyses.](#)

Baker EL, Coleman CI, Reinhart KM, Phung OJ, Kugelman L, Chen W, White CM, Mamolo CM, Cappelleri JC, Baker WL.

Dermatol Ther (Heidelb). 2012 Dec;2(1):9. doi: 10.1007/s13555-012-0009-3. Epub 2012 Jun 19.

[Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis \[Internet\].](#)

Lee S, Coleman CI, Limone B, Kaur R, White CM, Kluger J, Sobieraj DM.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov.

[Efficacy of systemic therapies for moderate-to-severe psoriasis: A systematic review and meta-analysis of long-term treatment.](#)

Lucka TC, Pathirana D, Sammain A, Bachmann F, Rosumeck S, Erdmann R, Schmitt J, Orawa H, Rzyany B, Nast A.

J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1331-44. doi: 10.1111/j.1468-3083.2012.04492.x.

Epub 2012 Mar 9. Review. Erratum in: J Eur Acad Dermatol Venereol. 2012 Jul;26(7):930.

[Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.](#)

Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P.

Adv Ther. 2012 Jul;29(7):620-34. doi: 10.1007/s12325-012-0035-7. Epub 2012 Jul 27.

[Off-label biologic regimens in psoriasis: A systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy.](#)

Brezinski EA, Armstrong AW.

PLoS One. 2012;7(4):e33486. doi: 10.1371/journal.pone.0033486. Epub 2012 Apr 11.

[Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials.](#)

Reich K, Burden AD, Eaton JN, Hawkins NS.

Br J Dermatol. 2012 Jan;166(1):179-88. doi: 10.1111/j.1365-2133.2011.10583.x. Epub 2011 Nov 11.

[Treatment of psoriasis with interleukin-12/23 monoclonal antibody: A systematic review.](#)

Wu Y, Chen J, Li YH, Ma GZ, Chen JZ, Gao XH, Chen HD.

Eur J Dermatol. 2012 Jan-Feb;22(1):72-82. doi: 10.1684/ejd.2011.1559.

Interleukin antagonists – secukinumab (IL-17 inhibitor)

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.](#)

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA.

J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.

[Effectiveness and safety of systemic therapy for psoriasis in older adults: A systematic review.](#)

van Winden MEC, van der Schoot LS, van de L'Isle Arias M, van Vugt LJ, van den Reek JMPA, van de Kerkhof PCM, de Jong EMGJ, Lubeek SFK.

JAMA Dermatol. 2020 Aug 19. doi: 10.1001/jamadermatol.2020.2311. Online ahead of print.

[Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Tada Y, Watanabe R, Noma H, Kanai Y, Nomura T, Kaneko K.

J Dermatol Sci. 2020 Jun 18. pii: S0923-1811(20)30199-7. doi: 10.1016/j.jdermsci.2020.06.003. [Epub ahead of print]

[Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.](#)

Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, de Brito M, McGuire A, Murphy R, Owen CM, Parslew R, Woolf RT, Yiu ZZN, Uthman OA, Mohd Mustapa MF, Smith CH.

Br J Dermatol. 2020 Jun 20. doi: 10.1111/bjd.19325. [Epub ahead of print]

[Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.](#)

Yasmeen N, Sawyer LM, Malottki K, Levin LÅ, Apol ED, Jemec GB.

J Dermatolog Treat. 2020 Mar 23:1-50. doi: 10.1080/09546634.2020.1743811. [Epub ahead of print]

[Risk of tuberculosis reactivation during IL-17 inhibitor therapy for psoriasis: A systematic review.](#)

Fowler E, Ghamrawi RI, Ghiam N, Liao W, Wu JJ.

J Eur Acad Dermatol Venereol. 2020 Feb 3. doi: 10.1111/jdv.16254. [Epub ahead of print]

[Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis.](#)

Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M.
JAMA Dermatol. 2020 Feb 5. doi: 10.1001/jamadermatol.2019.4029. [Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)
Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L.
Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

[Real-world evidence of secukinumab in psoriasis treatment - A meta-analysis of 43 studies.](#)
Augustin M, Jullien D, Martin A, Peralta C.
J Eur Acad Dermatol Venereol. 2020 Jan 9. doi: 10.1111/jdv.16180. [Epub ahead of print]

[Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.](#)
Warren RB, Gooderham M, Burge R, Zhu B, Amato D, Liu KH, Shrom D, Guo J, Brnabic A, Blauvelt A.
J Am Acad Dermatol. 2019 Dec 26. pii: S0190-9622(19)33315-8. doi: 10.1016/j.jaad.2019.12.038.
[Epub ahead of print]

[Review of treatments for generalized pustular psoriasis.](#)
Kearns DG, Chat VS, Zang PD, Han G, Wu JJ.
J Dermatolog Treat. 2019 Nov 7;1-13. doi: 10.1080/09546634.2019.1682502. [Epub ahead of print]

[Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies.](#)
Loft ND, Vaengebjerg S, Halling-Sønderby AS, Skov L, Egeberg A.
J Eur Acad Dermatol Venereol. 2019 Nov 13. doi: 10.1111/jdv.16073. [Epub ahead of print]

[Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: A comprehensive investigation using Bayesian and frequentist network meta-analyses.](#)
Warren RB, See K, Burge R, Zhang Y, Brnabic A, Gallo G, Garrelts A, Egeberg A.
Dermatol Ther (Heidelb). 2019 Nov 4. doi: 10.1007/s13555-019-00337-y. [Epub ahead of print]

[Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: A systematic review and network meta-analysis of randomized controlled trials.](#)
Bai F, Li GG, Liu Q, Niu X, Li R, Ma H.
J Immunol Res. 2019 Sep 10;2019:2546161. doi: 10.1155/2019/2546161. eCollection 2019.

[Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.](#)
Egeberg A, Andersen YMF, Halling-Overgaard AS, Alignah F, Thyssen JP, Burge R, Mallbris L.
J Eur Acad Dermatol Venereol. 2019 Aug 29. doi: 10.1111/jdv.15920. [Epub ahead of print]

[Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.](#)
Sawyer LM, Malottki K, Sabry-Grant C, Yasmeeen N, Wright E, Sohrt A, Borg E, Warren RB.
PLoS One. 2019 Aug 14;14(8):e0220868. doi: 10.1371/journal.pone.0220868. eCollection 2019.

[Biologic therapies targeting the IL-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis.](#)

Erichsen CY, Jensen P, Kofoed K.

J Eur Acad Dermatol Venereol. 2019 Aug 16. doi: 10.1111/jdv.15879. [Epub ahead of print]

[Biologics switch in psoriasis.](#)

Wang TS, Tsai TF.

Immunotherapy. 2019 Apr;11(6):531-541. doi: 10.2217/imt-2018-0131.

[Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis.](#)

Xu G, Xia M, Jiang C, Yu Y, Wang G, Yuan J, Duan X.

J Pharmacol Sci. 2019 Apr;139(4):289-303. doi: 10.1016/j.jphs.2018.12.006. Epub 2018 Dec 27.

[Adverse drug events observed with 150 mg versus 300 mg secukinumab for the treatment of moderate to severe plaque psoriasis: A systematic review and meta-analysis.](#)

Zhang L, Yang H, Chen Q, Zhao J.

Medicine (Baltimore). 2019 Jan;98(2):e14042. doi: 10.1097/MD.00000000000014042.

[Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.](#)

Sawyer LM, Cornic L, Levin LÅ, Gibbons C, Møller AH, Jemec GB.

J Eur Acad Dermatol Venereol. 2019 Feb;33(2):355-366. doi: 10.1111/jdv.15277. Epub 2018 Oct 31.

[Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.](#)

Cui L, Chen R, Subedi S, Yu Q, Gong Y, Chen Z, Shi Y.

Int Immunopharmacol. 2018 Sep;62:46-58. doi: 10.1016/j.intimp.2018.06.020. Epub 2018 Jul 3.

[Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis.](#)

Thomas LW, Lee EB, Wu JJ.

J Dermatolog Treat. 2019 Mar;30(2):110-116. doi: 10.1080/09546634.2018.1473552. Epub 2018 May 18.

[Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.](#)

Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.

Curr Med Res Opin. 2018 Jul;34(7):1325-1333. doi: 10.1080/03007995.2018.1457516. Epub 2018 Apr 23.

[A systematic review and meta-analysis of the efficacy and safety of the interleukin \(IL\)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, and tildrakizumab for the treatment of moderate to severe plaque psoriasis.](#)

Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB.

J Dermatolog Treat. 2018 Sep;29(6):569-578. doi: 10.1080/09546634.2017.1422591. Epub 2018 Mar 28.

[Quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.](#)

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.

Mol Pain. 2018 Jan-Dec;14:1744806918762205. doi: 10.1177/1744806918762205. Epub 2018 Feb 15.

[Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.](#)

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.

J Am Acad Dermatol. 2018 Jul;79(1):135-144.e7. doi: 10.1016/j.jaad.2018.02.027. Epub 2018 Feb 10.

[Biologicals and small molecules in psoriasis: A systematic review of economic evaluations.](#)

Kromer C, Celis D, Sonntag D, Peitsch WK.

PLoS One. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765. eCollection 2018.

[A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.](#)

No DJ, Amin M, Bhutani T, Wu JJ.

J Dermatolog Treat. 2018 Aug;29(5):467-474. doi: 10.1080/09546634.2017.1402116. Epub 2017 Nov 22.

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Thérén  C, Brenaut E, Barnette T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[\[A systematic review of anti-interleukin-17 antibody in the treatment of plaque psoriasis\].](#)

Fan XD, Xia X, Zhang CY, Kong WQ, Zhou CY, DU B.

Nan Fang Yi Ke Da Xue Xue Bao. 2017 Sep 20;37(9):1274-1279. Chinese.

[Immunogenicity of biologics in chronic inflammatory diseases: A systematic review.](#)

Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L.

BioDrugs. 2017 Aug;31(4):299-316. doi: 10.1007/s40259-017-0231-8.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.

Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: Systematic review and meta-analysis of randomized controlled trials.](#)

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.

Br J Dermatol. 2017 Apr;176(4):890-901. doi: 10.1111/bjd.14964. Epub 2017 Mar 14.

[Quantitative evaluation of biologic therapy options for psoriasis: A systematic review and network meta-analysis.](#)

Jabbar-Lopez ZK, Yiu ZZN, Ward V, Exton LS, Mustapa MFM, Samarasekera E, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Warren RB, Smith CH.

J Invest Dermatol. 2017 Aug;137(8):1646-1654. doi: 10.1016/j.jid.2017.04.009. Epub 2017 Apr 27.

[Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: A systematic review and meta-analysis of randomized clinical trials.](#)

de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR.

Drugs R D. 2017 Mar;17(1):29-51. doi: 10.1007/s40268-016-0152-x.

[Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Gómez-García F, Epstein D, Isla-Tejera B, Lorente A, Vélez García-Nieto A, Ruano J.
Br J Dermatol. 2017 Mar;176(3):594-603. doi: 10.1111/bjd.14814. Epub 2016 Oct 13

[Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: A meta-analysis from phase 3 randomized controlled trials.](#)

Wu D, Hou SY, Zhao S, Hou LX, Jiao T, Xu NN, Zhang N.
J Eur Acad Dermatol Venereol. 2017 Jun;31(6):992-1003. doi: 10.1111/jdv.14125. Epub 2017 Feb 8.

[No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents.](#)

Chiricozzi A, Romanelli M, Saraceno R, Torres T.
Expert Opin Drug Saf. 2016 Dec;15(12):1653-1659. Epub 2016 Aug 31.

[Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management.](#)

Saunte DM, Mrowietz U, Puig L, Zachariae C.
Br J Dermatol. 2017 Jul;177(1):47-62. doi: 10.1111/bjd.15015. Epub 2017 Jun 1.

[Review of maintenance of response to psoriasis treatments.](#)

Bartos S, Hill D, Feldman SR.
J Dermatolog Treat. 2016 Aug;27(4):293-7. doi: 10.1080/09546634.2016.1177158.

[Meta-analysis of the efficacy and safety of secukinumab for the treatment of plaque psoriasis.](#)

opical treatments for scalp psoriasis JY, Yang HJ, Ji E, Yoo BK.
Ann Pharmacother. 2016 May;50(5):341-51. doi: 10.1177/1060028015626545. Epub 2016 Jan 18.

[Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: A systematic review and meta-analysis.](#)

Nast A, Jacobs A, Rosumeck S, Werner RN.
J Invest Dermatol. 2015 Nov;135(11):2641-8. doi: 10.1038/jid.2015.206. Epub 2015 Jun 5.

[Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis.](#)

Chen Y, Qian T, Zhang D, Yan H, Hao F.
Immunotherapy. 2015;7(9):1023-37. doi: 10.2217/imt.15.50. Epub 2015 Jun 9.

[Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: A meta-analysis of randomized controlled trials.](#)

Xiong HZ, Gu JY, He ZG, Chen WJ, Zhang X, Wang JY, Shi YL.
Int J Clin Exp Med. 2015 Mar 15;8(3):3156-72. eCollection 2015.

[Anti-IL-17 phase II data for psoriasis: A review.](#)

Brown G, Malakouti M, Wang E, Koo JY, Levin E.
J Dermatolog Treat. 2015 Feb;26(1):32-6. doi: 10.3109/09546634.2013.878448. Epub 2014 Feb 20.

Interleukin antagonists - ixekizumab (IL-17 inhibitor)

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.](#)

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA.
J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.

[Efficacy of biologics targeting tumour necrosis factor-alpha, interleukin-17 -12/23, -23 and small molecules targeting JAK and PDE4 in the treatment of nail psoriasis: A network meta-analysis.](#)

Szebényi J, Gede N, Hegyi P, Szakács Z, Solymár M, Erőss B, Garami A, Farkas K, Csupor D, Gyulai R. Acta Derm Venereol. 2020 Sep 23. doi: 10.2340/00015555-3640. Online ahead of print.

[Efficacy of a second IL-17 inhibitor in patients with psoriasis: a systematic review and meta-analysis.](#)

Loft ND, Halling AS, Egeberg A, Skov L.

J Am Acad Dermatol. 2020 Jul 27:S0190-9622(20)32286-6. doi: 10.1016/j.jaad.2020.07.085. Online ahead of print.

[Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Tada Y, Watanabe R, Noma H, Kanai Y, Nomura T, Kaneko K.

J Dermatol Sci. 2020 Jun 18. pii: S0923-1811(20)30199-7. doi: 10.1016/j.jdermsci.2020.06.003. [Epub ahead of print]

[Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.](#)

Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, de Brito M, McGuire A, Murphy R, Owen CM, Parslew R, Woolf RT, Yiu ZZN, Uthman OA, Mohd Mustapa MF, Smith CH. Br J Dermatol. 2020 Jun 20. doi: 10.1111/bjd.19325. [Epub ahead of print]

[Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.](#)

Yasmeen N, Sawyer LM, Malottki K, Levin LÅ, Apol ED, Jemec GB.

J Dermatolog Treat. 2020 Mar 23:1-50. doi: 10.1080/09546634.2020.1743811. [Epub ahead of print]

[Risk of tuberculosis reactivation during IL-17 inhibitor therapy for psoriasis: A systematic review.](#)

Fowler E, Ghamrawi RI, Ghiam N, Liao W, Wu JJ.

J Eur Acad Dermatol Venereol. 2020 Feb 3. doi: 10.1111/jdv.16254. [Epub ahead of print]

[Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis.](#)

Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M.

JAMA Dermatol. 2020 Feb 5. doi: 10.1001/jamadermatol.2019.4029. [Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L.

Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

[Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.](#)

Warren RB, Gooderham M, Burge R, Zhu B, Amato D, Liu KH, Shrom D, Guo J, Brnabic A, Blauvelt A.

J Am Acad Dermatol. 2019 Dec 26. pii: S0190-9622(19)33315-8. doi: 10.1016/j.jaad.2019.12.038. [Epub ahead of print]

[Review of treatments for generalized pustular psoriasis.](#)

Kearns DG, Chat VS, Zang PD, Han G, Wu JJ.

J Dermatolog Treat. 2019 Nov 7;1-13. doi: 10.1080/09546634.2019.1682502. [Epub ahead of print]

[Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies.](#)

Loft ND, Vaengebjerg S, Halling-Sønderby AS, Skov L, Egeberg A.

J Eur Acad Dermatol Venereol. 2019 Nov 13. doi: 10.1111/jdv.16073. [Epub ahead of print]

[Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: A comprehensive investigation using Bayesian and frequentist network meta-analyses.](#)

Warren RB, See K, Burge R, Zhang Y, Brnabic A, Gallo G, Garrelts A, Egeberg A.

Dermatol Ther (Heidelb). 2019 Nov 4. doi: 10.1007/s13555-019-00337-y. [Epub ahead of print]

[Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: A systematic review and network meta-analysis of randomized controlled trials.](#)

Bai F, Li GG, Liu Q, Niu X, Li R, Ma H.

J Immunol Res. 2019 Sep 10;2019:2546161. doi: 10.1155/2019/2546161. eCollection 2019.

[Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.](#)

Egeberg A, Andersen YMF, Halling-Overgaard AS, Alignah F, Thyssen JP, Burge R, Mallbris L.

J Eur Acad Dermatol Venereol. 2019 Aug 29. doi: 10.1111/jdv.15920. [Epub ahead of print]

[Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.](#)

Sawyer LM, Malottki K, Sabry-Grant C, Yasmeeen N, Wright E, Sohrt A, Borg E, Warren RB.

PLoS One. 2019 Aug 14;14(8):e0220868. doi: 10.1371/journal.pone.0220868. eCollection 2019.

[Biologic therapies targeting the IL-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis.](#)

Erichsen CY, Jensen P, Kofoed K.

J Eur Acad Dermatol Venereol. 2019 Aug 16. doi: 10.1111/jdv.15879. [Epub ahead of print]

[Biologics switch in psoriasis.](#)

Wang TS, Tsai TF.

Immunotherapy. 2019 Apr;11(6):531-541. doi: 10.2217/imt-2018-0131.

[Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis.](#)

Xu G, Xia M, Jiang C, Yu Y, Wang G, Yuan J, Duan X.

J Pharmacol Sci. 2019 Apr;139(4):289-303. doi: 10.1016/j.jphs.2018.12.006. Epub 2018 Dec 27.

[Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.](#)

Sawyer LM, Cornic L, Levin LÅ, Gibbons C, Møller AH, Jemec GB.

J Eur Acad Dermatol Venereol. 2019 Feb;33(2):355-366. doi: 10.1111/jdv.15277. Epub 2018 Oct 31.

[Ixekizumab: A review of its use for the management of moderate to severe plaque psoriasis.](#)

Shelton SK, Bai SR, Jordan JK, Sheehan AH.

Ann Pharmacother. 2019 Mar;53(3):276-284. doi: 10.1177/1060028018799982. Epub 2018 Sep 6.

[Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.](#)

Cui L, Chen R, Subedi S, Yu Q, Gong Y, Chen Z, Shi Y.

Int Immunopharmacol. 2018 Sep;62:46-58. doi: 10.1016/j.intimp.2018.06.020. Epub 2018 Jul 3.

[Emerging therapies in psoriasis: A systematic review.](#)

Lee EB, Amin M, Bhutani T, Wu JJ.

Cutis. 2018 Mar;101(3S):5-9.

[Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis.](#)

Thomas LW, Lee EB, Wu JJ.

J Dermatolog Treat. 2019 Mar;30(2):110-116. doi: 10.1080/09546634.2018.1473552. Epub 2018 May 18.

[Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.](#)

Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.

Curr Med Res Opin. 2018 Jul;34(7):1325-1333. doi: 10.1080/03007995.2018.1457516. Epub 2018 Apr 23.

[A systematic review and meta-analysis of the efficacy and safety of the interleukin \(IL\)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, and tildrakizumab for the treatment of moderate to severe plaque psoriasis.](#)

Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB.

J Dermatolog Treat. 2018 Sep;29(6):569-578. doi: 10.1080/09546634.2017.1422591. Epub 2018 Mar 28.

[Quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.](#)

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.

Mol Pain. 2018 Jan-Dec;14:1744806918762205. doi: 10.1177/1744806918762205. Epub 2018 Feb 15.

[Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.](#)

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.

J Am Acad Dermatol. 2018 Jul;79(1):135-144.e7. doi: 10.1016/j.jaad.2018.02.027. Epub 2018 Feb 10.

[A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.](#)

No DJ, Amin M, Bhutani T, Wu JJ.

J Dermatolog Treat. 2018 Aug;29(5):467-474. doi: 10.1080/09546634.2017.1402116. Epub 2017 Nov 22.

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Thér  ne C, Brenaut E, Barnette T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[\[A systematic review of anti-interleukin-17 antibody in the treatment of plaque psoriasis\].](#)

Fan XD, Xia X, Zhang CY, Kong WQ, Zhou CY, DU B.

Nan Fang Yi Ke Da Xue Xue Bao. 2017 Sep 20;37(9):1274-1279. Chinese.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.

Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Quantitative evaluation of biologic therapy options for psoriasis: A systematic review and network meta-analysis.](#)

Jabbar-Lopez ZK, Yiu ZZN, Ward V, Exton LS, Mustapa MFM, Samarasekera E, Burden AD, Murphy R, Owen CM, Parslew R, Venning V, Warren RB, Smith CH.

J Invest Dermatol. 2017 Aug;137(8):1646-1654. doi: 10.1016/j.jid.2017.04.009. Epub 2017 Apr 27.

[Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: Systematic review and meta-analysis of randomized controlled trials.](#)

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM.

Br J Dermatol. 2017 Apr;176(4):890-901. doi: 10.1111/bjd.14964. Epub 2017 Mar 14.

[Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: A systematic review and meta-analysis of randomized clinical trials.](#)

de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR.

Drugs R D. 2017 Mar;17(1):29-51. doi: 10.1007/s40268-016-0152-x.

[Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: A meta-analysis from phase 3 randomized controlled trials.](#)

Wu D, Hou SY, Zhao S, Hou LX, Jiao T, Xu NN, Zhang N.

J Eur Acad Dermatol Venereol. 2017 Jun;31(6):992-1003. doi: 10.1111/jdv.14125. Epub 2017 Feb 8.

[No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents.](#)

Chiricozzi A, Romanelli M, Saraceno R, Torres T.

Expert Opin Drug Saf. 2016 Dec;15(12):1653-1659. Epub 2016 Aug 31.

[Review of maintenance of response to psoriasis treatments.](#)

Bartos S, Hill D, Feldman SR.

J Dermatolog Treat. 2016 Aug;27(4):293-7. doi: 10.1080/09546634.2016.1177158.

[Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management.](#)

Saunte DM, Mrowietz U, Puig L, Zachariae C.

Br J Dermatol. 2017 Jul;177(1):47-62. doi: 10.1111/bjd.15015. Epub 2017 Jun 1.

[Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis.](#)

Chen Y, Qian T, Zhang D, Yan H, Hao F.

Immunotherapy. 2015;7(9):1023-37. doi: 10.2217/imt.15.50. Epub 2015 Jun 9.

[Anti-IL-17 phase II data for psoriasis: A review.](#)

Brown G, Malakouti M, Wang E, Koo JY, Levin E.

J Dermatolog Treat. 2015 Feb;26(1):32-6. doi: 10.3109/09546634.2013.878448. Epub 2014 Feb 20.

Interleukin antagonists - brodalumab (IL-17 inhibitor)

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.](#)

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA.

J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.

[Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Tada Y, Watanabe R, Noma H, Kanai Y, Nomura T, Kaneko K.

J Dermatol Sci. 2020 Jun 18. pii: S0923-1811(20)30199-7. doi: 10.1016/j.jdermsci.2020.06.003. [Epub ahead of print]

[Efficacy of brodalumab for moderate to severe plaque psoriasis: A Canadian network meta-analysis.](#)

Xue W, Saharia P, Gray E, Khoudigian-Sinani S, Gaudet V, Barbeau M, Papp K.

J Cutan Med Surg. 2020 Jun 26:1203475420933174. doi: 10.1177/1203475420933174. [Epub ahead of print]

[Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.](#)

Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, de Brito M, McGuire A, Murphy R, Owen CM, Parslew R, Woolf RT, Yiu ZZN, Uthman OA, Mohd Mustapa MF, Smith CH.

Br J Dermatol. 2020 Jun 20. doi: 10.1111/bjd.19325. [Epub ahead of print]

[Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.](#)

Yasmeen N, Sawyer LM, Malottki K, Levin LÅ, Apol ED, Jemec GB.

J Dermatolog Treat. 2020 Mar 23:1-50. doi: 10.1080/09546634.2020.1743811. [Epub ahead of print]

[Risk of tuberculosis reactivation during IL-17 inhibitor therapy for psoriasis: A systematic review.](#)

Fowler E, Ghamrawi RI, Ghiam N, Liao W, Wu JJ.

J Eur Acad Dermatol Venereol. 2020 Feb 3. doi: 10.1111/jdv.16254. [Epub ahead of print]

[Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis.](#)

Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M.

JAMA Dermatol. 2020 Feb 5. doi: 10.1001/jamadermatol.2019.4029. [Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L.

Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

[Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.](#)

Warren RB, Gooderham M, Burge R, Zhu B, Amato D, Liu KH, Shrom D, Guo J, Brnabic A, Blauvelt A. J Am Acad Dermatol. 2019 Dec 26. pii: S0190-9622(19)33315-8. doi: 10.1016/j.jaad.2019.12.038. [Epub ahead of print]

[Review of treatments for generalized pustular psoriasis.](#)

Kearns DG, Chat VS, Zang PD, Han G, Wu JJ.

J Dermatolog Treat. 2019 Nov 7:1-13. doi: 10.1080/09546634.2019.1682502. [Epub ahead of print]

[Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies.](#)

Loft ND, Vaengebjerg S, Halling-Sønderby AS, Skov L, Egeberg A.

J Eur Acad Dermatol Venereol. 2019 Nov 13. doi: 10.1111/jdv.16073. [Epub ahead of print]

[Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: A comprehensive investigation using Bayesian and frequentist network meta-analyses.](#)

Warren RB, See K, Burge R, Zhang Y, Brnabic A, Gallo G, Garrelts A, Egeberg A.

Dermatol Ther (Heidelb). 2019 Nov 4. doi: 10.1007/s13555-019-00337-y. [Epub ahead of print]

[Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: A systematic review and network meta-analysis of randomized controlled trials.](#)

Bai F, Li GG, Liu Q, Niu X, Li R, Ma H.

J Immunol Res. 2019 Sep 10;2019:2546161. doi: 10.1155/2019/2546161. eCollection 2019.

[Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.](#)

Egeberg A, Andersen YMF, Halling-Overgaard AS, Alignah F, Thyssen JP, Burge R, Mallbris L.

J Eur Acad Dermatol Venereol. 2019 Aug 29. doi: 10.1111/jdv.15920. [Epub ahead of print]

[Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.](#)

Sawyer LM, Malottki K, Sabry-Grant C, Yasmeeen N, Wright E, Sohr A, Borg E, Warren RB.

PLoS One. 2019 Aug 14;14(8):e0220868. doi: 10.1371/journal.pone.0220868. eCollection 2019.

[Biologic therapies targeting the IL-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis.](#)

Erichsen CY, Jensen P, Kofoed K.

J Eur Acad Dermatol Venereol. 2019 Aug 16. doi: 10.1111/jdv.15879. [Epub ahead of print]

[Biologics switch in psoriasis.](#)

Wang TS, Tsai TF.

Immunotherapy. 2019 Apr;11(6):531-541. doi: 10.2217/imt-2018-0131.

[Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis.](#)

Xu G, Xia M, Jiang C, Yu Y, Wang G, Yuan J, Duan X.

J Pharmacol Sci. 2019 Apr;139(4):289-303. doi: 10.1016/j.jphs.2018.12.006. Epub 2018 Dec 27.

[Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.](#)

Sawyer LM, Cornic L, Levin LÅ, Gibbons C, Møller AH, Jemec GB.
J Eur Acad Dermatol Venereol. 2019 Feb;33(2):355-366. doi: 10.1111/jdv.15277. Epub 2018 Oct 31.

[Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.](#)

Cui L, Chen R, Subedi S, Yu Q, Gong Y, Chen Z, Shi Y.
Int Immunopharmacol. 2018 Sep;62:46-58. doi: 10.1016/j.intimp.2018.06.020. Epub 2018 Jul 3.

[Emerging therapies in psoriasis: A systematic review.](#)

Lee EB, Amin M, Bhutani T, Wu JJ.
Cutis. 2018 Mar;101(3S):5-9.

[Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis.](#)

Thomas LW, Lee EB, Wu JJ.
J Dermatolog Treat. 2019 Mar;30(2):110-116. doi: 10.1080/09546634.2018.1473552. Epub 2018 May 18.

[A systematic review and meta-analysis of the efficacy and safety of the interleukin \(IL\)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, and tildrakizumab for the treatment of moderate to severe plaque psoriasis.](#)

J Dermatolog Treat. 2018 Sep;29(6):569-578. doi: 10.1080/09546634.2017.1422591. Epub 2018 Mar 28.

[Quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.](#)

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.
Mol Pain. 2018 Jan-Dec;14:1744806918762205. doi: 10.1177/1744806918762205. Epub 2018 Feb 15.

[Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.](#)

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.
J Am Acad Dermatol. 2018 Jul;79(1):135-144.e7. doi: 10.1016/j.jaad.2018.02.027. Epub 2018 Feb 10.

[The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis.](#)

Sawyer L, Fotheringham I, Wright E, Yasmeen N, Gibbons C, Holmen Møller A.
J Dermatolog Treat. 2018 Sep;29(6):557-568. doi: 10.1080/09546634.2018.1427205. Epub 2018 Jan 29.

[A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.](#)

No DJ, Amin M, Bhutani T, Wu JJ.
J Dermatolog Treat. 2018 Aug;29(5):467-474. doi: 10.1080/09546634.2017.1402116. Epub 2017 Nov 22.

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Théréné C, Brenaut E, Barnette T, Misery L.
J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[\[A systematic review of anti-interleukin-17 antibody in the treatment of plaque psoriasis\].](#)

Fan XD, Xia X, Zhang CY, Kong WQ, Zhou CY, DU B.
Nan Fang Yi Ke Da Xue Xue Bao. 2017 Sep 20;37(9):1274-1279. Chinese.

[Safety and efficacy of brodalumab for moderate-to-severe plaque psoriasis: A systematic review and meta-analysis.](#)

Attia A, Abushouk AI, Ahmed H, Gadelkarim M, Elgebaly A, Hassan Z, Abdel-Daim MM, Negida A.
Clin Drug Investig. 2017 May;37(5):439-451. doi: 10.1007/s40261-017-0500-9.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.
Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: A systematic review and meta-analysis of randomized clinical trials.](#)

de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR.
Drugs R D. 2017 Mar;17(1):29-51. doi: 10.1007/s40268-016-0152-x.

[Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: A meta-analysis from phase 3 randomized controlled trials.](#)

Wu D, Hou SY, Zhao S, Hou LX, Jiao T, Xu NN, Zhang N.
J Eur Acad Dermatol Venereol. 2017 Jun;31(6):992-1003. doi: 10.1111/jdv.14125. Epub 2017 Feb 8.

[No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents.](#)

Chiricozzi A, Romanelli M, Saraceno R, Torres T.
Expert Opin Drug Saf. 2016 Dec;15(12):1653-1659. Epub 2016 Aug 31.

[Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management.](#)

Saunte DM, Mrowietz U, Puig L, Zachariae C.
Br J Dermatol. 2017 Jul;177(1):47-62. doi: 10.1111/bjd.15015. Epub 2017 Jun 1.

[Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis.](#)

Chen Y, Qian T, Zhang D, Yan H, Hao F.
Immunotherapy. 2015;7(9):1023-37. doi: 10.2217/imt.15.50. Epub 2015 Jun 9.

[Anti-IL-17 phase II data for psoriasis: A review.](#)

Brown G, Malakouti M, Wang E, Koo JY, Levin E.
J Dermatolog Treat. 2015 Feb;26(1):32-6. doi: 10.3109/09546634.2013.878448. Epub 2014 Feb 20.

Interleukin antagonists – bimekizumab (IL-17 inhibitor)

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L.
Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

Interleukin antagonists - guselkumab (IL-23 inhibitor)

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.](#)

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA.
J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.

[A systematic literature review and Bucher indirect comparison: Tildrakizumab versus guselkumab.](#)

Du Jardin KG, Hurtado Lopez P, Lange M, McCool R, Maeso Naval S, Quickert S.
J Health Econ Outcomes Res. 2020 Jul 24;7(2):123-129. doi: 10.36469/jheor.2020.13671. eCollection 2020.

[The risk of respiratory tract infections and interstitial lung disease with IL-12/23 and IL-23 antagonists in patients with autoimmune diseases: a systematic review and meta-analysis.](#)

Akiyama S, Yamada A, Micic D, Sakuraba A.
J Am Acad Dermatol. 2020 Aug 10:S0190-9622(20)32414-2. doi: 10.1016/j.jaad.2020.08.026. Online ahead of print.

[Assessing the short-term efficacy and safety of guselkumab for moderate-to-severe plaque psoriasis: Meta-analysis of randomized controlled trials.](#)

Yang J, Wang Z, Zhang X.
J Immunol Res. 2020 Jul 17;2020:4975628. doi: 10.1155/2020/4975628. eCollection 2020.

[Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Tada Y, Watanabe R, Noma H, Kanai Y, Nomura T, Kaneko K.
J Dermatol Sci. 2020 Jun 18. pii: S0923-1811(20)30199-7. doi: 10.1016/j.jdermsci.2020.06.003. [Epub ahead of print]

[A network meta-analysis for the comparison of efficacy and safety of interleukin \(IL\)-23 targeted drugs in the treatment of moderate to severe psoriasis.](#)

Jianzhen S, Xu J, Yanmei C.
Dermatol Ther. 2020 Jun 10:e13802. doi: 10.1111/dth.13802. [Epub ahead of print]

[Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.](#)

Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, de Brito M, McGuire A, Murphy R, Owen CM, Parslew R, Woolf RT, Yiu ZZN, Uthman OA, Mohd Mustapa MF, Smith CH.
Br J Dermatol. 2020 Jun 20. doi: 10.1111/bjd.19325. [Epub ahead of print]

[Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.](#)

Yasmeen N, Sawyer LM, Malottki K, Levin LÅ, Apol ED, Jemec GB.
J Dermatolog Treat. 2020 Mar 23:1-50. doi: 10.1080/09546634.2020.1743811. [Epub ahead of print]

[Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis.](#)

Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M.

JAMA Dermatol. 2020 Feb 5. doi: 10.1001/jamadermatol.2019.4029. [Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L.

Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

[Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.](#)

Warren RB, Gooderham M, Burge R, Zhu B, Amato D, Liu KH, Shrom D, Guo J, Brnabic A, Blauvelt A.

J Am Acad Dermatol. 2019 Dec 26. pii: S0190-9622(19)33315-8. doi: 10.1016/j.jaad.2019.12.038.

[Epub ahead of print]

[Review of treatments for generalized pustular psoriasis.](#)

Kearns DG, Chat VS, Zang PD, Han G, Wu JJ.

J Dermatolog Treat. 2019 Nov 7;1-13. doi: 10.1080/09546634.2019.1682502. [Epub ahead of print]

[Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies.](#)

Loft ND, Vaengebjerg S, Halling-Sønderby AS, Skov L, Egeberg A.

J Eur Acad Dermatol Venereol. 2019 Nov 13. doi: 10.1111/jdv.16073. [Epub ahead of print]

[Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: A comprehensive investigation using Bayesian and frequentist network meta-analyses.](#)

Warren RB, See K, Burge R, Zhang Y, Brnabic A, Gallo G, Garrelts A, Egeberg A.

Dermatol Ther (Heidelb). 2019 Nov 4. doi: 10.1007/s13555-019-00337-y. [Epub ahead of print]

[Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: A systematic review and network meta-analysis of randomized controlled trials.](#)

Bai F, Li GG, Liu Q, Niu X, Li R, Ma H.

J Immunol Res. 2019 Sep 10;2019:2546161. doi: 10.1155/2019/2546161. eCollection 2019.

[Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis.](#)

Xu S, Zhang X, Pan M, Shuai Z, Xu S, Pan F.

Int Immunopharmacol. 2019 Aug 26;75:105841. doi: 10.1016/j.intimp.2019.105841. [Epub ahead of print]

[Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.](#)

Egeberg A, Andersen YMF, Halling-Overgaard AS, Alignah F, Thyssen JP, Burge R, Mallbris L.

J Eur Acad Dermatol Venereol. 2019 Aug 29. doi: 10.1111/jdv.15920. [Epub ahead of print]

[Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.](#)

Sawyer LM, Malottki K, Sabry-Grant C, Yasmeeen N, Wright E, Sohrt A, Borg E, Warren RB.

PLoS One. 2019 Aug 14;14(8):e0220868. doi: 10.1371/journal.pone.0220868. eCollection 2019.

[Biologic therapies targeting the IL-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis.](#)

Erichsen CY, Jensen P, Kofoed K.

J Eur Acad Dermatol Venereol. 2019 Aug 16. doi: 10.1111/jdv.15879. [Epub ahead of print]

[Biologics switch in psoriasis.](#)

Wang TS, Tsai TF.

Immunotherapy. 2019 Apr;11(6):531-541. doi: 10.2217/imt-2018-0131.

[Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis.](#)

Xu G, Xia M, Jiang C, Yu Y, Wang G, Yuan J, Duan X.

J Pharmacol Sci. 2019 Apr;139(4):289-303. doi: 10.1016/j.jphs.2018.12.006. Epub 2018 Dec 27.

[Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review.](#)

Bartos G, Cline A, Beroukhi K, Burrall BA, Feldman SR.

Dermatol Online J. 2018 Nov 15;24(11). pii: 13030/qt3db748cg.

[Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.](#)

Cui L, Chen R, Subedi S, Yu Q, Gong Y, Chen Z, Shi Y.

Int Immunopharmacol. 2018 Sep;62:46-58. doi: 10.1016/j.intimp.2018.06.020. Epub 2018 Jul 3.

[Emerging therapies in psoriasis: A systematic review.](#)

Lee EB, Amin M, Bhutani T, Wu JJ.

Cutis. 2018 Mar;101(3S):5-9.

[A systematic review and meta-analysis of the efficacy and safety of the interleukin \(IL\)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, and tildrakizumab for the treatment of moderate to severe plaque psoriasis.](#)

Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB.

J Dermatolog Treat. 2018 Sep;29(6):569-578. doi: 10.1080/09546634.2017.1422591. Epub 2018 Mar 28.

[Clinical Review Report: Guselkumab \(Tremfya\): \(Janssen Inc.\): Indication: For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy \[Internet\].](#)

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Mar.

[Quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.](#)

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.

Mol Pain. 2018 Jan-Dec;14:1744806918762205. doi: 10.1177/1744806918762205. Epub 2018 Feb 15.

[Treating moderate-to-severe plaque psoriasis with guselkumab: a review of phase II and phase III trials.](#)

Howell ST, Cardwell LA, Feldman SR.

Ann Pharmacother. 2018 Apr;52(4):380-387. doi: 10.1177/1060028017743268. Epub 2017 Nov 14.

[A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.](#)

No DJ, Amin M, Bhutani T, Wu JJ.

J Dermatolog Treat. 2018 Aug;29(5):467-474. doi: 10.1080/09546634.2017.1402116. Epub 2017 Nov 22.

[Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis.](#)

Amin M, Darji K, No DJ, Wu JJ.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1627-1632. doi: 10.1111/jdv.14451. Epub 2017 Jul 17.

Interleukin antagonists - tildrakizumab (IL-23 inhibitor)

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.](#)

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmetts CA.

J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.

[A systematic literature review and Bucher indirect comparison: Tildrakizumab versus guselkumab.](#)

Du Jardin KG, Hurtado Lopez P, Lange M, McCool R, Maeso Naval S, Quickert S.

J Health Econ Outcomes Res. 2020 Jul 24;7(2):123-129. doi: 10.36469/jheor.2020.13671. eCollection 2020.

[The risk of respiratory tract infections and interstitial lung disease with IL-12/23 and IL-23 antagonists in patients with autoimmune diseases: a systematic review and meta-analysis.](#)

Akiyama S, Yamada A, Micic D, Sakuraba A.

J Am Acad Dermatol. 2020 Aug 10:S0190-9622(20)32414-2. doi: 10.1016/j.jaad.2020.08.026. Online ahead of print.

[A network meta-analysis for the comparison of efficacy and safety of interleukin \(IL\)-23 targeted drugs in the treatment of moderate to severe psoriasis.](#)

Jianzhen S, Xu J, Yanmei C.

Dermatol Ther. 2020 Jun 10:e13802. doi: 10.1111/dth.13802. [Epub ahead of print]

[Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.](#)

Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, de Brito M, McGuire A, Murphy R, Owen CM, Parslew R, Woolf RT, Yiu ZZN, Uthman OA, Mohd Mustapa MF, Smith CH. Br J Dermatol. 2020 Jun 20. doi: 10.1111/bjd.19325. [Epub ahead of print]

[Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis.](#)

Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M.

JAMA Dermatol. 2020 Feb 5. doi: 10.1001/jamadermatol.2019.4029. [Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L.

Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

[Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies.](#)

Loft ND, Vaengebjerg S, Halling-Sønderby AS, Skov L, Egeberg A.
J Eur Acad Dermatol Venereol. 2019 Nov 13. doi: 10.1111/jdv.16073. [Epub ahead of print]

[Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: A comprehensive investigation using Bayesian and frequentist network meta-analyses.](#)

Warren RB, See K, Burge R, Zhang Y, Brnabic A, Gallo G, Garrelts A, Egeberg A.
Dermatol Ther (Heidelb). 2019 Nov 4. doi: 10.1007/s13555-019-00337-y. [Epub ahead of print]

[Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: A systematic review and network meta-analysis of randomized controlled trials.](#)

Bai F, Li GG, Liu Q, Niu X, Li R, Ma H.
J Immunol Res. 2019 Sep 10;2019:2546161. doi: 10.1155/2019/2546161. eCollection 2019.

[Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis.](#)

Xu S, Zhang X, Pan M, Shuai Z, Xu S, Pan F.
Int Immunopharmacol. 2019 Aug 26;75:105841. doi: 10.1016/j.intimp.2019.105841. [Epub ahead of print]

[Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.](#)

Egeberg A, Andersen YMF, Halling-Overgaard AS, Alignahi F, Thyssen JP, Burge R, Mallbris L.
J Eur Acad Dermatol Venereol. 2019 Aug 29. doi: 10.1111/jdv.15920. [Epub ahead of print]

[Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.](#)

Sawyer LM, Malottki K, Sabry-Grant C, Yasmeen N, Wright E, Sohr A, Borg E, Warren RB.
PLoS One. 2019 Aug 14;14(8):e0220868. doi: 10.1371/journal.pone.0220868. eCollection 2019.

[Biologic therapies targeting the IL-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis.](#)

Erichsen CY, Jensen P, Kofoed K.
J Eur Acad Dermatol Venereol. 2019 Aug 16. doi: 10.1111/jdv.15879. [Epub ahead of print]

[Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis.](#)

Xu G, Xia M, Jiang C, Yu Y, Wang G, Yuan J, Duan X.
J Pharmacol Sci. 2019 Apr;139(4):289-303. doi: 10.1016/j.jphs.2018.12.006. Epub 2018 Dec 27.

[Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.](#)

Cui L, Chen R, Subedi S, Yu Q, Gong Y, Chen Z, Shi Y.
Int Immunopharmacol. 2018 Sep;62:46-58. doi: 10.1016/j.intimp.2018.06.020. Epub 2018 Jul 3.

[Emerging therapies in psoriasis: A systematic review.](#)

Lee EB, Amin M, Bhutani T, Wu JJ.

Cutis. 2018 Mar;101(3S):5-9.

[A systematic review and meta-analysis of the efficacy and safety of the interleukin \(IL\)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, and tildrakizumab for the treatment of moderate to severe plaque psoriasis.](#)

Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB.

J Dermatolog Treat. 2018 Sep;29(6):569-578. doi: 10.1080/09546634.2017.1422591. Epub 2018 Mar 28.

[Quantitative evaluation to efficacy and safety of therapies for psoriasis: a network meta-analysis.](#)

Lv J, Zhou D, Wang Y, Zhao J, Chen Z, Zhang J, Di T, Hu J, Li B, Li P.

Mol Pain. 2018 Jan-Dec;14:1744806918762205. doi: 10.1177/1744806918762205. Epub 2018 Feb 15.

[A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.](#)

No DJ, Amin M, Bhutani T, Wu JJ.

J Dermatolog Treat. 2018 Aug;29(5):467-474. doi: 10.1080/09546634.2017.1402116. Epub 2017 Nov 22.

[Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis.](#)

Amin M, Darji K, No DJ, Wu JJ.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1627-1632. doi: 10.1111/jdv.14451. Epub 2017 Jul 17.

Interleukin antagonists - risankizumab (IL-23 inhibitor)

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.](#)

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA.

J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.

[The risk of respiratory tract infections and interstitial lung disease with IL-12/23 and IL-23 antagonists in patients with autoimmune diseases: a systematic review and meta-analysis.](#)

Akiyama S, Yamada A, Micic D, Sakuraba A.

J Am Acad Dermatol. 2020 Aug 10:S0190-9622(20)32414-2. doi: 10.1016/j.jaad.2020.08.026. Online ahead of print.

[Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.](#)

Tada Y, Watanabe R, Noma H, Kanai Y, Nomura T, Kaneko K.

J Dermatol Sci. 2020 Jun 18. pii: S0923-1811(20)30199-7. doi: 10.1016/j.jdermsci.2020.06.003. [Epub ahead of print]

[A network meta-analysis for the comparison of efficacy and safety of interleukin \(IL\)-23 targeted drugs in the treatment of moderate to severe psoriasis.](#)

Jianzhen S, Xu J, Yanmei C.

Dermatol Ther. 2020 Jun 10:e13802. doi: 10.1111/dth.13802. [Epub ahead of print]

[Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.](#)

Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, de Brito M, McGuire A, Murphy R, Owen CM, Parslew R, Woolf RT, Yiu ZZN, Uthman OA, Mohd Mustapa MF, Smith CH. Br J Dermatol. 2020 Jun 20. doi: 10.1111/bjd.19325. [Epub ahead of print]

[Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.](#)

Yasmeen N, Sawyer LM, Malottki K, Levin LÅ, Apol ED, Jemec GB. J Dermatolog Treat. 2020 Mar 23:1-50. doi: 10.1080/09546634.2020.1743811. [Epub ahead of print]

[Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis.](#)

Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M. JAMA Dermatol. 2020 Feb 5. doi: 10.1001/jamadermatol.2019.4029. [Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L. Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

[Risankizumab for the treatment of moderate to severe plaque psoriasis.](#)

Li W, Ghamrawi R, Haidari W, Feldman SR. Ann Pharmacother. 2019 Oct 31:1060028019885836. doi: 10.1177/1060028019885836. [Epub ahead of print]

[Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies.](#)

Loft ND, Vaengebjerg S, Halling-Sønderby AS, Skov L, Egeberg A. J Eur Acad Dermatol Venereol. 2019 Nov 13. doi: 10.1111/jdv.16073. [Epub ahead of print]

[Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: A comprehensive investigation using Bayesian and frequentist network meta-analyses.](#)

Warren RB, See K, Burge R, Zhang Y, Brnabic A, Gallo G, Garrelts A, Egeberg A. Dermatol Ther (Heidelb). 2019 Nov 4. doi: 10.1007/s13555-019-00337-y. [Epub ahead of print]

[Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: A systematic review and network meta-analysis of randomized controlled trials.](#)

Bai F, Li GG, Liu Q, Niu X, Li R, Ma H. J Immunol Res. 2019 Sep 10;2019:2546161. doi: 10.1155/2019/2546161. eCollection 2019.

[Meta-analyses of clinical efficacy of risankizumab and adalimumab in chronic plaque psoriasis: Supporting evidence of risankizumab superiority.](#)

Witjes H, Khatri A, Diderichsen PM, Mandema J, Othman AA. Clin Pharmacol Ther. 2019 Sep 10. doi: 10.1002/cpt.1624. [Epub ahead of print]

[Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis.](#)

Xu S, Zhang X, Pan M, Shuai Z, Xu S, Pan F.

Int Immunopharmacol. 2019 Aug 26;75:105841. doi: 10.1016/j.intimp.2019.105841. [Epub ahead of print]

[Clinical Review Report: Risankizumab \(Skyrizi\): \(AbbVie\): Indication: For the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy](#) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun.

[Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.](#)

Egeberg A, Andersen YMF, Halling-Overgaard AS, Alignahi F, Thyssen JP, Burge R, Mallbris L. J Eur Acad Dermatol Venereol. 2019 Aug 29. doi: 10.1111/jdv.15920. [Epub ahead of print]

[Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.](#)

Sawyer LM, Malottki K, Sabry-Grant C, Yasmeen N, Wright E, Sohr A, Borg E, Warren RB. PLoS One. 2019 Aug 14;14(8):e0220868. doi: 10.1371/journal.pone.0220868. eCollection 2019.

[Biologic therapies targeting the IL-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis.](#)

Erichsen CY, Jensen P, Kofoed K.

J Eur Acad Dermatol Venereol. 2019 Aug 16. doi: 10.1111/jdv.15879. [Epub ahead of print]

[Emerging therapies in psoriasis: A systematic review.](#)

Lee EB, Amin M, Bhutani T, Wu JJ. Cutis. 2018 Mar;101(3S):5-9.

New small molecule systemic therapies

Small molecule systemic therapies – general

[Biologics and small molecules in patients with scalp psoriasis: a systematic review.](#)

Alsenaid A, Ezmerli M, Srouf J, Heppt M, Illigens BM, Prinz JC.

J Dermatolog Treat. 2020 May 14;1:1-38. doi: 10.1080/09546634.2020.1770167. [Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L.

Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

[Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.](#)

Sawyer LM, Cornic L, Levin LÅ, Gibbons C, Møller AH, Jemec GB.

J Eur Acad Dermatol Venereol. 2019 Feb;33(2):355-366. doi: 10.1111/jdv.15277. Epub 2018 Oct 31.

[Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.](#)

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.

J Am Acad Dermatol. 2018 Jul;79(1):135-144.e7. doi: 10.1016/j.jaad.2018.02.027. Epub 2018 Feb 10.

[Biologics and small molecules in psoriasis: A systematic review of economic evaluations.](#)

Kromer C, Celis D, Sonntag D, Peitsch WK.

PLoS One. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765. eCollection 2018.

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Théréné C, Brenaut E, Barnette T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.

Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: A systematic review and meta-analysis of randomized clinical trials.](#)

de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR.

Drugs R D. 2017 Mar;17(1):29-51. doi: 10.1007/s40268-016-0152-x.

[Review of maintenance of response to psoriasis treatments.](#)

Bartos S, Hill D, Feldman SR.

J Dermatolog Treat. 2016 Aug;27(4):293-7. doi: 10.1080/09546634.2016.1177158.

[Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: A systematic review and meta-analysis.](#)

Nast A, Jacobs A, Rosumeck S, Werner RN.

J Invest Dermatol. 2015 Nov;135(11):2641-8. doi: 10.1038/jid.2015.206. Epub 2015 Jun 5.

Phosphodiesterase-4 inhibitors - apremilast

[Joint AAD-NPF Guidelines of Care for the Management of Psoriasis with Systemic Non-Biological Therapies.](#)

Menter A, Gelfand JM, et al.

J Am Acad Dermatol. 2020 Feb 28. pii: S0190-9622(20)30284-X. doi: 10.1016/j.jaad.2020.02.044. [Epub ahead of print]

[Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.](#)

Yasmeen N, Sawyer LM, Malottki K, Levin LÅ, Apol ED, Jemec GB.

J Dermatolog Treat. 2020 Mar 23:1-50. doi: 10.1080/09546634.2020.1743811. [Epub ahead of print]

[Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis.](#)

Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M.

JAMA Dermatol. 2020 Feb 5. doi: 10.1001/jamadermatol.2019.4029. [Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L.

Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

[Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.](#)

Sawyer LM, Cornic L, Levin LÅ, Gibbons C, Møller AH, Jemec GB.

J Eur Acad Dermatol Venereol. 2019 Feb;33(2):355-366. doi: 10.1111/jdv.15277. Epub 2018 Oct 31.

[Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.](#)

Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.

Curr Med Res Opin. 2018 Jul;34(7):1325-1333. doi: 10.1080/03007995.2018.1457516. Epub 2018 Apr 23.

[Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.](#)

Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA.

J Am Acad Dermatol. 2018 Jul;79(1):135-144.e7. doi: 10.1016/j.jaad.2018.02.027. Epub 2018 Feb 10.

[Biologics and small molecules in psoriasis: A systematic review of economic evaluations.](#)

Kromer C, Celis D, Sonntag D, Peitsch WK.

PLoS One. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765. eCollection 2018.

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Thérén  C, Brenaut E, Barnette T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.
Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: A systematic review and meta-analysis of randomized clinical trials.](#)

de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR.
Drugs R D. 2017 Mar;17(1):29-51. doi: 10.1007/s40268-016-0152-x.

[Review of maintenance of response to psoriasis treatments.](#)

Bartos S, Hill D, Feldman SR.
J Dermatolog Treat. 2016 Aug;27(4):293-7. doi: 10.1080/09546634.2016.1177158.

[Apremilast: A novel drug for treatment of psoriasis and psoriatic arthritis.](#)

Haber SL, Hamilton S, Bank M, Leong SY, Pierce E.
Ann Pharmacother. 2016 Apr;50(4):282-90. doi: 10.1177/1060028015627467. Epub 2016 Jan 18.

[Efficacy and safety of systemic long-term treatments for moderate-to-severe psoriasis: A systematic review and meta-analysis.](#)

Nast A, Jacobs A, Rosumeck S, Werner RN.
J Invest Dermatol. 2015 Nov;135(11):2641-8. doi: 10.1038/jid.2015.206. Epub 2015 Jun 5.

[Apremilast for the treatment of psoriasis.](#)

Chimenti MS, Gramiccia T, Saraceno R, Bianchi L, Garofalo V, Buonomo O, Perricone R, Chimenti S, Chiricozzi A.
Expert Opin Pharmacother. 2015;16(13):2083-94. Epub 2015 Aug 4

Janus kinase inhibitors - general

[Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: A systematic review and meta-analysis.](#)

Olivera P, Lasa J, Bonovas S, Danese S, Peyrin-Biroulet L.
Gastroenterology. 2020 Jan 8. pii: S0016-5085(20)30011-1. doi: 10.1053/j.gastro.2020.01.001. [Epub ahead of print]

[JAK-inhibitors in dermatology. Current evidence and future applications.](#)

Ciechanowicz P, Rakowska A, Sikora M, Rudnicka L.
J Dermatolog Treat. 2019 Nov;30(7):648-658. doi: 10.1080/09546634.2018.1546043. Epub 2018 Dec 3.

[Topical Janus kinase inhibitors: A review of applications in dermatology.](#)

Hosking AM, Juhasz M, Mesinkovska NA.
J Am Acad Dermatol. 2018 Sep;79(3):535-544. doi: 10.1016/j.jaad.2018.04.018. Epub 2018 Apr 16.

[Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis.](#)

Thér  ne C, Brenaut E, Barnette T, Misery L.
J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[Janus kinase inhibitors in dermatology: A systematic review.](#)

Shreberk-Hassidim R, Ramot Y, Zlotogorski A.

J Am Acad Dermatol. 2017 Apr;76(4):745-753.e19. doi: 10.1016/j.jaad.2016.12.004. Epub 2017 Feb 4.

Janus kinase inhibitors - tofacitinib

[Joint AAD-NPF Guidelines of Care for the Management of Psoriasis with Systemic Non-Biological Therapies.](#)

Menter A, Gelfand JM, et al.

J Am Acad Dermatol. 2020 Feb 28. pii: S0190-9622(20)30284-X. doi: 10.1016/j.jaad.2020.02.044. [Epub ahead of print]

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L.

Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

[Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: A systematic review and meta-analysis.](#)

Olivera P, Lasa J, Bonovas S, Danese S, Peyrin-Biroulet L.

Gastroenterology. 2020 Jan 8. pii: S0016-5085(20)30011-1. doi: 10.1053/j.gastro.2020.01.001. [Epub ahead of print]

[Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis.](#)

Tian F, Chen Z, Xu T.

J Int Med Res. 2019 Jun;47(6):2342-2350. doi: 10.1177/0300060519847414. Epub 2019 May 17.

[JAK-inhibitors in dermatology. Current evidence and future applications.](#)

Ciechanowicz P, Rakowska A, Sikora M, Rudnicka L.

J Dermatolog Treat. 2019 Nov;30(7):648-658. doi: 10.1080/09546634.2018.1546043. Epub 2018 Dec 3.

[Topical Janus kinase inhibitors: A review of applications in dermatology.](#)

Hosking AM, Juhasz M, Mesinkovska NA.

J Am Acad Dermatol. 2018 Sep;79(3):535-544. doi: 10.1016/j.jaad.2018.04.018. Epub 2018 Apr 16.

[Adverse drug events associated with 5mg versus 10mg tofacitinib \(Janus kinase inhibitor\) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials.](#)

Huang F, Luo ZC.

Clin Rheumatol. 2019 Feb;38(2):523-534. doi: 10.1007/s10067-018-4299-4. Epub 2018 Sep 22.

[Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.](#)

Kuo CM, Tung TH, Wang SH, Chi CC.

J Eur Acad Dermatol Venereol. 2018 Mar;32(3):355-362. doi: 10.1111/jdv.14695. Epub 2017 Dec 5.

[Efficacy of systemic treatments of psoriasis on pruritus: A systematic literature review and meta-analysis.](#)

Thér  n   C, Brenaut E, Barn  tche T, Misery L.

J Invest Dermatol. 2018 Jan;138(1):38-45. doi: 10.1016/j.jid.2017.05.039. Epub 2017 Sep 5.

[Quantitative evaluations of time-course and treatment effects of systemic agents for psoriasis: a model-based meta-analysis.](#)

Checchio T, Ahadieh S, Gupta P, Mandema J, Puig L, Wolk R, Valdez H, Tan H, Krishnaswami S, Tallman A, Kaur M, Ito K.

Clin Pharmacol Ther. 2017 Dec;102(6):1006-1016. doi: 10.1002/cpt.732. Epub 2017 Jun 21.

[Janus kinase inhibitors in dermatology: A systematic review.](#)

Shreberk-Hassidim R, Ramot Y, Zlotogorski A.

J Am Acad Dermatol. 2017 Apr;76(4):745-753.e19. doi: 10.1016/j.jaad.2016.12.004. Epub 2017 Feb 4.

[Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: A systematic review and meta-analysis of randomized clinical trials.](#)

de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR.

Drugs R D. 2017 Mar;17(1):29-51. doi: 10.1007/s40268-016-0152-x.

Tyrosine kinase inhibitors

[Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.](#)

Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L.

Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3.

Combination therapies

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.](#)

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA.

J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.

[Beyond monotherapy: a systematic review on creative strategies in topical therapy of psoriasis.](#)

Koo K, Jeon C, Bhutani T.

J Dermatolog Treat. 2017 Dec;28(8):702-708. doi: 10.1080/09546634.2017.1328098. Epub 2017 Jun 6.

[Combining biologics with methotrexate in psoriasis: A systematic review.](#)

van Bezooijen JS, Prens EP, Pradeepti MS, Atiqi R, Schreurs MW, Koch BC, van Gelder T, van Doorn MB.

Br J Dermatol. 2015 Jun;172(6):1676-80. doi: 10.1111/bjd.13573. Epub 2015 Apr 29.

[Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.](#)

Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.

JAMA Dermatol. 2015 Apr;151(4):432-8. doi: 10.1001/jamadermatol.2014.3456.

[Combined use of systemic agents for psoriasis: A systematic review.](#)

Busard C, Zweegers J, Limpens J, Langendam M, Spuls PI.

JAMA Dermatol. 2014 Nov;150(11):1213-20. doi: 10.1001/jamadermatol.2014.1111.

[The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: A systematic review of the literature with a meta-analysis.](#)

Garcês S, Demengeot J, Benito-Garcia E.

Ann Rheum Dis. 2013 Dec;72(12):1947-55. doi: 10.1136/annrheumdis-2012-202220. Epub 2012 Dec 6.

[Combination therapy in psoriasis: An evidence-based review.](#)

Gustafson CJ, Watkins C, Hix E, Feldman SR.

Am J Clin Dermatol. 2013 Feb;14(1):9-25. doi: 10.1007/s40257-012-0003-7.

[Combination treatments for psoriasis: A systematic review and meta-analysis.](#)

Bailey EE, Ference EH, Alikhan A, Hession MT, Armstrong AW.

Arch Dermatol. 2012 Apr;148(4):511-22. doi: 10.1001/archdermatol.2011.1916. Epub 2011 Dec 19.

Other treatments

Psychological & educational interventions

NICE Clinical guideline [CG153] - Psoriasis: assessment and management

<https://www.nice.org.uk/guidance/cg153/evidence>

[A systematic review of cognitive and behavioral treatments for individuals with psoriasis.](#)

Sijercic I, Ennis N, Monson CM.

J Dermatolog Treat. 2019 Nov 7;1-26. doi: 10.1080/09546634.2019.1690625. [Epub ahead of print]

[Therapeutic patient education and self-management support for patients with psoriasis - a systematic review.](#)

Dressler C, Lambert J, Grine L, Galdas P, Paul C, Zidane M, Nast A.

J Dtsch Dermatol Ges. 2019 Jul;17(7):685-695. doi: 10.1111/ddg.13840. Epub 2019 Apr 23.

[Psychological therapies in management of psoriatic skin disease: A systematic review.](#)

Qureshi AA, Awosika O, Baruffi F, Rengifo-Pardo M, Ehrlich A.

Am J Clin Dermatol. 2019 Apr 2. doi: 10.1007/s40257-019-00437-7. [Epub ahead of print]

[The efficacy of psychological interventions on psoriasis treatment: a systematic review and meta-analysis of randomized controlled trials.](#)

Xiao Y, Zhang X, Luo D, Kuang Y, Zhu W, Chen X, Shen M.

Psychol Res Behav Manag. 2019 Feb 7;12:97-106. doi: 10.2147/PRBM.S195181. eCollection 2019.

[Shared decision making in psoriasis: A systematic review of quantitative and qualitative studies.](#)

Larsen MH, Hagen KB, Krogstad AL, Wahl AK.

Am J Clin Dermatol. 2019 Feb;20(1):13-29. doi: 10.1007/s40257-018-0390-5.

[Effects of psychosocial interventions on patient-reported outcomes in patients with psoriasis: A systematic review and meta-analysis.](#)

Zill JM, Christalle E, Tillenburg N, Mrowietz U, Augustin M, Härter M, Dirmaier J.

Br J Dermatol. 2018 Oct 6. doi: 10.1111/bjd.17272. [Epub ahead of print]

[Education to improve quality of life of people with chronic inflammatory skin conditions: A systematic review of the evidence.](#)

Pickett K, Frampton G, Loveman E.

Br J Dermatol. 2016 Jun;174(6):1228-41. doi: 10.1111/bjd.14435. Epub 2016 Apr 28.

[Does therapeutic writing help people with long-term conditions? Systematic review, realist synthesis and economic considerations.](#)

Nyssen OP, Taylor SJ, Wong G, Steed E, Bourke L, Lord J, Ross CA, Hayman S, Field V, Higgins A, Greenhalgh T, Meads C.

Health Technol Assess. 2016 Apr;20(27):vii-xxxvii, 1-367. doi: 10.3310/hta20270.

[Educational interventions to improve quality of life in people with chronic inflammatory skin diseases: Systematic reviews of clinical effectiveness and cost-effectiveness.](#)

Pickett K, Loveman E, Kalita N, Frampton GK, Jones J.

Health Technol Assess. 2015 Oct;19(86):1-176, v-vi. doi: 10.3310/hta19860.

[Limited evidence of the effects of patient education and self-management interventions in psoriasis patients: A systematic review.](#)

Larsen MH, Hagen KB, Krogstad AL, Aas E, Wahl AK.

Patient Educ Couns. 2014 Feb;94(2):158-69. doi: 10.1016/j.pec.2013.10.005. Epub 2013 Oct 14.

[Evaluating the effectiveness of psychological and/or educational interventions in psoriasis: A narrative review.](#)

Chen Y, Xin T, Cheng AS.

J Dermatol. 2014 Sep;41(9):775-8. doi: 10.1111/1346-8138.12583. Epub 2014 Aug 11.

[Can stress reduction interventions improve psoriasis? A review.](#)

Fordham B, Griffiths CE, Bundy C.

Psychol Health Med. 2013;18(5):501-14. doi: 10.1080/13548506.2012.736625. Epub 2012 Nov 2.

[A systematic review of self-help for disfigurement: effectiveness, usability, and acceptability.](#)

Muftin Z, Thompson AR.

Body Image. 2013 Sep;10(4):442-50. doi: 10.1016/j.bodyim.2013.07.005. Epub 2013 Aug 17.

Lifestyle changes

[Lifestyle changes for treating psoriasis.](#)

Ko SH, Chi CC, Yeh ML, Wang SH, Tsai YS, Hsu MY.

Cochrane Database Syst Rev. 2019 Jul 16;7:CD011972. doi: 10.1002/14651858.CD011972.pub2.

Weight loss

[Lifestyle changes for treating psoriasis.](#)

Ko SH, Chi CC, Yeh ML, Wang SH, Tsai YS, Hsu MY.

Cochrane Database Syst Rev. 2019 Jul 16;7:CD011972. doi: 10.1002/14651858.CD011972.pub2.

[Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A critically-appraised topic.](#)

Mahil SK, McSweeney SM, Kloczko E, McGowan B, Barker JN, Smith CH.

Br J Dermatol. 2019 Feb 6. doi: 10.1111/bjd.17741. [Epub ahead of print]

[Effects of weight loss on psoriasis: A review of clinical trials.](#)

Alotaibi HA.

Cureus. 2018 Oct 24;10(10):e3491. doi: 10.7759/cureus.3491.

[Dietary recommendations for adults with psoriasis or psoriatic arthritis from the Medical Board of the National Psoriasis Foundation: A systematic review.](#)

Ford AR, Siegel M, Bagel J, Cordoro KM, Garg A, Gottlieb A, Green LJ, Gudjonsson JE, Koo J, Lebwohl M, Liao W, Mandelin AM 2nd, Markenson JA, Mehta N, Merola JF, Prussick R, Ryan C, Schwartzman S, Siegel EL, Van Voorhees AS, Wu JJ, Armstrong AW.

JAMA Dermatol. 2018 Aug 1;154(8):934-950. doi: 10.1001/jamadermatol.2018.1412.

[Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: A systematic review and meta-analysis.](#)

Upala S, Sanguankeo A.

Int J Obes (Lond). 2015 Aug;39(8):1197-202. doi: 10.1038/ijo.2015.64. Epub 2015 Apr 29.

[Diet and psoriasis, part I: Impact of weight loss interventions.](#)

Debbaneh M, Millsop JW, Bhatia BK, Koo J, Liao W.

J Am Acad Dermatol. 2014 Jul;71(1):133-40. doi: 10.1016/j.jaad.2014.02.012. Epub 2014 Apr 4.

Diet & supplements

[Benefits of turmeric supplementation for skin health in chronic diseases: a systematic review.](#)

Mata IRD, Mata SRD, Menezes RCR, Faccioli LS, Bandeira KK, Bosco SMD.

Crit Rev Food Sci Nutr. 2020 Jul 27:1-15. doi: 10.1080/10408398.2020.1798353. Online ahead of print.

[Efficacy of fish oil and its components in the management of psoriasis: a systematic review of 18 randomized controlled trials.](#)

Chen X, Hong S, Sun X, Xu W, Li H, Ma T, Zheng Q, Zhao H, Zhou Y, Qiang Y, Li B, Li X.

Nutr Rev. 2020 Jan 29. pii: nuz098. doi: 10.1093/nutrit/nuz098. [Epub ahead of print]

[Effects of fish oil supplement on psoriasis: a meta-analysis of randomized controlled trials.](#)

Yang SJ, Chi CC.

BMC Complement Altern Med. 2019 Dec 5;19(1):354. doi: 10.1186/s12906-019-2777-0.

[Hypovitaminosis D is associated with psoriasis: A systematic review and meta-analysis.](#)

Pitukweerakul S, Thavaraputta S, Prachuapthunyachart S, Karnchanasorn R.

Kans J Med. 2019 Nov 25;12(4):103-108. eCollection 2019 Nov.

[Effects of zinc supplementation on inflammatory skin diseases: A systematic review of the clinical evidence.](#)

Dhaliwal S, Nguyen M, Vaughn AR, Notay M, Chambers CJ, Sivamani RK.

Am J Clin Dermatol. 2019 Nov 19. doi: 10.1007/s40257-019-00484-0. [Epub ahead of print]

[Lifestyle changes for treating psoriasis.](#)

Ko SH, Chi CC, Yeh ML, Wang SH, Tsai YS, Hsu MY.

Cochrane Database Syst Rev. 2019 Jul 16;7:CD011972. doi: 10.1002/14651858.CD011972.pub2.

[Efficacy of \$\omega\$ -3 supplementation in patients with psoriasis: a meta-analysis of randomized controlled trials.](#)

Clark CCT, Taghizadeh M, Nahavandi M, Jafarnejad S.

Clin Rheumatol. 2019 Apr;38(4):977-988. doi: 10.1007/s10067-019-04456-x. Epub 2019 Feb 18.

[Nutritional strategies for psoriasis: current scientific evidence in clinical trials.](#)

Zuccotti E, Oliveri M, Girometta C, Ratto D, Di Iorio C, Occhinegro A, Rossi P.

Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8537-8551. doi: 10.26355/eurrev_201812_16554.

[Complementary and alternative medicine therapies for psoriasis: a systematic review.](#)

Gamret AC, Price A, Fertig RM, Lev-Tov H, Nichols AJ.

JAMA Dermatol. 2018 Nov 1;154(11):1330-1337. doi: 10.1001/jamadermatol.2018.2972.

[Dietary recommendations for adults with psoriasis or psoriatic arthritis from the Medical Board of the National Psoriasis Foundation: A systematic review.](#)

Ford AR, Siegel M, Bagel J, Cordoro KM, Garg A, Gottlieb A, Green LJ, Gudjonsson JE, Koo J, Lebwohl M, Liao W, Mandelin AM 2nd, Markenson JA, Mehta N, Merola JF, Prussick R, Ryan C, Schwartzman S, Siegel EL, Van Voorhees AS, Wu JJ, Armstrong AW.
JAMA Dermatol. 2018 Aug 1;154(8):934-950. doi: 10.1001/jamadermatol.2018.1412.

[Probiotics, prebiotics, and synbiotics for the treatment and prevention of adult dermatological diseases.](#)

Notay M, Foolad N, Vaughn AR, Sivamani RK.
Am J Clin Dermatol. 2017 Dec;18(6):721-732. doi: 10.1007/s40257-017-0300-2.

[Effect of omega-3 fatty acids on disease severity in patients with psoriasis: A systematic review.](#)

Upala S, Yong WC, Theparee T, Sanguankeo A.
Int J Rheum Dis. 2017 Apr;20(4):442-450. doi: 10.1111/1756-185X.13051. Epub 2017 Mar 5.

[Diet and psoriasis, part II: Celiac disease and role of a gluten-free diet.](#)

Bhatia BK, Millsop JW, Debbaneh M, Koo J, Linos E, Liao W.
J Am Acad Dermatol. 2014 Aug;71(2):350-8. doi: 10.1016/j.jaad.2014.03.017. Epub 2014 Apr 26.

[Diet and psoriasis, part III: Role of nutritional supplements.](#)

Millsop JW, Bhatia BK, Debbaneh M, Koo J, Liao W.
J Am Acad Dermatol. 2014 Sep;71(3):561-9. doi: 10.1016/j.jaad.2014.03.016. Epub 2014 Apr 26.

Tonsillectomy

[Antistreptococcal interventions for guttate and chronic plaque psoriasis.](#)

Dupire G, Droitcourt C, Hughes C, Le Cleach L.
Cochrane Database Syst Rev. 2019 Mar 5;3:CD011571. doi: 10.1002/14651858.CD011571.pub2.

[Indications for tonsillectomy stratified by the level of evidence.](#)

Windfuhr JP.
GMS Curr Top Otorhinolaryngol Head Neck Surg. 2016 Dec 15;15:Doc09. doi: 10.3205/cto000136. eCollection 2016.

[\[Evidence-based Indications for Tonsillectomy\].](#)

Windfuhr JP.
Laryngorhinootologie. 2016 Apr;95 Suppl 1:S38-87. doi: 10.1055/s-0041-109590. Epub 2016 Apr 29. German.

[Effect of tonsillectomy on psoriasis: A systematic review.](#)

Rachakonda TD, Dhillon JS, Florek AG, Armstrong AW.
J Am Acad Dermatol. 2015 Feb;72(2):261-75. doi: 10.1016/j.jaad.2014.10.013. Epub 2014 Nov 20.

Herbal medicine (including Chinese herbal medicine)

[Total glucosides of paeony for the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials.](#)

Zheng Q, Jiang W, Sun X, Ma T, Xu W, Shen F, Li H, Xie S, Li B, Li X.
Phytomedicine. 2019 Apr 25;62:152940. doi: 10.1016/j.phymed.2019.152940. [Epub ahead of print]

[Review of the efficacy and safety of topical Mahonia aquifolium for the treatment of psoriasis and atopic dermatitis.](#)

Janeczek M, Moy L, Lake EP, Swan J.

J Clin Aesthet Dermatol. 2018 Dec;11(12):42-47. Epub 2018 Dec 1.

[Complementary and alternative medicine therapies for psoriasis: a systematic review.](#)

Gamret AC, Price A, Fertig RM, Lev-Tov H, Nichols AJ.

JAMA Dermatol. 2018 Nov 1;154(11):1330-1337. doi: 10.1001/jamadermatol.2018.2972.

[Efficacy and safety of Tripterygium wilfordii Hook F on psoriasis vulgaris: a systematic review and meta-analysis of randomized controlled trials.](#)

Lv M, Deng J, Tang N, Zeng Y, Lu C.

Evid Based Complement Alternat Med. 2018 Apr 22;2018:2623085. doi: 10.1155/2018/2623085. eCollection 2018.

[Topical botanical agents for the treatment of psoriasis: A systematic review.](#)

Farahnik B, Sharma D, Alban J, Sivamani RK.

Am J Clin Dermatol. 2017 Aug;18(4):451-468. doi: 10.1007/s40257-017-0266-0.

[Effectiveness and safety of traditional Chinese medical bath therapy combined with ultraviolet irradiation in the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials.](#)

Guan J, Yuan S, Wu H, Na R, Wu X, Wang X, Bao S.

PLoS One. 2017 Mar 21;12(3):e0173276. doi: 10.1371/journal.pone.0173276. eCollection 2017.

[Oral \(systemic\) botanical agents for the treatment of psoriasis: A review.](#)

Farahnik B, Sharma D, Alban J, Sivamani R.

J Altern Complement Med. 2017 Jun;23(6):418-425. doi: 10.1089/acm.2016.0324. Epub 2017 Feb 3.

[Oral Chinese herbal medicine versus placebo for psoriasis vulgaris: A systematic review.](#)

Parker S, Zhang CS, Yu JJ, Lu C, Zhang AL, Xue CC.

J Dermatolog Treat. 2017 Feb;28(1):21-31. doi: 10.1080/09546634.2016.1178377. Epub 2016 Jul 1.

[Compound glycyrrhizin plus conventional therapy for psoriasis vulgaris: A systematic review and meta-analysis of randomized controlled trials.](#)

Yu JJ, Zhang CS, Coyle ME, Du Y, Zhang AL, Guo X, Xue CC, Lu C.

Curr Med Res Opin. 2017 Feb;33(2):279-287. doi: 10.1080/03007995.2016.1254605. Epub 2016 Nov 10.

[Effects of turmeric \(Curcuma longa\) on skin health: A systematic review of the clinical evidence.](#)

Vaughn AR, Branum A, Sivamani RK.

Phytother Res. 2016 Aug;30(8):1243-64. doi: 10.1002/ptr.5640. Epub 2016 May 23.

[Is oral Chinese herbal medicine beneficial for psoriasis vulgaris? A meta-analysis of comparisons with acitretin.](#)

Zhang CS, Yang L, Zhang AL, May BH, Yu JJ, Guo X, Lu C, Xue CC.

J Altern Complement Med. 2016 Mar;22(3):174-88. doi: 10.1089/acm.2014.0212. Epub 2016 Feb 26.

[Efficacy of combining oral Chinese herbal medicine and NB-UVB in treating psoriasis vulgaris: A systematic review and meta-analysis.](#)

Yang L, Zhang CS, May B, Yu J, Guo X, Zhang AL, Xue CC, Lu C.

Chin Med. 2015 Sep 26;10:27. doi: 10.1186/s13020-015-0060-y. eCollection 2015.

[Review of clinical pharmacology of Aloe vera L. in the treatment of psoriasis.](#)

Miroddi M, Navarra M, Calapai F, Mancari F, Giofrè SV, Gangemi S, Calapai G.
Phytother Res. 2015 May;29(5):648-55. doi: 10.1002/ptr.5316. Epub 2015 Mar 10.

[Oral Chinese herbal medicine combined with pharmacotherapy for psoriasis vulgaris: A systematic review.](#)

Zhang CS, Yu JJ, Parker S, Zhang AL, May B, Lu C, Xue CC.
Int J Dermatol. 2014 Nov;53(11):1305-18. doi: 10.1111/ijd.12607. Epub 2014 Sep 10.

[Topical herbal formulae in the management of psoriasis: Systematic review with meta-analysis of clinical studies and investigation of the pharmacological actions of the main herbs.](#)

Deng S, May BH, Zhang AL, Lu C, Xue CC.
Phytother Res. 2014 Apr;28(4):480-97. doi: 10.1002/ptr.5028. Epub 2013 Jul 1.

[Plant extracts for the topical management of psoriasis: A systematic review and meta-analysis.](#)

Deng S, May BH, Zhang AL, Lu C, Xue CC.
Br J Dermatol. 2013 Oct;169(4):769-82. doi: 10.1111/bjd.12557

[Add-on effect of Chinese herbal medicine bath to phototherapy for psoriasis vulgaris: A systematic review.](#)

Yu JJ, Zhang CS, Zhang AL, May B, Xue CC, Lu C.
Evid Based Complement Alternat Med. 2013;2013:673078. doi: 10.1155/2013/673078. Epub 2013 Jul 25.

[Topical herbal medicine combined with pharmacotherapy for psoriasis: A systematic review and meta-analysis.](#)

Deng S, May BH, Zhang AL, Lu C, Xue CC.
Arch Dermatol Res. 2013 Apr;305(3):179-89. doi: 10.1007/s00403-013-1316-y. Epub 2013 Jan 26.

[Efficacy of externally applied Chinese herbal drugs in treating psoriasis: A systematic review.](#)

Li N, Li YQ, Li HY, Guo W, Bai YP.
Chin J Integr Med. 2012 Mar;18(3):222-9. doi: 10.1007/s11655-012-1004-3. Epub 2012 Apr 2.

[Oral herbal medicines for psoriasis: A review of clinical studies.](#)

May BH, Zhang AL, Zhou W, Lu CJ, Deng S, Xue CC.
Chin J Integr Med. 2012 Mar;18(3):172-8. doi: 10.1007/s11655-012-1008-z. Epub 2012 Apr 2.

Other complementary & alternative therapies

[Moving cupping therapy for plaque psoriasis: A PRISMA-compliant study of 16 randomized controlled trials.](#)

Xing M, Ding X, Zhang J, Kuai L, Ru Y, Sun X, Ma T, Miao X, Liu L, Wang Y, Li B, Li X.
Medicine (Baltimore). 2020 Oct 9;99(41):e22539. doi: 10.1097/MD.00000000000022539.

[Fire needle therapy for the treatment of psoriasis: A quantitative evidence synthesis.](#)

Liu L, Sun XY, Lu Y, Song JK, Xing M, Chen X, Luo Y, Ru Y, Chen ST, Li HJ, Li B, Li X.
J Altern Complement Med. 2020 Jul 31. doi: 10.1089/acm.2019.0409. Online ahead of print.

[Evidence and potential mechanisms of traditional Chinese medicine for the treatment of psoriasis vulgaris: A systematic review and meta-analysis.](#)

Dai D, Wu H, He C, Wang X, Luo Y, Song P.

J Dermatolog Treat. 2020 Jul 1;1-40. doi: 10.1080/09546634.2020.1789048. [Epub ahead of print]

[Indoor salt water baths followed by artificial ultraviolet B-light for chronic plaque psoriasis: abridged Cochrane review.](#)

Peinemann F, Harari M, Peternel S, Chan T, Chan D, Labeit AM, Gambichler T.

Br J Dermatol. 2020 Jul 6. doi: 10.1111/bjd.19385. [Epub ahead of print]

[Indoor salt water baths followed by artificial ultraviolet B light for chronic plaque psoriasis.](#)

Peinemann F, Harari M, Peternel S, Chan T, Chan D, Labeit AM, Gambichler T.

Cochrane Database Syst Rev. 2020 May 5;5:CD011941. doi: 10.1002/14651858.CD011941.pub2

[Complementary and alternative medicine therapies for psoriasis: a systematic review.](#)

Gamret AC, Price A, Fertig RM, Lev-Tov H, Nichols AJ.

JAMA Dermatol. 2018 Nov 1;154(11):1330-1337. doi: 10.1001/jamadermatol.2018.2972.

[Acupuncture-related techniques for psoriasis: A systematic review with pairwise and network meta-analyses of randomized controlled trials.](#)

Yeh ML, Ko SH, Wang MH, Chi CC, Chung YC.

J Altern Complement Med. 2017 Dec;23(12):930-940. doi: 10.1089/acm.2016.0158. Epub 2017 Jun 19.

[Immune signatures in patients with psoriasis vulgaris of blood-heat syndrome: A systematic review and meta-analysis.](#)

Li X, Xiao QQ, Li FL, Xu R, Fan B, Wu MF, Zhou M, Li S, Chen J, Peng SG, Li B.

Evid Based Complement Alternat Med. 2016;2016:9503652. doi: 10.1155/2016/9503652. Epub 2016 May 4.

[Acupuncture therapies for psoriasis vulgaris: A systematic review of randomized controlled trials.](#)

Coyle M, Deng J, Zhang AL, Yu J, Guo X, Xue CC, Lu C.

Forsch Komplementmed. 2015;22(2):102-9. doi: 10.1159/000381225. Epub 2015 Mar 20.

[Scientific evidence of the therapeutic effects of Dead Sea treatments: A systematic review.](#)

Katz U, Shoenfeld Y, Zakin V, Sherer Y, Sukenik S.

Semin Arthritis Rheum. 2012 Oct;42(2):186-200. doi: 10.1016/j.semarthrit.2012.02.006. Epub 2012 Apr 12.